0001213900-22-026812.txt : 20220516 0001213900-22-026812.hdr.sgml : 20220516 20220516104836 ACCESSION NUMBER: 0001213900-22-026812 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 61 CONFORMED PERIOD OF REPORT: 20220331 FILED AS OF DATE: 20220516 DATE AS OF CHANGE: 20220516 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OCEAN BIO CHEM INC CENTRAL INDEX KEY: 0000350737 STANDARD INDUSTRIAL CLASSIFICATION: SPECIALTY CLEANING, POLISHING AND SANITATION PREPARATIONS [2842] IRS NUMBER: 591564329 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-11102 FILM NUMBER: 22926460 BUSINESS ADDRESS: STREET 1: 4041 SW 47TH AVE CITY: FORT LAUDERDALE STATE: FL ZIP: 33314 BUSINESS PHONE: 9545876280 MAIL ADDRESS: STREET 1: 4041 SW 47TH AVE CITY: FT LAUDERDALE STATE: FL ZIP: 33028 FORMER COMPANY: FORMER CONFORMED NAME: STAR BRITE CORP DATE OF NAME CHANGE: 19841204 10-Q 1 f10q0322_oceanbio.htm QUARTERLY REPORT

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2022

 

or

 

   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _____ to _____

 

Commission File Number: 0-11102

 

OCEAN BIO-CHEM, INC.

(Exact name of registrant as specified in its charter)

 

Florida   59-1564329

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

4041 SW 47 Avenue, Fort Lauderdale, Florida   33314
(Address of principal executive offices)   (Zip Code)

 

954-587-6280

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act.

 

Title of each class   Trading Symbol   Name of each exchange on which
registered
Common Stock, $0.01 par value   OBCI   The NASDAQ Stock Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company.  See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   Accelerated filer 
 Non-accelerated filer   Smaller reporting company
    Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No 

 

At May 13, 2022, 9,509,799 shares of the registrant’s common stock were outstanding.

 

 

 

 

 

 

OCEAN BIO-CHEM, INC. AND SUBSIDIARIES

TABLE OF CONTENTS

 

    Page
PART I Financial Information:  
     
Item 1. Financial Statements 1
     
  Condensed consolidated balance sheets at March 31, 2022 (unaudited) and December 31, 2021 1
     
  Condensed consolidated statements of operations (unaudited) for the three months ended March 31, 2022 and 2021 2
     
  Condensed consolidated statements of comprehensive income (unaudited) for the three months ended March 31, 2022 and 2021 3
     
  Condensed consolidated statements of shareholders’ equity (unaudited) for the three months ended March 31, 2022 and 2021 4
     
  Condensed consolidated statements of cash flows (unaudited) for the three months ended March 31, 2022 and 2021 5
     
  Notes to condensed consolidated financial statements 6-12
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 13-15
     
Item 3. Quantitative and Qualitative Disclosures about Market Risk 15
     
Item 4. Controls and Procedures 15
     
PART II Other Information:  
     
Item 1A. Risk Factors 16
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 16
     
Item 6. Exhibits 16
     
  Signatures 17

 

i

 

 

PART I - FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

OCEAN BIO-CHEM, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

 

   March 31, 2022   December 31,
2021
 
   (Unaudited)     
ASSETS        
Current Assets:        
Cash  $10,216,924   $12,684,935 
Trade accounts receivable less allowances of approximately $712,000 and $632,000, respectively   10,261,547    9,544,133 
Receivables due from affiliated companies   847,026    1,211,999 
Inventories, net   19,974,898    16,819,253 
Prepaid expenses and other current assets   1,585,477    2,093,971 
Total Current Assets   42,885,872    42,354,291 
           
Property, plant and equipment, net   17,642,008    16,360,218 
Operating lease – right to use   160,449    182,543 
Intangible assets, net   1,309,683    1,380,652 
Total Assets  $61,998,012   $60,277,704 
           
LIABILITIES AND SHAREHOLDERS’ EQUITY          
Current Liabilities:          
Current portion of long-term debt, net  $743,740   $736,531 
Current portion of operating lease liability   90,424    89,600 
Accounts payable - trade   3,376,982    2,877,623 
Income taxes payable   208,342    45,295 
Accrued expenses payable   1,120,234    900,982 
Total Current Liabilities   5,539,722    4,650,031 
           
Deferred tax liability   453,086    347,723 
Operating lease liability, less current portion   70,025    92,943 
Long-term debt, less current portion and debt issuance costs   7,515,735    7,750,889 
Total Liabilities   13,578,568    12,841,586 
           
COMMITMENTS AND CONTINGENCIES   
 
    
 
 
Shareholders’ Equity:          
Common stock - $0.01 par value, 12,000,000 shares authorized; 9,509,799 shares and 9,503,999 shares issued and outstanding, respectively   95,098    95,040 
Additional paid in capital   11,141,123    11,077,706 
Accumulated other comprehensive loss   (291,374)   (292,336)
Retained earnings   37,474,597    36,555,708 
Total Shareholders’ Equity   48,419,444    47,436,118 
           
Total Liabilities and Shareholders’ Equity  $61,998,012   $60,277,704 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

1

 

 

OCEAN BIO-CHEM, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

 

   Three Months Ended 
   March 31, 
   2022   2021 
         
Net sales  $12,737,329   $13,131,224 
           
Cost of goods sold   8,001,347    7,750,503 
           
Gross profit   4,735,982    5,380,721 
           
Operating Expenses:          
Advertising and promotion   1,071,579    941,814 
Selling and administrative   2,000,030    1,972,812 
Total operating expenses   3,071,609    2,914,626 
           
Operating income   1,664,373    2,466,095 
           
Other (expense) income          
Interest (expense), net   (31,682)   (37,187)
           
Income before income taxes   1,632,691    2,428,908 
           
Provision for income taxes   (333,410)   (524,639)
           
Net income  $1,299,281   $1,904,269 
           
Earnings per common share  $0.14   $0.20 
           
Dividends declared per common share  $0.04   $0.03 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

2

 

 

OCEAN BIO-CHEM, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(UNAUDITED)

 

   Three Months Ended 
   March 31, 
   2022   2021 
         
Net income  $1,299,281   $1,904,269 
           
Foreign currency translation adjustment   962    (596)
           
Comprehensive income  $1,300,243   $1,903,673 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

3

 

 

OCEAN BIO-CHEM, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

THREE MONTHS ENDED MARCH 31, 2022 AND 2021

(UNAUDITED)

 

       Additional   Accumulated Other         
   Common Stock   Paid In   Comprehensive   Retained     
   Shares   Amount   Capital   Loss   Earnings   Total 
                         
December 31, 2021   9,503,999   $95,040   $11,077,706   $(292,336)  $36,555,708   $47,436,118 
                               
Net income   -    
-
    
-
    
-
    1,299,281    1,299,281 
                               
Dividends, common stock   -    
-
    
-
    
-
    (380,392)   (380,392)
                               
Common stock repurchased and retired   (600)   (6)   (5,639)   
-
    
-
    (5,645)
                               
Portion of 2021 stock based compensation for shares issued in 2022   6,400    64    69,056    
-
    
-
    69,120 
                               
Foreign currency
translation adjustment
   -    
-
    
-
    962    
-
    962 
                               
March 31, 2022   9,509,799   $95,098   $11,141,123   $(291,374)  $37,474,597   $48,419,444 

 

       Additional   Accumulated Other         
   Common Stock   Paid In   Comprehensive   Retained     
   Shares   Amount   Capital   Loss   Earnings   Total 
                         
December 31, 2020   9,481,799   $94,818   $10,816,100   $(294,324)  $29,290,477   $39,907,071 
                               
Net income   -    
-
    
-
    
-
    1,904,269    1,904,269 
                               
Dividends, common stock   -    
-
    
-
    
-
    (284,454)   (284,454)
                               
Foreign currency
translation adjustment
   -    
-
    
-
    (596)   
-
    (596)
                               
March 31, 2021   9,481,799   $94,818   $10,816,100   $(294,920)  $30,910,292   $41,526,290 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

4

 

 

OCEAN BIO-CHEM, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

   Three Months Ended 
   March 31, 
   2022   2021 
Cash flows from operating activities:        
Net income  $1,299,281   $1,904,269 
Adjustments to reconcile net income to net cash (used in) provided by operating activities:          
           
Depreciation and amortization   405,022    357,594 
Deferred income taxes   105,363    (88,566)
Provision for bad debts   80,003    88,289 
Provision for slow moving and obsolete inventory   70,049    9,756 
Other operating non-cash items   311    (1,572)
           
Changes in assets and liabilities:          
           
Trade accounts receivable   (797,417)   (2,110,546)
Receivables due from affiliated companies   364,973    358,826 
Inventories   (3,225,694)   (1,068,795)
Prepaid expenses and other current assets   508,494    (162,596)
Accounts payable – trade   499,359    1,174,548 
Income taxes payable   163,047    576,626 
Accrued expenses payable   288,372    169,969 
Net cash (used in) provided by operating activities   (238,837)   1,207,802 
           
Cash flows from investing activities:          
Purchases of property, plant and equipment   (1,610,684)   (915,899)
Net cash used in investing activities   (1,610,684)   (915,899)
           
Cash flows from financing activities:          
Payments on long-term debt   (233,104)   (130,092)
Dividends paid to common shareholders   (380,392)   (284,454)
Repurchase of common stock   (5,645)   
-
 
Net cash used in financing activities   (619,141)   (414,546)
           
Effect of exchange rate on cash   651    976 
           
Net decrease in cash and restricted cash   (2,468,011)   (121,667)
           
Cash and restricted cash at beginning of period   12,684,935    11,601,152 
Cash and restricted cash at end of period  $10,216,924   $11,479,485 
           
Supplemental disclosure of cash flow information:          
Cash paid for interest during period  $28,786   $32,606 
Cash paid for income taxes during period  $65,000   $
-
 
Cash paid under operating lease  $23,700   $23,700 
           
Cash  $10,216,924   $11,161,761 
Restricted cash   
-
    317,724 
Total cash and restricted cash  $10,216,924   $11,479,485 
           

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

5

 

 

OCEAN BIO-CHEM, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

1. SUMMARY OF ACCOUNTING POLICIES

 

Interim reporting

 

The accompanying unaudited condensed consolidated financial statements include the accounts of Ocean Bio-Chem, Inc. and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. Unless the context indicates otherwise, the term “Company” refers to Ocean Bio-Chem, Inc. and its subsidiaries.

 

The unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Securities and Exchange Commission Regulation S-X.  Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements.

 

The financial information furnished herein reflects all adjustments, consisting of normal recurring items that, in the opinion of management, are necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the interim periods. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022.

 

The information included in this Form 10-Q should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

 

Use of estimates

 

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and assumptions.

 

2. INVENTORIES

 

The Company’s inventories at March 31, 2022 and December 31, 2021 consisted of the following:

 

  

March 31,

2022

  

December 31,

2021

 
Raw materials  $8,745,696   $7,465,011 
Finished goods   11,552,825    9,669,073 
Inventories, gross   20,298,521    17,134,084 
           
Inventory reserves   (323,623)   (314,831)
           
Inventories, net  $19,974,898   $16,819,253 

 

The inventory reserves shown in the table above reflect slow moving and obsolete inventory.

 

The Company operates a vendor managed inventory program with one of its customers to improve the promotion of the Company’s products. The Company manages the inventory levels at this customer’s warehouses and recognizes revenue as the products are sold by the customer. The inventories managed at the customer’s warehouses, which are included in inventories, net, amounted to approximately $987,000 and $1,051,000 at March 31, 2022 and December 31, 2021, respectively.

 

6

 

 

3. PROPERTY, PLANT & EQUIPMENT

 

The Company’s property, plant and equipment at March 31, 2022 and December 31, 2021 consisted of the following:

 

  

Estimated

Useful Life

  March 31,
2022
  

December 31,

2021

 
            
Land     $278,325   $278,325 
Building and improvements  30 years   15,180,235    9,710,244 
Manufacturing and warehouse equipment  6-20 years   13,577,478    12,858,638 
Office equipment and furniture  3-5 years   1,941,521    1,805,002 
Leasehold improvements  10-15 years   621,903    587,183 
Finance leases – right to use  5 years   113,741    113,741 
Vehicles  3 years   10,020    10,020 
Construction in process (1)      1,883,726    6,633,112 
 Property, plant and equipment, gross      33,606,949    31,996,265 
              
Less accumulated depreciation      (15,964,941)   (15,636,047)
              
Property, plant and equipment, net     $17,642,008   $16,360,218 

 

(1)In April 2022, the Company’s wholly owned subsidiary, KINPAK Inc. (“Kinpak”), placed into service assets relating to an expansion of its manufacturing and distribution facilities.

 

Depreciation expense totaled $328,893 (of which $303,992 is included in cost of goods sold and $24,901 is included in selling and administrative expenses) and $281,529 (of which $257,140 is included in cost of goods sold and $24,389 is included in selling and administrative expenses) for the three months ended March 31, 2022 and 2021, respectively.

 

4. LEASES

 

The Company has one operating lease and two finance leases.

 

Under the operating lease, the Company leases its executive offices and warehouse facilities in Fort Lauderdale, Florida from an entity controlled by Peter G. Dornau, the Company’s Chairman, President and Chief Executive Officer. The lease, as extended, expires on December 31, 2023. The lease requires an annual minimum base rent of $94,800 and provides for a maximum annual 2% increase in subsequent years, although the entity has not raised the minimum base rent since the Company entered into a previous lease agreement in 1998. Additionally, the leasing entity is entitled to reimbursement of all taxes, assessments, and any other expenses that arise from ownership. Each of the parties to the lease has agreed to review the terms of the lease every three years at the request of the other party. Operating lease expense was $24,553 and $24,339 for the three months ended March 31, 2022 and 2021, respectively. At March 31, 2022 and December 31, 2021, the Company had a right to use asset and a corresponding liability of $160,449 and $182,543, respectively, related to the operating lease. Set forth below is a schedule of future minimum rent payments under the operating lease.

 

Twelve-month period ending March 31,
2023  $94,800 
2024   71,100 
Total future minimum lease payments   165,900 
Less imputed interest   (5,451)
Total operating lease liability  $160,449 

 

The Company’s two finance leases relate to office equipment. See Note 3 for information regarding the carrying value of the Company’s finance lease right to use assets and Note 7 for information regarding the finance lease payment schedule.

 

7

 

 

Expenses incurred with respect to the Company’s leases during the three months ended March 31, 2022 and 2021 are set forth below.

 

   Three
Months
Ended
March 31,
2022
  

Three

Months

Ended
March 31,
2021

 
Operating lease expense  $24,553   $24,339 
Finance lease amortization   5,350    5,254 
Finance lease interest   337    433 
Total lease expense  $30,240   $30,026 

 

The remaining lease term with respect to the operating lease, weighted average remaining lease term with respect to the finance leases and discount rate with respect to the operating lease and finance leases at March 31, 2022 and December 31, 2021 are set forth below:

 

   March 31,
2022
 
Remaining lease term – operating lease   1.75 years 
Weighted average remaining lease term – finance leases   3.4 years 
Discount rate – operating lease   3.7%
Weighted average discount rate – finance leases   1.8%

 

   December 31,
2021
 
Remaining lease term – operating lease   2.0 years 
Weighted average remaining lease term – finance leases   3.7 years 
Discount rate – operating lease   3.7%
Weighted average discount rate – finance leases   1.8%

 

5. INTANGIBLE ASSETS

 

The Company’s intangible assets at March 31, 2022 and December 31, 2021 consisted of the following:

 

March 31, 2022

 

Intangible Assets  Cost   Accumulated
Amortization
   Net 
Patents  $622,733   $609,871   $12,862 
Trade names and trademarks   1,715,325    675,195    1,040,130 
Customer list   584,468    416,328    168,140 
Product formulas   292,234    208,168    84,066 
Royalty rights   160,000    155,515    4,485 
Total intangible assets  $3,374,760   $2,065,077   $1,309,683 

 

December 31, 2021

 

Intangible Assets  Cost   Accumulated
Amortization
   Net 
Patents  $622,733   $596,980   $25,753 
Trade names and trademarks   1,715,325    665,440    1,049,885 
Customer list   584,468    387,105    197,363 
Product formulas   292,234    193,554    98,680 
Royalty rights   160,000    151,029    8,971 
Total intangible assets  $3,374,760   $1,994,108   $1,380,652 

 

Amortization expense related to intangible assets was $70,969 and $71,161 for the three months ended March 31, 2022 and 2021, respectively.

 

8

 

 

6. REVOLVING LINE OF CREDIT

 

On August 6, 2021, the Company and Regions Bank (“the “Lender”) entered into a Business Loan Agreement (the “Business Loan Agreement”), effective as of July 30, 2021, under which the Company was provided a revolving line of credit in the amount of Six Million Dollars ($6,000,000). The Business Loan Agreement supersedes the Company’s previous $6,000,000 revolving line of credit from the Lender, entered into on August 31, 2018, that was scheduled to expire on August 31, 2021. The revolving line of credit under the Business Loan Agreement is evidenced by a promissory note and is secured principally by the Company’s inventory and accounts receivable.

 

The Business Loan Agreement bears interest at a variable annual rate of LIBOR plus 1.35%, computed on a 365/360 basis. All outstanding principal plus all accrued unpaid interest is due upon Lender’s demand or when the Business Loan Agreement expires on August 30, 2024.

 

There has been no negative impact in the availability of funds to the Company as a result of the COVID-19 pandemic.

 

At March 31, 2022 and December 31, 2021, the Company had no borrowings under the revolving line of credit provided by the current and former Business Loan Agreements.

 

7. LONG TERM DEBT

 

Term Loan

 

On July 30, 2021, Kinpak  and Regions Bank (the “Lender”) entered into a Credit Agreement (the “Credit Agreement”), effective as of July 20, 2021, under which the Company was extended a term loan (the “Term Loan”) in the original principal amount of Five Million Dollars ($5,000,000). The Company is using the proceeds of the Term Loan for a 69,000 square foot expansion of Kinpak’s manufacturing, warehouse and distribution facilities in Montgomery, Alabama. The Term Loan is evidenced by a promissory note (the “Note”) and is secured by a second priority mortgage of the assets pledged in Kinpak’s industrial development bond financing obtained on September 26, 2017 (see below for further information).

 

The Company has unconditionally guaranteed the payment to the Lender promptly when due, by acceleration or otherwise, of all obligations of Kinpak to the Lender.

 

The Term Loan bears interest at an annual rate of 3.25% and is due in 119 monthly installments of $35,249 each, plus interest then accrued, beginning on August 20, 2021. The final installment shall be due and payable on July 20, 2031 in an amount equal to all principal and interest then remaining unpaid. Assuming that all amounts due prior to that date are paid in a timely manner, the final installment would be $1,977,047.

 

The Credit Agreement provides that prepayments on the Term Loan are subject to a prepayment penalty of 5% during the first year the Term Loan is outstanding, with such penalty declining 1% each year thereafter until there is no prepayment penalty after five years. However, the Lender has agreed to waive the prepayment provisions.

 

The Credit Agreement includes financial covenants requiring that the Company maintain a minimum fixed charge coverage ratio (generally, the ratio of (A) EBITDA for the most recently completed four fiscal quarters minus the sum of the Company’s distributions to its shareholders, taxes paid and unfunded capital expenditures during such period to (B) prior period current maturities of Company long term debt plus interest expense incurred over the most recently completed four fiscal quarters) of at least 1.20 to 1, tested quarterly, and a maximum “debt to cap” ratio (generally, funded debt divided by the sum of net worth and funded debt) of 0.75 to 1, as of the end of each fiscal quarter. For purposes of computing the fixed charge coverage ratio, “EBITDA” generally is defined as net income before taxes and depreciation expense plus amortization expense, plus interest expense, plus non-recurring and/or non-cash losses and expenses, minus non-recurring and/or non-cash gains and income. The Credit Agreement also requires that the majority shareholder’s ownership does not drop below 50% of the outstanding shares of Kinpak.

 

The Credit Agreement contains cross-default and cross-collateral provisions relating to any other indebtedness with the Lender, including without limitation the Company’s obligations under its $6,000,000 revolving line of credit from the Lender.

 

The Credit Agreement also contains negative covenants restricting the Company’s ability to, among other things, create or assume indebtedness for borrowed money exceeding $250,000 other than trade payables incurred in the normal course of business, create liens other than permitted liens (as defined in the Credit Agreement), acquire an interest in another entity or incur any obligation as surety or guarantor other than in the ordinary course of business.

 

Industrial Development Bond Financing

 

On September 26, 2017, Kinpak indirectly obtained a $4,500,000 loan from Regions Capital Advantage, Inc. (the “Lender”). The proceeds of the loan have been used in full as of June 30, 2021, principally to pay or reimburse costs relating to the expansion of Kinpak’s manufacturing, warehouse and distribution facilities in Montgomery, Alabama, as well as the purchase and installation of associated machinery and equipment (the “Expansion Project”).

 

9

 

 

The loan was funded by the Lender’s purchase of a $4,500,000 industrial development bond (the “Bond”) issued by The Industrial Development Board of the City of Montgomery, Alabama (the “IDB”). The Bond is a limited obligation of the IDB and is payable solely out of revenues and receipts derived from the leasing or sale of Kinpak’s facilities. In this regard, Kinpak is obligated to fund the IDB’s payment obligations by providing rental payments under a lease between the IDB and Kinpak (the “Lease”), under which Kinpak leases its facilities from the IDB. Kinpak inherited the lease structure when it first acquired its facilities from its predecessor-in-interest in 1996. The Lease provides that prior to the maturity date of the Bond, Kinpak may repurchase the facilities for $1,000 if the Bond has been redeemed or fully paid.

 

The Bond bears interest at the rate of 3.07% per annum, calculated on the basis of a 360-day year and the actual number of days elapsed (subject to increase to 6.07% per annum upon the occurrence of an event of default), and is payable in 118 monthly installments of $31,324 beginning on November 1, 2017 and ending on August 1, 2027, with a final principal and interest payment to be made on September 1, 2027. The amount of the final payment was originally scheduled to be $1,799,201, however at March 31, 2022 the final payment is scheduled to be $1,600,861 because the Company has made additional debt payments. The Bond provides that the interest rate will be subject to adjustment if it is determined by the United States Treasury Department, the Internal Revenue Service, or a similar government entity that the interest on the Bond is includable in the gross income of the Lender for federal income tax purposes.

 

Under the Lease, Kinpak is required to make rental payments for the account of the IDB to the Lender in such amounts and at such times as are necessary to enable the payment of all principal and interest due on the Bond and other charges, if any, payable in respect of the Bond. The Lease also provides that Kinpak may redeem the Bond, in whole or in part, by prepaying its rental payment obligations in an amount sufficient to effect the redemption. In addition, the Lease contains provisions relating to the Expansion Project, including limitations on utilization of Bond proceeds, deposit of unused proceeds into a custodial account (as described below) and investment of monies held in the custodial account.

 

Payment of amounts due and payable under the Bond and other related agreements are guaranteed by the Company and its other consolidated subsidiaries. In connection with the guarantee agreement under which the Company provided its guarantee, the Company is subject to certain covenants, including financial covenants requiring that the Company maintain (i) a minimum fixed charge ratio (generally, the ratio of (A) EBITDA minus the sum of Company’s distributions to its shareholders, taxes paid and unfunded capital expenditures to (B) current maturities of Company long-term debt plus interest expense) of 1.20 to 1, tested quarterly, and (ii) a ratio of funded debt (as defined in the guaranty agreement) divided by the sum of net worth and funded debt of 0.75 to 1, tested quarterly. For purposes of computing the fixed charge coverage ratio, “EBITDA” generally is defined as net income before taxes and depreciation expense plus amortization expense, plus interest expense, plus non-recurring and/or non-cash losses and expenses, minus non-recurring and/or non-cash gains and income; “unfunded capital expenditures” generally is defined as capital expenditures made from Company funds other than funds borrowed through term debt incurred to finance such capital expenditures. At March 31, 2022, the Company was in compliance with these financial covenants.

  

The Company incurred debt financing costs of $196,095 in connection with the financing. These costs are shown as a reduction of the debt balance and are being amortized over the life of the Bond.

 

Other Long-Term Obligations

 

In connection with the Company’s agreement to purchase assets of Snappy Marine, Inc. (“Snappy Marine”) on July 13, 2018, the Company provided to Snappy Marine a promissory note in the amount of $1,000,000, including interest (of the $1,000,000 amount of the promissory note, $930,528 was recorded as principal, and the remaining $69,472, representing an imputed interest rate of 2.87% per annum, is being recorded as interest expense over the term of the note). The note is payable in equal installments of $16,667 over a 60- month period that commenced on August 1, 2018, with a final payment due and payable on July 1, 2023. If the note is prepaid in full, the entire outstanding balance of the note (including all unpaid amounts allocated to interest over the remaining term of the note) must be paid.

 

On June 22, 2020, the Company entered into a lease agreement with Canon Solutions America, Inc. to lease office equipment. The lease obligates the Company to pay $100,009 in 63 equal monthly payments of $1,587. The lease is classified as a finance lease. The Company recorded a lease liability which is included in long term debt and a corresponding right to use asset that is included in property, plant and equipment of $96,039 based on a discount rate of 1.53%.

 

At March 31, 2022 and December 31, 2021, the Company was obligated under lease agreements covering office equipment utilized in the Company’s operations (inclusive of the lease referenced in the preceding paragraph). The office equipment leases, aggregating approximately $73,000 and $79,000 at March 31, 2022 and December 31, 2021, respectively, have maturities through 2025 and carry interest rates ranging from approximately 1.53% to 3.86% per annum. The office equipment leases are classified as finance leases. During the three months ended March 31, 2022 and 2021, the Company paid $5,687 ($5,350 principal and $337 interest) and $5,687 ($5,254 principal and $433 interest), respectively, under the lease agreements.

 

10

 

 

The following table provides information regarding the Company’s long-term debt at March 31, 2022 and December 31, 2021:

 

   Current Portion   Long Term Portion 
   March 31,
2022
   December 31,
2021
   March 31,
2022
   December 31,
2021
 
Term loan  $268,085   $265,918   $4,553,837   $4,622,204 
Obligations related to industrial development bond financing   279,585    276,036    2,940,566    3,057,773 
Note payable related to Snappy Marine asset acquisition   195,052    193,660    66,270    115,558 
Obligation related to Check Corporation asset acquisition        
-
    
-
    
-
 
Office equipment finance leases   21,655    21,554    51,841    57,292 
Total principal of long- term debt   764,377    757,168    7,612,514    7,852,827 
Debt issuance costs   (20,637)   (20,637)   (96,779)   (101,938)
Total long- term debt  $743,740   $736,531   $7,515,735   $7,750,889 

 

Required principal payments under the Company’s long- term obligations are set forth below:

 

Twelve-month period ending March 31,   
2023  $764,377 
2024   653,179 
2025   602,545 
2026   613,847 
2027   622,381 
Thereafter   5,120,562 
Total  $8,376,891 

 

8. RELATED PARTY TRANSACTIONS

 

The Company sells products to companies affiliated with Peter G. Dornau, who is the Company’s Chairman, President and Chief Executive Officer. The affiliated companies resell, outside of the United States and Canada, products they purchase from the Company. The Company also provides administrative services to these companies and pays certain business-related expenditures for the affiliated companies, for which the Company is reimbursed. Sales to the affiliated companies aggregated approximately $492,000 and $513,000 for the three months ended March 31, 2022 and 2021, respectively. Fees for administrative services aggregated approximately $188,000 and $168,000 for the three months ended March 31, 2022 and 2021, respectively. Amounts billed to the affiliated companies to reimburse the Company for business related expenditures made on behalf of the affiliated companies aggregated approximately $29,000 and $36,000 during the three months ended March 31, 2022 and 2021, respectively.  The Company had accounts receivable from the affiliated companies in connection with the product sales, administrative services and business- related expenditures aggregating approximately $847,000 and $1,212,000 at March 31, 2022 and December 31, 2021, respectively.

 

An entity that is owned by the Company’s Chairman, President and Chief Executive Officer provides several services to the Company.  Under this arrangement, the Company paid the entity an aggregate of approximately $35,000 ($12,000 for research and development services and $6,000 for charter boat services that the Company used to provide sales incentives to customers and $17,000 for the production of television commercials) and $23,000 ($12,000 for research and development services, $7,000 for charter boat services that the Company used to provide sales incentives for customers and $4,000 for the production of television commercials ) for the three months ended March 31, 2022 and 2021, respectively. Expenditures for the research and development services are included in the condensed consolidated statements of operations within selling and administrative expenses. Expenditures for the charter boat services are included in the condensed consolidated statements of operations within advertising and promotion expenses.

 

The Company leases office and warehouse facilities in Fort Lauderdale, Florida from an entity controlled by its Chairman, President and Chief Executive Officer. See Note 4 for a description of the lease terms.

 

A director of the Company is Regional Executive Vice President of an insurance broker through which the Company sources most of its insurance needs.  During the three months ended March 31, 2022 and 2021, the Company paid an aggregate of approximately $283,000 and $397,000, respectively, in insurance premiums on policies obtained through the insurance broker.

 

11

 

 

9. EARNINGS PER COMMON SHARE

 

The Company did not have any potentially dilutive securities during the three months ended March 31, 2022 and 2021. Therefore, the Company’s earnings per share are calculated by dividing net income by the weighted average number of shares outstanding during the reporting period.

 

   Three Months Ended
March 31,
 
   2022   2021 
        
         
Net income  $1,299,281   $1,904,269 
           
Weighted average number of common shares outstanding   9,509,670    9,481,799 
           
Earnings per common share  $0.14   $0.20 
           
           

 

10. SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS

 

No stock compensation expense was incurred during each of the three months ended March 31, 2022 and 2021, and at March 31, 2022, there were no outstanding stock options or unrecognized compensation expense related to stock options. 

 

11. CASH DIVIDENDS

 

On February 24, 2022, the Company’s Board of Directors declared a regular quarterly dividend of $0.04 per common share payable on March 25, 2022 to all shareholders of record on March 10, 2022. There were 9,509,799 shares of common stock outstanding on March 10, 2022; therefore, dividends aggregating $380,392 were paid on March 25, 2022.

 

On February 25, 2021, the Company’s Board of Directors declared a regular quarterly dividend of $0.03 per common share payable on March 25, 2021 to all shareholders of record on March 11, 2021. There were 9,481,799 shares of common stock outstanding on March 11, 2021; therefore, dividends aggregating $284,454 were paid on March 25, 2021.

 

12. CUSTOMER CONCENTRATION

 

During the three months ended March 31, 2022 and 2021, the Company had net sales to each of two customers that constituted in excess of 10% of its net sales. Net sales to these two customers represented approximately 38.7% (22.6% and 16.1%) and 43.2% (29.5% and 13.7%) of the Company’s net sales for the three months ended March 31, 2022 and 2021, respectively.

 

  At March 31, 2022 and December 31, 2021, three customers constituted at least 10% of the Company’s gross trade accounts receivable. The gross trade accounts receivable balances for these customers represented approximately 65.5% (26.9%, 24.9%, and 13.7%) and 60.1% (22.2%, 19.0%, and 18.9%) of the Company’s gross trade accounts receivable at March 31, 2022 and December 31, 2021, respectively.

 

12

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Forward-looking Statements:

 

Certain statements contained in this Quarterly Report on Form 10-Q, including without limitation, our ability to provide required capital to support inventory levels, the effect of price increases in raw materials that are petroleum or chemical based or commodity chemicals on our margins, and the sufficiency of funds provided through operations and existing sources of financing to satisfy our cash requirements constitute forward-looking statements. For this purpose, any statements contained in this report that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “believe,” “may,” “will,” “expect,” “anticipate,” “intend,” or “could,” including the negative or other variations thereof or comparable terminology, are intended to identify forward-looking statements. These statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those expressed or implied by such forward-looking statements. Factors that may affect these results include, but are not limited to, the impact of the COVID-19 pandemic on our business and the economy in general, the highly competitive nature of our industry; reliance on certain key customers; changes in consumer demand for marine, recreational vehicle and automotive products; expenditures on, and the effectiveness of our advertising and promotional efforts; adverse weather conditions; unanticipated litigation developments; exposure to market risks relating to changes in interest rates, foreign currency exchange rates and prices for raw materials that are petroleum or chemical based, availability in general of raw materials and other factors addressed in the sections entitled “Risk Factors” in Part I, Item 1A of our annual report on Form 10-K for the year ended December 31, 2021.

 

Overview:

 

We are engaged in the manufacture, marketing and distribution of a broad line of appearance, performance, and maintenance products for the marine, automotive, power sports, recreational vehicle and outdoor power equipment markets, under the Star brite® and other trademarks within the United States and Canada. In addition, we produce private label formulations of many of our products for various customers and provide custom blending and packaging services for these and other products.  We also manufacture, market and distribute chlorine dioxide-based deodorizing, disinfectant and sanitizing products. We sell our products through national retailers and to national and regional distributors. In addition, we sell products to two companies affiliated with Peter G. Dornau, our Chairman, President and Chief Executive Officer; these companies distribute the products outside of the United States and Canada.

 

Critical accounting estimates:

 

See “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Estimates” in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2021 for information regarding our critical accounting estimates.

 

Results of Operations:

 

Three Months Ended March 31, 2022 Compared to the Three Months Ended March 31, 2021

 

The following table provides a summary of our financial results for the three months ended March 31, 2022 and 2021:

 

   For The Three Months Ended March 31, 
           Percent   Percentage of Net Sales 
   2022   2021   Change   2022   2021 
Net sales  $12,737,329   $13,131,224    (3.0)%   100.0%   100.0%
Cost of goods sold   8,001,347    7,750,503    3.2%   62.8%   59.0%
Gross profit   4,735,982    5,380,721    (12.0)%   37.2%   41.0%
Advertising and promotion   1,071,579    941,814    13.8%   8.4%   7.2%
Selling and administrative   2,000,030    1,972,812    1.4%   15.7%   15.0%
Operating income   1,664,373    2,466,095    (32.5)%   13.1%   18.8%
Interest (expense), net   (31,682)   (37,187)   (14.8)%   0.2%   0.3%
Provision for income taxes   (333,410)   (524,639)   (36.4)%   2.6%   4.0%
Net income  $1,299,281   $1,904,269    (31.8)%   10.2%   14.5%

 

Net sales for the three months ended March 31, 2022 decreased by approximately $394,000, or 3.0%, as compared to the three months ended March 31, 2021. The three months ended March 31, 2021 benefitted from an unusually high amount of open orders at the end of 2020, which was caused by an increase in demand for marine products as the economy began to open from the pandemic.

 

Cost of goods sold increased by approximately $251,000, or 3.2%, during the three months ended March 31, 2022, as compared to the three months ended March 31, 2021. The increase was principally a result of the mix of sales, and increases in freight, raw materials and other manufacturing cost increases.

 

13

 

 

Gross profit decreased by approximately $645,000, or 12.0%, for the three months ended March 31, 2022, as compared to the three months ended March 31, 2021. Gross profit decreased due to the changes in net sales and cost of goods sold described above. As a percentage of net sales, gross profit was approximately 37.2% and 41.0% for the three months ended March 31, 2022 and 2021, respectively.

 

Advertising and promotion expenses increased by approximately $130,000, or 13.8%, during the three months ended March 31, 2022, as compared to the three months ended March 31, 2021. The increase in advertising and promotion expenses was principally a result of an increased focus on social media and digital marketing. As a percentage of net sales, advertising and promotion expenses increased to 8.4% for the three months ended March 31, 2022, from 7.2% for the three months ended March 31, 2021.  

 

Selling and administrative expenses increased by approximately $27,000, or 1.4%, during the three months ended March 31, 2022, as compared to the three months ended March 31, 2021. As a percentage of net sales, selling and administrative expenses increased to 15.7% for the three months ended March 31, 2022, from 15.0% for the three months ended March 31, 2021. 

 

Interest (expense), net for the three months ended March 31, 2022 decreased by approximately $6,000 or 14.8%, as compared to the three months ended March 31, 2021.

 

Provision for income taxes for the three months ended March 31, 2022 was approximately $333,000, or 20.4% of our income before income taxes. For the three months ended March 31, 2021 the provision was approximately $525,000, or 21.6% of our income before income taxes.  

 

Liquidity and capital resources:

 

Our cash balance was approximately $10,217,000 at March 31, 2022 and approximately $12,685,000 at December 31, 2021.

 

The following table summarizes our cash flows for the three months ended March 31, 2022 and 2021:

 

  

Three Months Ended

March 31,

 
   2022   2021 
Net cash (used in) provided by operating activities  $(238,837)  $1,207,802 
Net cash used in investing activities   (1,610,684)   (915,899)
Net cash used in financing activities   (619,141)   (414,546)
Effect of exchange rate fluctuations on cash   651    976 
Net decrease in cash and restricted cash  $(2,468,011)  $(121,667)

 

Net cash used in operating activities for the three months ended March 31, 2022 was approximately $238,000, as compared to net cash provided by operating activities of approximately $1,208,000 for the three months ended March 31, 2021. During the three months ended March 31, 2022, net income decreased by approximately $605,000, noncash adjustments to net income increased by approximately $295,000, and changes in working capital used approximately $1,137,000 more in cash, as compared to the three months ended March 31, 2021.

 

Net trade accounts receivable at March 31, 2022 aggregated approximately $10,261,000, an increase of approximately $717,000, or 7.5%, as compared to approximately $9,544,000 in net trade accounts receivable outstanding at December 31, 2021.  The increase was principally a result of our net sales during the first quarter of 2022. Receivables due from affiliated companies aggregated approximately $847,000 at March 31, 2022, a decrease of approximately $365,000, or 30.1%, from receivables due from affiliated companies of approximately $1,212,000 at December 31, 2021. The decrease was a result of payments received during the three months ended March 31, 2022.

 

Inventories, net were approximately $19,975,000 and $16,819,000 at March 31, 2022 and December 31, 2021, respectively, representing an increase of approximately $3,156,000, or 18.8%, during the three months ended March 31, 2022. We believe the higher levels of inventories were necessary in order to reduce potential supply chain problems and material price increases.

   

Net cash used in investing activities for the three months ended March 31, 2022 increased by approximately $695,000, or 75.9%, as compared to the three months ended March 31, 2021. The increase in cash used was principally to expand our manufacturing, warehouse and distribution facilities at Kinpak.

 

Net cash used in financing activities for the three months ended March 31, 2022 increased by approximately $205,000, or 49.4%, as compared to the three months ended March 31, 2021. During the three months ended March 31, 2022, the Company paid dividends to common shareholders aggregating approximately $380,000 and made payments on long term debt of approximately $233,000, as compared to dividends paid to common shareholders aggregating approximately $284,000 and payments on long term debt of approximately $130,000 during the three months ended March 31, 2021.

 

See Notes 6 and 7 to the condensed consolidated financial statements included in this report for information concerning our principal credit facilities, consisting of Kinpak’s obligations relating to a term loan, the payment of which we have guaranteed, an industrial development bond financing, the payment of which we have guaranteed, and a revolving line of credit. At March 31, 2022 and December 31, 2021, we had outstanding balances of approximately $4,822,000 and $4,888,000, respectively under Kinpak’s obligation relating to the term loan, $3,220,000 and $3,334,000, respectively, under Kinpak’s obligations relating to the industrial development bond financing, and no borrowings under our revolving credit facility.

 

14

 

 

The loan agreement pertaining to our revolving credit facility, as amended, has a stated term that expires on August 30, 2024, although as was the case with earlier revolving lines of credit provided to us in recent years, amounts outstanding are payable on demand. Nevertheless, the loan agreement pertaining to our revolving line of credit contains various covenants, including financial covenants that are described in Note 6 to the condensed consolidated financial statements included in this report.  At March 31, 2022, we were in compliance with these financial covenants. The revolving credit facility is subject to several events of default, including a decline of the majority shareholder’s ownership below 50% of our outstanding shares.

 

Our guarantee of Kinpak’s obligations related to the industrial development bond financing are subject to various covenants, including financial covenants that are described in Note 7 to the condensed consolidated financial statements included in this report. At March 31, 2022, we were in compliance with these financial covenants.

 

In connection with our acquisition of assets of Snappy Marine, we issued a promissory note in the amount of $1,000,000, including interest (of the $1,000,000 amount of the promissory note, $930,528 was recorded as principal, and the remaining $69,472, representing an imputed interest rate of 2.87% per annum, is being recorded as interest expense over the term of the note). At March 31, 2022, we had an outstanding balance of $266,666 under the promissory note (including $261,322 recorded as principal and $5,344 to be recorded as interest expense over the remaining term of the note).

 

We also obtained financing through leases for office equipment, totaling approximately $73,000 and $79,000 at March 31, 2022 and December 31, 2021, respectively.

 

Some of our assets and liabilities are denominated in Canadian dollars and are subject to currency exchange rate fluctuations. We do not engage in currency hedging and address currency risk as a pricing issue. For the three months ended March 31, 2022, we recorded $962 in foreign currency translation adjustments (increasing shareholders’ equity by $962).

 

During the past few years, we have introduced a number of new products.  At times, new product introductions have required us to increase our overall inventory and have resulted in lower inventory turnover rates.  The effects of reduced inventory turnover have not been material to our overall operations.  We believe that all required capital to maintain such increases will continue to be provided by operations and our current revolving line of credit or a renewal or replacement of the facility.

 

Many of the raw materials that we use in the manufacturing process are petroleum or chemical based and commodity chemicals that are subject to fluctuating prices. The nature of our business does not enable us to pass through the price increases to our national retailer customers and to our distributors as promptly as we experience increases in raw material costs. This may, at times, adversely affect our margins.

 

We believe that funds provided through operations and our revolving line of credit will be sufficient to satisfy our cash requirements over at least the next twelve months.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

Not applicable

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures:

 

The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company’s disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) at the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures as of the end of the period covered by this report are effective to provide reasonable assurance that the information required to be disclosed by the Company in reports filed under the Exchange Act are (i) recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and (ii) accumulated and communicated to the Company’s management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding the disclosure.

 

Change in Internal Controls over Financial Reporting:

 

No change in internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the Company’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

15

 

 

PART II - OTHER INFORMATION

 

Item 1A. Risk Factors

 

The business, results of operations, financial condition, cash flow, and stock price of the Company can be affected by a number of factors, whether currently known or unknown, including but not limited to those described in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2021 under the heading “Risk Factors,” any one or more of which could, directly or indirectly, cause the Company’s actual financial condition, operating results and cash flow to vary materially from past, or from anticipated future, financial condition operating results and cash flow.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

Period  Total Number of Shares Purchased   Weighted Average Price Paid per Share   Total Number of Shares Purchased as Part of Publicly Announced Program   Approximate Dollar Value of Shares that May Yet Be Purchased Under the Program (1) 
January 1 - January 31, 2022   600   $9.41    600   $2,955,243 
February 1 - February 28, 2022   -    -    -   $2,955,243 
March 1 - March 31, 2022   -    -    -   $2,955,243 
Total   600         600      

 

(1)Represents approximate dollar value of shares that could have been purchased under the plan in effect at the end of the month.

 

Item 6. Exhibits

 

Exhibit No.   Description
31.1     Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act.
31.2   Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act.
32.1   Certification of Chief Executive Officer pursuant to Rule 13a-14(b) under the Exchange Act and 18 U.S.C. Section 1350.
32.2   Certification of Chief Financial Officer pursuant to Rule 13a-14(b) under the Exchange Act and 18 U.S.C. Section 1350.
101.INS   XBRL Instance Document - The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH   Inline XBRL Taxonomy Extension Schema Document
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
104   Cover Page Interactive Data File––the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

 

16

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  OCEAN BIO-CHEM, INC.
   
Dated: May 16, 2022 /s/ Peter G. Dornau
  Peter G. Dornau
  Chairman of the Board, President and
  Chief Executive Officer
   
Dated: May 16, 2022 /s/ Jeffrey S. Barocas
  Jeffrey S. Barocas
  Vice President and
  Chief Financial Officer

 

 

17

 

 

In April 2022, the Company’s wholly owned subsidiary, KINPAK Inc. (“Kinpak”), placed into service assets relating to an expansion of its manufacturing and distribution facilities. false 954 --12-31 Q1 0000350737 587-6280 0000350737 2022-01-01 2022-03-31 0000350737 2022-05-13 0000350737 2022-03-31 0000350737 2021-12-31 0000350737 2021-01-01 2021-03-31 0000350737 us-gaap:CommonStockMember 2021-12-31 0000350737 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000350737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000350737 us-gaap:RetainedEarningsMember 2021-12-31 0000350737 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000350737 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000350737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0000350737 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000350737 us-gaap:CommonStockMember 2022-03-31 0000350737 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000350737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0000350737 us-gaap:RetainedEarningsMember 2022-03-31 0000350737 us-gaap:CommonStockMember 2020-12-31 0000350737 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000350737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000350737 us-gaap:RetainedEarningsMember 2020-12-31 0000350737 2020-12-31 0000350737 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000350737 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000350737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0000350737 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000350737 us-gaap:CommonStockMember 2021-03-31 0000350737 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000350737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0000350737 us-gaap:RetainedEarningsMember 2021-03-31 0000350737 2021-03-31 0000350737 us-gaap:LandMember 2022-03-31 0000350737 us-gaap:LandMember 2021-12-31 0000350737 us-gaap:BuildingImprovementsMember 2022-01-01 2022-03-31 0000350737 us-gaap:BuildingImprovementsMember 2022-03-31 0000350737 us-gaap:BuildingImprovementsMember 2021-12-31 0000350737 pf0:MinimumMember obci:ManufacturingAndWarehouseEquipmentMember 2022-01-01 2022-03-31 0000350737 pf0:MaximumMember obci:ManufacturingAndWarehouseEquipmentMember 2022-01-01 2022-03-31 0000350737 obci:ManufacturingAndWarehouseEquipmentMember 2022-01-01 2022-03-31 0000350737 obci:ManufacturingAndWarehouseEquipmentMember 2021-01-01 2021-12-31 0000350737 pf0:MinimumMember us-gaap:OfficeEquipmentMember 2022-01-01 2022-03-31 0000350737 pf0:MaximumMember us-gaap:OfficeEquipmentMember 2022-01-01 2022-03-31 0000350737 us-gaap:OfficeEquipmentMember 2022-03-31 0000350737 us-gaap:OfficeEquipmentMember 2021-12-31 0000350737 pf0:MinimumMember us-gaap:LeaseholdImprovementsMember 2022-01-01 2022-03-31 0000350737 pf0:MaximumMember us-gaap:LeaseholdImprovementsMember 2022-01-01 2022-03-31 0000350737 us-gaap:LeaseholdImprovementsMember 2022-03-31 0000350737 us-gaap:LeaseholdImprovementsMember 2021-12-31 0000350737 obci:FinanceLeasesMember 2022-01-01 2022-03-31 0000350737 obci:FinanceLeasesMember 2022-03-31 0000350737 obci:FinanceLeasesMember 2021-12-31 0000350737 us-gaap:VehiclesMember 2022-01-01 2022-03-31 0000350737 us-gaap:VehiclesMember 2021-01-01 2021-12-31 0000350737 us-gaap:ConstructionInProgressMember 2022-03-31 0000350737 us-gaap:ConstructionInProgressMember 2021-12-31 0000350737 us-gaap:PatentsMember 2022-03-31 0000350737 us-gaap:TrademarksAndTradeNamesMember 2022-03-31 0000350737 us-gaap:CustomerListsMember 2022-03-31 0000350737 obci:ProductFormulasMember 2022-03-31 0000350737 obci:RoyaltyRightsMember 2022-03-31 0000350737 us-gaap:PatentsMember 2021-12-31 0000350737 us-gaap:TrademarksAndTradeNamesMember 2021-12-31 0000350737 us-gaap:CustomerListsMember 2021-12-31 0000350737 obci:ProductFormulasMember 2021-12-31 0000350737 obci:RoyaltyRightsMember 2021-12-31 0000350737 2021-07-30 0000350737 2018-08-31 0000350737 obci:TermLoanMember 2021-07-20 0000350737 obci:TermLoanMember 2021-07-30 0000350737 obci:TermLoanMember 2022-01-01 2022-03-31 0000350737 pf0:MaximumMember obci:TermLoanMember 2022-01-01 2022-03-31 0000350737 pf0:MinimumMember obci:TermLoanMember 2022-01-01 2022-03-31 0000350737 obci:TermLoanMember 2022-03-31 0000350737 obci:IndustrialDevelopmentBondFinancingMember 2017-09-01 2017-09-26 0000350737 obci:IndustrialDevelopmentBondFinancingMember 2022-01-01 2022-03-31 0000350737 obci:IndustrialDevelopmentBondFinancingMember 2022-03-31 0000350737 obci:OtherLongTermObligationsMember 2022-01-01 2022-03-31 0000350737 obci:OtherLongTermObligationsMember obci:CanonSolutionsAmericaIncMember 2020-06-01 2020-06-22 0000350737 obci:OtherLongTermObligationsMember 2022-03-31 0000350737 obci:OtherLongTermObligationsMember 2021-12-31 0000350737 pf0:MinimumMember 2022-03-31 0000350737 pf0:MaximumMember 2022-03-31 0000350737 obci:TermLoanMember 2022-03-31 0000350737 obci:TermLoanMember 2021-12-31 0000350737 obci:ObligationsRelatedToIndustrialDevelopmentBondFinancingMember 2022-03-31 0000350737 obci:ObligationsRelatedToIndustrialDevelopmentBondFinancingMember 2021-12-31 0000350737 obci:NotePayableRelatedToAssetAcquisitionMember 2022-03-31 0000350737 obci:NotePayableRelatedToAssetAcquisitionMember 2021-12-31 0000350737 obci:ObligationRelatedToCheckCorporationAssetAcquisitionMember 2021-12-31 0000350737 obci:ObligationRelatedToCheckCorporationAssetAcquisitionMember 2022-03-31 0000350737 obci:OfficeEquipmentFinanceLeasesMember 2022-03-31 0000350737 obci:OfficeEquipmentFinanceLeasesMember 2021-12-31 0000350737 us-gaap:ServiceMember 2022-01-01 2022-03-31 0000350737 us-gaap:ServiceMember 2021-01-01 2021-03-31 0000350737 pf0:BoardOfDirectorsChairmanMember 2022-03-01 2022-03-25 0000350737 pf0:BoardOfDirectorsChairmanMember 2022-03-10 0000350737 pf0:BoardOfDirectorsChairmanMember 2021-03-01 2021-03-25 0000350737 pf0:BoardOfDirectorsChairmanMember 2021-03-11 0000350737 us-gaap:SalesRevenueNetMember 2022-01-01 2022-03-31 0000350737 us-gaap:SalesRevenueNetMember 2021-01-01 2021-03-31 0000350737 obci:CustomerOneMember us-gaap:SalesRevenueNetMember 2022-01-01 2022-03-31 0000350737 obci:CustomerTwoMember us-gaap:SalesRevenueNetMember 2022-01-01 2022-03-31 0000350737 obci:CustomerOneMember us-gaap:SalesRevenueNetMember 2021-01-01 2021-03-31 0000350737 obci:CustomerTwoMember us-gaap:SalesRevenueNetMember 2021-01-01 2021-03-31 0000350737 us-gaap:AccountsReceivableMember 2022-01-01 2022-03-31 0000350737 us-gaap:AccountsReceivableMember 2021-01-01 2021-12-31 0000350737 obci:CustomerOneMember us-gaap:AccountsReceivableMember 2022-01-01 2022-03-31 0000350737 obci:CustomerTwoMember us-gaap:AccountsReceivableMember 2022-01-01 2022-03-31 0000350737 obci:CustomerThreeMember us-gaap:AccountsReceivableMember 2022-01-01 2022-03-31 0000350737 obci:CustomerOneMember us-gaap:AccountsReceivableMember 2021-01-01 2021-12-31 0000350737 obci:CustomerTwoMember us-gaap:AccountsReceivableMember 2021-01-01 2021-12-31 0000350737 obci:CustomerThreeMember us-gaap:AccountsReceivableMember 2021-01-01 2021-12-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure utr:sqm
EX-31.1 2 f10q0322ex31-1_oceanbio.htm CERTIFICATION

EXHIBIT 31.1

 

CERTIFICATION

 

I, Peter G. Dornau certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Ocean Bio-Chem, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated:  May 16, 2022 By: /s/ Peter G. Dornau
    Peter G. Dornau
    Chairman of the Board, President and
    Chief Executive Officer

 

 

EX-31.2 3 f10q0322ex31-2_oceanbio.htm CERTIFICATION

EXHIBIT 31.2

 

CERTIFICATION

 

I, Jeffrey S. Barocas certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Ocean Bio-Chem, Inc;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated:  May 16, 2022 By: /s/ Jeffrey S. Barocas
    Jeffrey S. Barocas
    Vice President
    Chief Financial Officer

 

 

EX-32.1 4 f10q0322ex32-1_oceanbio.htm CERTIFICATION

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO RULE 13a-14(b)

UNDER THE SECURITIES EXCHANGE ACT AND 18 U.S.C. 1350

 

I, Peter G. Dornau, Chief Executive Officer of Ocean Bio-Chem, Inc. (the “Company”), hereby certify that, based on my knowledge:

 

  1.

The Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

 

  

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Dated:  May 16, 2022 By: /s/ Peter G. Dornau
    Peter G. Dornau
    Chairman of the Board, President and
   

Chief Executive Officer 

 

 

EX-32.2 5 f10q0322ex32-2_oceanbio.htm CERTIFICATION

EXHIBIT 32.2

 

CERTIFICATION PURSUANT TO RULE 13a-14(b)

UNDER THE SECURITIES EXCHANGE ACT AND 18 U.S.C. 1350

 

I, Jeffrey S. Barocas, Chief Financial Officer of Ocean Bio-Chem, Inc. (the “Company”), hereby certify that, based on my knowledge:

 

  1.

The Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

     
  2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Dated:  May 16, 2022 By: /s/ Jeffrey S. Barocas
    Jeffrey S. Barocas
    Vice President
   

Chief Financial Officer 

 

EX-101.SCH 6 obci-20220331.xsd XBRL SCHEMA FILE 001 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Condensed Consolidated Statements of Shareholders’ Equity (Unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Summary of Accounting Policies link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Inventories link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Property, Plant & Equipment link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Leases link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Intangible Assets link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Revolving Line of Credit link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Long Term Debt link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Earnings Per Common Share link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Securities Authorized for Issuance under Equity Compensation Plans link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Cash Dividends link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Customer Concentration link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Inventories (Tables) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Property, Plant & Equipment (Tables) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Leases (Tables) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Intangible Assets (Tables) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Long Term Debt (Tables) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Earnings Per Common Share (Tables) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Inventories (Details) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Inventories (Details) - Schedule of inventories link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Property, Plant & Equipment (Details) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Property, Plant & Equipment (Details) - Schedule of property, plant and equipment link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Leases (Details) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Leases (Details) - Schedule of future minimum rent payments link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Leases (Details) - Schedule of expenses incurred with respect to the company's leases link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Leases (Details) - Schedule of finance leases and discount rate with respect to the operating lease and finance leases link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - Intangible Assets (Details) link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - Intangible Assets (Details) - Schedule of intangible assets link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - Revolving Line of Credit (Details) link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - Long Term Debt (Details) link:presentationLink link:definitionLink link:calculationLink 038 - Disclosure - Long Term Debt (Details) - Schedule of long-term debt link:presentationLink link:definitionLink link:calculationLink 039 - Disclosure - Long Term Debt (Details) - Schedule of long- term obligation link:presentationLink link:definitionLink link:calculationLink 040 - Disclosure - Related Party Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 041 - Disclosure - Earnings Per Common Share (Details) - Schedule of weighted average number of shares outstanding link:presentationLink link:definitionLink link:calculationLink 042 - Disclosure - Cash Dividends (Details) link:presentationLink link:definitionLink link:calculationLink 043 - Disclosure - Customer Concentration (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 obci-20220331_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 obci-20220331_def.xml XBRL DEFINITION FILE EX-101.LAB 9 obci-20220331_lab.xml XBRL LABEL FILE EX-101.PRE 10 obci-20220331_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document And Entity Information - shares
3 Months Ended
Mar. 31, 2022
May 13, 2022
Document Information Line Items    
Entity Registrant Name OCEAN BIO-CHEM, INC  
Trading Symbol OBCI  
Document Type 10-Q  
Current Fiscal Year End Date --12-31  
Entity Common Stock, Shares Outstanding   9,509,799
Amendment Flag false  
Entity Central Index Key 0000350737  
Entity Current Reporting Status Yes  
Entity Filer Category Non-accelerated Filer  
Document Period End Date Mar. 31, 2022  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q1  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Document Quarterly Report true  
Document Transition Report false  
Entity File Number 0-11102  
Entity Incorporation, State or Country Code FL  
Entity Tax Identification Number 59-1564329  
Entity Address, Address Line One 4041 SW  
Entity Address, Address Line Two 47 Avenue  
Entity Address, City or Town Fort Lauderdale  
Entity Address, State or Province FL  
Entity Address, Postal Zip Code 33314  
Title of 12(b) Security Common Stock, $0.01 par value  
Security Exchange Name NASDAQ  
Entity Interactive Data Current Yes  
City Area Code 954  
Local Phone Number 587-6280  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Current Assets:    
Cash $ 10,216,924 $ 12,684,935
Trade accounts receivable less allowances of approximately $712,000 and $632,000, respectively 10,261,547 9,544,133
Receivables due from affiliated companies 847,026 1,211,999
Inventories, net 19,974,898 16,819,253
Prepaid expenses and other current assets 1,585,477 2,093,971
Total Current Assets 42,885,872 42,354,291
Property, plant and equipment, net 17,642,008 16,360,218
Operating lease – right to use 160,449 182,543
Intangible assets, net 1,309,683 1,380,652
Total Assets 61,998,012 60,277,704
Current Liabilities:    
Current portion of long-term debt, net 743,740 736,531
Current portion of operating lease liability 90,424 89,600
Accounts payable - trade 3,376,982 2,877,623
Income taxes payable 208,342 45,295
Accrued expenses payable 1,120,234 900,982
Total Current Liabilities 5,539,722 4,650,031
Deferred tax liability 453,086 347,723
Operating lease liability, less current portion 70,025 92,943
Long-term debt, less current portion and debt issuance costs 7,515,735 7,750,889
Total Liabilities 13,578,568 12,841,586
COMMITMENTS AND CONTINGENCIES
Shareholders’ Equity:    
Common stock - $0.01 par value, 12,000,000 shares authorized; 9,509,799 shares and 9,503,999 shares issued and outstanding, respectively 95,098 95,040
Additional paid in capital 11,141,123 11,077,706
Accumulated other comprehensive loss (291,374) (292,336)
Retained earnings 37,474,597 36,555,708
Total Shareholders’ Equity 48,419,444 47,436,118
Total Liabilities and Shareholders’ Equity $ 61,998,012 $ 60,277,704
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Balance Sheets (Parentheticals) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Trade accounts receivable allowance for doubtful accounts (in Dollars) $ 712,000 $ 632,000
Common stock, par value (in Dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized 12,000,000 12,000,000
Common stock, shares issued 9,509,799 9,503,999
Common stock, shares outstanding 9,509,799 9,503,999
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Income Statement [Abstract]    
Net sales $ 12,737,329 $ 13,131,224
Cost of goods sold 8,001,347 7,750,503
Gross profit 4,735,982 5,380,721
Operating Expenses:    
Advertising and promotion 1,071,579 941,814
Selling and administrative 2,000,030 1,972,812
Total operating expenses 3,071,609 2,914,626
Operating income 1,664,373 2,466,095
Other (expense) income    
Interest (expense), net (31,682) (37,187)
Income before income taxes 1,632,691 2,428,908
Provision for income taxes (333,410) (524,639)
Net income $ 1,299,281 $ 1,904,269
Earnings per common share (in Dollars per share) $ 0.14 $ 0.2
Dividends declared per common share (in Dollars per share) $ 0.04 $ 0.03
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Statement of Comprehensive Income [Abstract]    
Net income $ 1,299,281 $ 1,904,269
Foreign currency translation adjustment 962 (596)
Comprehensive income $ 1,300,243 $ 1,903,673
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Shareholders’ Equity (Unaudited) - USD ($)
Common Stock
Additional Paid In Capital
Accumulated Other Comprehensive Loss
Retained Earnings
Total
Balance at Dec. 31, 2020 $ 94,818 $ 10,816,100 $ (294,324) $ 29,290,477 $ 39,907,071
Balance (in Shares) at Dec. 31, 2020 9,481,799        
Net income 1,904,269 1,904,269
Dividends, common stock (284,454) (284,454)
Foreign currency translation adjustment (596) (596)
Balance at Mar. 31, 2021 $ 94,818 10,816,100 (294,920) 30,910,292 41,526,290
Balance (in Shares) at Mar. 31, 2021 9,481,799        
Balance at Dec. 31, 2021 $ 95,040 11,077,706 (292,336) 36,555,708 47,436,118
Balance (in Shares) at Dec. 31, 2021 9,503,999        
Net income 1,299,281 1,299,281
Dividends, common stock (380,392) (380,392)
Common stock repurchased and retired $ (6) (5,639) (5,645)
Common stock repurchased and retired (in Shares) (600)        
Portion of 2021 stock based compensation for shares issued in 2022 $ 64 69,056 69,120
Portion of 2021 stock based compensation for shares issued in 2022 (in Shares) 6,400        
Foreign currency translation adjustment 962 962
Balance at Mar. 31, 2022 $ 95,098 $ 11,141,123 $ (291,374) $ 37,474,597 $ 48,419,444
Balance (in Shares) at Mar. 31, 2022 9,509,799        
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Cash flows from operating activities:    
Net income $ 1,299,281 $ 1,904,269
Adjustments to reconcile net income to net cash (used in) provided by operating activities:    
Depreciation and amortization 405,022 357,594
Deferred income taxes 105,363 (88,566)
Provision for bad debts 80,003 88,289
Provision for slow moving and obsolete inventory 70,049 9,756
Other operating non-cash items 311 (1,572)
Changes in assets and liabilities:    
Trade accounts receivable (797,417) (2,110,546)
Receivables due from affiliated companies 364,973 358,826
Inventories (3,225,694) (1,068,795)
Prepaid expenses and other current assets 508,494 (162,596)
Accounts payable – trade 499,359 1,174,548
Income taxes payable 163,047 576,626
Accrued expenses payable 288,372 169,969
Net cash (used in) provided by operating activities (238,837) 1,207,802
Cash flows from investing activities:    
Purchases of property, plant and equipment (1,610,684) (915,899)
Net cash used in investing activities (1,610,684) (915,899)
Cash flows from financing activities:    
Payments on long-term debt (233,104) (130,092)
Dividends paid to common shareholders (380,392) (284,454)
Repurchase of common stock (5,645)
Net cash used in financing activities (619,141) (414,546)
Effect of exchange rate on cash 651 976
Net decrease in cash and restricted cash (2,468,011) (121,667)
Cash and restricted cash at beginning of period 12,684,935 11,601,152
Cash and restricted cash at end of period 10,216,924 11,479,485
Supplemental disclosure of cash flow information:    
Cash paid for interest during period 28,786 32,606
Cash paid for income taxes during period 65,000
Cash paid under operating lease 23,700 23,700
Cash 10,216,924 11,161,761
Restricted cash 317,724
Total cash and restricted cash $ 10,216,924 $ 11,479,485
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Accounting Policies
3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
SUMMARY OF ACCOUNTING POLICIES

1. SUMMARY OF ACCOUNTING POLICIES

 

Interim reporting

 

The accompanying unaudited condensed consolidated financial statements include the accounts of Ocean Bio-Chem, Inc. and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. Unless the context indicates otherwise, the term “Company” refers to Ocean Bio-Chem, Inc. and its subsidiaries.

 

The unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Securities and Exchange Commission Regulation S-X.  Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements.

 

The financial information furnished herein reflects all adjustments, consisting of normal recurring items that, in the opinion of management, are necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the interim periods. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022.

 

The information included in this Form 10-Q should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

 

Use of estimates

 

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and assumptions.

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.1
Inventories
3 Months Ended
Mar. 31, 2022
Inventory Disclosure [Abstract]  
INVENTORIES

2. INVENTORIES

 

The Company’s inventories at March 31, 2022 and December 31, 2021 consisted of the following:

 

  

March 31,

2022

  

December 31,

2021

 
Raw materials  $8,745,696   $7,465,011 
Finished goods   11,552,825    9,669,073 
Inventories, gross   20,298,521    17,134,084 
           
Inventory reserves   (323,623)   (314,831)
           
Inventories, net  $19,974,898   $16,819,253 

 

The inventory reserves shown in the table above reflect slow moving and obsolete inventory.

 

The Company operates a vendor managed inventory program with one of its customers to improve the promotion of the Company’s products. The Company manages the inventory levels at this customer’s warehouses and recognizes revenue as the products are sold by the customer. The inventories managed at the customer’s warehouses, which are included in inventories, net, amounted to approximately $987,000 and $1,051,000 at March 31, 2022 and December 31, 2021, respectively.

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.1
Property, Plant & Equipment
3 Months Ended
Mar. 31, 2022
Property, Plant and Equipment [Abstract]  
PROPERTY, PLANT & EQUIPMENT

3. PROPERTY, PLANT & EQUIPMENT

 

The Company’s property, plant and equipment at March 31, 2022 and December 31, 2021 consisted of the following:

 

  

Estimated

Useful Life

  March 31,
2022
  

December 31,

2021

 
            
Land     $278,325   $278,325 
Building and improvements  30 years   15,180,235    9,710,244 
Manufacturing and warehouse equipment  6-20 years   13,577,478    12,858,638 
Office equipment and furniture  3-5 years   1,941,521    1,805,002 
Leasehold improvements  10-15 years   621,903    587,183 
Finance leases – right to use  5 years   113,741    113,741 
Vehicles  3 years   10,020    10,020 
Construction in process (1)      1,883,726    6,633,112 
 Property, plant and equipment, gross      33,606,949    31,996,265 
              
Less accumulated depreciation      (15,964,941)   (15,636,047)
              
Property, plant and equipment, net     $17,642,008   $16,360,218 

 

(1)In April 2022, the Company’s wholly owned subsidiary, KINPAK Inc. (“Kinpak”), placed into service assets relating to an expansion of its manufacturing and distribution facilities.

 

Depreciation expense totaled $328,893 (of which $303,992 is included in cost of goods sold and $24,901 is included in selling and administrative expenses) and $281,529 (of which $257,140 is included in cost of goods sold and $24,389 is included in selling and administrative expenses) for the three months ended March 31, 2022 and 2021, respectively.

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.1
Leases
3 Months Ended
Mar. 31, 2022
Leases [Abstract]  
LEASES

4. LEASES

 

The Company has one operating lease and two finance leases.

 

Under the operating lease, the Company leases its executive offices and warehouse facilities in Fort Lauderdale, Florida from an entity controlled by Peter G. Dornau, the Company’s Chairman, President and Chief Executive Officer. The lease, as extended, expires on December 31, 2023. The lease requires an annual minimum base rent of $94,800 and provides for a maximum annual 2% increase in subsequent years, although the entity has not raised the minimum base rent since the Company entered into a previous lease agreement in 1998. Additionally, the leasing entity is entitled to reimbursement of all taxes, assessments, and any other expenses that arise from ownership. Each of the parties to the lease has agreed to review the terms of the lease every three years at the request of the other party. Operating lease expense was $24,553 and $24,339 for the three months ended March 31, 2022 and 2021, respectively. At March 31, 2022 and December 31, 2021, the Company had a right to use asset and a corresponding liability of $160,449 and $182,543, respectively, related to the operating lease. Set forth below is a schedule of future minimum rent payments under the operating lease.

 

Twelve-month period ending March 31,
2023  $94,800 
2024   71,100 
Total future minimum lease payments   165,900 
Less imputed interest   (5,451)
Total operating lease liability  $160,449 

 

The Company’s two finance leases relate to office equipment. See Note 3 for information regarding the carrying value of the Company’s finance lease right to use assets and Note 7 for information regarding the finance lease payment schedule.

 

Expenses incurred with respect to the Company’s leases during the three months ended March 31, 2022 and 2021 are set forth below.

 

   Three
Months
Ended
March 31,
2022
  

Three

Months

Ended
March 31,
2021

 
Operating lease expense  $24,553   $24,339 
Finance lease amortization   5,350    5,254 
Finance lease interest   337    433 
Total lease expense  $30,240   $30,026 

 

The remaining lease term with respect to the operating lease, weighted average remaining lease term with respect to the finance leases and discount rate with respect to the operating lease and finance leases at March 31, 2022 and December 31, 2021 are set forth below:

 

   March 31,
2022
 
Remaining lease term – operating lease   1.75 years 
Weighted average remaining lease term – finance leases   3.4 years 
Discount rate – operating lease   3.7%
Weighted average discount rate – finance leases   1.8%

 

   December 31,
2021
 
Remaining lease term – operating lease   2.0 years 
Weighted average remaining lease term – finance leases   3.7 years 
Discount rate – operating lease   3.7%
Weighted average discount rate – finance leases   1.8%
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.1
Intangible Assets
3 Months Ended
Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
INTANGIBLE ASSETS

5. INTANGIBLE ASSETS

 

The Company’s intangible assets at March 31, 2022 and December 31, 2021 consisted of the following:

 

March 31, 2022

 

Intangible Assets  Cost   Accumulated
Amortization
   Net 
Patents  $622,733   $609,871   $12,862 
Trade names and trademarks   1,715,325    675,195    1,040,130 
Customer list   584,468    416,328    168,140 
Product formulas   292,234    208,168    84,066 
Royalty rights   160,000    155,515    4,485 
Total intangible assets  $3,374,760   $2,065,077   $1,309,683 

 

December 31, 2021

 

Intangible Assets  Cost   Accumulated
Amortization
   Net 
Patents  $622,733   $596,980   $25,753 
Trade names and trademarks   1,715,325    665,440    1,049,885 
Customer list   584,468    387,105    197,363 
Product formulas   292,234    193,554    98,680 
Royalty rights   160,000    151,029    8,971 
Total intangible assets  $3,374,760   $1,994,108   $1,380,652 

 

Amortization expense related to intangible assets was $70,969 and $71,161 for the three months ended March 31, 2022 and 2021, respectively.

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.1
Revolving Line of Credit
3 Months Ended
Mar. 31, 2022
Revolving Line of Credit [Abstract]  
REVOLVING LINE OF CREDIT

6. REVOLVING LINE OF CREDIT

 

On August 6, 2021, the Company and Regions Bank (“the “Lender”) entered into a Business Loan Agreement (the “Business Loan Agreement”), effective as of July 30, 2021, under which the Company was provided a revolving line of credit in the amount of Six Million Dollars ($6,000,000). The Business Loan Agreement supersedes the Company’s previous $6,000,000 revolving line of credit from the Lender, entered into on August 31, 2018, that was scheduled to expire on August 31, 2021. The revolving line of credit under the Business Loan Agreement is evidenced by a promissory note and is secured principally by the Company’s inventory and accounts receivable.

 

The Business Loan Agreement bears interest at a variable annual rate of LIBOR plus 1.35%, computed on a 365/360 basis. All outstanding principal plus all accrued unpaid interest is due upon Lender’s demand or when the Business Loan Agreement expires on August 30, 2024.

 

There has been no negative impact in the availability of funds to the Company as a result of the COVID-19 pandemic.

 

At March 31, 2022 and December 31, 2021, the Company had no borrowings under the revolving line of credit provided by the current and former Business Loan Agreements.

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.1
Long Term Debt
3 Months Ended
Mar. 31, 2022
Debt Disclosure [Abstract]  
LONG TERM DEBT

7. LONG TERM DEBT

 

Term Loan

 

On July 30, 2021, Kinpak  and Regions Bank (the “Lender”) entered into a Credit Agreement (the “Credit Agreement”), effective as of July 20, 2021, under which the Company was extended a term loan (the “Term Loan”) in the original principal amount of Five Million Dollars ($5,000,000). The Company is using the proceeds of the Term Loan for a 69,000 square foot expansion of Kinpak’s manufacturing, warehouse and distribution facilities in Montgomery, Alabama. The Term Loan is evidenced by a promissory note (the “Note”) and is secured by a second priority mortgage of the assets pledged in Kinpak’s industrial development bond financing obtained on September 26, 2017 (see below for further information).

 

The Company has unconditionally guaranteed the payment to the Lender promptly when due, by acceleration or otherwise, of all obligations of Kinpak to the Lender.

 

The Term Loan bears interest at an annual rate of 3.25% and is due in 119 monthly installments of $35,249 each, plus interest then accrued, beginning on August 20, 2021. The final installment shall be due and payable on July 20, 2031 in an amount equal to all principal and interest then remaining unpaid. Assuming that all amounts due prior to that date are paid in a timely manner, the final installment would be $1,977,047.

 

The Credit Agreement provides that prepayments on the Term Loan are subject to a prepayment penalty of 5% during the first year the Term Loan is outstanding, with such penalty declining 1% each year thereafter until there is no prepayment penalty after five years. However, the Lender has agreed to waive the prepayment provisions.

 

The Credit Agreement includes financial covenants requiring that the Company maintain a minimum fixed charge coverage ratio (generally, the ratio of (A) EBITDA for the most recently completed four fiscal quarters minus the sum of the Company’s distributions to its shareholders, taxes paid and unfunded capital expenditures during such period to (B) prior period current maturities of Company long term debt plus interest expense incurred over the most recently completed four fiscal quarters) of at least 1.20 to 1, tested quarterly, and a maximum “debt to cap” ratio (generally, funded debt divided by the sum of net worth and funded debt) of 0.75 to 1, as of the end of each fiscal quarter. For purposes of computing the fixed charge coverage ratio, “EBITDA” generally is defined as net income before taxes and depreciation expense plus amortization expense, plus interest expense, plus non-recurring and/or non-cash losses and expenses, minus non-recurring and/or non-cash gains and income. The Credit Agreement also requires that the majority shareholder’s ownership does not drop below 50% of the outstanding shares of Kinpak.

 

The Credit Agreement contains cross-default and cross-collateral provisions relating to any other indebtedness with the Lender, including without limitation the Company’s obligations under its $6,000,000 revolving line of credit from the Lender.

 

The Credit Agreement also contains negative covenants restricting the Company’s ability to, among other things, create or assume indebtedness for borrowed money exceeding $250,000 other than trade payables incurred in the normal course of business, create liens other than permitted liens (as defined in the Credit Agreement), acquire an interest in another entity or incur any obligation as surety or guarantor other than in the ordinary course of business.

 

Industrial Development Bond Financing

 

On September 26, 2017, Kinpak indirectly obtained a $4,500,000 loan from Regions Capital Advantage, Inc. (the “Lender”). The proceeds of the loan have been used in full as of June 30, 2021, principally to pay or reimburse costs relating to the expansion of Kinpak’s manufacturing, warehouse and distribution facilities in Montgomery, Alabama, as well as the purchase and installation of associated machinery and equipment (the “Expansion Project”).

 

The loan was funded by the Lender’s purchase of a $4,500,000 industrial development bond (the “Bond”) issued by The Industrial Development Board of the City of Montgomery, Alabama (the “IDB”). The Bond is a limited obligation of the IDB and is payable solely out of revenues and receipts derived from the leasing or sale of Kinpak’s facilities. In this regard, Kinpak is obligated to fund the IDB’s payment obligations by providing rental payments under a lease between the IDB and Kinpak (the “Lease”), under which Kinpak leases its facilities from the IDB. Kinpak inherited the lease structure when it first acquired its facilities from its predecessor-in-interest in 1996. The Lease provides that prior to the maturity date of the Bond, Kinpak may repurchase the facilities for $1,000 if the Bond has been redeemed or fully paid.

 

The Bond bears interest at the rate of 3.07% per annum, calculated on the basis of a 360-day year and the actual number of days elapsed (subject to increase to 6.07% per annum upon the occurrence of an event of default), and is payable in 118 monthly installments of $31,324 beginning on November 1, 2017 and ending on August 1, 2027, with a final principal and interest payment to be made on September 1, 2027. The amount of the final payment was originally scheduled to be $1,799,201, however at March 31, 2022 the final payment is scheduled to be $1,600,861 because the Company has made additional debt payments. The Bond provides that the interest rate will be subject to adjustment if it is determined by the United States Treasury Department, the Internal Revenue Service, or a similar government entity that the interest on the Bond is includable in the gross income of the Lender for federal income tax purposes.

 

Under the Lease, Kinpak is required to make rental payments for the account of the IDB to the Lender in such amounts and at such times as are necessary to enable the payment of all principal and interest due on the Bond and other charges, if any, payable in respect of the Bond. The Lease also provides that Kinpak may redeem the Bond, in whole or in part, by prepaying its rental payment obligations in an amount sufficient to effect the redemption. In addition, the Lease contains provisions relating to the Expansion Project, including limitations on utilization of Bond proceeds, deposit of unused proceeds into a custodial account (as described below) and investment of monies held in the custodial account.

 

Payment of amounts due and payable under the Bond and other related agreements are guaranteed by the Company and its other consolidated subsidiaries. In connection with the guarantee agreement under which the Company provided its guarantee, the Company is subject to certain covenants, including financial covenants requiring that the Company maintain (i) a minimum fixed charge ratio (generally, the ratio of (A) EBITDA minus the sum of Company’s distributions to its shareholders, taxes paid and unfunded capital expenditures to (B) current maturities of Company long-term debt plus interest expense) of 1.20 to 1, tested quarterly, and (ii) a ratio of funded debt (as defined in the guaranty agreement) divided by the sum of net worth and funded debt of 0.75 to 1, tested quarterly. For purposes of computing the fixed charge coverage ratio, “EBITDA” generally is defined as net income before taxes and depreciation expense plus amortization expense, plus interest expense, plus non-recurring and/or non-cash losses and expenses, minus non-recurring and/or non-cash gains and income; “unfunded capital expenditures” generally is defined as capital expenditures made from Company funds other than funds borrowed through term debt incurred to finance such capital expenditures. At March 31, 2022, the Company was in compliance with these financial covenants.

  

The Company incurred debt financing costs of $196,095 in connection with the financing. These costs are shown as a reduction of the debt balance and are being amortized over the life of the Bond.

 

Other Long-Term Obligations

 

In connection with the Company’s agreement to purchase assets of Snappy Marine, Inc. (“Snappy Marine”) on July 13, 2018, the Company provided to Snappy Marine a promissory note in the amount of $1,000,000, including interest (of the $1,000,000 amount of the promissory note, $930,528 was recorded as principal, and the remaining $69,472, representing an imputed interest rate of 2.87% per annum, is being recorded as interest expense over the term of the note). The note is payable in equal installments of $16,667 over a 60- month period that commenced on August 1, 2018, with a final payment due and payable on July 1, 2023. If the note is prepaid in full, the entire outstanding balance of the note (including all unpaid amounts allocated to interest over the remaining term of the note) must be paid.

 

On June 22, 2020, the Company entered into a lease agreement with Canon Solutions America, Inc. to lease office equipment. The lease obligates the Company to pay $100,009 in 63 equal monthly payments of $1,587. The lease is classified as a finance lease. The Company recorded a lease liability which is included in long term debt and a corresponding right to use asset that is included in property, plant and equipment of $96,039 based on a discount rate of 1.53%.

 

At March 31, 2022 and December 31, 2021, the Company was obligated under lease agreements covering office equipment utilized in the Company’s operations (inclusive of the lease referenced in the preceding paragraph). The office equipment leases, aggregating approximately $73,000 and $79,000 at March 31, 2022 and December 31, 2021, respectively, have maturities through 2025 and carry interest rates ranging from approximately 1.53% to 3.86% per annum. The office equipment leases are classified as finance leases. During the three months ended March 31, 2022 and 2021, the Company paid $5,687 ($5,350 principal and $337 interest) and $5,687 ($5,254 principal and $433 interest), respectively, under the lease agreements.

 

The following table provides information regarding the Company’s long-term debt at March 31, 2022 and December 31, 2021:

 

   Current Portion   Long Term Portion 
   March 31,
2022
   December 31,
2021
   March 31,
2022
   December 31,
2021
 
Term loan  $268,085   $265,918   $4,553,837   $4,622,204 
Obligations related to industrial development bond financing   279,585    276,036    2,940,566    3,057,773 
Note payable related to Snappy Marine asset acquisition   195,052    193,660    66,270    115,558 
Obligation related to Check Corporation asset acquisition        
-
    
-
    
-
 
Office equipment finance leases   21,655    21,554    51,841    57,292 
Total principal of long- term debt   764,377    757,168    7,612,514    7,852,827 
Debt issuance costs   (20,637)   (20,637)   (96,779)   (101,938)
Total long- term debt  $743,740   $736,531   $7,515,735   $7,750,889 

 

Required principal payments under the Company’s long- term obligations are set forth below:

 

Twelve-month period ending March 31,   
2023  $764,377 
2024   653,179 
2025   602,545 
2026   613,847 
2027   622,381 
Thereafter   5,120,562 
Total  $8,376,891 
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.1
Related Party Transactions
3 Months Ended
Mar. 31, 2022
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

8. RELATED PARTY TRANSACTIONS

 

The Company sells products to companies affiliated with Peter G. Dornau, who is the Company’s Chairman, President and Chief Executive Officer. The affiliated companies resell, outside of the United States and Canada, products they purchase from the Company. The Company also provides administrative services to these companies and pays certain business-related expenditures for the affiliated companies, for which the Company is reimbursed. Sales to the affiliated companies aggregated approximately $492,000 and $513,000 for the three months ended March 31, 2022 and 2021, respectively. Fees for administrative services aggregated approximately $188,000 and $168,000 for the three months ended March 31, 2022 and 2021, respectively. Amounts billed to the affiliated companies to reimburse the Company for business related expenditures made on behalf of the affiliated companies aggregated approximately $29,000 and $36,000 during the three months ended March 31, 2022 and 2021, respectively.  The Company had accounts receivable from the affiliated companies in connection with the product sales, administrative services and business- related expenditures aggregating approximately $847,000 and $1,212,000 at March 31, 2022 and December 31, 2021, respectively.

 

An entity that is owned by the Company’s Chairman, President and Chief Executive Officer provides several services to the Company.  Under this arrangement, the Company paid the entity an aggregate of approximately $35,000 ($12,000 for research and development services and $6,000 for charter boat services that the Company used to provide sales incentives to customers and $17,000 for the production of television commercials) and $23,000 ($12,000 for research and development services, $7,000 for charter boat services that the Company used to provide sales incentives for customers and $4,000 for the production of television commercials ) for the three months ended March 31, 2022 and 2021, respectively. Expenditures for the research and development services are included in the condensed consolidated statements of operations within selling and administrative expenses. Expenditures for the charter boat services are included in the condensed consolidated statements of operations within advertising and promotion expenses.

 

The Company leases office and warehouse facilities in Fort Lauderdale, Florida from an entity controlled by its Chairman, President and Chief Executive Officer. See Note 4 for a description of the lease terms.

 

A director of the Company is Regional Executive Vice President of an insurance broker through which the Company sources most of its insurance needs.  During the three months ended March 31, 2022 and 2021, the Company paid an aggregate of approximately $283,000 and $397,000, respectively, in insurance premiums on policies obtained through the insurance broker.

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.1
Earnings Per Common Share
3 Months Ended
Mar. 31, 2022
Earnings Per Share [Abstract]  
EARNINGS PER COMMON SHARE

9. EARNINGS PER COMMON SHARE

 

The Company did not have any potentially dilutive securities during the three months ended March 31, 2022 and 2021. Therefore, the Company’s earnings per share are calculated by dividing net income by the weighted average number of shares outstanding during the reporting period.

 

   Three Months Ended
March 31,
 
   2022   2021 
        
         
Net income  $1,299,281   $1,904,269 
           
Weighted average number of common shares outstanding   9,509,670    9,481,799 
           
Earnings per common share  $0.14   $0.20 
           
           
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.1
Securities Authorized for Issuance under Equity Compensation Plans
3 Months Ended
Mar. 31, 2022
Disclosure Text Block Supplement [Abstract]  
SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS

10. SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS

 

No stock compensation expense was incurred during each of the three months ended March 31, 2022 and 2021, and at March 31, 2022, there were no outstanding stock options or unrecognized compensation expense related to stock options. 

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.1
Cash Dividends
3 Months Ended
Mar. 31, 2022
Cash Dividends [Abstract]  
CASH DIVIDENDS

11. CASH DIVIDENDS

 

On February 24, 2022, the Company’s Board of Directors declared a regular quarterly dividend of $0.04 per common share payable on March 25, 2022 to all shareholders of record on March 10, 2022. There were 9,509,799 shares of common stock outstanding on March 10, 2022; therefore, dividends aggregating $380,392 were paid on March 25, 2022.

 

On February 25, 2021, the Company’s Board of Directors declared a regular quarterly dividend of $0.03 per common share payable on March 25, 2021 to all shareholders of record on March 11, 2021. There were 9,481,799 shares of common stock outstanding on March 11, 2021; therefore, dividends aggregating $284,454 were paid on March 25, 2021.

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.1
Customer Concentration
3 Months Ended
Mar. 31, 2022
Risks and Uncertainties [Abstract]  
CUSTOMER CONCENTRATION

12. CUSTOMER CONCENTRATION

 

During the three months ended March 31, 2022 and 2021, the Company had net sales to each of two customers that constituted in excess of 10% of its net sales. Net sales to these two customers represented approximately 38.7% (22.6% and 16.1%) and 43.2% (29.5% and 13.7%) of the Company’s net sales for the three months ended March 31, 2022 and 2021, respectively.

 

  At March 31, 2022 and December 31, 2021, three customers constituted at least 10% of the Company’s gross trade accounts receivable. The gross trade accounts receivable balances for these customers represented approximately 65.5% (26.9%, 24.9%, and 13.7%) and 60.1% (22.2%, 19.0%, and 18.9%) of the Company’s gross trade accounts receivable at March 31, 2022 and December 31, 2021, respectively.

XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.1
Accounting Policies, by Policy (Policies)
3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Interim reporting

Interim reporting

 

The accompanying unaudited condensed consolidated financial statements include the accounts of Ocean Bio-Chem, Inc. and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. Unless the context indicates otherwise, the term “Company” refers to Ocean Bio-Chem, Inc. and its subsidiaries.

 

The unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Securities and Exchange Commission Regulation S-X.  Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements.

 

The financial information furnished herein reflects all adjustments, consisting of normal recurring items that, in the opinion of management, are necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the interim periods. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022.

 

The information included in this Form 10-Q should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

 

Use of estimates

Use of estimates

 

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and assumptions.

XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.1
Inventories (Tables)
3 Months Ended
Mar. 31, 2022
Inventory Disclosure [Abstract]  
Schedule of inventories
  

March 31,

2022

  

December 31,

2021

 
Raw materials  $8,745,696   $7,465,011 
Finished goods   11,552,825    9,669,073 
Inventories, gross   20,298,521    17,134,084 
           
Inventory reserves   (323,623)   (314,831)
           
Inventories, net  $19,974,898   $16,819,253 

 

XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.1
Property, Plant & Equipment (Tables)
3 Months Ended
Mar. 31, 2022
Property, Plant and Equipment [Abstract]  
Schedule of property, plant and equipment
  

Estimated

Useful Life

  March 31,
2022
  

December 31,

2021

 
            
Land     $278,325   $278,325 
Building and improvements  30 years   15,180,235    9,710,244 
Manufacturing and warehouse equipment  6-20 years   13,577,478    12,858,638 
Office equipment and furniture  3-5 years   1,941,521    1,805,002 
Leasehold improvements  10-15 years   621,903    587,183 
Finance leases – right to use  5 years   113,741    113,741 
Vehicles  3 years   10,020    10,020 
Construction in process (1)      1,883,726    6,633,112 
 Property, plant and equipment, gross      33,606,949    31,996,265 
              
Less accumulated depreciation      (15,964,941)   (15,636,047)
              
Property, plant and equipment, net     $17,642,008   $16,360,218 

 

XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.1
Leases (Tables)
3 Months Ended
Mar. 31, 2022
Leases Disclosure [Abstract]  
Schedule of future minimum rent payments
Twelve-month period ending March 31,
2023  $94,800 
2024   71,100 
Total future minimum lease payments   165,900 
Less imputed interest   (5,451)
Total operating lease liability  $160,449 

 

Schedule of expenses incurred with respect to the company's leases
   Three
Months
Ended
March 31,
2022
  

Three

Months

Ended
March 31,
2021

 
Operating lease expense  $24,553   $24,339 
Finance lease amortization   5,350    5,254 
Finance lease interest   337    433 
Total lease expense  $30,240   $30,026 

 

Schedule of finance leases and discount rate with respect to the operating lease and finance leases
   March 31,
2022
 
Remaining lease term – operating lease   1.75 years 
Weighted average remaining lease term – finance leases   3.4 years 
Discount rate – operating lease   3.7%
Weighted average discount rate – finance leases   1.8%

 

   December 31,
2021
 
Remaining lease term – operating lease   2.0 years 
Weighted average remaining lease term – finance leases   3.7 years 
Discount rate – operating lease   3.7%
Weighted average discount rate – finance leases   1.8%
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.1
Intangible Assets (Tables)
3 Months Ended
Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of intangible assets
Intangible Assets  Cost   Accumulated
Amortization
   Net 
Patents  $622,733   $609,871   $12,862 
Trade names and trademarks   1,715,325    675,195    1,040,130 
Customer list   584,468    416,328    168,140 
Product formulas   292,234    208,168    84,066 
Royalty rights   160,000    155,515    4,485 
Total intangible assets  $3,374,760   $2,065,077   $1,309,683 

 

Intangible Assets  Cost   Accumulated
Amortization
   Net 
Patents  $622,733   $596,980   $25,753 
Trade names and trademarks   1,715,325    665,440    1,049,885 
Customer list   584,468    387,105    197,363 
Product formulas   292,234    193,554    98,680 
Royalty rights   160,000    151,029    8,971 
Total intangible assets  $3,374,760   $1,994,108   $1,380,652 

 

XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.1
Long Term Debt (Tables)
3 Months Ended
Mar. 31, 2022
Debt Disclosure [Abstract]  
Schedule of long-term debt
   Current Portion   Long Term Portion 
   March 31,
2022
   December 31,
2021
   March 31,
2022
   December 31,
2021
 
Term loan  $268,085   $265,918   $4,553,837   $4,622,204 
Obligations related to industrial development bond financing   279,585    276,036    2,940,566    3,057,773 
Note payable related to Snappy Marine asset acquisition   195,052    193,660    66,270    115,558 
Obligation related to Check Corporation asset acquisition        
-
    
-
    
-
 
Office equipment finance leases   21,655    21,554    51,841    57,292 
Total principal of long- term debt   764,377    757,168    7,612,514    7,852,827 
Debt issuance costs   (20,637)   (20,637)   (96,779)   (101,938)
Total long- term debt  $743,740   $736,531   $7,515,735   $7,750,889 

 

Schedule of long- term obligation
Twelve-month period ending March 31,   
2023  $764,377 
2024   653,179 
2025   602,545 
2026   613,847 
2027   622,381 
Thereafter   5,120,562 
Total  $8,376,891 
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.1
Earnings Per Common Share (Tables)
3 Months Ended
Mar. 31, 2022
Earnings Per Share [Abstract]  
Schedule of weighted average number of shares outstanding
   Three Months Ended
March 31,
 
   2022   2021 
        
         
Net income  $1,299,281   $1,904,269 
           
Weighted average number of common shares outstanding   9,509,670    9,481,799 
           
Earnings per common share  $0.14   $0.20 
           
           
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.1
Inventories (Details) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Inventory Disclosure [Abstract]    
Inventories managed at the customer's warehouses $ 987,000 $ 1,051,000
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.1
Inventories (Details) - Schedule of inventories - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Schedule of inventories [Abstract]    
Raw materials $ 8,745,696 $ 7,465,011
Finished goods 11,552,825 9,669,073
Inventories, gross 20,298,521 17,134,084
Inventory reserves (323,623) (314,831)
Inventories, net $ 19,974,898 $ 16,819,253
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.1
Property, Plant & Equipment (Details) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Property, Plant and Equipment [Abstract]    
Depreciation expense $ 328,893 $ 281,529
Depreciation included in cost of goods sold 303,992 257,140
Selling and administrative expenses $ 24,901 $ 24,389
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.1
Property, Plant & Equipment (Details) - Schedule of property, plant and equipment - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2022
Dec. 31, 2021
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross $ 33,606,949 $ 31,996,265
Less accumulated depreciation (15,964,941) (15,636,047)
Property, plant and equipment, net 17,642,008 16,360,218
Land [Member]    
Property, Plant and Equipment [Line Items]    
Land $ 278,325 278,325
Building and improvements [Member]    
Property, Plant and Equipment [Line Items]    
Estimated Useful Life 30 years  
Building and improvements $ 15,180,235 9,710,244
Manufacturing and warehouse equipment [Member]    
Property, Plant and Equipment [Line Items]    
Manufacturing and warehouse equipment $ 13,577,478 12,858,638
Manufacturing and warehouse equipment [Member] | Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Estimated Useful Life 6 years  
Manufacturing and warehouse equipment [Member] | Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Estimated Useful Life 20 years  
Office equipment and furniture [Member]    
Property, Plant and Equipment [Line Items]    
Office equipment and furniture $ 1,941,521 1,805,002
Office equipment and furniture [Member] | Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Estimated Useful Life 3 years  
Office equipment and furniture [Member] | Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Estimated Useful Life 5 years  
Leasehold improvements [Member]    
Property, Plant and Equipment [Line Items]    
Leasehold improvements $ 621,903 587,183
Leasehold improvements [Member] | Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Estimated Useful Life 10 years  
Leasehold improvements [Member] | Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Estimated Useful Life 15 years  
Finance leases – right to use [Member]    
Property, Plant and Equipment [Line Items]    
Estimated Useful Life 5 years  
Finance leases – right to use $ 113,741 113,741
Vehicles [Member]    
Property, Plant and Equipment [Line Items]    
Estimated Useful Life 3 years  
Vehicles $ 10,020 10,020
Construction in process [Member]    
Property, Plant and Equipment [Line Items]    
Construction in process [1] $ 1,883,726 $ 6,633,112
[1] In April 2022, the Company’s wholly owned subsidiary, KINPAK Inc. (“Kinpak”), placed into service assets relating to an expansion of its manufacturing and distribution facilities.
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.1
Leases (Details) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Leases [Abstract]      
Expires date Dec. 31, 2023    
Annual minimum base rent $ 94,800    
Percentage of maximum annual increase from base rent 2.00%    
Operating lease expense $ 24,553 $ 24,339  
Operating lease right to use asset and corresponding liability $ 160,449   $ 182,543
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.1
Leases (Details) - Schedule of future minimum rent payments
Mar. 31, 2022
USD ($)
Schedule of future minimum rent payments [Abstract]  
2023 $ 94,800
2024 71,100
Total future minimum lease payments 165,900
Less imputed interest (5,451)
Total operating lease liability $ 160,449
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.1
Leases (Details) - Schedule of expenses incurred with respect to the company's leases - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Schedule of expenses incurred with respect to the company's leases [Abstract]    
Operating lease expense $ 24,553 $ 24,339
Finance lease amortization 5,350 5,254
Finance lease interest 337 433
Total lease expense $ 30,240 $ 30,026
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.1
Leases (Details) - Schedule of finance leases and discount rate with respect to the operating lease and finance leases
Mar. 31, 2022
Dec. 31, 2021
Schedule of finance leases and discount rate with respect to the operating lease and finance leases [Abstract]    
Remaining lease term – operating lease 1 year 9 months 2 years
Weighted average remaining lease term – finance leases 3 years 4 months 24 days 3 years 8 months 12 days
Discount rate – operating lease 3.70% 3.70%
Weighted average discount rate – finance leases 1.80% 1.80%
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.1
Intangible Assets (Details) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]    
Amortization expense related to intangible assets $ 70,969 $ 71,161
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.22.1
Intangible Assets (Details) - Schedule of intangible assets - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Intangible Assets (Details) - Schedule of intangible assets [Line Items]    
Intangible assets, Cost $ 3,374,760 $ 3,374,760
Intangible assets, Accumulated Amortization 2,065,077 1,994,108
Intangible assets, Net 1,309,683 1,380,652
Patents [Member]    
Intangible Assets (Details) - Schedule of intangible assets [Line Items]    
Intangible assets, Cost 622,733 622,733
Intangible assets, Accumulated Amortization 609,871 596,980
Intangible assets, Net 12,862 25,753
Trade names and trademarks [Member]    
Intangible Assets (Details) - Schedule of intangible assets [Line Items]    
Intangible assets, Cost 1,715,325 1,715,325
Intangible assets, Accumulated Amortization 675,195 665,440
Intangible assets, Net 1,040,130 1,049,885
Customer list [Member]    
Intangible Assets (Details) - Schedule of intangible assets [Line Items]    
Intangible assets, Cost 584,468 584,468
Intangible assets, Accumulated Amortization 416,328 387,105
Intangible assets, Net 168,140 197,363
Product formulas [Member]    
Intangible Assets (Details) - Schedule of intangible assets [Line Items]    
Intangible assets, Cost 292,234 292,234
Intangible assets, Accumulated Amortization 208,168 193,554
Intangible assets, Net 84,066 98,680
Royalty rights [Member]    
Intangible Assets (Details) - Schedule of intangible assets [Line Items]    
Intangible assets, Cost 160,000 160,000
Intangible assets, Accumulated Amortization 155,515 151,029
Intangible assets, Net $ 4,485 $ 8,971
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.22.1
Revolving Line of Credit (Details) - USD ($)
3 Months Ended
Mar. 31, 2022
Jul. 30, 2021
Aug. 31, 2018
Line Of Credit Facilities [Abstract]      
Maximum revolving credit line of credit provided in business loan agreement   $ 6,000,000 $ 6,000,000
Description of interest on the revolving line of credit The Business Loan Agreement bears interest at a variable annual rate of LIBOR plus 1.35%, computed on a 365/360 basis.    
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.22.1
Long Term Debt (Details)
1 Months Ended 3 Months Ended
Jun. 22, 2020
Sep. 26, 2017
USD ($)
Mar. 31, 2022
USD ($)
Mar. 31, 2021
USD ($)
Dec. 31, 2021
USD ($)
Jul. 30, 2021
Jul. 20, 2021
USD ($)
Long Term Debt (Details) [Line Items]              
Final payment     $ 1,799,201        
Amount paid related to finance lease     5,687 $ 5,687      
Principal under lease agreement     5,350 5,254      
Interest paid under lease agreement     $ 337 $ 433      
Maximum [Member]              
Long Term Debt (Details) [Line Items]              
Percentage of interest rates     3.86%        
Minimum [Member]              
Long Term Debt (Details) [Line Items]              
Percentage of interest rates     1.53%        
Term Loan [Member]              
Long Term Debt (Details) [Line Items]              
Original principal amount             $ 5,000,000
Area of square foot (in Square Meters) | m²           69,000  
Term loan, description     The Term Loan bears interest at an annual rate of 3.25% and is due in 119 monthly installments of $35,249 each, plus interest then accrued, beginning on August 20, 2021. The final installment shall be due and payable on July 20, 2031 in an amount equal to all principal and interest then remaining unpaid. Assuming that all amounts due prior to that date are paid in a timely manner, the final installment would be $1,977,047.         
Financial covenants under credit agreement, description     The Credit Agreement includes financial covenants requiring that the Company maintain a minimum fixed charge coverage ratio (generally, the ratio of (A) EBITDA for the most recently completed four fiscal quarters minus the sum of the Company’s distributions to its shareholders, taxes paid and unfunded capital expenditures during such period to (B) prior period current maturities of Company long term debt plus interest expense incurred over the most recently completed four fiscal quarters) of at least 1.20 to 1, tested quarterly, and a maximum “debt to cap” ratio (generally, funded debt divided by the sum of net worth and funded debt) of 0.75 to 1, as of the end of each fiscal quarter.        
Majority shareholder's ownership, percentage     50.00%        
Revolving line of credit     $ 6,000,000        
Indebtedness excluding trade payables     250,000        
Final payment     $ 1,600,861        
Term Loan [Member] | Maximum [Member]              
Long Term Debt (Details) [Line Items]              
Prepayment penalty, percentage     5.00%        
Term Loan [Member] | Minimum [Member]              
Long Term Debt (Details) [Line Items]              
Prepayment penalty, percentage     1.00%        
Industrial Development Bond Financing [Member]              
Long Term Debt (Details) [Line Items]              
Proceeds of the bond sale   $ 4,500,000          
Lender's purchase of industrial development bond     $ 4,500,000        
Repurchase price of facilities if bond has been redeemed or fully paid     $ 1,000        
Bond redemptions, description     The Bond bears interest at the rate of 3.07% per annum, calculated on the basis of a 360-day year and the actual number of days elapsed (subject to increase to 6.07% per annum upon the occurrence of an event of default), and is payable in 118 monthly installments of $31,324 beginning on November 1, 2017 and ending on August 1, 2027, with a final principal and interest payment to be made on September 1, 2027.        
Bond financing, description     In addition, the Lease contains provisions relating to the Expansion Project, including limitations on utilization of Bond proceeds, deposit of unused proceeds into a custodial account (as described below) and investment of monies held in the custodial account.        
Guarantee agreement, description     the Company is subject to certain covenants, including financial covenants requiring that the Company maintain (i) a minimum fixed charge ratio (generally, the ratio of (A) EBITDA minus the sum of Company’s distributions to its shareholders, taxes paid and unfunded capital expenditures to (B) current maturities of Company long-term debt plus interest expense) of 1.20 to 1, tested quarterly, and (ii) a ratio of funded debt (as defined in the guaranty agreement) divided by the sum of net worth and funded debt of 0.75 to 1, tested quarterly. For purposes of computing the fixed charge coverage ratio, “EBITDA” generally is defined as net income before taxes and depreciation expense plus amortization expense, plus interest expense, plus non-recurring and/or non-cash losses and expenses, minus non-recurring and/or non-cash gains and income; “unfunded capital expenditures” generally is defined as capital expenditures made from Company funds other than funds borrowed through term debt incurred to finance such capital expenditures.        
Debt financing costs     $ 196,095        
Other Long-Term Obligations [Member]              
Long Term Debt (Details) [Line Items]              
Promissory note, description     In connection with the Company’s agreement to purchase assets of Snappy Marine, Inc. (“Snappy Marine”) on July 13, 2018, the Company provided to Snappy Marine a promissory note in the amount of $1,000,000, including interest (of the $1,000,000 amount of the promissory note, $930,528 was recorded as principal, and the remaining $69,472, representing an imputed interest rate of 2.87% per annum, is being recorded as interest expense over the term of the note). The note is payable in equal installments of $16,667 over a 60- month period that commenced on August 1, 2018, with a final payment due and payable on July 1, 2023.        
Office equipment leases     $ 73,000   $ 79,000    
Canon Solutions America, Inc [Member] | Other Long-Term Obligations [Member]              
Long Term Debt (Details) [Line Items]              
Lease agreement, description the Company entered into a lease agreement with Canon Solutions America, Inc. to lease office equipment. The lease obligates the Company to pay $100,009 in 63 equal monthly payments of $1,587. The lease is classified as a finance lease. The Company recorded a lease liability which is included in long term debt and a corresponding right to use asset that is included in property, plant and equipment of $96,039 based on a discount rate of 1.53%.            
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.22.1
Long Term Debt (Details) - Schedule of long-term debt - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Debt Instrument [Line Items]    
Total principal of long- term debt, Current Portion $ 764,377 $ 757,168
Total principal of long- term debt, Long Term Portion 7,612,514 7,852,827
Debt issuance costs, Current Portion (20,637) (20,637)
Debt issuance costs, Long Term Portion (96,779) (101,938)
Total long- term debt, Current Portion 743,740 736,531
Total long- term debt, Long Term Portion 7,515,735 7,750,889
Term loan [Member]    
Debt Instrument [Line Items]    
Term loan, Current Portion 268,085 265,918
Term loan, Long Term portion 4,553,837 4,622,204
Obligations related to industrial development bond financing [Member]    
Debt Instrument [Line Items]    
Obligations related to industrial development bond financing, Current Portion 279,585 276,036
Obligations related to industrial development bond financing, Long Term portion 2,940,566 3,057,773
Note payable related to Snappy Marine asset acquisition [Member]    
Debt Instrument [Line Items]    
Note payable related to Snappy Marine asset acquisition, Current Portion 195,052 193,660
Note payable related to Snappy Marine asset acquisition, Long Term Portion 66,270 115,558
Obligation related to Check Corporation asset acquisition [Member]    
Debt Instrument [Line Items]    
Obligation related to Check Corporation asset acquisition, Current Portion  
Obligation related to Check Corporation asset acquisition, Long Term Portion
Office equipment finance leases [Member]    
Debt Instrument [Line Items]    
Office equipment finance leases, Current Portion 21,655 21,554
Office equipment finance leases, Long Term Portion $ 51,841 $ 57,292
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.22.1
Long Term Debt (Details) - Schedule of long- term obligation
Mar. 31, 2022
USD ($)
Schedule of long- term obligation [Abstract]  
2023 $ 764,377
2024 653,179
2025 602,545
2026 613,847
2027 622,381
Thereafter 5,120,562
Total $ 8,376,891
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.22.1
Related Party Transactions (Details) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Related Party Transactions (Details) [Line Items]    
Sales to the affiliated companies $ 492,000 $ 513,000
Charges to the affiliated companies for services 188,000 168,000
Reimburse business related expenditures 29,000 36,000
Receivables due from affiliated companies 847,000 1,212,000
Insurance premiums paid 283,000 397,000
Service [Member]    
Related Party Transactions (Details) [Line Items]    
Total payments to affiliated company 35,000 23,000
Research and development costs 12,000 12,000
Charter boat services 6,000 7,000
The production of television commercials $ 17,000 $ 4,000
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.22.1
Earnings Per Common Share (Details) - Schedule of weighted average number of shares outstanding - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Schedule of weighted average number of shares outstanding [Abstract]    
Net income $ 1,299,281 $ 1,904,269
Weighted average number of common shares outstanding 9,509,670 9,481,799
Earnings per common share $ 0.14 $ 0.2
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.22.1
Cash Dividends (Details) - Board of Directors [Member] - USD ($)
1 Months Ended
Mar. 25, 2022
Mar. 25, 2021
Mar. 10, 2022
Mar. 11, 2021
Cash Dividends (Details) [Line Items]        
Dividends paid per common share $ 0.04 $ 0.03    
Common stock, shares outstanding     9,509,799 9,481,799
Dividends paid to common shareholders $ 380,392 $ 284,454    
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.22.1
Customer Concentration (Details)
3 Months Ended 12 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Net Sales [Member]      
Customer Concentration (Details) [Line Items]      
Concentration risk, description constituted in excess of 10% of its net sales. constituted in excess of 10% of its net sales.  
Number of customers 2 2  
Concentration risk, percentage 38.70% 43.20%  
Trade Accounts Receivable [Member]      
Customer Concentration (Details) [Line Items]      
Concentration risk, description constituted at least 10% of the Company’s gross trade accounts receivable.   constituted at least 10% of the Company’s gross trade accounts receivable.
Number of customers 3   3
Concentration risk, percentage 65.50%   60.10%
Customer One [Member] | Net Sales [Member]      
Customer Concentration (Details) [Line Items]      
Concentration risk, percentage 22.60% 29.50%  
Customer One [Member] | Trade Accounts Receivable [Member]      
Customer Concentration (Details) [Line Items]      
Concentration risk, percentage 26.90%   22.20%
Customer Two [Member] | Net Sales [Member]      
Customer Concentration (Details) [Line Items]      
Concentration risk, percentage 16.10% 13.70%  
Customer Two [Member] | Trade Accounts Receivable [Member]      
Customer Concentration (Details) [Line Items]      
Concentration risk, percentage 24.90%   19.00%
Customer Three [Member] | Trade Accounts Receivable [Member]      
Customer Concentration (Details) [Line Items]      
Concentration risk, percentage 13.70%   18.90%
XML 55 f10q0322_oceanbio_htm.xml IDEA: XBRL DOCUMENT 0000350737 2022-01-01 2022-03-31 0000350737 2022-05-13 0000350737 2022-03-31 0000350737 2021-12-31 0000350737 2021-01-01 2021-03-31 0000350737 us-gaap:CommonStockMember 2021-12-31 0000350737 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000350737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000350737 us-gaap:RetainedEarningsMember 2021-12-31 0000350737 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000350737 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000350737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0000350737 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000350737 us-gaap:CommonStockMember 2022-03-31 0000350737 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000350737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0000350737 us-gaap:RetainedEarningsMember 2022-03-31 0000350737 us-gaap:CommonStockMember 2020-12-31 0000350737 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000350737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000350737 us-gaap:RetainedEarningsMember 2020-12-31 0000350737 2020-12-31 0000350737 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000350737 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000350737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0000350737 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000350737 us-gaap:CommonStockMember 2021-03-31 0000350737 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000350737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0000350737 us-gaap:RetainedEarningsMember 2021-03-31 0000350737 2021-03-31 0000350737 us-gaap:LandMember 2022-03-31 0000350737 us-gaap:LandMember 2021-12-31 0000350737 us-gaap:BuildingImprovementsMember 2022-01-01 2022-03-31 0000350737 us-gaap:BuildingImprovementsMember 2022-03-31 0000350737 us-gaap:BuildingImprovementsMember 2021-12-31 0000350737 pf0:MinimumMember obci:ManufacturingAndWarehouseEquipmentMember 2022-01-01 2022-03-31 0000350737 pf0:MaximumMember obci:ManufacturingAndWarehouseEquipmentMember 2022-01-01 2022-03-31 0000350737 obci:ManufacturingAndWarehouseEquipmentMember 2022-01-01 2022-03-31 0000350737 obci:ManufacturingAndWarehouseEquipmentMember 2021-01-01 2021-12-31 0000350737 pf0:MinimumMember us-gaap:OfficeEquipmentMember 2022-01-01 2022-03-31 0000350737 pf0:MaximumMember us-gaap:OfficeEquipmentMember 2022-01-01 2022-03-31 0000350737 us-gaap:OfficeEquipmentMember 2022-03-31 0000350737 us-gaap:OfficeEquipmentMember 2021-12-31 0000350737 pf0:MinimumMember us-gaap:LeaseholdImprovementsMember 2022-01-01 2022-03-31 0000350737 pf0:MaximumMember us-gaap:LeaseholdImprovementsMember 2022-01-01 2022-03-31 0000350737 us-gaap:LeaseholdImprovementsMember 2022-03-31 0000350737 us-gaap:LeaseholdImprovementsMember 2021-12-31 0000350737 obci:FinanceLeasesMember 2022-01-01 2022-03-31 0000350737 obci:FinanceLeasesMember 2022-03-31 0000350737 obci:FinanceLeasesMember 2021-12-31 0000350737 us-gaap:VehiclesMember 2022-01-01 2022-03-31 0000350737 us-gaap:VehiclesMember 2021-01-01 2021-12-31 0000350737 us-gaap:ConstructionInProgressMember 2022-03-31 0000350737 us-gaap:ConstructionInProgressMember 2021-12-31 0000350737 us-gaap:PatentsMember 2022-03-31 0000350737 us-gaap:TrademarksAndTradeNamesMember 2022-03-31 0000350737 us-gaap:CustomerListsMember 2022-03-31 0000350737 obci:ProductFormulasMember 2022-03-31 0000350737 obci:RoyaltyRightsMember 2022-03-31 0000350737 us-gaap:PatentsMember 2021-12-31 0000350737 us-gaap:TrademarksAndTradeNamesMember 2021-12-31 0000350737 us-gaap:CustomerListsMember 2021-12-31 0000350737 obci:ProductFormulasMember 2021-12-31 0000350737 obci:RoyaltyRightsMember 2021-12-31 0000350737 2021-07-30 0000350737 2018-08-31 0000350737 obci:TermLoanMember 2021-07-20 0000350737 obci:TermLoanMember 2021-07-30 0000350737 obci:TermLoanMember 2022-01-01 2022-03-31 0000350737 pf0:MaximumMember obci:TermLoanMember 2022-01-01 2022-03-31 0000350737 pf0:MinimumMember obci:TermLoanMember 2022-01-01 2022-03-31 0000350737 obci:TermLoanMember 2022-03-31 0000350737 obci:IndustrialDevelopmentBondFinancingMember 2017-09-01 2017-09-26 0000350737 obci:IndustrialDevelopmentBondFinancingMember 2022-01-01 2022-03-31 0000350737 obci:IndustrialDevelopmentBondFinancingMember 2022-03-31 0000350737 obci:OtherLongTermObligationsMember 2022-01-01 2022-03-31 0000350737 obci:OtherLongTermObligationsMember obci:CanonSolutionsAmericaIncMember 2020-06-01 2020-06-22 0000350737 obci:OtherLongTermObligationsMember 2022-03-31 0000350737 obci:OtherLongTermObligationsMember 2021-12-31 0000350737 pf0:MinimumMember 2022-03-31 0000350737 pf0:MaximumMember 2022-03-31 0000350737 obci:TermLoanMember 2022-03-31 0000350737 obci:TermLoanMember 2021-12-31 0000350737 obci:ObligationsRelatedToIndustrialDevelopmentBondFinancingMember 2022-03-31 0000350737 obci:ObligationsRelatedToIndustrialDevelopmentBondFinancingMember 2021-12-31 0000350737 obci:NotePayableRelatedToAssetAcquisitionMember 2022-03-31 0000350737 obci:NotePayableRelatedToAssetAcquisitionMember 2021-12-31 0000350737 obci:ObligationRelatedToCheckCorporationAssetAcquisitionMember 2021-12-31 0000350737 obci:ObligationRelatedToCheckCorporationAssetAcquisitionMember 2022-03-31 0000350737 obci:OfficeEquipmentFinanceLeasesMember 2022-03-31 0000350737 obci:OfficeEquipmentFinanceLeasesMember 2021-12-31 0000350737 us-gaap:ServiceMember 2022-01-01 2022-03-31 0000350737 us-gaap:ServiceMember 2021-01-01 2021-03-31 0000350737 pf0:BoardOfDirectorsChairmanMember 2022-03-01 2022-03-25 0000350737 pf0:BoardOfDirectorsChairmanMember 2022-03-10 0000350737 pf0:BoardOfDirectorsChairmanMember 2021-03-01 2021-03-25 0000350737 pf0:BoardOfDirectorsChairmanMember 2021-03-11 0000350737 us-gaap:SalesRevenueNetMember 2022-01-01 2022-03-31 0000350737 us-gaap:SalesRevenueNetMember 2021-01-01 2021-03-31 0000350737 obci:CustomerOneMember us-gaap:SalesRevenueNetMember 2022-01-01 2022-03-31 0000350737 obci:CustomerTwoMember us-gaap:SalesRevenueNetMember 2022-01-01 2022-03-31 0000350737 obci:CustomerOneMember us-gaap:SalesRevenueNetMember 2021-01-01 2021-03-31 0000350737 obci:CustomerTwoMember us-gaap:SalesRevenueNetMember 2021-01-01 2021-03-31 0000350737 us-gaap:AccountsReceivableMember 2022-01-01 2022-03-31 0000350737 us-gaap:AccountsReceivableMember 2021-01-01 2021-12-31 0000350737 obci:CustomerOneMember us-gaap:AccountsReceivableMember 2022-01-01 2022-03-31 0000350737 obci:CustomerTwoMember us-gaap:AccountsReceivableMember 2022-01-01 2022-03-31 0000350737 obci:CustomerThreeMember us-gaap:AccountsReceivableMember 2022-01-01 2022-03-31 0000350737 obci:CustomerOneMember us-gaap:AccountsReceivableMember 2021-01-01 2021-12-31 0000350737 obci:CustomerTwoMember us-gaap:AccountsReceivableMember 2021-01-01 2021-12-31 0000350737 obci:CustomerThreeMember us-gaap:AccountsReceivableMember 2021-01-01 2021-12-31 shares iso4217:USD iso4217:USD shares pure utr:sqm 10-Q true 2022-03-31 2022 false 0-11102 OCEAN BIO-CHEM, INC FL 59-1564329 4041 SW 47 Avenue Fort Lauderdale FL 33314 Common Stock, $0.01 par value OBCI NASDAQ Yes Yes Non-accelerated Filer true false false 9509799 10216924 12684935 712000 632000 10261547 9544133 847026 1211999 19974898 16819253 1585477 2093971 42885872 42354291 17642008 16360218 160449 182543 1309683 1380652 61998012 60277704 743740 736531 90424 89600 3376982 2877623 208342 45295 1120234 900982 5539722 4650031 453086 347723 70025 92943 7515735 7750889 13578568 12841586 0.01 0.01 12000000 12000000 9509799 9509799 9503999 9503999 95098 95040 11141123 11077706 -291374 -292336 37474597 36555708 48419444 47436118 61998012 60277704 12737329 13131224 8001347 7750503 4735982 5380721 1071579 941814 2000030 1972812 3071609 2914626 1664373 2466095 31682 37187 1632691 2428908 333410 524639 1299281 1904269 0.14 0.2 0.04 0.03 1299281 1904269 962 -596 1300243 1903673 9503999 95040 11077706 -292336 36555708 47436118 1299281 1299281 380392 380392 -600 6 5639 5645 6400 64 69056 69120 962 962 9509799 95098 11141123 -291374 37474597 48419444 9481799 94818 10816100 -294324 29290477 39907071 1904269 1904269 284454 284454 -596 -596 9481799 94818 10816100 -294920 30910292 41526290 1299281 1904269 405022 357594 105363 -88566 80003 88289 70049 9756 -311 1572 797417 2110546 -364973 -358826 3225694 1068795 -508494 162596 499359 1174548 163047 576626 288372 169969 -238837 1207802 1610684 915899 -1610684 -915899 233104 130092 380392 284454 5645 -619141 -414546 651 976 -2468011 -121667 12684935 11601152 10216924 11479485 28786 32606 65000 23700 23700 10216924 11161761 317724 10216924 11479485 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. SUMMARY OF ACCOUNTING POLICIES</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Interim reporting</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited condensed consolidated financial statements include the accounts of Ocean Bio-Chem, Inc. and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. Unless the context indicates otherwise, the term “Company” refers to Ocean Bio-Chem, Inc. and its subsidiaries.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Securities and Exchange Commission Regulation S-X.  Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial information furnished herein reflects all adjustments, consisting of normal recurring items that, in the opinion of management, are necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the interim periods. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information included in this Form 10-Q should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and assumptions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Interim reporting</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited condensed consolidated financial statements include the accounts of Ocean Bio-Chem, Inc. and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. Unless the context indicates otherwise, the term “Company” refers to Ocean Bio-Chem, Inc. and its subsidiaries.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Securities and Exchange Commission Regulation S-X.  Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial information furnished herein reflects all adjustments, consisting of normal recurring items that, in the opinion of management, are necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the interim periods. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information included in this Form 10-Q should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and assumptions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2. INVENTORIES</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s inventories at March 31, 2022 and December 31, 2021 consisted of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>March 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2022</b></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2021</b></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Raw materials</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8,745,696</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,465,011</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -29.7pt; padding-left: 29.7pt">Finished goods</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,552,825</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,669,073</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -29.7pt; padding-left: 29.7pt">Inventories, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,298,521</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,134,084</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -29.7pt; padding-left: 29.7pt">Inventory reserves</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(323,623</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(314,831</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; text-indent: -29.7pt; padding-left: 29.7pt">Inventories, net</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">19,974,898</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">16,819,253</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The inventory reserves shown in the table above reflect slow moving and obsolete inventory.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company operates a vendor managed inventory program with one of its customers to improve the promotion of the Company’s products. The Company manages the inventory levels at this customer’s warehouses and recognizes revenue as the products are sold by the customer. The inventories managed at the customer’s warehouses, which are included in inventories, net, amounted to approximately $987,000 and $1,051,000 at March 31, 2022 and December 31, 2021, respectively.</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>March 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2022</b></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2021</b></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Raw materials</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8,745,696</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,465,011</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -29.7pt; padding-left: 29.7pt">Finished goods</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,552,825</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,669,073</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -29.7pt; padding-left: 29.7pt">Inventories, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,298,521</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,134,084</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -29.7pt; padding-left: 29.7pt">Inventory reserves</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(323,623</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(314,831</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; text-indent: -29.7pt; padding-left: 29.7pt">Inventories, net</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">19,974,898</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">16,819,253</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"> </p> 8745696 7465011 11552825 9669073 20298521 17134084 323623 314831 19974898 16819253 987000 1051000 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3. PROPERTY, PLANT &amp; EQUIPMENT</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company’s property, plant and equipment at March 31, 2022 and December 31, 2021 consisted of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Estimated </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Useful Life</b></p></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2021</b></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Land</td><td style="width: 1%"> </td> <td style="width: 11%; text-align: center"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">278,325</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">278,325</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Building and improvements</td><td> </td> <td style="text-align: center">30 years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,180,235</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,710,244</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Manufacturing and warehouse equipment</td><td> </td> <td style="text-align: center">6-20 years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,577,478</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,858,638</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Office equipment and furniture</td><td> </td> <td style="text-align: center">3-5 years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,941,521</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,805,002</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: center">10-15 years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">621,903</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">587,183</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Finance leases – right to use</td><td> </td> <td style="text-align: center">5 years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">113,741</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">113,741</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vehicles</td><td> </td> <td style="text-align: center">3 years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,020</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,020</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Construction in process <sup>(1)</sup></span></td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,883,726</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,633,112</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> Property, plant and equipment, gross</td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">33,606,949</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31,996,265</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(15,964,941</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(15,636,047</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Property, plant and equipment, net</td><td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">17,642,008</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">16,360,218</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0%"/><td style="width: 0.25in">(1)</td><td style="text-align: justify">In April 2022, the Company’s wholly owned subsidiary, KINPAK Inc. (“Kinpak”), placed into service assets relating to an expansion of its manufacturing and distribution facilities.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-indent: -18pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span>Depreciation expense totaled $328,893 (of which $303,992 is included in cost of goods sold and $24,901 is included in selling and administrative expenses) and $281,529 (of which $257,140 is included in cost of goods sold and $24,389 is included in selling and administrative expenses) for the three months ended March 31, 2022 and 2021, respectively. </span></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Estimated </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Useful Life</b></p></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2021</b></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Land</td><td style="width: 1%"> </td> <td style="width: 11%; text-align: center"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">278,325</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">278,325</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Building and improvements</td><td> </td> <td style="text-align: center">30 years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,180,235</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,710,244</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Manufacturing and warehouse equipment</td><td> </td> <td style="text-align: center">6-20 years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,577,478</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,858,638</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Office equipment and furniture</td><td> </td> <td style="text-align: center">3-5 years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,941,521</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,805,002</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: center">10-15 years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">621,903</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">587,183</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Finance leases – right to use</td><td> </td> <td style="text-align: center">5 years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">113,741</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">113,741</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vehicles</td><td> </td> <td style="text-align: center">3 years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,020</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,020</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Construction in process <sup>(1)</sup></span></td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,883,726</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,633,112</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> Property, plant and equipment, gross</td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">33,606,949</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31,996,265</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(15,964,941</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(15,636,047</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Property, plant and equipment, net</td><td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">17,642,008</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">16,360,218</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p> 278325 278325 P30Y 15180235 9710244 P6Y P20Y 13577478 12858638 P3Y P5Y 1941521 1805002 P10Y P15Y 621903 587183 P5Y 113741 113741 P3Y 10020 10020 1883726 6633112 33606949 31996265 15964941 15636047 17642008 16360218 328893 303992 24901 281529 257140 24389 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4. LEASES</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has one operating lease and two finance leases.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the operating lease, the Company leases its executive offices and warehouse facilities in Fort Lauderdale, Florida from an entity controlled by Peter G. Dornau, the Company’s Chairman, President and Chief Executive Officer. The lease, as extended, expires on December 31, 2023. The lease requires an annual minimum base rent of $94,800 and provides for a maximum annual 2% increase in subsequent years, although the entity has not raised the minimum base rent since the Company entered into a previous lease agreement in 1998. Additionally, the leasing entity is entitled to reimbursement of all taxes, assessments, and any other expenses that arise from ownership. Each of the parties to the lease has agreed to review the terms of the lease every three years at the request of the other party. Operating lease expense was $24,553 and $24,339 for the three months ended March 31, 2022 and 2021, respectively. At March 31, 2022 and December 31, 2021, the Company had a right to use asset and a corresponding liability of $160,449 and $182,543, respectively, related to the operating lease. Set forth below is a schedule of future minimum rent payments under the operating lease.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="5">Twelve-month period ending March 31,</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left; padding-left: 9pt">2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">94,800</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">2024</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">71,100</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt">Total future minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">165,900</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Less imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,451</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Total operating lease liability</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">160,449</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s two finance leases relate to office equipment. See Note 3 for information regarding the carrying value of the Company’s finance lease right to use assets and Note 7 for information regarding the finance lease payment schedule.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Expenses incurred with respect to the Company’s leases during the three months ended March 31, 2022 and 2021 are set forth below.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three <br/> Months <br/> Ended <br/> March 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Three </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Months</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Ended<br/> March 31,<br/> 2021</b></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Operating lease expense</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">24,553</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">24,339</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Finance lease amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,350</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,254</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Finance lease interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">337</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">433</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Total lease expense</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">30,240</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">30,026</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The remaining lease term with respect to the operating lease, weighted average remaining lease term with respect to the finance leases and discount rate with respect to the operating lease and finance leases at March 31, 2022 and December 31, 2021 are set forth below:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Remaining lease term – operating lease</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.75 years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Weighted average remaining lease term – finance leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4 years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Discount rate – operating lease</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3.7</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Weighted average discount rate – finance leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.8</td><td style="text-align: left">%</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Remaining lease term – operating lease</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.0 years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Weighted average remaining lease term – finance leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7 years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Discount rate – operating lease</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3.7</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Weighted average discount rate – finance leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.8</td><td style="text-align: left">%</td></tr> </table> 2023-12-31 94800 0.02 24553 24339 160449 182543 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="5">Twelve-month period ending March 31,</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left; padding-left: 9pt">2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">94,800</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">2024</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">71,100</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt">Total future minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">165,900</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Less imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,451</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Total operating lease liability</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">160,449</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 94800 71100 165900 5451 160449 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three <br/> Months <br/> Ended <br/> March 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Three </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Months</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Ended<br/> March 31,<br/> 2021</b></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Operating lease expense</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">24,553</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">24,339</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Finance lease amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,350</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,254</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Finance lease interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">337</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">433</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Total lease expense</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">30,240</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">30,026</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 24553 24339 5350 5254 337 433 30240 30026 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Remaining lease term – operating lease</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.75 years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Weighted average remaining lease term – finance leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4 years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Discount rate – operating lease</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3.7</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Weighted average discount rate – finance leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.8</td><td style="text-align: left">%</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Remaining lease term – operating lease</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.0 years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Weighted average remaining lease term – finance leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7 years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Discount rate – operating lease</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3.7</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Weighted average discount rate – finance leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.8</td><td style="text-align: left">%</td></tr> </table> P1Y9M P3Y4M24D 0.037 0.018 P2Y P3Y8M12D 0.037 0.018 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5. INTANGIBLE ASSETS</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company’s intangible assets at March 31, 2022 and December 31, 2021 consisted of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">March 31, 2022</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Intangible Assets</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Accumulated<br/> Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Net</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Patents</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">622,733</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">609,871</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">12,862</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Trade names and trademarks</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,715,325</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">675,195</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,040,130</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Customer list</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">584,468</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">416,328</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">168,140</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Product formulas</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">292,234</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">208,168</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">84,066</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Royalty rights</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">160,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">155,515</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,485</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Total intangible assets</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,374,760</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,065,077</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,309,683</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">December 31, 2021</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Intangible Assets</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Accumulated<br/> Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Net</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Patents</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">622,733</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">596,980</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">25,753</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Trade names and trademarks</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,715,325</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">665,440</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,049,885</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Customer list</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">584,468</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">387,105</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">197,363</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Product formulas</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">292,234</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">193,554</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">98,680</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Royalty rights</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">160,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">151,029</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,971</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Total intangible assets</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,374,760</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,994,108</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,380,652</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span>Amortization expense related to intangible assets was $70,969 and $71,161 for the three months ended March 31, 2022 and 2021, respectively.</span></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Intangible Assets</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Accumulated<br/> Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Net</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Patents</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">622,733</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">609,871</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">12,862</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Trade names and trademarks</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,715,325</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">675,195</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,040,130</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Customer list</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">584,468</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">416,328</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">168,140</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Product formulas</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">292,234</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">208,168</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">84,066</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Royalty rights</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">160,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">155,515</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,485</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Total intangible assets</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,374,760</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,065,077</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,309,683</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Intangible Assets</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Accumulated<br/> Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Net</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Patents</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">622,733</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">596,980</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">25,753</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Trade names and trademarks</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,715,325</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">665,440</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,049,885</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Customer list</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">584,468</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">387,105</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">197,363</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Product formulas</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">292,234</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">193,554</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">98,680</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Royalty rights</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">160,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">151,029</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,971</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Total intangible assets</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,374,760</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,994,108</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,380,652</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 622733 609871 12862 1715325 675195 1040130 584468 416328 168140 292234 208168 84066 160000 155515 4485 3374760 2065077 1309683 622733 596980 25753 1715325 665440 1049885 584468 387105 197363 292234 193554 98680 160000 151029 8971 3374760 1994108 1380652 70969 71161 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6. REVOLVING LINE OF CREDIT</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 6, 2021, the Company and Regions Bank (“the “Lender”) entered into a Business Loan Agreement (the “Business Loan Agreement”), effective as of July 30, 2021, under which the Company was provided a revolving line of credit in the amount of Six Million Dollars ($6,000,000). The Business Loan Agreement supersedes the Company’s previous $6,000,000 revolving line of credit from the Lender, entered into on August 31, 2018, that was scheduled to expire on August 31, 2021. The revolving line of credit under the Business Loan Agreement is evidenced by a promissory note and is secured principally by the Company’s inventory and accounts receivable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Business Loan Agreement bears interest at a variable annual rate of LIBOR plus 1.35%, computed on a 365/360 basis. All outstanding principal plus all accrued unpaid interest is due upon Lender’s demand or when the Business Loan Agreement expires on August 30, 2024.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There has been no negative impact in the availability of funds to the Company as a result of the COVID-19 pandemic.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At March 31, 2022 and December 31, 2021, the Company had no borrowings under the revolving line of credit provided by the current and former Business Loan Agreements.</p> 6000000 6000000 The Business Loan Agreement bears interest at a variable annual rate of LIBOR plus 1.35%, computed on a 365/360 basis. <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7. LONG TERM DEBT</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Term Loan</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 30, 2021, Kinpak  and Regions Bank (the “Lender”) entered into a Credit Agreement (the “Credit Agreement”), effective as of July 20, 2021, under which the Company was extended a term loan (the “Term Loan”) in the original principal amount of Five Million Dollars ($5,000,000). The Company is using the proceeds of the Term Loan for a <span>69,000 square foot expansion of Kinpak’s </span>manufacturing, warehouse and distribution facilities in Montgomery, Alabama. The Term Loan is evidenced by a promissory note (the “Note”) and is secured by a second priority mortgage of the assets pledged in Kinpak’s industrial development bond financing obtained on September 26, 2017 (see below for further information).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has unconditionally guaranteed the payment to the Lender promptly when due, by acceleration or otherwise, of all obligations of Kinpak to the Lender.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Term Loan bears interest at an annual rate of 3.25% and is due in 119 monthly installments of $35,249 each, plus interest then accrued, beginning on August 20, 2021. The final installment shall be due and payable on July 20, 2031 in an amount equal to all principal and interest then remaining unpaid. Assuming that all amounts due prior to that date are paid in a timely manner, the final installment would be $1,977,047.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Credit Agreement provides that prepayments on the Term Loan are subject to a prepayment penalty of 5% during the first year the Term Loan is outstanding, with such penalty declining 1% each year thereafter until there is no prepayment penalty after five years. However, the Lender has agreed to waive the prepayment provisions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Credit Agreement includes financial covenants requiring that the Company maintain a minimum fixed charge coverage ratio (generally, the ratio of (A) EBITDA for the most recently completed four fiscal quarters minus the sum of the Company’s distributions to its shareholders, taxes paid and unfunded capital expenditures during such period to (B) prior period current maturities of Company long term debt plus interest expense incurred over the most recently completed four fiscal quarters) of at least 1.20 to 1, tested quarterly, and a maximum “debt to cap” ratio (generally, funded debt divided by the sum of net worth and funded debt) of 0.75 to 1, as of the end of each fiscal quarter. For purposes of computing the fixed charge coverage ratio, “EBITDA” generally is defined as net income before taxes and depreciation expense plus amortization expense, plus interest expense, plus non-recurring and/or non-cash losses and expenses, minus non-recurring and/or non-cash gains and income. The Credit Agreement also requires that the majority shareholder’s ownership does not drop below 50% of the outstanding shares of Kinpak.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Credit Agreement contains cross-default and cross-collateral provisions relating to any other indebtedness with the Lender, including without limitation the Company’s obligations under its $6,000,000 revolving line of credit from the Lender.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Credit Agreement also contains negative covenants restricting the Company’s ability to, among other things, create or assume indebtedness for borrowed money exceeding $250,000 other than trade payables incurred in the normal course of business, create liens other than permitted liens (as defined in the Credit Agreement), acquire an interest in another entity or incur any obligation as surety or guarantor other than in the ordinary course of business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Industrial Development Bond Financing</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 26, 2017, Kinpak indirectly obtained a $4,500,000 loan from Regions Capital Advantage, Inc. (the “Lender”). The proceeds of the loan have been used in full as of June 30, 2021, principally to pay or reimburse costs relating to the expansion of Kinpak’s manufacturing, warehouse and distribution facilities in Montgomery, Alabama, as well as the purchase and installation of associated machinery and equipment (the “Expansion Project”).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The loan was funded by the Lender’s purchase of a $4,500,000 industrial development bond (the “Bond”) issued by The Industrial Development Board of the City of Montgomery, Alabama (the “IDB”). The Bond is a limited obligation of the IDB and is payable solely out of revenues and receipts derived from the leasing or sale of Kinpak’s facilities. In this regard, Kinpak is obligated to fund the IDB’s payment obligations by providing rental payments under a lease between the IDB and Kinpak (the “Lease”), under which Kinpak leases its facilities from the IDB. Kinpak inherited the lease structure when it first acquired its facilities from its predecessor-in-interest in 1996. The Lease provides that prior to the maturity date of the Bond, Kinpak may repurchase the facilities for $1,000 if the Bond has been redeemed or fully paid.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Bond bears interest at the rate of 3.07% per annum, calculated on the basis of a 360-day year and the actual number of days elapsed (subject to increase to 6.07% per annum upon the occurrence of an event of default), and is payable in 118 monthly installments of $31,324 beginning on November 1, 2017 and ending on August 1, 2027, with a final principal and interest payment to be made on September 1, 2027. The amount of the final payment was originally scheduled to be $1,799,201, however at March 31, 2022 the final payment is scheduled to be $1,600,861 because the Company has made additional debt payments. The Bond provides that the interest rate will be subject to adjustment if it is determined by the United States Treasury Department, the Internal Revenue Service, or a similar government entity that the interest on the Bond is includable in the gross income of the Lender for federal income tax purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Lease, Kinpak is required to make rental payments for the account of the IDB to the Lender in such amounts and at such times as are necessary to enable the payment of all principal and interest due on the Bond and other charges, if any, payable in respect of the Bond. The Lease also provides that Kinpak may redeem the Bond, in whole or in part, by prepaying its rental payment obligations in an amount sufficient to effect the redemption. In addition, the Lease contains provisions relating to the Expansion Project, including limitations on utilization of Bond proceeds, deposit of unused proceeds into a custodial account (as described below) and investment of monies held in the custodial account.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Payment of amounts due and payable under the Bond and other related agreements are guaranteed by the Company and its other consolidated subsidiaries. In connection with the guarantee agreement under which the Company provided its guarantee, the Company is subject to certain covenants, including financial covenants requiring that the Company maintain (i) a minimum fixed charge ratio (generally, the ratio of (A) EBITDA minus the sum of Company’s distributions to its shareholders, taxes paid and unfunded capital expenditures to (B) current maturities of Company long-term debt plus interest expense) of 1.20 to 1, tested quarterly, and (ii) a ratio of funded debt (as defined in the guaranty agreement) divided by the sum of net worth and funded debt of 0.75 to 1, tested quarterly. For purposes of computing the fixed charge coverage ratio, “EBITDA” generally is defined as net income before taxes and depreciation expense plus amortization expense, plus interest expense, plus non-recurring and/or non-cash losses and expenses, minus non-recurring and/or non-cash gains and income; “unfunded capital expenditures” generally is defined as capital expenditures made from Company funds other than funds borrowed through term debt incurred to finance such capital expenditures. At March 31, 2022, the Company was in compliance with these financial covenants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company incurred debt financing costs of $196,095 in connection with the financing. These costs are shown as a reduction of the debt balance and are being amortized over the life of the Bond.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Other Long-Term Obligations</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Company’s agreement to purchase assets of Snappy Marine, Inc. (“Snappy Marine”) on July 13, 2018, the Company provided to Snappy Marine a promissory note in the amount of $1,000,000, including interest (of the $1,000,000 amount of the promissory note, $930,528 was recorded as principal, and the remaining $69,472, representing an imputed interest rate of 2.87% per annum, is being recorded as interest expense over the term of the note). The note is payable in equal installments of $16,667 over a 60- month period that commenced on August 1, 2018, with a final payment due and payable on July 1, 2023. If the note is prepaid in full, the entire outstanding balance of the note (including all unpaid amounts allocated to interest over the remaining term of the note) must be paid.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On June 22, 2020, the Company entered into a lease agreement with Canon Solutions America, Inc. to lease office equipment. The lease obligates the Company to pay $100,009 in 63 equal monthly payments of $1,587. The lease is classified as a finance lease. The Company recorded a lease liability which is included in long term debt and a corresponding right to use asset that is included in property, plant and equipment of $96,039 based on a discount rate of 1.53%. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At March 31, 2022 and December 31, 2021, the Company was obligated under lease agreements covering office equipment utilized in the Company’s operations (inclusive of the lease referenced in the preceding paragraph). The office equipment leases, aggregating approximately $73,000 and $79,000 at March 31, 2022 and December 31, 2021, respectively, have maturities through 2025 and carry interest rates ranging from approximately 1.53% to 3.86% per annum. The office equipment leases are classified as finance leases. During the three months ended March 31, 2022 and 2021, the Company paid $5,687 ($5,350 principal and $337 interest) and $5,687 ($5,254 principal and $433 interest), respectively, under the lease agreements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table provides information regarding the Company’s long-term debt at March 31, 2022 and December 31, 2021:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Current Portion</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Long Term Portion</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Term loan</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">268,085</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">265,918</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,553,837</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,622,204</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Obligations related to industrial development bond financing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">279,585</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">276,036</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,940,566</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,057,773</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Note payable related to Snappy Marine asset acquisition</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">195,052</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">193,660</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">66,270</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">115,558</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Obligation related to Check Corporation asset acquisition</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Office equipment finance leases</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,655</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,554</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">51,841</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">57,292</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Total principal of long- term debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">764,377</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">757,168</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,612,514</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,852,827</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Debt issuance costs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(20,637</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(20,637</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(96,779</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(101,938</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total long- term debt</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">743,740</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">736,531</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,515,735</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,750,889</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Required principal payments under the Company’s long- term obligations are set forth below:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>Twelve-month period ending March 31,</td><td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left; padding-left: 9pt">2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">764,377</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-left: 9pt">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">653,179</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">602,545</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-left: 9pt">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">613,847</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">622,381</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; padding-left: 9pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,120,562</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,376,891</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 5000000 69000 The Term Loan bears interest at an annual rate of 3.25% and is due in 119 monthly installments of $35,249 each, plus interest then accrued, beginning on August 20, 2021. The final installment shall be due and payable on July 20, 2031 in an amount equal to all principal and interest then remaining unpaid. Assuming that all amounts due prior to that date are paid in a timely manner, the final installment would be $1,977,047.  0.05 0.01 The Credit Agreement includes financial covenants requiring that the Company maintain a minimum fixed charge coverage ratio (generally, the ratio of (A) EBITDA for the most recently completed four fiscal quarters minus the sum of the Company’s distributions to its shareholders, taxes paid and unfunded capital expenditures during such period to (B) prior period current maturities of Company long term debt plus interest expense incurred over the most recently completed four fiscal quarters) of at least 1.20 to 1, tested quarterly, and a maximum “debt to cap” ratio (generally, funded debt divided by the sum of net worth and funded debt) of 0.75 to 1, as of the end of each fiscal quarter. 0.50 6000000 250000 4500000 4500000 1000 The Bond bears interest at the rate of 3.07% per annum, calculated on the basis of a 360-day year and the actual number of days elapsed (subject to increase to 6.07% per annum upon the occurrence of an event of default), and is payable in 118 monthly installments of $31,324 beginning on November 1, 2017 and ending on August 1, 2027, with a final principal and interest payment to be made on September 1, 2027. 1799201 1600861 In addition, the Lease contains provisions relating to the Expansion Project, including limitations on utilization of Bond proceeds, deposit of unused proceeds into a custodial account (as described below) and investment of monies held in the custodial account. the Company is subject to certain covenants, including financial covenants requiring that the Company maintain (i) a minimum fixed charge ratio (generally, the ratio of (A) EBITDA minus the sum of Company’s distributions to its shareholders, taxes paid and unfunded capital expenditures to (B) current maturities of Company long-term debt plus interest expense) of 1.20 to 1, tested quarterly, and (ii) a ratio of funded debt (as defined in the guaranty agreement) divided by the sum of net worth and funded debt of 0.75 to 1, tested quarterly. For purposes of computing the fixed charge coverage ratio, “EBITDA” generally is defined as net income before taxes and depreciation expense plus amortization expense, plus interest expense, plus non-recurring and/or non-cash losses and expenses, minus non-recurring and/or non-cash gains and income; “unfunded capital expenditures” generally is defined as capital expenditures made from Company funds other than funds borrowed through term debt incurred to finance such capital expenditures. 196095 In connection with the Company’s agreement to purchase assets of Snappy Marine, Inc. (“Snappy Marine”) on July 13, 2018, the Company provided to Snappy Marine a promissory note in the amount of $1,000,000, including interest (of the $1,000,000 amount of the promissory note, $930,528 was recorded as principal, and the remaining $69,472, representing an imputed interest rate of 2.87% per annum, is being recorded as interest expense over the term of the note). The note is payable in equal installments of $16,667 over a 60- month period that commenced on August 1, 2018, with a final payment due and payable on July 1, 2023. the Company entered into a lease agreement with Canon Solutions America, Inc. to lease office equipment. The lease obligates the Company to pay $100,009 in 63 equal monthly payments of $1,587. The lease is classified as a finance lease. The Company recorded a lease liability which is included in long term debt and a corresponding right to use asset that is included in property, plant and equipment of $96,039 based on a discount rate of 1.53%. 73000 79000 0.0153 0.0386 5687 5350 337 5687 5254 433 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Current Portion</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Long Term Portion</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Term loan</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">268,085</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">265,918</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,553,837</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,622,204</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Obligations related to industrial development bond financing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">279,585</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">276,036</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,940,566</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,057,773</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Note payable related to Snappy Marine asset acquisition</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">195,052</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">193,660</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">66,270</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">115,558</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Obligation related to Check Corporation asset acquisition</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Office equipment finance leases</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,655</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,554</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">51,841</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">57,292</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Total principal of long- term debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">764,377</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">757,168</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,612,514</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,852,827</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Debt issuance costs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(20,637</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(20,637</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(96,779</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(101,938</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total long- term debt</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">743,740</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">736,531</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,515,735</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,750,889</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 268085 265918 4553837 4622204 279585 276036 2940566 3057773 195052 193660 66270 115558 21655 21554 51841 57292 764377 757168 7612514 7852827 20637 20637 96779 101938 743740 736531 7515735 7750889 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>Twelve-month period ending March 31,</td><td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left; padding-left: 9pt">2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">764,377</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-left: 9pt">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">653,179</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">602,545</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-left: 9pt">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">613,847</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">622,381</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; padding-left: 9pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,120,562</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,376,891</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 764377 653179 602545 613847 622381 5120562 8376891 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8. RELATED PARTY TRANSACTIONS</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company sells products to companies affiliated with Peter G. Dornau, who is the Company’s Chairman, President and Chief Executive Officer. The affiliated companies resell, outside of the United States and Canada, products they purchase from the Company. The Company also provides administrative services to these companies and pays certain business-related expenditures for the affiliated companies, for which the Company is reimbursed. Sales to the affiliated companies aggregated approximately $492,000 and $513,000 for the three months ended March 31, 2022 and 2021, respectively. Fees for administrative services aggregated approximately $188,000 and $168,000 for the three months ended March 31, 2022 and 2021, respectively. Amounts billed to the affiliated companies to reimburse the Company for business related expenditures made on behalf of the affiliated companies aggregated approximately $29,000 and $36,000 during the three months ended March 31, 2022 and 2021, respectively.  The Company had accounts receivable from the affiliated companies in connection with the product sales, administrative services and business- related expenditures aggregating approximately $847,000 and $1,212,000 at March 31, 2022 and December 31, 2021, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An entity that is owned by the Company’s Chairman, President and Chief Executive Officer provides several services to the Company.  Under this arrangement, the Company paid the entity an aggregate of approximately $35,000 ($12,000 for research and development services and $6,000 for charter boat services that the Company used to provide sales incentives to customers and $17,000 for the production of television commercials) and $23,000 ($12,000 for research and development services, $7,000 for charter boat services that the Company used to provide sales incentives for customers and $4,000 for the production of television commercials ) for the three months ended March 31, 2022 and 2021, respectively. Expenditures for the research and development services are included in the condensed consolidated statements of operations within selling and administrative expenses. Expenditures for the charter boat services are included in the condensed consolidated statements of operations within advertising and promotion expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company leases office and warehouse facilities in Fort Lauderdale, Florida from an entity controlled by its Chairman, President and Chief Executive Officer. See Note 4 for a description of the lease terms.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A director of the Company is Regional Executive Vice President of an insurance broker through which the Company sources most of its insurance needs.  During the three months ended March 31, 2022 and 2021, the Company paid an aggregate of approximately $283,000 and $397,000, respectively, in insurance premiums on policies obtained through the insurance broker.</p> 492000 513000 188000 168000 29000 36000 847000 1212000 35000 12000 6000 17000 23000 12000 7000 4000 283000 397000 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9. EARNINGS PER COMMON SHARE</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company did not have any potentially dilutive securities during the three months ended March 31, 2022 and 2021. Therefore, the Company’s earnings per share are calculated by dividing net income by the weighted average number of shares outstanding during the reporting period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"/><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Net income</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,299,281</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,904,269</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Weighted average number of common shares outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,509,670</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,481,799</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Earnings per common share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.14</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.20</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"/><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Net income</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,299,281</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,904,269</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Weighted average number of common shares outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,509,670</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,481,799</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Earnings per common share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.14</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.20</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table> 1299281 1904269 9509670 9481799 0.14 0.2 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10. SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>No stock compensation expense was incurred during each of the three months ended March 31, 2022 and 2021, and</span> at March 31, 2022, there were no outstanding stock options or unrecognized compensation expense related to stock<b> </b>options. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11. CASH DIVIDENDS</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 24, 2022, the Company’s Board of Directors declared a regular quarterly dividend of $0.04 per common share payable on March 25, 2022 to all shareholders of record on March 10, 2022. There were 9,509,799 shares of common stock outstanding on March 10, 2022; therefore, dividends aggregating $380,392 were paid on March 25, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 25, 2021, the Company’s Board of Directors declared a regular quarterly dividend of $0.03 per common share payable on March 25, 2021 to all shareholders of record on March 11, 2021. There were 9,481,799 shares of common stock outstanding on March 11, 2021; therefore, dividends aggregating $284,454 were paid on March 25, 2021.</p> 0.04 9509799 380392 0.03 9481799 284454 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12. CUSTOMER CONCENTRATION</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended March 31, 2022 and 2021, the Company had net sales to each of two customers that constituted in excess of 10% of its net sales. Net sales to these two customers represented approximately 38.7% (22.6% and 16.1%) and 43.2% (29.5% and 13.7%) of the Company’s net sales for the three months ended March 31, 2022 and 2021, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  At March 31, 2022 and December 31, 2021, three customers constituted at least 10% of the Company’s gross trade accounts receivable. The gross trade accounts receivable balances for these customers represented approximately 65.5% (26.9%, 24.9%, and 13.7%) and 60.1% (22.2%, 19.0%, and 18.9%) of the Company’s gross trade accounts receivable at March 31, 2022 and December 31, 2021, respectively.</p> constituted in excess of 10% of its net sales. constituted in excess of 10% of its net sales. 2 2 0.387 0.226 0.161 0.432 0.295 0.137 3 3 constituted at least 10% of the Company’s gross trade accounts receivable. constituted at least 10% of the Company’s gross trade accounts receivable. 0.655 0.269 0.249 0.137 0.601 0.222 0.19 0.189 false 954 --12-31 Q1 0000350737 587-6280 In April 2022, the Company’s wholly owned subsidiary, KINPAK Inc. (“Kinpak”), placed into service assets relating to an expansion of its manufacturing and distribution facilities. EXCEL 56 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 57 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 58 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 59 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 112 235 1 true 35 0 false 5 false false R1.htm 000 - Document - Document And Entity Information Sheet http://oceanbiochem.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets Sheet http://oceanbiochem.com/role/ConsolidatedBalanceSheet Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals) Sheet http://oceanbiochem.com/role/ConsolidatedBalanceSheet_Parentheticals Condensed Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://oceanbiochem.com/role/ConsolidatedIncomeStatement Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) Sheet http://oceanbiochem.com/role/ConsolidatedComprehensiveIncome Condensed Consolidated Statements of Comprehensive Income (Unaudited) Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated Statements of Shareholders??? Equity (Unaudited) Sheet http://oceanbiochem.com/role/ShareholdersEquityType2or3 Condensed Consolidated Statements of Shareholders??? Equity (Unaudited) Statements 6 false false R7.htm 006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://oceanbiochem.com/role/ConsolidatedCashFlow Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 007 - Disclosure - Summary of Accounting Policies Sheet http://oceanbiochem.com/role/SummaryofAccountingPolicies Summary of Accounting Policies Notes 8 false false R9.htm 008 - Disclosure - Inventories Sheet http://oceanbiochem.com/role/Inventories Inventories Notes 9 false false R10.htm 009 - Disclosure - Property, Plant & Equipment Sheet http://oceanbiochem.com/role/PropertyPlantEquipment Property, Plant & Equipment Notes 10 false false R11.htm 010 - Disclosure - Leases Sheet http://oceanbiochem.com/role/Leases Leases Notes 11 false false R12.htm 011 - Disclosure - Intangible Assets Sheet http://oceanbiochem.com/role/IntangibleAssets Intangible Assets Notes 12 false false R13.htm 012 - Disclosure - Revolving Line of Credit Sheet http://oceanbiochem.com/role/RevolvingLineofCredit Revolving Line of Credit Notes 13 false false R14.htm 013 - Disclosure - Long Term Debt Sheet http://oceanbiochem.com/role/LongTermDebt Long Term Debt Notes 14 false false R15.htm 014 - Disclosure - Related Party Transactions Sheet http://oceanbiochem.com/role/RelatedPartyTransactions Related Party Transactions Notes 15 false false R16.htm 015 - Disclosure - Earnings Per Common Share Sheet http://oceanbiochem.com/role/EarningsPerCommonShare Earnings Per Common Share Notes 16 false false R17.htm 016 - Disclosure - Securities Authorized for Issuance under Equity Compensation Plans Sheet http://oceanbiochem.com/role/SecuritiesAuthorizedforIssuanceunderEquityCompensationPlans Securities Authorized for Issuance under Equity Compensation Plans Notes 17 false false R18.htm 017 - Disclosure - Cash Dividends Sheet http://oceanbiochem.com/role/CashDividends Cash Dividends Notes 18 false false R19.htm 018 - Disclosure - Customer Concentration Sheet http://oceanbiochem.com/role/CustomerConcentration Customer Concentration Notes 19 false false R20.htm 019 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://oceanbiochem.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://oceanbiochem.com/role/SummaryofAccountingPolicies 20 false false R21.htm 020 - Disclosure - Inventories (Tables) Sheet http://oceanbiochem.com/role/InventoriesTables Inventories (Tables) Tables http://oceanbiochem.com/role/Inventories 21 false false R22.htm 021 - Disclosure - Property, Plant & Equipment (Tables) Sheet http://oceanbiochem.com/role/PropertyPlantEquipmentTables Property, Plant & Equipment (Tables) Tables http://oceanbiochem.com/role/PropertyPlantEquipment 22 false false R23.htm 022 - Disclosure - Leases (Tables) Sheet http://oceanbiochem.com/role/LeasesTables Leases (Tables) Tables http://oceanbiochem.com/role/Leases 23 false false R24.htm 023 - Disclosure - Intangible Assets (Tables) Sheet http://oceanbiochem.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://oceanbiochem.com/role/IntangibleAssets 24 false false R25.htm 024 - Disclosure - Long Term Debt (Tables) Sheet http://oceanbiochem.com/role/LongTermDebtTables Long Term Debt (Tables) Tables http://oceanbiochem.com/role/LongTermDebt 25 false false R26.htm 025 - Disclosure - Earnings Per Common Share (Tables) Sheet http://oceanbiochem.com/role/EarningsPerCommonShareTables Earnings Per Common Share (Tables) Tables http://oceanbiochem.com/role/EarningsPerCommonShare 26 false false R27.htm 026 - Disclosure - Inventories (Details) Sheet http://oceanbiochem.com/role/InventoriesDetails Inventories (Details) Details http://oceanbiochem.com/role/InventoriesTables 27 false false R28.htm 027 - Disclosure - Inventories (Details) - Schedule of inventories Sheet http://oceanbiochem.com/role/ScheduleofinventoriesTable Inventories (Details) - Schedule of inventories Details http://oceanbiochem.com/role/InventoriesTables 28 false false R29.htm 028 - Disclosure - Property, Plant & Equipment (Details) Sheet http://oceanbiochem.com/role/PropertyPlantEquipmentDetails Property, Plant & Equipment (Details) Details http://oceanbiochem.com/role/PropertyPlantEquipmentTables 29 false false R30.htm 029 - Disclosure - Property, Plant & Equipment (Details) - Schedule of property, plant and equipment Sheet http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable Property, Plant & Equipment (Details) - Schedule of property, plant and equipment Details http://oceanbiochem.com/role/PropertyPlantEquipmentTables 30 false false R31.htm 030 - Disclosure - Leases (Details) Sheet http://oceanbiochem.com/role/LeasesDetails Leases (Details) Details http://oceanbiochem.com/role/LeasesTables 31 false false R32.htm 031 - Disclosure - Leases (Details) - Schedule of future minimum rent payments Sheet http://oceanbiochem.com/role/ScheduleoffutureminimumrentpaymentsTable Leases (Details) - Schedule of future minimum rent payments Details http://oceanbiochem.com/role/LeasesTables 32 false false R33.htm 032 - Disclosure - Leases (Details) - Schedule of expenses incurred with respect to the company's leases Sheet http://oceanbiochem.com/role/ScheduleofexpensesincurredwithrespecttothecompanysleasesTable Leases (Details) - Schedule of expenses incurred with respect to the company's leases Details http://oceanbiochem.com/role/LeasesTables 33 false false R34.htm 033 - Disclosure - Leases (Details) - Schedule of finance leases and discount rate with respect to the operating lease and finance leases Sheet http://oceanbiochem.com/role/ScheduleoffinanceleasesanddiscountratewithrespecttotheoperatingleaseandfinanceleasesTable Leases (Details) - Schedule of finance leases and discount rate with respect to the operating lease and finance leases Details http://oceanbiochem.com/role/LeasesTables 34 false false R35.htm 034 - Disclosure - Intangible Assets (Details) Sheet http://oceanbiochem.com/role/IntangibleAssetsDetails Intangible Assets (Details) Details http://oceanbiochem.com/role/IntangibleAssetsTables 35 false false R36.htm 035 - Disclosure - Intangible Assets (Details) - Schedule of intangible assets Sheet http://oceanbiochem.com/role/ScheduleofintangibleassetsTable Intangible Assets (Details) - Schedule of intangible assets Details http://oceanbiochem.com/role/IntangibleAssetsTables 36 false false R37.htm 036 - Disclosure - Revolving Line of Credit (Details) Sheet http://oceanbiochem.com/role/RevolvingLineofCreditDetails Revolving Line of Credit (Details) Details http://oceanbiochem.com/role/RevolvingLineofCredit 37 false false R38.htm 037 - Disclosure - Long Term Debt (Details) Sheet http://oceanbiochem.com/role/LongTermDebtDetails Long Term Debt (Details) Details http://oceanbiochem.com/role/LongTermDebtTables 38 false false R39.htm 038 - Disclosure - Long Term Debt (Details) - Schedule of long-term debt Sheet http://oceanbiochem.com/role/ScheduleoflongtermdebtTable Long Term Debt (Details) - Schedule of long-term debt Details http://oceanbiochem.com/role/LongTermDebtTables 39 false false R40.htm 039 - Disclosure - Long Term Debt (Details) - Schedule of long- term obligation Sheet http://oceanbiochem.com/role/ScheduleoflongtermobligationTable Long Term Debt (Details) - Schedule of long- term obligation Details http://oceanbiochem.com/role/LongTermDebtTables 40 false false R41.htm 040 - Disclosure - Related Party Transactions (Details) Sheet http://oceanbiochem.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://oceanbiochem.com/role/RelatedPartyTransactions 41 false false R42.htm 041 - Disclosure - Earnings Per Common Share (Details) - Schedule of weighted average number of shares outstanding Sheet http://oceanbiochem.com/role/ScheduleofweightedaveragenumberofsharesoutstandingTable Earnings Per Common Share (Details) - Schedule of weighted average number of shares outstanding Details http://oceanbiochem.com/role/EarningsPerCommonShareTables 42 false false R43.htm 042 - Disclosure - Cash Dividends (Details) Sheet http://oceanbiochem.com/role/CashDividendsDetails Cash Dividends (Details) Details http://oceanbiochem.com/role/CashDividends 43 false false R44.htm 043 - Disclosure - Customer Concentration (Details) Sheet http://oceanbiochem.com/role/CustomerConcentrationDetails Customer Concentration (Details) Details http://oceanbiochem.com/role/CustomerConcentration 44 false false All Reports Book All Reports f10q0322_oceanbio.htm f10q0322ex31-1_oceanbio.htm f10q0322ex31-2_oceanbio.htm f10q0322ex32-1_oceanbio.htm f10q0322ex32-2_oceanbio.htm obci-20220331.xsd obci-20220331_cal.xml obci-20220331_def.xml obci-20220331_lab.xml obci-20220331_pre.xml http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 62 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f10q0322_oceanbio.htm": { "axisCustom": 0, "axisStandard": 11, "contextCount": 112, "dts": { "calculationLink": { "local": [ "obci-20220331_cal.xml" ] }, "definitionLink": { "local": [ "obci-20220331_def.xml" ] }, "inline": { "local": [ "f10q0322_oceanbio.htm" ] }, "labelLink": { "local": [ "obci-20220331_lab.xml" ] }, "presentationLink": { "local": [ "obci-20220331_pre.xml" ] }, "schema": { "local": [ "obci-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd" ] } }, "elementCount": 351, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 26, "http://oceanbiochem.com/20220331": 4, "http://xbrl.sec.gov/dei/2022": 6, "total": 36 }, "keyCustom": 55, "keyStandard": 180, "memberCustom": 15, "memberStandard": 19, "nsprefix": "obci", "nsuri": "http://oceanbiochem.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://oceanbiochem.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Property, Plant & Equipment", "role": "http://oceanbiochem.com/role/PropertyPlantEquipment", "shortName": "Property, Plant & Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "obci:LeasesOfLesseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Leases", "role": "http://oceanbiochem.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "obci:LeasesOfLesseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Intangible Assets", "role": "http://oceanbiochem.com/role/IntangibleAssets", "shortName": "Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "obci:LineOfCreditFacilitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Revolving Line of Credit", "role": "http://oceanbiochem.com/role/RevolvingLineofCredit", "shortName": "Revolving Line of Credit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "obci:LineOfCreditFacilitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Long Term Debt", "role": "http://oceanbiochem.com/role/LongTermDebt", "shortName": "Long Term Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Related Party Transactions", "role": "http://oceanbiochem.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Earnings Per Common Share", "role": "http://oceanbiochem.com/role/EarningsPerCommonShare", "shortName": "Earnings Per Common Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Securities Authorized for Issuance under Equity Compensation Plans", "role": "http://oceanbiochem.com/role/SecuritiesAuthorizedforIssuanceunderEquityCompensationPlans", "shortName": "Securities Authorized for Issuance under Equity Compensation Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "obci:CashDividendsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Cash Dividends", "role": "http://oceanbiochem.com/role/CashDividends", "shortName": "Cash Dividends", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "obci:CashDividendsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Customer Concentration", "role": "http://oceanbiochem.com/role/CustomerConcentration", "shortName": "Customer Concentration", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Condensed Consolidated Balance Sheets", "role": "http://oceanbiochem.com/role/ConsolidatedBalanceSheet", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "obci:InterimReportingPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Accounting Policies, by Policy (Policies)", "role": "http://oceanbiochem.com/role/AccountingPoliciesByPolicy", "shortName": "Accounting Policies, by Policy (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "obci:InterimReportingPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Inventories (Tables)", "role": "http://oceanbiochem.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Property, Plant & Equipment (Tables)", "role": "http://oceanbiochem.com/role/PropertyPlantEquipmentTables", "shortName": "Property, Plant & Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "obci:ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Leases (Tables)", "role": "http://oceanbiochem.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "obci:ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Intangible Assets (Tables)", "role": "http://oceanbiochem.com/role/IntangibleAssetsTables", "shortName": "Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Long Term Debt (Tables)", "role": "http://oceanbiochem.com/role/LongTermDebtTables", "shortName": "Long Term Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Earnings Per Common Share (Tables)", "role": "http://oceanbiochem.com/role/EarningsPerCommonShareTables", "shortName": "Earnings Per Common Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherInventoryInventoryAtOffSitePremises", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Inventories (Details)", "role": "http://oceanbiochem.com/role/InventoriesDetails", "shortName": "Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherInventoryInventoryAtOffSitePremises", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Inventories (Details) - Schedule of inventories", "role": "http://oceanbiochem.com/role/ScheduleofinventoriesTable", "shortName": "Inventories (Details) - Schedule of inventories", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Property, Plant & Equipment (Details)", "role": "http://oceanbiochem.com/role/PropertyPlantEquipmentDetails", "shortName": "Property, Plant & Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)", "role": "http://oceanbiochem.com/role/ConsolidatedBalanceSheet_Parentheticals", "shortName": "Condensed Consolidated Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Property, Plant & Equipment (Details) - Schedule of property, plant and equipment", "role": "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable", "shortName": "Property, Plant & Equipment (Details) - Schedule of property, plant and equipment", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseExpirationDate1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Leases (Details)", "role": "http://oceanbiochem.com/role/LeasesDetails", "shortName": "Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseExpirationDate1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "obci:ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "obci:OperatingLeasesFutureMinimumPaymentDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Leases (Details) - Schedule of future minimum rent payments", "role": "http://oceanbiochem.com/role/ScheduleoffutureminimumrentpaymentsTable", "shortName": "Leases (Details) - Schedule of future minimum rent payments", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "obci:ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "obci:OperatingLeasesFutureMinimumPaymentDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "obci:OperatingLeasesExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Leases (Details) - Schedule of expenses incurred with respect to the company's leases", "role": "http://oceanbiochem.com/role/ScheduleofexpensesincurredwithrespecttothecompanysleasesTable", "shortName": "Leases (Details) - Schedule of expenses incurred with respect to the company's leases", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "obci:OperatingLeasesExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "obci:ComponentsOfLeaseCostsLeaseTermAndDiscountRate", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c2", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Leases (Details) - Schedule of finance leases and discount rate with respect to the operating lease and finance leases", "role": "http://oceanbiochem.com/role/ScheduleoffinanceleasesanddiscountratewithrespecttotheoperatingleaseandfinanceleasesTable", "shortName": "Leases (Details) - Schedule of finance leases and discount rate with respect to the operating lease and finance leases", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "obci:ComponentsOfLeaseCostsLeaseTermAndDiscountRate", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c2", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Intangible Assets (Details)", "role": "http://oceanbiochem.com/role/IntangibleAssetsDetails", "shortName": "Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Intangible Assets (Details) - Schedule of intangible assets", "role": "http://oceanbiochem.com/role/ScheduleofintangibleassetsTable", "shortName": "Intangible Assets (Details) - Schedule of intangible assets", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c65", "decimals": "0", "first": true, "lang": null, "name": "obci:MaximumRevolvingCreditLineOfCreditProvidedInBusinessLoanAgreement", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Revolving Line of Credit (Details)", "role": "http://oceanbiochem.com/role/RevolvingLineofCreditDetails", "shortName": "Revolving Line of Credit (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c65", "decimals": "0", "first": true, "lang": null, "name": "obci:MaximumRevolvingCreditLineOfCreditProvidedInBusinessLoanAgreement", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Long Term Debt (Details)", "role": "http://oceanbiochem.com/role/LongTermDebtDetails", "shortName": "Long Term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "obci:LongTermDebtPrincipalCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Long Term Debt (Details) - Schedule of long-term debt", "role": "http://oceanbiochem.com/role/ScheduleoflongtermdebtTable", "shortName": "Long Term Debt (Details) - Schedule of long-term debt", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "obci:LongTermDebtPrincipalCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "role": "http://oceanbiochem.com/role/ConsolidatedIncomeStatement", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Long Term Debt (Details) - Schedule of long- term obligation", "role": "http://oceanbiochem.com/role/ScheduleoflongtermobligationTable", "shortName": "Long Term Debt (Details) - Schedule of long- term obligation", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromRelatedParties", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Related Party Transactions (Details)", "role": "http://oceanbiochem.com/role/RelatedPartyTransactionsDetails", "shortName": "Related Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromRelatedParties", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Earnings Per Common Share (Details) - Schedule of weighted average number of shares outstanding", "role": "http://oceanbiochem.com/role/ScheduleofweightedaveragenumberofsharesoutstandingTable", "shortName": "Earnings Per Common Share (Details) - Schedule of weighted average number of shares outstanding", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": "0", "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c94", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Cash Dividends (Details)", "role": "http://oceanbiochem.com/role/CashDividendsDetails", "shortName": "Cash Dividends (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c94", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "obci:CustomerConcentrationDescription", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c98", "decimals": null, "first": true, "lang": "en-US", "name": "obci:CustomerConcentrationDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Customer Concentration (Details)", "role": "http://oceanbiochem.com/role/CustomerConcentrationDetails", "shortName": "Customer Concentration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "obci:CustomerConcentrationDescription", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c98", "decimals": null, "first": true, "lang": "en-US", "name": "obci:CustomerConcentrationDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)", "role": "http://oceanbiochem.com/role/ConsolidatedComprehensiveIncome", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": "0", "lang": null, "name": "obci:ForeignCurrencyTranslationAdjustment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c17", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Condensed Consolidated Statements of Shareholders\u2019 Equity (Unaudited)", "role": "http://oceanbiochem.com/role/ShareholdersEquityType2or3", "shortName": "Condensed Consolidated Statements of Shareholders\u2019 Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c17", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://oceanbiochem.com/role/ConsolidatedCashFlow", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": "0", "lang": null, "name": "us-gaap:DepreciationAmortizationAndAccretionNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Summary of Accounting Policies", "role": "http://oceanbiochem.com/role/SummaryofAccountingPolicies", "shortName": "Summary of Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Inventories", "role": "http://oceanbiochem.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0322_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 35, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r411" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "obci_BondFinancingDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bond financing, description.", "label": "BondFinancingDescription", "terseLabel": "Bond financing, description" } } }, "localname": "BondFinancingDescription", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "obci_CanonSolutionsAmericaIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CanonSolutionsAmericaIncMember", "terseLabel": "Canon Solutions America, Inc [Member]" } } }, "localname": "CanonSolutionsAmericaIncMember", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "obci_CashDividendsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Dividends [Abstract]" } } }, "localname": "CashDividendsAbstract", "nsuri": "http://oceanbiochem.com/20220331", "xbrltype": "stringItemType" }, "obci_CashDividendsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Dividends (Details) [Line Items]" } } }, "localname": "CashDividendsDetailsLineItems", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/CashDividendsDetails" ], "xbrltype": "stringItemType" }, "obci_CashDividendsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Dividends (Details) [Table]" } } }, "localname": "CashDividendsDetailsTable", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/CashDividendsDetails" ], "xbrltype": "stringItemType" }, "obci_CashDividendsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for cash dividends including all tables.", "label": "CashDividendsTextBlock", "terseLabel": "CASH DIVIDENDS" } } }, "localname": "CashDividendsTextBlock", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/CashDividends" ], "xbrltype": "textBlockItemType" }, "obci_CashPaidUnderOperatingLease": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid under operating lease.", "label": "CashPaidUnderOperatingLease", "terseLabel": "Cash paid under operating lease" } } }, "localname": "CashPaidUnderOperatingLease", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "obci_ChargesToAffiliatedCompaniesForServices": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Charges to the affiliated companies for services.", "label": "ChargesToAffiliatedCompaniesForServices", "terseLabel": "Charges to the affiliated companies for services" } } }, "localname": "ChargesToAffiliatedCompaniesForServices", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "obci_ComponentsOfLeaseCostsLeaseTermAndDiscountRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Components of lease costs, lease term and discount rate.", "label": "ComponentsOfLeaseCostsLeaseTermAndDiscountRate", "terseLabel": "Schedule of finance leases and discount rate with respect to the operating lease and finance leases" } } }, "localname": "ComponentsOfLeaseCostsLeaseTermAndDiscountRate", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "obci_ConcentrationRiskPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "ConcentrationRiskPercentage", "terseLabel": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskPercentage", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/CustomerConcentrationDetails" ], "xbrltype": "percentItemType" }, "obci_CustomerConcentrationDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identifies or describes that serves as the denominator in the calculation of the percentage of concentration risk.", "label": "CustomerConcentrationDescription", "terseLabel": "Concentration risk, description" } } }, "localname": "CustomerConcentrationDescription", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/CustomerConcentrationDetails" ], "xbrltype": "stringItemType" }, "obci_CustomerConcentrationDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Customer Concentration (Details) [Line Items]" } } }, "localname": "CustomerConcentrationDetailsLineItems", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/CustomerConcentrationDetails" ], "xbrltype": "stringItemType" }, "obci_CustomerConcentrationDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Customer Concentration (Details) [Table]" } } }, "localname": "CustomerConcentrationDetailsTable", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/CustomerConcentrationDetails" ], "xbrltype": "stringItemType" }, "obci_CustomerOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CustomerOneMember", "terseLabel": "Customer One [Member]" } } }, "localname": "CustomerOneMember", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/CustomerConcentrationDetails" ], "xbrltype": "domainItemType" }, "obci_CustomerThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CustomerThreeMember", "terseLabel": "Customer Three [Member]" } } }, "localname": "CustomerThreeMember", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/CustomerConcentrationDetails" ], "xbrltype": "domainItemType" }, "obci_CustomerTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CustomerTwoMember", "terseLabel": "Customer Two [Member]" } } }, "localname": "CustomerTwoMember", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/CustomerConcentrationDetails" ], "xbrltype": "domainItemType" }, "obci_DebtFinancingCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of charge against earnings over the life of the debt.", "label": "DebtFinancingCosts", "terseLabel": "Debt financing costs" } } }, "localname": "DebtFinancingCosts", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "obci_DepreciationExpenseIncludesInCostOfGoodsSold": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period included in cost of goods sold that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production related depreciation.", "label": "DepreciationExpenseIncludesInCostOfGoodsSold", "terseLabel": "Depreciation included in cost of goods sold" } } }, "localname": "DepreciationExpenseIncludesInCostOfGoodsSold", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/PropertyPlantEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "obci_DepreciationExpenseIncludesInSellingAndAdministrativeExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period included in selling and administrative expenses that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes non-production related depreciation.", "label": "DepreciationExpenseIncludesInSellingAndAdministrativeExpenses", "terseLabel": "Selling and administrative expenses" } } }, "localname": "DepreciationExpenseIncludesInSellingAndAdministrativeExpenses", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/PropertyPlantEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "obci_DocumentAndEntityInformationAbstract": { "auth_ref": [], "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://oceanbiochem.com/20220331", "xbrltype": "stringItemType" }, "obci_EffectOfExchangeRateOnCash1": { "auth_ref": [], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Effect of exchange rate on cash.", "label": "EffectOfExchangeRateOnCash1", "terseLabel": "Effect of exchange rate on cash" } } }, "localname": "EffectOfExchangeRateOnCash1", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "obci_FinanceLeasePayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finance lease payment.", "label": "FinanceLeasePayment", "terseLabel": "Amount paid related to finance lease" } } }, "localname": "FinanceLeasePayment", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "obci_FinanceLeasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FinanceLeasesMember", "terseLabel": "Finance leases \u2013 right to use [Member]" } } }, "localname": "FinanceLeasesMember", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "domainItemType" }, "obci_FinancialCovenantsUnderCreditAgreementDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial covenants under credit agreement, description.", "label": "FinancialCovenantsUnderCreditAgreementDescription", "terseLabel": "Financial covenants under credit agreement, description" } } }, "localname": "FinancialCovenantsUnderCreditAgreementDescription", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "obci_ForeignCurrencyTranslationAdjustment": { "auth_ref": [], "calculation": { "http://oceanbiochem.com/role/ConsolidatedComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "ForeignCurrencyTranslationAdjustment", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "ForeignCurrencyTranslationAdjustment", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "obci_IndebtednessExcludingTradePayables": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Financial covenant that restricts our indebtedness excluding trade payables in the normal course of business.", "label": "IndebtednessExcludingTradePayables", "terseLabel": "Indebtedness excluding trade payables" } } }, "localname": "IndebtednessExcludingTradePayables", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "obci_IndustrialDevelopmentBondFinancingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IndustrialDevelopmentBondFinancingMember", "terseLabel": "Industrial Development Bond Financing [Member]" } } }, "localname": "IndustrialDevelopmentBondFinancingMember", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "obci_InsurancePremiumsPaid": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Insurance premiums paid.", "label": "InsurancePremiumsPaid", "terseLabel": "Insurance premiums paid" } } }, "localname": "InsurancePremiumsPaid", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "obci_IntangibleAssetsDetailsScheduleofintangibleassetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets (Details) - Schedule of intangible assets [Line Items]" } } }, "localname": "IntangibleAssetsDetailsScheduleofintangibleassetsLineItems", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "stringItemType" }, "obci_IntangibleAssetsDetailsScheduleofintangibleassetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets (Details) - Schedule of intangible assets [Table]" } } }, "localname": "IntangibleAssetsDetailsScheduleofintangibleassetsTable", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "stringItemType" }, "obci_InterimReportingPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "InterimReportingPolicyTextBlock", "terseLabel": "Interim reporting" } } }, "localname": "InterimReportingPolicyTextBlock", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "obci_LeaseWithImputedInterestDiscount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disclosure of the unamortized amount of the discount on the note or receivable which is deducted from the face amount of the lease.", "label": "LeaseWithImputedInterestDiscount", "negatedLabel": "Less imputed interest" } } }, "localname": "LeaseWithImputedInterestDiscount", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/ScheduleoffutureminimumrentpaymentsTable" ], "xbrltype": "monetaryItemType" }, "obci_LeasesOfLesseDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LeasesOfLesseDisclosureTextBlock", "terseLabel": "LEASES" } } }, "localname": "LeasesOfLesseDisclosureTextBlock", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "obci_LeasesTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases Disclosure [Abstract]" } } }, "localname": "LeasesTablesLineItems", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/LeasesTables" ], "xbrltype": "stringItemType" }, "obci_LeasesTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases (Tables) [Table]" } } }, "localname": "LeasesTablesTable", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/LeasesTables" ], "xbrltype": "stringItemType" }, "obci_LendersPurchaseOfIndustrialDevelopmentBond": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lender's purchase of industrial development bond.", "label": "LendersPurchaseOfIndustrialDevelopmentBond", "terseLabel": "Lender's purchase of industrial development bond" } } }, "localname": "LendersPurchaseOfIndustrialDevelopmentBond", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "obci_LineOfCreditFacilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Line Of Credit Facilities [Abstract]" } } }, "localname": "LineOfCreditFacilitiesAbstract", "nsuri": "http://oceanbiochem.com/20220331", "xbrltype": "stringItemType" }, "obci_LineOfCreditFacilitiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revolving line of credit.", "label": "LineOfCreditFacilitiesTextBlock", "terseLabel": "REVOLVING LINE OF CREDIT" } } }, "localname": "LineOfCreditFacilitiesTextBlock", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/RevolvingLineofCredit" ], "xbrltype": "textBlockItemType" }, "obci_LongTermDebtDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Debt (Details) [Line Items]" } } }, "localname": "LongTermDebtDetailsLineItems", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "obci_LongTermDebtDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Debt (Details) [Table]" } } }, "localname": "LongTermDebtDetailsTable", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "obci_LongTermDebtPrincipalCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current having initial terms less than one year or the normal operating cycle, if longer.", "label": "LongTermDebtPrincipalCurrent", "terseLabel": "Total principal of long- term debt, Current Portion" } } }, "localname": "LongTermDebtPrincipalCurrent", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/ScheduleoflongtermdebtTable" ], "xbrltype": "monetaryItemType" }, "obci_LongTermDebtPrincipalNonCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer.", "label": "LongTermDebtPrincipalNonCurrent", "terseLabel": "Total principal of long- term debt, Long Term Portion" } } }, "localname": "LongTermDebtPrincipalNonCurrent", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/ScheduleoflongtermdebtTable" ], "xbrltype": "monetaryItemType" }, "obci_ManufacturingAndWarehouseEquipment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount at the balance sheet date of manufacturing and warehouse equipment.", "label": "ManufacturingAndWarehouseEquipment", "terseLabel": "Manufacturing and warehouse equipment" } } }, "localname": "ManufacturingAndWarehouseEquipment", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "monetaryItemType" }, "obci_ManufacturingAndWarehouseEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Manufacturing and warehouse equipment.", "label": "ManufacturingAndWarehouseEquipmentMember", "terseLabel": "Manufacturing and warehouse equipment [Member]" } } }, "localname": "ManufacturingAndWarehouseEquipmentMember", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "domainItemType" }, "obci_MaximumRevolvingCreditLineOfCreditProvidedInBusinessLoanAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity of the credit facility without consideration of any restrictions on the amount that could be borrowed or the amounts outstanding under the facility.", "label": "MaximumRevolvingCreditLineOfCreditProvidedInBusinessLoanAgreement", "terseLabel": "Maximum revolving credit line of credit provided in business loan agreement" } } }, "localname": "MaximumRevolvingCreditLineOfCreditProvidedInBusinessLoanAgreement", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/RevolvingLineofCreditDetails" ], "xbrltype": "monetaryItemType" }, "obci_NotePayableRelatedToAssetAcquisitionCurrentPortion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of note payable related to asset acquisition current portion.", "label": "NotePayableRelatedToAssetAcquisitionCurrentPortion", "terseLabel": "Note payable related to Snappy Marine asset acquisition, Current Portion" } } }, "localname": "NotePayableRelatedToAssetAcquisitionCurrentPortion", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/ScheduleoflongtermdebtTable" ], "xbrltype": "monetaryItemType" }, "obci_NotePayableRelatedToAssetAcquisitionLongTermPortion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of note payable related to asset acquisition, long term portion.", "label": "NotePayableRelatedToAssetAcquisitionLongTermPortion", "terseLabel": "Note payable related to Snappy Marine asset acquisition, Long Term Portion" } } }, "localname": "NotePayableRelatedToAssetAcquisitionLongTermPortion", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/ScheduleoflongtermdebtTable" ], "xbrltype": "monetaryItemType" }, "obci_NotePayableRelatedToAssetAcquisitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NotePayableRelatedToAssetAcquisitionMember", "terseLabel": "Note payable related to Snappy Marine asset acquisition [Member]" } } }, "localname": "NotePayableRelatedToAssetAcquisitionMember", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/ScheduleoflongtermdebtTable" ], "xbrltype": "domainItemType" }, "obci_NumberOfCustomer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of customers.", "label": "NumberOfCustomer", "terseLabel": "Number of customers" } } }, "localname": "NumberOfCustomer", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/CustomerConcentrationDetails" ], "xbrltype": "integerItemType" }, "obci_ObligationRelatedToCheckCorporationAssetAcquisitionCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, check corporation asset acquisition, classified as current having initial terms less than one year or the normal operating cycle, if longer.", "label": "ObligationRelatedToCheckCorporationAssetAcquisitionCurrent", "terseLabel": "Obligation related to Check Corporation asset acquisition, Current Portion" } } }, "localname": "ObligationRelatedToCheckCorporationAssetAcquisitionCurrent", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/ScheduleoflongtermdebtTable" ], "xbrltype": "monetaryItemType" }, "obci_ObligationRelatedToCheckCorporationAssetAcquisitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ObligationRelatedToCheckCorporationAssetAcquisitionMember", "terseLabel": "Obligation related to Check Corporation asset acquisition [Member]" } } }, "localname": "ObligationRelatedToCheckCorporationAssetAcquisitionMember", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/ScheduleoflongtermdebtTable" ], "xbrltype": "domainItemType" }, "obci_ObligationRelatedToCheckCorporationAssetAcquisitionNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, check corporation asset acquisition non current.", "label": "ObligationRelatedToCheckCorporationAssetAcquisitionNoncurrent", "terseLabel": "Obligation related to Check Corporation asset acquisition, Long Term Portion" } } }, "localname": "ObligationRelatedToCheckCorporationAssetAcquisitionNoncurrent", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/ScheduleoflongtermdebtTable" ], "xbrltype": "monetaryItemType" }, "obci_ObligationsRelatedToIndustrialDevelopmentBondFinancingCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, industrial development bond financing, classified as current having initial terms less than one year or the normal operating cycle, if longer.", "label": "ObligationsRelatedToIndustrialDevelopmentBondFinancingCurrent", "terseLabel": "Obligations related to industrial development bond financing, Current Portion" } } }, "localname": "ObligationsRelatedToIndustrialDevelopmentBondFinancingCurrent", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/ScheduleoflongtermdebtTable" ], "xbrltype": "monetaryItemType" }, "obci_ObligationsRelatedToIndustrialDevelopmentBondFinancingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ObligationsRelatedToIndustrialDevelopmentBondFinancingMember", "terseLabel": "Obligations related to industrial development bond financing [Member]" } } }, "localname": "ObligationsRelatedToIndustrialDevelopmentBondFinancingMember", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/ScheduleoflongtermdebtTable" ], "xbrltype": "domainItemType" }, "obci_ObligationsRelatedToIndustrialDevelopmentBondFinancingNonCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, industrial development bond financing non current.", "label": "ObligationsRelatedToIndustrialDevelopmentBondFinancingNonCurrent", "terseLabel": "Obligations related to industrial development bond financing, Long Term portion" } } }, "localname": "ObligationsRelatedToIndustrialDevelopmentBondFinancingNonCurrent", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/ScheduleoflongtermdebtTable" ], "xbrltype": "monetaryItemType" }, "obci_OfficeEquipmentFinanceLeasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OfficeEquipmentFinanceLeasesMember", "terseLabel": "Office equipment finance leases [Member]" } } }, "localname": "OfficeEquipmentFinanceLeasesMember", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/ScheduleoflongtermdebtTable" ], "xbrltype": "domainItemType" }, "obci_OfficeEquipmentLeases": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of office equipment for finance leases.", "label": "OfficeEquipmentLeases", "terseLabel": "Office equipment leases" } } }, "localname": "OfficeEquipmentLeases", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "obci_OperatingLeaseLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "OperatingLeaseLiabilities", "terseLabel": "Total operating lease liability" } } }, "localname": "OperatingLeaseLiabilities", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/ScheduleoffutureminimumrentpaymentsTable" ], "xbrltype": "monetaryItemType" }, "obci_OperatingLeaseRightOfUseAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease right to use asset and corresponding liability.", "label": "OperatingLeaseRightOfUseAssets", "terseLabel": "Operating lease right to use asset and corresponding liability" } } }, "localname": "OperatingLeaseRightOfUseAssets", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "obci_OperatingLeasesExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "OperatingLeasesExpense", "terseLabel": "Operating lease expense" } } }, "localname": "OperatingLeasesExpense", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/ScheduleofexpensesincurredwithrespecttothecompanysleasesTable" ], "xbrltype": "monetaryItemType" }, "obci_OperatingLeasesFutureMinimumPaymentDue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "OperatingLeasesFutureMinimumPaymentDue", "terseLabel": "Total future minimum lease payments" } } }, "localname": "OperatingLeasesFutureMinimumPaymentDue", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/ScheduleoffutureminimumrentpaymentsTable" ], "xbrltype": "monetaryItemType" }, "obci_OperatingLeasesFutureMinimumPaymentDueCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "OperatingLeasesFutureMinimumPaymentDueCurrent", "terseLabel": "2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentDueCurrent", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/ScheduleoffutureminimumrentpaymentsTable" ], "xbrltype": "monetaryItemType" }, "obci_OperatingLeasesFutureMinimumPaymentDueInTwoYears": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "OperatingLeasesFutureMinimumPaymentDueInTwoYears", "terseLabel": "2024" } } }, "localname": "OperatingLeasesFutureMinimumPaymentDueInTwoYears", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/ScheduleoffutureminimumrentpaymentsTable" ], "xbrltype": "monetaryItemType" }, "obci_OtherLongTermObligationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OtherLongTermObligationsMember", "terseLabel": "Other Long-Term Obligations [Member]" } } }, "localname": "OtherLongTermObligationsMember", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "obci_PercentageOfMaximumAnnaulIncreaseFromBaseRent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of maximum annaul increase from base rent.", "label": "PercentageOfMaximumAnnaulIncreaseFromBaseRent", "terseLabel": "Percentage of maximum annual increase from base rent" } } }, "localname": "PercentageOfMaximumAnnaulIncreaseFromBaseRent", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/LeasesDetails" ], "xbrltype": "percentItemType" }, "obci_PrepaymentPenaltyPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepayment penalty percentage.", "label": "PrepaymentPenaltyPercentage", "terseLabel": "Prepayment penalty, percentage" } } }, "localname": "PrepaymentPenaltyPercentage", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "percentItemType" }, "obci_ProceedsOfBondSale": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds of the Bond sale.", "label": "ProceedsOfBondSale", "terseLabel": "Proceeds of the bond sale" } } }, "localname": "ProceedsOfBondSale", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "obci_ProductFormulasMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ProductFormulasMember", "terseLabel": "Product formulas [Member]" } } }, "localname": "ProductFormulasMember", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "domainItemType" }, "obci_ProductionOfTelevisionCommercials": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The production of television commercials.", "label": "ProductionOfTelevisionCommercials", "terseLabel": "The production of television commercials" } } }, "localname": "ProductionOfTelevisionCommercials", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "obci_ProvisionForSlowMovingAndObsoleteInventory": { "auth_ref": [], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Provision for slow moving and obsolete inventory.", "label": "ProvisionForSlowMovingAndObsoleteInventory", "terseLabel": "Provision for slow moving and obsolete inventory" } } }, "localname": "ProvisionForSlowMovingAndObsoleteInventory", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "obci_ReimburseBusinessRelatedExpenditures": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount the Company will be reimbursed by the affiliates for business related expenditures in addition to other administrative services.", "label": "ReimburseBusinessRelatedExpenditures", "terseLabel": "Reimburse business related expenditures" } } }, "localname": "ReimburseBusinessRelatedExpenditures", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "obci_RelatedPartyTransactionsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions (Details) [Line Items]" } } }, "localname": "RelatedPartyTransactionsDetailsLineItems", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "obci_RelatedPartyTransactionsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions (Details) [Table]" } } }, "localname": "RelatedPartyTransactionsDetailsTable", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "obci_RepurchasePriceOfFacilitiesIfBondHasBeenRedeemedOrFullyPaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Repurchase price of facilities if bond has been redeemed or fully paid.", "label": "RepurchasePriceOfFacilitiesIfBondHasBeenRedeemedOrFullyPaid", "terseLabel": "Repurchase price of facilities if bond has been redeemed or fully paid" } } }, "localname": "RepurchasePriceOfFacilitiesIfBondHasBeenRedeemedOrFullyPaid", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "obci_RevolvingLineOfCredit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity of the credit facility without consideration of any restrictions on the amount that could be borrowed or the amounts outstanding under the facility.", "label": "RevolvingLineOfCredit", "terseLabel": "Revolving line of credit" } } }, "localname": "RevolvingLineOfCredit", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "obci_RevolvingLineOfCreditMajorityShareholdersOwnershipPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum percentage of shares required by the majority shareholder to own.", "label": "RevolvingLineOfCreditMajorityShareholdersOwnershipPercentage", "terseLabel": "Majority shareholder's ownership, percentage" } } }, "localname": "RevolvingLineOfCreditMajorityShareholdersOwnershipPercentage", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "percentItemType" }, "obci_RevolvingLineofCreditLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revolving Line of Credit [Abstract]" } } }, "localname": "RevolvingLineofCreditLineItems", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/RevolvingLineofCredit" ], "xbrltype": "stringItemType" }, "obci_RevolvingLineofCreditTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revolving Line of Credit [Table]" } } }, "localname": "RevolvingLineofCreditTable", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/RevolvingLineofCredit" ], "xbrltype": "stringItemType" }, "obci_RoyaltyRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RoyaltyRightsMember", "terseLabel": "Royalty rights [Member]" } } }, "localname": "RoyaltyRightsMember", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "domainItemType" }, "obci_ScheduleOfExpensesIncurredWithRespectToTheCompanysLeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of expenses incurred with respect to the company's leases [Abstract]" } } }, "localname": "ScheduleOfExpensesIncurredWithRespectToTheCompanysLeasesAbstract", "nsuri": "http://oceanbiochem.com/20220331", "xbrltype": "stringItemType" }, "obci_ScheduleOfFinanceLeasesAndDiscountRateWithRespectToTheOperatingLeaseAndFinanceLeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of finance leases and discount rate with respect to the operating lease and finance leases [Abstract]" } } }, "localname": "ScheduleOfFinanceLeasesAndDiscountRateWithRespectToTheOperatingLeaseAndFinanceLeasesAbstract", "nsuri": "http://oceanbiochem.com/20220331", "xbrltype": "stringItemType" }, "obci_ScheduleOfFutureMinimumRentPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of future minimum rent payments [Abstract]" } } }, "localname": "ScheduleOfFutureMinimumRentPaymentsAbstract", "nsuri": "http://oceanbiochem.com/20220331", "xbrltype": "stringItemType" }, "obci_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock", "terseLabel": "Schedule of future minimum rent payments" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "obci_ScheduleOfIntangibleAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of intangible assets [Abstract]" } } }, "localname": "ScheduleOfIntangibleAssetsAbstract", "nsuri": "http://oceanbiochem.com/20220331", "xbrltype": "stringItemType" }, "obci_ScheduleOfInventoriesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of inventories [Abstract]" } } }, "localname": "ScheduleOfInventoriesAbstract", "nsuri": "http://oceanbiochem.com/20220331", "xbrltype": "stringItemType" }, "obci_ScheduleOfLongTermDebtAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of long-term debt [Abstract]" } } }, "localname": "ScheduleOfLongTermDebtAbstract", "nsuri": "http://oceanbiochem.com/20220331", "xbrltype": "stringItemType" }, "obci_ScheduleOfLongTermObligationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of long- term obligation [Abstract]" } } }, "localname": "ScheduleOfLongTermObligationAbstract", "nsuri": "http://oceanbiochem.com/20220331", "xbrltype": "stringItemType" }, "obci_ScheduleOfPropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of property, plant and equipment [Abstract]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentAbstract", "nsuri": "http://oceanbiochem.com/20220331", "xbrltype": "stringItemType" }, "obci_ScheduleOfWeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of weighted average number of shares outstanding [Abstract]" } } }, "localname": "ScheduleOfWeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://oceanbiochem.com/20220331", "xbrltype": "stringItemType" }, "obci_SupplementalDisclosureCash": { "auth_ref": [], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "obci_SupplementalDisclosureCashAndRestrictedCash", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "SupplementalDisclosureCash", "terseLabel": "Cash" } } }, "localname": "SupplementalDisclosureCash", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "obci_SupplementalDisclosureCashAndRestrictedCash": { "auth_ref": [], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "SupplementalDisclosureCashAndRestrictedCash", "totalLabel": "Total cash and restricted cash" } } }, "localname": "SupplementalDisclosureCashAndRestrictedCash", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "obci_SupplementalDisclosureRestrictedCash": { "auth_ref": [], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "obci_SupplementalDisclosureCashAndRestrictedCash", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "SupplementalDisclosureRestrictedCash", "terseLabel": "Restricted cash" } } }, "localname": "SupplementalDisclosureRestrictedCash", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "obci_TermLoanDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term loan, description.", "label": "TermLoanDescription", "terseLabel": "Term loan, description" } } }, "localname": "TermLoanDescription", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "obci_TermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TermLoanMember", "terseLabel": "Term loan [Member]", "verboseLabel": "Term Loan [Member]" } } }, "localname": "TermLoanMember", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails", "http://oceanbiochem.com/role/ScheduleoflongtermdebtTable" ], "xbrltype": "domainItemType" }, "obci_TotalPaymentsToAffiliatedCompany": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total payments to affiliated company.", "label": "TotalPaymentsToAffiliatedCompany", "terseLabel": "Total payments to affiliated company" } } }, "localname": "TotalPaymentsToAffiliatedCompany", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "obci_Vehicles": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of vehicles.", "label": "Vehicles", "terseLabel": "Vehicles" } } }, "localname": "Vehicles", "nsuri": "http://oceanbiochem.com/20220331", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "monetaryItemType" }, "srt_BoardOfDirectorsChairmanMember": { "auth_ref": [ "r141" ], "lang": { "en-us": { "role": { "label": "Board of Directors Chairman [Member]", "terseLabel": "Board of Directors [Member]" } } }, "localname": "BoardOfDirectorsChairmanMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://oceanbiochem.com/role/CashDividendsDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r140", "r234", "r236", "r381" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://oceanbiochem.com/role/CustomerConcentrationDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r181", "r182", "r183", "r184", "r202", "r225", "r239", "r240", "r321", "r322", "r323", "r324", "r325", "r326", "r345", "r379", "r382", "r396", "r397" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails", "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r181", "r182", "r183", "r184", "r202", "r225", "r239", "r240", "r321", "r322", "r323", "r324", "r325", "r326", "r345", "r379", "r382", "r396", "r397" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails", "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r140", "r234", "r236", "r381" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://oceanbiochem.com/role/CustomerConcentrationDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r138", "r182", "r183", "r234", "r235", "r347", "r378", "r380" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://oceanbiochem.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r138", "r182", "r183", "r234", "r235", "r347", "r378", "r380" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://oceanbiochem.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r180", "r181", "r182", "r183", "r184", "r202", "r225", "r237", "r239", "r240", "r241", "r242", "r243", "r321", "r322", "r323", "r324", "r325", "r326", "r345", "r379", "r382", "r396", "r397" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails", "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r180", "r181", "r182", "r183", "r184", "r202", "r225", "r237", "r239", "r240", "r241", "r242", "r243", "r321", "r322", "r323", "r324", "r325", "r326", "r345", "r379", "r382", "r396", "r397" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails", "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r141", "r307" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://oceanbiochem.com/role/CashDividendsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableTradeCurrent": { "auth_ref": [ "r6", "r33" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Trade, Current", "terseLabel": "Accounts payable - trade" } } }, "localname": "AccountsPayableTradeCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r392" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Trade Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/CustomerConcentrationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r142", "r143" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Trade accounts receivable less allowances of approximately $712,000 and $632,000, respectively" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r15", "r352", "r367" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "terseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r36" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses payable" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r10", "r177" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r21", "r44", "r45", "r46", "r368", "r387", "r388" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r43", "r46", "r52", "r53", "r54", "r87", "r88", "r89", "r265", "r302", "r383", "r384" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r19" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r87", "r88", "r89", "r244", "r245", "r246", "r269" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash (used in) provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r25", "r144", "r153" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Trade accounts receivable allowance for doubtful accounts (in Dollars)" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r75", "r168", "r172" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization expense related to intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/IntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AreaOfLand": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of land held.", "label": "Area of Land", "terseLabel": "Area of square foot (in Square Meters)" } } }, "localname": "AreaOfLand", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "areaItemType" }, "us-gaap_Assets": { "auth_ref": [ "r13", "r82", "r127", "r130", "r136", "r151", "r186", "r187", "r188", "r190", "r191", "r192", "r193", "r194", "r195", "r197", "r198", "r263", "r266", "r274", "r312", "r314", "r350", "r366" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r32", "r82", "r151", "r186", "r187", "r188", "r190", "r191", "r192", "r193", "r194", "r195", "r197", "r198", "r263", "r266", "r274", "r312", "r314" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current Assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_BuildingImprovementsMember": { "auth_ref": [ "r176" ], "lang": { "en-us": { "role": { "documentation": "Addition, improvement, or renovation to a facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building Improvements [Member]", "terseLabel": "Building and improvements [Member]" } } }, "localname": "BuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingsAndImprovementsGross": { "auth_ref": [ "r176" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Buildings and Improvements, Gross", "terseLabel": "Building and improvements" } } }, "localname": "BuildingsAndImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r8", "r77" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r70", "r77", "r79" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and restricted cash at end of period", "periodStartLabel": "Cash and restricted cash at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r70", "r275" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r40", "r355", "r372" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Cash Paid", "terseLabel": "Dividends paid per common share" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/CashDividendsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Dividends declared per common share (in Dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r87", "r88", "r269" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in Dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r18", "r227" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/CashDividendsDetails", "http://oceanbiochem.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r18", "r314" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock - $0.01 par value, 12,000,000 shares authorized; 9,509,799 shares and 9,503,999 shares issued and outstanding, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r48", "r50", "r51", "r59", "r358", "r374" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r117", "r118", "r140", "r272", "r273", "r389", "r392" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/CustomerConcentrationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r122" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "Concentration Risk Disclosure [Text Block]", "terseLabel": "CUSTOMER CONCENTRATION" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/CustomerConcentration" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressGross": { "auth_ref": [ "r176" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress, Gross", "terseLabel": "Construction in process" } } }, "localname": "ConstructionInProgressGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in process [Member]" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r64", "r347" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of goods sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerListsMember": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "Information about customers such as their name and contact information; it may also be an extensive database that includes other information about the customers such as their order history and demographic information.", "label": "Customer Lists [Member]", "terseLabel": "Customer list [Member]" } } }, "localname": "CustomerListsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r14", "r15", "r16", "r81", "r85", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r219", "r220", "r221", "r222", "r286", "r351", "r353", "r364" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleoflongtermdebtTable" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r16", "r217", "r353", "r364" ], "calculation": { "http://oceanbiochem.com/role/ScheduleoflongtermobligationTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-Term Debt, Gross", "totalLabel": "Total" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleoflongtermobligationTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r199", "r219", "r220", "r284", "r286", "r287" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Original principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r38", "r218", "r284", "r286" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Percentage of interest rates" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleoflongtermdebtTable" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r39", "r81", "r85", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r219", "r220", "r221", "r222", "r286" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleoflongtermdebtTable" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.", "label": "Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid", "terseLabel": "Final payment" } } }, "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r39", "r81", "r85", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r219", "r220", "r221", "r222", "r228", "r229", "r230", "r231", "r283", "r284", "r286", "r287", "r363" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleoflongtermdebtTable" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredFinanceCostsCurrentNet": { "auth_ref": [ "r285" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Current, Net", "negatedLabel": "Debt issuance costs, Current Portion" } } }, "localname": "DeferredFinanceCostsCurrentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleoflongtermdebtTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNoncurrentNet": { "auth_ref": [ "r285" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Noncurrent, Net", "negatedLabel": "Debt issuance costs, Long Term Portion" } } }, "localname": "DeferredFinanceCostsNoncurrentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleoflongtermdebtTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r75", "r83", "r252", "r256", "r257", "r258" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r249", "r250" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r75", "r175" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/PropertyPlantEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAmortizationAndAccretionNet": { "auth_ref": [ "r75" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Depreciation, Amortization and Accretion, Net", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAmortizationAndAccretionNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureTextBlockSupplementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Text Block Supplement [Abstract]" } } }, "localname": "DisclosureTextBlockSupplementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r232" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedLabel": "Dividends, common stock" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueFromAffiliateCurrent": { "auth_ref": [ "r306", "r307", "r311" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of receivables due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership, due within 1 year (or 1 business cycle).", "label": "Due from Affiliate, Current", "terseLabel": "Receivables due from affiliated companies" } } }, "localname": "DueFromAffiliateCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueFromAffiliateNoncurrent": { "auth_ref": [ "r306", "r307", "r311", "r349", "r365", "r390" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of receivables due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership, due after 1 year (or 1 business cycle).", "label": "Due from Affiliate, Noncurrent", "terseLabel": "Receivables due from affiliated companies" } } }, "localname": "DueFromAffiliateNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r60", "r92", "r93", "r94", "r95", "r96", "r100", "r101", "r103", "r104", "r105", "r109", "r110", "r270", "r271", "r359", "r375" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Earnings per common share (in Dollars per share)", "verboseLabel": "Earnings per common share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedIncomeStatement", "http://oceanbiochem.com/role/ScheduleofweightedaveragenumberofsharesoutstandingTable" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r106", "r107", "r108", "r111" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "EARNINGS PER COMMON SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/EarningsPerCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r52", "r53", "r54", "r87", "r88", "r89", "r91", "r97", "r99", "r112", "r152", "r227", "r232", "r244", "r245", "r246", "r253", "r254", "r269", "r276", "r277", "r278", "r279", "r280", "r281", "r302", "r383", "r384", "r385" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r290", "r296", "r301" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "terseLabel": "Finance lease interest" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleofexpensesincurredwithrespecttothecompanysleasesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "auth_ref": [ "r293", "r297" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest paid on finance lease liability.", "label": "Finance Lease, Interest Payment on Liability", "terseLabel": "Interest paid under lease agreement" } } }, "localname": "FinanceLeaseInterestPaymentOnLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r289" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Office equipment finance leases, Current Portion" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleoflongtermdebtTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r289" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Office equipment finance leases, Long Term Portion" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleoflongtermdebtTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r292", "r297" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "terseLabel": "Principal under lease agreement" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r290", "r296", "r301" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "terseLabel": "Finance lease amortization" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleofexpensesincurredwithrespecttothecompanysleasesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": { "auth_ref": [ "r288" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization", "terseLabel": "Finance leases \u2013 right to use" } } }, "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r299", "r301" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate \u2013 finance leases" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleoffinanceleasesanddiscountratewithrespecttotheoperatingleaseandfinanceleasesTable" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r298", "r301" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term \u2013 finance leases" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleoffinanceleasesanddiscountratewithrespecttotheoperatingleaseandfinanceleasesTable" ], "xbrltype": "durationItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r146", "r147", "r148", "r149", "r150", "r154", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r216", "r226", "r268", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r404", "r405", "r406", "r407", "r408", "r409", "r410" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r12", "r171" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Intangible assets, Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesGross": { "auth_ref": [ "r176" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures, Gross", "terseLabel": "Office equipment and furniture" } } }, "localname": "FurnitureAndFixturesGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r63", "r82", "r127", "r129", "r132", "r135", "r137", "r151", "r186", "r187", "r188", "r191", "r192", "r193", "r194", "r195", "r197", "r198", "r274" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r57", "r127", "r129", "r132", "r135", "r137", "r348", "r356", "r361", "r376" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r84", "r98", "r99", "r126", "r251", "r255", "r259", "r377" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r72", "r78" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Cash paid for income taxes during period" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseDueFromAffiliates": { "auth_ref": [ "r74" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in receivables to be collected from an entity that is controlling, under the control of, or within the same control group as the reporting entity by means of direct or indirect ownership.", "label": "Increase (Decrease) Due from Affiliates", "negatedLabel": "Receivables due from affiliated companies" } } }, "localname": "IncreaseDecreaseDueFromAffiliates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r74" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable \u2013 trade" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r74" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Trade accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r74" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "Income taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r74" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses payable" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r74" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r74" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r169", "r173" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r169", "r173" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r174" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "INTANGIBLE ASSETS" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/IntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [ "r11" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Intangible Assets, Gross (Excluding Goodwill)", "terseLabel": "Intangible assets, Cost" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r167", "r170" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net", "verboseLabel": "Intangible assets, Net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet", "http://oceanbiochem.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r55", "r125", "r282", "r285", "r360" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest (expense), net" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r69", "r71", "r78" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest during period" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r165" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "INVENTORIES" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r26" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleofinventoriesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryGross": { "auth_ref": [ "r31" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Inventory, Gross", "terseLabel": "Inventories, gross" } } }, "localname": "InventoryGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleofinventoriesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r31", "r314" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet", "http://oceanbiochem.com/role/ScheduleofinventoriesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r27" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleofinventoriesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r31", "r164" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Inventory Valuation Reserves", "negatedLabel": "Inventory reserves" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleofinventoriesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_Land": { "auth_ref": [ "r9" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.", "label": "Land", "terseLabel": "Land" } } }, "localname": "Land", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r235" ], "lang": { "en-us": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land [Member]" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r300", "r301" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "terseLabel": "Total lease expense" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleofexpensesincurredwithrespecttothecompanysleasesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of expenses incurred with respect to the company's leases" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseExpirationDate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.", "label": "Lease Expiration Date", "terseLabel": "Expires date" } } }, "localname": "LeaseExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/LeasesDetails" ], "xbrltype": "dateItemType" }, "us-gaap_LeaseholdImprovementsGross": { "auth_ref": [ "r176" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements, Gross", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r176" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LesseeFinanceLeaseDescription": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "Description of lessee's finance lease.", "label": "Lessee, Finance Lease, Description", "terseLabel": "Lease agreement, description" } } }, "localname": "LesseeFinanceLeaseDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r35", "r82", "r131", "r151", "r186", "r187", "r188", "r191", "r192", "r193", "r194", "r195", "r197", "r198", "r264", "r266", "r267", "r274", "r312", "r313" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r24", "r82", "r151", "r274", "r314", "r354", "r370" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Shareholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r5", "r37", "r82", "r151", "r186", "r187", "r188", "r191", "r192", "r193", "r194", "r195", "r197", "r198", "r264", "r266", "r267", "r274", "r312", "r313", "r314" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current Liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityCovenantTerms": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "Description of the conditions for borrowing under the credit facility including the nature of any restrictions.", "label": "Line of Credit Facility, Covenant Terms", "terseLabel": "Guarantee agreement, description" } } }, "localname": "LineOfCreditFacilityCovenantTerms", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityInterestRateDescription": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "Description of interest rate for borrowing under credit facility. Includes, but is not limited to, terms and method for determining interest rate.", "label": "Line of Credit Facility, Interest Rate Description", "terseLabel": "Description of interest on the revolving line of credit" } } }, "localname": "LineOfCreditFacilityInterestRateDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/RevolvingLineofCreditDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LoansPayableCurrent": { "auth_ref": [ "r36" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.", "label": "Loans Payable, Current", "terseLabel": "Term loan, Current Portion" } } }, "localname": "LoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleoflongtermdebtTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "auth_ref": [ "r16" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.", "label": "Long-Term Debt and Lease Obligation", "terseLabel": "Long-term debt, less current portion and debt issuance costs", "verboseLabel": "Total long- term debt, Long Term Portion" } } }, "localname": "LongTermDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet", "http://oceanbiochem.com/role/ScheduleoflongtermdebtTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": { "auth_ref": [ "r36" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as current.", "label": "Long-Term Debt and Lease Obligation, Current", "terseLabel": "Current portion of long-term debt, net", "verboseLabel": "Total long- term debt, Current Portion" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet", "http://oceanbiochem.com/role/ScheduleoflongtermdebtTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtDescription": { "auth_ref": [ "r39", "r228" ], "lang": { "en-us": { "role": { "documentation": "Description of long-term debt arrangements, which are debt arrangements that originally require full repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer, and disclosures pertaining to the underlying arrangements, including repayment terms, conversion features, interest rates, restrictions on assets and activities, debt covenants, and other matters important to users of the financial statements. Types of long-term debt arrangements include borrowing under notes payable, bonds payable, debentures, term loans, and other contractual obligations for payment.", "label": "Long-Term Debt, Description", "terseLabel": "Promissory note, description" } } }, "localname": "LongTermDebtDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "auth_ref": [ "r85", "r185", "r211" ], "calculation": { "http://oceanbiochem.com/role/ScheduleoflongtermobligationTable": { "order": 6.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleoflongtermobligationTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r85", "r185", "r211" ], "calculation": { "http://oceanbiochem.com/role/ScheduleoflongtermobligationTable": { "order": 1.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleoflongtermobligationTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r85", "r185", "r211" ], "calculation": { "http://oceanbiochem.com/role/ScheduleoflongtermobligationTable": { "order": 5.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Five", "terseLabel": "2027" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleoflongtermobligationTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r85", "r185", "r211" ], "calculation": { "http://oceanbiochem.com/role/ScheduleoflongtermobligationTable": { "order": 4.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2026" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleoflongtermobligationTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r85", "r185", "r211" ], "calculation": { "http://oceanbiochem.com/role/ScheduleoflongtermobligationTable": { "order": 3.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleoflongtermobligationTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r85", "r185", "r211" ], "calculation": { "http://oceanbiochem.com/role/ScheduleoflongtermobligationTable": { "order": 2.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleoflongtermobligationTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-Term Debt [Text Block]", "terseLabel": "LONG TERM DEBT" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/LongTermDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermLoansPayable": { "auth_ref": [ "r39" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Loans Payable, Noncurrent", "terseLabel": "Term loan, Long Term portion" } } }, "localname": "LongTermLoansPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleoflongtermdebtTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketingAndAdvertisingExpense": { "auth_ref": [ "r65" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total expense recognized in the period for promotion, public relations, and brand or product advertising.", "label": "Marketing and Advertising Expense", "terseLabel": "Advertising and promotion" } } }, "localname": "MarketingAndAdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketingExpense": { "auth_ref": [ "r65" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs.", "label": "Marketing Expense", "terseLabel": "Charter boat services" } } }, "localname": "MarketingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r70" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r70" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r70", "r73", "r76" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash (used in) provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r47", "r49", "r54", "r58", "r76", "r82", "r90", "r92", "r93", "r94", "r95", "r98", "r99", "r102", "r127", "r129", "r132", "r135", "r137", "r151", "r186", "r187", "r188", "r191", "r192", "r193", "r194", "r195", "r197", "r198", "r271", "r274", "r357", "r373" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://oceanbiochem.com/role/ConsolidatedComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://oceanbiochem.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income", "totalLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow", "http://oceanbiochem.com/role/ConsolidatedComprehensiveIncome", "http://oceanbiochem.com/role/ConsolidatedIncomeStatement", "http://oceanbiochem.com/role/ScheduleofweightedaveragenumberofsharesoutstandingTable", "http://oceanbiochem.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]", "terseLabel": "Office equipment and furniture [Member]" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://oceanbiochem.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating Expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r127", "r129", "r132", "r135", "r137" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Operating income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r291" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r289" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of operating lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r289" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liability, less current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r294", "r297" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Annual minimum base rent" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r288" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease \u2013 right to use" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r299", "r301" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Discount rate \u2013 operating lease" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleoffinanceleasesanddiscountratewithrespecttotheoperatingleaseandfinanceleasesTable" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r298", "r301" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Remaining lease term \u2013 operating lease" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleoffinanceleasesanddiscountratewithrespecttotheoperatingleaseandfinanceleasesTable" ], "xbrltype": "durationItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r42" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherInventoryInventoryAtOffSitePremises": { "auth_ref": [ "r28" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount of merchandise or materials to which the entity holds the title, but physically at another entity's facilities (for example, but not limited to, work in process may be temporarily at the site of a subcontractor).", "label": "Other Inventory, Inventory at off Site Premises, Gross", "terseLabel": "Inventories managed at the customer's warehouses" } } }, "localname": "OtherInventoryInventoryAtOffSitePremises", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r76" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other operating non-cash items" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other (expense) income" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]", "terseLabel": "Patents [Member]" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r67" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Repurchase of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r67" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Dividends paid to common shareholders", "terseLabel": "Dividends paid to common shareholders" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/CashDividendsDetails", "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r66" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property, plant and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r32" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r178" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r179", "r393", "r394", "r395" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "PROPERTY, PLANT & EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/PropertyPlantEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r9", "r176" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property, plant and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r178", "r314", "r362", "r371" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet", "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r178" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/PropertyPlantEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r176" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated Useful Life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r61", "r155" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Provision for bad debts" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r238", "r305", "r306", "r308" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r303", "r304", "r306", "r309", "r310" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r68" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-Term Debt", "negatedLabel": "Payments on long-term debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r248", "r346", "r398" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development costs" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r20", "r232", "r314", "r369", "r386", "r388" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r87", "r88", "r89", "r91", "r97", "r99", "r152", "r244", "r245", "r246", "r253", "r254", "r269", "r383", "r385" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromRelatedParties": { "auth_ref": [ "r62", "r189", "r191", "r192", "r196", "r197", "r198", "r391" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.", "label": "Revenue from Related Parties", "terseLabel": "Sales to the affiliated companies" } } }, "localname": "RevenueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r56", "r82", "r123", "r124", "r128", "r133", "r134", "r138", "r139", "r140", "r151", "r186", "r187", "r188", "r191", "r192", "r193", "r194", "r195", "r197", "r198", "r274", "r361" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Net sales" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Abstract]" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r117", "r140" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Net Sales [Member]", "verboseLabel": "Revenue Benchmark [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/CustomerConcentrationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r39", "r85", "r219", "r221", "r228", "r229", "r230", "r231", "r283", "r284", "r287", "r363" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of long-term debt" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r105" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of weighted average number of shares outstanding" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/EarningsPerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.", "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "terseLabel": "Schedule of intangible assets" } } }, "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r7", "r28", "r29", "r30" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r185" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "terseLabel": "Schedule of long- term obligation" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r178" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r65" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r235" ], "lang": { "en-us": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]", "terseLabel": "Service [Member]" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "auth_ref": [ "r233", "r247" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).", "label": "Shareholders' Equity and Share-Based Payments [Text Block]", "terseLabel": "SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS" } } }, "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/SecuritiesAuthorizedforIssuanceunderEquityCompensationPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in Shares)", "periodStartLabel": "Balance (in Shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsDescription": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "Describe the nature and terms of the financial instrument, and the rights and obligations embodied in the instrument. Include settlement alternatives, if any, in the contract and identify the entity that controls the settlement alternatives.", "label": "Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Description", "terseLabel": "Bond redemptions, description" } } }, "localname": "SharesSubjectToMandatoryRedemptionSettlementTermsDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r80", "r86" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/SummaryofAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r41", "r52", "r53", "r54", "r87", "r88", "r89", "r91", "r97", "r99", "r112", "r152", "r227", "r232", "r244", "r245", "r246", "r253", "r254", "r269", "r276", "r277", "r278", "r279", "r280", "r281", "r302", "r383", "r384", "r385" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r87", "r88", "r89", "r112", "r347" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r17", "r18", "r227", "r232" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Portion of 2021 stock based compensation for shares issued in 2022 (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r17", "r18", "r227", "r232" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Portion of 2021 stock based compensation for shares issued in 2022" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "auth_ref": [ "r17", "r18", "r227", "r232" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased and retired during the period.", "label": "Stock Repurchased and Retired During Period, Shares", "terseLabel": "Common stock repurchased and retired (in Shares)" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "auth_ref": [ "r17", "r18", "r227", "r232" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).", "label": "Stock Repurchased and Retired During Period, Value", "negatedLabel": "Common stock repurchased and retired" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r18", "r22", "r23", "r82", "r145", "r151", "r274", "r314" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total Shareholders\u2019 Equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet", "http://oceanbiochem.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Shareholders\u2019 Equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_TrademarksAndTradeNamesMember": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trademarks and Trade Names [Member]", "terseLabel": "Trade names and trademarks [Member]" } } }, "localname": "TrademarksAndTradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r146", "r147", "r148", "r149", "r150", "r216", "r226", "r268", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r404", "r405", "r406", "r407", "r408", "r409", "r410" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r113", "r114", "r115", "r116", "r119", "r120", "r121" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_VehiclesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment used primarily for road transportation.", "label": "Vehicles [Member]", "terseLabel": "Vehicles [Member]" } } }, "localname": "VehiclesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r100", "r105" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average number of common shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://oceanbiochem.com/role/ScheduleofweightedaveragenumberofsharesoutstandingTable" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r111": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r122": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r165": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r174": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/subtopic&trid=2144471" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r179": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r223": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262807&loc=d3e22026-110879" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r233": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r247": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=d3e56071-112765" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(3))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-06(3)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.1(c))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r399": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r401": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r402": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r403": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r404": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r405": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r406": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r407": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r408": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r409": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r411": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r86": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" } }, "version": "2.1" } ZIP 63 0001213900-22-026812-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-22-026812-xbrl.zip M4$L#!!0 ( !!6L%3GI$0SSY4 ->F!@ 5 9C$P<3 S,C)?;V-E86YB M:6\N:'1M[+UK<^)(LC#\G5]1C\_TB>X(X482U^X9/T';>(;WN&VOH7?//E\V M!!1&.T)B)&&W]]>_F562$""$KB"P-F*G;2-*57G/K+S\^G]_SC7R0DU+-?3? M+L3+V@6A^MB8J/KS;Q?=P76_?_%_KRJ__I]JE?Q.=6HJ-IV0T1NY-N:+P5@E M0U/1K:EASLE'>_Z)5,G,MA=?/G]^?7V]',,SUE@UJ64LS3&U\ ^D6G66NS8I M+O:%_ -6_*Z\$5$D8OV+W/A2[Y ?PVLBU22)/SZS89.P4=WZXJSYVX7SGJ!W M7#C/3NCJN9\C4[NTZ/CRV7CY#!]\QM6]!VW3>Q WSAXVS.?/\,%G^VU!\>E: MM296)=']CFH9=4EL!7]/JM7DS\X3WA=^[GI6A&=U3=7I_WY[NEL];@<_OWKT ML^T"7[$!?GBK6B*UKF?8:BI96]5E1%ML/.A]L M/HQ8LP*?9I^L/[X+_7"XSF?XU'T0/YALT)3S7/,S_]#_J!I&'+IE*_K8 ]E/ M+>3A_[T# *^>W$3&J\P>%3N=SF?VJ?>H%?0<+"E^_M_O=P/$B%+=VHFEQO_6 M[OT@[WI+S[6@!V%5?+C]65?FU%HHL.K5KS.J3*XJ!/_WJZW:&KTBOW[F/U0J MO\ZIK9"QH=M4!S:QZ4_[,W\1KEZE?RW5E]\NKOGGU2%@_()\!D'RF:_ZZ\B8 MO%W].E%?B&6_:?2WBRD\^H6(M85-ABIL@MS35_)DS!5=X'\0R(":ZO2"?0MW M\!G__77A+H!;J"J:^JQ_(6-X*36_DJB+?B5SQ7Q6]:IM++X0>-S[P\BP;6/. M_G9Q]=__)39K7W_]O-C8 PK36Y5J($J?EAJM/BK/%.6F_WP17O"5O*H3>X8; MKGVXV().U5+_0^%#?'!DF!-J\M6^:A^[*_'/1_7QU#+;W MK1-\WCI" +"C S8(+9& O0WF!&^/!/7M+>Y&=>(]L'>16O#;?AU=_;CO#WLW M9##L#GN#7S^/LCS_OGM<_GOK#?F] NO_UW]T[W_OD>N'[]_[@T'_ MX?[ &_J'8LW _K$-^/[-Y?4E6"*->N>0FS@X_F\?GKZ37]6?7W1#OU_.X:MC M+EY_VD]T^MO%&.Q"E,Z_78#M].7&&,,SNLT$ZY58J_[MU\]KW[TZ8V"% XE; M4;]=@.7U9:K^I).J;2YI$/#^ME1,6%%[>Z(+PV3RO=.J-[]N@I(?SSGDR/GU M;S^Z3\/>T]T_R5/O\>%I2!Y_/ U^=.^'E>$# 88: M<0428/3T1L?)Q\(@^W M9/A'C_AXS>.S[O40/Q8[";@@L1 [ 0< ME^H<'I@A6JL3Y:WZ1A6S2O4@1#^RM_3TR0U\[>+JNV*.9T06A?C\=JM:8T7[ M)[SJ%OYB75RA%;O->N^&%4=7AGG&QXLK:::*9@6*&N:DJ^C;KJBL\23. M\*E[/^@SB7*RPL83G =^J2MS; \#KM"9FL:<_ O_1VR#_W#&I#RZNC;F<]7" M,!.8^AHE0'(C:GZ)+@1[.GA_;_A=_M6+JUI5%,5:@ \8S#&!-<3?58M)#[[ M'CZYN'JX[G7OR;?^0_7ZC]YW@?3OKS?!=WE@%OG8^ZF,;;9S8DR)Z>V8*!:Q M%G2L3E50SZI.5-NJC&=,>7\J I)M902$/*::ME F/&(**,#?,8CA_AY[1SXW MW/.FQX:F*0L+''#WIXLK\JMMNJN_4--6P39PMPXN)WM@XC[@+%KO?-CRT$?< M0[]LK'SX7=$,-PC 7>3(^@ECD%\L&\R?A6F\(*;7+25.JWU];)B@GE@0&YO'.2R9ICJ1.%4A L'F$WV) B" MTH>(X'&I)GB9 R)B$\Y#Y6=_ FL!7XT9K%UYFBF$&YVJV&C69:FS#\CP'Y,1 M\QJ<=E!T?F*(41P!?6V PC;)OY>F:DW4,=/9QM25-SGN0/73/]N(^:SHZG_8 M[RN!MTE0FX#BU)2.2(/7S!?^_2L:#(60S%E8W^(5NHVR%)W-$,<=9N;=HVM3)T3/QH &^W_J8L<;!59EL5Z9"4:F5%S M9[V/#FS0JE^80 CJ0M$(_4G'2UM]06,?1"^U/H5100S4YW\>0"]!_&[MN#"* M(C=5V6G4JXUVJ]J4VK5#^XTJ@'LXUI:H M&BN*2?%JV$/36028+JX&P#:F:JOP%>XB4Q.\XL72M);H*]L&?(\;JZ+T1^?G*)S-V M**]0RP&."<=Z-HVE/D&^,\POY+^NKWN]V]L(1D54B\H1<6^B-&+\D"68,/P, M$!G8QOA/@?Q2NZR)9*&8Y$71T/:.%@)*:XU$!81#[)S6LX3"P[?K_J$.F]FF MAZ#&8M-0SV$#'O:^[PYNNEM)"IP:R'?%_)/:[\">^_?2LM7IV\557Y]@T(-B M(N]X1@$&\*T_05Q0%OI"NV$5AJ]\%#^1F6*1J:J!Q:%H&GR(MXAHB/RU5-$, M >MC1)T'8$W/$I$QC,7O!!U[Q&?&N"A"&P4_QCM!,H%/0V/OY%59WR5ND7_9.<,G@2CZA'R4 M^!E'X-;"YZ-_PPGP>?8H? EWX:R#%ZI69>I<["T4RR:=&IDH;]:E@\9X'N3U MTC1A27XSBUP/SC/>[?^36KNN9UF>"/_EWO#]L9X#"16<.!%I@*^Y:F-B.K@% M8]LT=%1?VANAH,K>2!]Y3!DSG_-&L15^_[A!NZLU_"8U)B.2>JV!Y ENR%+C MD<)!=1A(J!6/4$E:0N7[\>@/W.1DU.4[/)[=(;:2NJ)1EVH1A6BP+"7*&)P8 MI_X!$6*BX C\*P&85@,^L.9 E/ .T^5T@L4+BOZ&0A+6 LF"^W\F8&>]VC/W MTTM_.L: T@KN<4*GJL[R"5AX!1UCJ?9UUT[9Q^)7][&]#^S9^\NA1W$SW$4&O;%X%4*9=&.Q0G#X;YEO0A0"J6O/:>0#L M\"#)&)KPNH&1K,'?S/,-@YT"?_NE:;.*.;C9&[\M+56GEI4YK?J E>H&8M.- MW/H]NWWW@K53>OAOY5IR!+CO^YV][IJ_+4^AL1L1.7JOJHXWY_#]=EA=4EX6 MW#3$6,*+@ T#K\(,/'6Z:7&CY\#\!9!#NL',_:5%V5/P6IX3'I"V";8:ODM[ MPY>_JO!J9&@=3F0@I[^H%I-KNJ*/545#38M)3.@<8,'<1#$G%L$K5'6R*WPO M?U0^!5I*)#HBV^;6S.PW3RQ^A%0RBQCGB^X;7@"%#]=$O!]UMR:=5\G M*U$PP*UY$F!'<<>YHK)K\Y)N66!EW%ZFP2WS18'*U\ J7@#:QBHH+^NWB_[] M[3J4]>6\.C'LJO-(0 2%Q799,&\P4TQJ/2QMQFS =6#-@PJBS*Y?@L?$7FBQ MIRZN.D*CUA%:G8Z+%G=[5X0_XM*-N74%61GS@++%0HBOU*3$6+TU!Z[J*NO"=SS?IM>V[+UZUU9&)E7^K(XH<#CL?,%.XM]>,V!W MN.7D+_=333X$'93^QF_X:.*::(ND^()56> M-U5^)8ZA5]7HU+'F-IRWJD-S.5%O?2?U6IYLQ,B"L:"\V,M:HUHWM<2&):F; M3\#CD1NTCO1=7)*62I(^&Y)N1"1IC,2:= ;/8;8-5C3.Z5D2MUP2]]D0=S,B M<;.8\,S0P#VVG#@PP90M^^TL2;Q>DOC9D'@KJOQ6K!F9:L;K>9HDC9*D"^_[ MM13,$[)A!=M 4@TBVM7]NE7P:$.S*I9V\,%B8E)Q8F)M[/2G*\^,.+W"U1O5 M&B]Y%RR4E%U=T=XLE8G>500-)35/.L%GGJBUU+AT?O )9X&\!;%YG9[=OEM&=)1*Y".#E"W MM:-.($*FN73X3//H1P[J>!MMV)/OQ.Y9OQ*<;O.%W!FOU&2O^TJPF0R'R;V! M@%#7_Z>)HN&_=.^"1'AG\T>N=8&7'SA*-C5*.J#N_V#"@ M=G5,=TV--?MK97DPEGFEZO/,QN]HDU6J@"?P42T&&U9P!N2>WRZDBY %@]3B M?@6\?J^_N>_ 33H2P/_VBT.=^W6FVK2*B ?2)#EE 9MLBCTE0^^!T]?&'E\X1])TH2^Q^/,'^=U+"Q55W,& B)MJVW(7\ MF#5QN= -Y[5N D0Z/;E(U[*H;7TY[W,'=1+=[VHZ(KK5_+"92M5AS3T5:[;) MAZY4#Z^'\YY:EPRX]L75+SO6[&P\[4 GM,1=\I>XUR(5N#N3K;_@Z;KZ!/_! MJ-N+HJ'QU+6O%=/$+A1_QQ:F@77N2VN"XSD%26P*':F^5>6^$V9!T @6Y 4# MLWP\,$M"LUT7.G(C.S!'9ZIMEME<>3/?L(-::2,MD;5SP>:SU.U;@DT)QQ2 M@::6ALW\%4TS7K$$AX6!E<7"-'X".&VJO9%?\F*!KOO26\.\,98C>[K4NLX. MG[P-NLT-=^*H!4BJU6K;W1XP=AV^^12$E='FFW+PY@5 $8Y)PS0+[2U4RN\@ MC5V\?4 9MPV/>VKO!0F*MJ8H-.JMO3RW[\S'@%<:FDH$KPZ JBZ(LIP27/DJ M^VW)%:#R5P>WR&1)^3A-98JM>EF&*&\)I&+L]R09XF9);^%(7?=$>W';KK>$ MFM1\;XP0&TXB6$.BT GH^9,7#R2D\+[^ @4(!G\4X M=CQDA7G(D2(NH>[(OH!/=/[ E?]C#] 58KZI,P5-:$>CUMJ.7DZ#XIM-J2T*@? MSL-/[+]C<,I6]&<5;X6X4[XFUL_3U4L5!'/!Q0TPD'^]G\[ XM\-8_*J:EJ8 M:R[7.D*SO9\R2M<\JZ!<2GRU:T*SD=A%.J9:VV.X>]W0-[=>7[GJB5WT>A)J M@R^1B;$$7$7T.K;R#=(N>Q#//.1B&*\SVD)-C$]O]?P=\C/&:6H_/ 2G8/^V M6D*KMC]I)QN<)K$:BNO/%FHS1Y77?#MW_>ZW_EU_V.\->'KY']VGWA\/=S>] MIX';R:[WMQ_]X3\+"+]";2;;2(D;U+Y3E9&JL3K:\/S/$@-%2#YQT<;&^H%6 M,*9$,^ 1FYIS4 FC-$&N+4UV0$OC#@XQA#/:C[@> MP7'%\]O^#+N:4(^0:'W6\:[HT&IWA&9 1NO)Z0,W&Q,^>V.9TE6<'#DYU6"O M>YQ'?AJ6$+X7E[(@MYI"I[W?"3TSXD\$+4EH@WO7E(H9[%W+0F0MW&WE)_7( M^W3)VES2"3_1$ ^T'TVUMB#7WR-)QX54O2%(G?VE+\44Y?N3$QV(K)(3-UCA M/"/HZ9G-Y]A&R$ 4I1K@+W[(J[SF.!B2.K5:)"5_9EF'/A EB(&_AZ2T-&&' M&/37 >Y([2D,OWP%-,/XV"Z+C0;-:$6(1Q2IB"^J[!N0D_FADZIB3TLP9QC/1/=Q5FAR7;TA"[7V^RL33 HON=X";7.J55<^\M],3O0X0.!U_>/U MH.Z)\L6.2.2]H8_W!M]!V4AI/=B38XP4 .M(0N<4LA4#V>%NX[XNB =8XCI^ M3%3+6K*QLV/#*@L04UZ#A;"@T! ;0BM""Y4R G#(B\LPC+7 2&^W]Z=XGUZJ M8V@"- \/E&&!PX0%0H*&LM!HM85&G[W9;#AP)* M1[_0^5L75]^WC]<#_LW__>N[]FO77SM=I]S;ZK%AU7U9_5 MF3J94'B$_UN= B57:ZLU66O;8F WZN[%-+O/-J%R$#"BF8\J*?,J"\67D=L1 M7AOSN8'MR W07-4X+0:E>.T?V7L&^)I'Q7PP69OR"6OZ^$A-1E>[-!1\SD:# M6W'TY#%V5[NL!473-[LA+A23O.#2 LFMI^GJ/&SS5G=ISPQ3_0^=!)XC/GP/ MLQ_>4#*P+^,V7/F7B.(M_?5P\.U;UC(-;+/W_-Z>+!)W7*?^YW@-T)'ZRM:(3UFE,!5#SD=:($O#K0(YRGKSL!/!_>0MQJ M41#KF'25-H9_"W?%X.5]JK&&NTVG1F"_ @:*ZA4.[ M-/;4?ID/EIQ_A%FP0/-ZM9.".*,BM M),4=@1,W#@;$= F"F0-1$F0Y">]\.NZ%X1.U%57'%&#%U.&S\A9P%]&XD.HY M@/(1T0V=JF,U+-VB)=1;=:'1*=N0'DH9ID)74V@T&J ,$]^^G/;]W^YP8WE5 ME+5887:9 VL.XY LM[90%SM"O9ZXEJ"\%3SBK6 L5(/& #$D1N@66%X.OO-+ MB$0"OQZ8[L'"89F*_S-NE)1-$DA7G\01#&5;K--KBY4"V\=JF+4VKCVS2;BK M=V4]8Q=DV8R/=\,!23C8CNB&C0+-A#_K1 5,/ILL0&K:V-H#_'Z+ K2=Z:&( MZPG6P$XJ\!,S%UC\:.H->+:\ <^7QQX1G-.0Y*WW^,:J/[(I[NXL^"]$_DH> M%BR+\@N^=$ 947XE+)X.6UI-8&<28&M&O']D-\Y^WYK9S8;$[Q]AFP06VX>/ M.D+.)^#Z]Y ((AKP^G=;S'P[)YG[P/4R*3* MG]41!7$#ZRX8&OR;;09L%@'J!XT/^6M$%?QR_W[Q'"M4%F*&>;V<8;XQPWPP MA']X)MC#+7EX[#UUAWUXX,"[^_CCOOOCI@\[^E3.48]D[L>?HQYL7'ECCIOQ M!J:CTC0I)=_AX9E%>J !)_&V$-FS.=3(^)@0B#4R/JGC76R(2=E#3*IA(7L6 MP#J1TXH%(8U]9P]Y/.6W#S!2;5UG^8941Q2N$;X8=_QW!MYH M+!,=G2G=Y7B.P];S=B?LVQ:B #,N0)/,C6/WITJA#+XKYI\4"0K,+]_9'.H* MZXU;:XE"HW6:HS13"/.D .O41:$MIIW$4! _=$ US>4 93)7==6R42Z]G'G_ MZ12,YH#L=ZJ#!-<8\?CAMI=^G+I>>7])6^F;9L/I:3$F"IV6!#Q?P-[4,;/* M5\-TW';SZ8FF@+K0,ZY;S;H@M_;'F\M0 M6*: EX1ZLRG4(DSQ*3OKOY>(3#0IQUH'?'2,U4\;LJY D"C49@X=R^QCFA:U M[!6B!+Z=B*-JCZSVPWLG-9-=0VER6AV.WTZ<^2D%L$QD-.0ZJ !,[R%*&W7TY:=R3N*8.%- MQ*#PN^H>D4+6 DBC!9BE3D>0VO$'BY9]08YD*T?&; >YM1E?0*?K 5**[1,3 MVSM,(+<%(EGP5KAL\ 3V>#J."16-2[/+L(HWDL(%ECM_XIMBJ>-(0R@BI.6= MQ*7V ?!3/P9^I)R2WDIQ>5[B\D9]42=4GUA(HYJ"L[5+P1EKJ(('09=);QQ M1AOF4\K1 \C1[-"5ZT^RX]C[:TT7H&UR.VJ>B6QA+EB#+Y]]*RT:<_^5R7K"6=,1JK7QS@ M73NP&ZY U_4@%])*H9E32?4)HRGSE*1$>-HQ8['1R;"M+OV# M7X/MOLQS5;)(3#F@M1@P_31H\NFFM2/7:H)4CQ_\KZ>1H">)FU2=+1/AIE.3 MA6:$4N,$N#G,M8R*MQWP?;FY$8\N;V42PBKD3J91WLELWUQ-.B>LAT5QMUIT="?:7_R+F?0'+\S])T\K(RROK/"W>LDF M9[O$\:BH$]+7S_R4:Q[HF9_UB=J*JF^G-13NF*G$UZ&NF_.1M86YR6>9LM%* MQ M/*E'.VYT;RX@W46=QWFMEH=K;=M[Y'ABOM]_/:=TZHO=S8M:%^=WG'KW7 M;Q\DYTIJATP<=./459%%#5W*PRL&'MRXN+JA8SH?4=.-*FVERAUL4&1H4E-& MTR(;*;K*,^/C86E;MJ(C& -O@]PBG0[..1,ZG7*_+N\!.>+=3*"T$[TH.DCB3( M%1J,!'+2_.=^[XZ!0_,B'P4^])=0!1Z*8+WY2 M#YJ)8#X6-A>NW$RYF9/>S*&3.:-R_'8U3TY JQ8$>?X&MDW(SY6;.Q:)]-$PF*8TIR^5U3-L1,VJQY0;5 M+=[H#.B(+ M]_@79]G#C>F^<+!Q^W;_X(@B BRUD9L"8AVAUDCB%A3*5@0 %LQ8C+QSL7 [ MS]/*346H8H3Y3>5%^6E8+.5FRLT4W/)*9EJ:N-W;;CX[0BM#V(UG;O#!0%@G9"08Q'QO/,;N'=/;7 M;I)*,BM_=>9:;"]U=?D M72 Z',\':BHDMX1ZJRXT.JV2GX^ YA0E.;$:J[2%NM@1ZO5\^3C(8=@8SG., M>3/E( 2['(10#D(X$W0GVE\Y"*$X3&O1.MM,=*5:-F+ M.C,,Q;G,K OMG!M1GR%R#M3)7:P!'0^%(RA%=GNLN]F.T*FUA%IK?UO> MYXP,H1;+K@>%3&E?E9LK-G.IFBFIM"O9&D-]QQFQ^GL+>. *32YBHW4V[F5#=3-M<* M0T;97.LT.N-(N]MIEB#; ;*R'UE$FS6%.99_.Z$=:0"-SO[FOI'1O'7W?W(8 MCLP49<>YW%V4L^*)TODI-U-NYE0W<])MML3-LQ:IOT-2191%OEB:7AXYY927 MS3P*AN?L,]-+%.> X@,5'\3(;R_1G$.;+2FW.H:0+/E.A+$B99NM;/DYMVJ( MC53NFM !GI8BS/HN^3E[-,L'*JFHBT)#:F)9Q7GUV7+>OMD68K/15MJW75P- M9Y0H8YS(I^AO !ZB&S9\':Q;HNA$A=<_FXH&Y&O:.,O/GE&+ @Z4Y42UV2@_ M=%DL.JG 3XQ\6,>EJ:HK^EB%+X(5;5.,TEB7V6\_(K!R?M_VN?Y/M4IN5:I- MOI!'Y9E^A<7^6E)]3+^0YE?"YE[!VTFUZGR/<3[_JB]*R5]=M8T%/"PAK3I_ M<2FXB7_;7_*>Y-C;Y_3>SO93"]@.\T_]9W=/_94,WQ9PXJZIC-3Q5W(/[,XA M>?.L_5*__ MZ'T72/_^^I)T[V_(X,>W0?^FWWWJ]P:_?AX%<$AN>[I^N+_IW0]Z-P1^&CS< M]6^Z0_AE,(1_OO?NAP/R<$NNNX,_R.W=PS\.O;N//^Z[/V[ZL*-/AWSS+K(Y MJ3Z-46VM8*,J>3?&X?D&S,RCP;WGE1R:1&5[$A MED,?FJ A">?;=2I---JQFU_'F[.'%CJ9.O44_A\$:ND)(Z'4%JYUN< M?GZ8*5+MVE';!@1F8?++Q0YJA55*A45L@Y@4P#A6P4+4/>[%O^-O8Y2<'Y?@ M^,,'G\C"-##I?$)&;PF$:'D-G9.X+NYY"[69/!E+;/.6;@O@)M7)3M8G1)D; M\(;_L#_D#)&\M);_3%W?<;KZI#L>FQ1_!OD9$KNM-01F!;^O>NC4<),;+:'1 M25*N4X2L_W6VF%+39#J$*Q?EYZJ9\,FQ S\+MQ>&RL_>SP5&QK]1G4[5$'2* MP 9R<_]TIR.Q07YU:M$!MN,*M]T6&LW]"9WY96[N)?!'M(LLA!H !AAI M : MV:=*XMYI;@WSQEB.[.E2 Y&%';%#C.-V3:C5"DO>>5%W0EB!/&T?K@-&?I)] MG? MS7@E<_@+.@5@_1@CR]"H34'NOX"W89AO)\81QFBLKJ%X "?\S@X(:OS! M.5[?/=UNA+> .>KOIB5,9F#K"*U&$L%_6*N?E3GX_&'8:Y4YSJI-YZ>J!-BA M[@T=#\)5MZ.W(RAL6=P?NSHW,R<2O#;#28U6$KV4(LS$Y+J(O[.TZ'9"^?FLI-!S!)$,6:T*@? M)+"0GP>V.JI%)DO*+[B5Z12TA,(S-S'E4SW9>-LFDF^6]!:.V'5/:$6Q1YMU MH=-Z=[&)3$#7: MMZ9@^6!#1NZYC_F1]0&GO.U3(I8 @20VAF>A:X(P$?218 MB4*MV19:G<9I2_A'DRYP^BKE_B1W! P6<^"]D6S'0S@3"=_7G1.[-P>.(XVA M(SQUEQTV2A>(6ENHI[Y .P=VB0O0#3YJ2D*4CAI'O(!Q#3_X\(TE.__W?[4E M4?R*[<(F>7L$AW<('ODI0^[<.QU!;KR;@',&$!,%L54'=V!_^7?Q;V7ZOFMV MER/.B0?,I>\ZF4; ;5,6:O4DOO'Y<4-:2KAL"ZG$<'\M_>?EBHF1Y1@ :VRF5J+:%=.UP#D"3&3'%OZ@JUF:,KC>UB M0-S M4\S@$K+:L*'1'0.T3/KHP/$1H=C5)ST7AF%"N2G6A&9[?_#U';6FSBW@FP7& M.F)#:"?O;WFD&Y1,W #'"PB4]._7YCNTX=]WH1_+\$\M:$K3/PT99&_[)R.# ME-(K#A&4UG\!K,:#6?].A[O2^C^^]>\W\QV#AX \T@SXS*;FG-7I/"JKCC_U,&,P!=G?".1C- M"9K'?*:A@ SXZ=8P5^![F$8BE(;0K._/E7Q' 9O(L\3JVK$0ZTAVG/ =D30.Q!1Z87=YMM MS49B45[FV^6.G4XKPU&D91;*&4C5R(V4)TY2)]K9S.C&! :36K:ICEEI;X < MC=?!-]O91X*OEW(X ==?;+^!]^3C]14C)";*80%K%S MCQ@@KXEBDQ%]5G4=8R:8I,9(]KP-+OE(XB#D7DC"G!&A(V<8[WP/IK,D%@^5 M()YKHB V*GU563R,;3A)]:4: YB<2ZBT+ MJI9,EB::X6>L7%-5@G,H/0+80@=52&VAU8X?Y7Q_JC)5H7=$9,C@V=1R04;N MAG DSO5U-BFY-[PSP*K'ASH)NSX2:K7X8]7/DWNC)OPT(B?\',V@S)+UX(5K M'>XU#*N>+)+SN+EEB1D JA\(*:]^_0[A%);"+;1*ULOQQK9@6"G#_B?J> 1U MEKKVW;[& \06OQQ*2/G=W1O/V\6#9!(+RY9<4D,IJ=!(!"51$)NBT&JF'7QR MM$9I3^%Y!:=WC1'5E&MFF[M]RB ['#>M!W5#O%FQ);02A.$+D&:?BAN'!D8D MHR;]'(;2HIEY1\F;W"VRMRX0QHSJE%[NDK>3+FBB[P/PAD0$UU M^I7,%?-9A5?AH[5UG(\I1E57[U^XK\OH;2#'9WQ$$>.S 6WLX&_"GW5V M#_%L@J!?*"9+E;=GU*) YLIRHO+A+>"XZA:=5. GQJ-LIHM3= 5?M&SX ROX MN\Q^^PZP5-P#?%]N^JEX\V7_IUHEMRK5)E_(H_(,/OZ _K6D^IA^(:VOY.^* MMH2?1%*M.M]C5,:_ZK/4^/NKMK& AR7D4>H#9 M!:B1294_JR,*$A?673"(^S?;#-@L M0/&A^RU_ :_'+_?O$<*U0>ASG9?Q2B M3GZ[4/Y5J[44.-IGY2K7O?PZNGJX[G7OR;?^0_7ZC]YW@?3OKR])]_Z&#'Y\ M&_1O^MVG?F_PZ^?156[\N+VG^X=A;T"&#^3ZX?ZF=S_HW>!/@X>[_DUW"+_< M]N^[]]?][AT9#.$/WWOWPX-N<1<*N=:^7\YAI?&6)8B_J_J23KI@4?QK "NJ M4]"^NNWT] =Q^@CU?^+U_B1>$@N&P0'UC+NGF[4BT MU9+)D6@RPP*-X%\;O-&YJKU]V;]92_T/Y9AC^Q4N@ON_?NT__) ^WI'M] M_?#C?MB__YT\ @E<>_2(K^0XSQ;-_UY:MCI]VZU.S;Q*&@WW%,SH3 MDX)TP81$? J*1Z#LAE:=/]&%87HKOT6F3&87[UDC#3V&88X1D?-N\#6=EWL2 MHA#4\GF#)@*T03[D(R @?K5-%:]X:"'Y_4,&%;%/1+>XD6F2FO% RHE0G5%/GL%&; M]S18'0 >N^0T^4/7J&6Q'3MB )ZO)6%'.C!7EF*PHYD1\Z6WA@,PI_ICH%1U5C[$07^(GB M01[6 8Y6%SB"]*-#][]WNX\.T7]:Y=RIA F]^(Q,#/71/0,&)G1VM;W5J&#;WY$W*&NZRP1%X9G96 M%#T:M6F(H_[>6;F1C)7KF;%R/28KR_FRFKEHS("]0,!2X%/2'1L>H MS( RE0DNP8A*8'RO\N[%P!/@T>-* HM-Z70,VDXQWQ@Y*V2JJ"9*"PLCMK;S)5BCXE-O8NNKY3O&PK!4 M?%+ RXNEQA6\DT&$?(ULY.586^P]G-.X%\ M4<7$Y1&:-[#0?$1-[Q4E4R./-),Q=2. J6/Q9CU?WO1SI*,9)IR)5,NGG*R9 ML=0FE1%2DN(:DO]>ZOS>Q--NFRS3U>',&N&'Q/8H[HK_LT5Z\-I-RA-SI+RB MDEDK&9DU8SKT/[!Q7@\@,4<3*&ID:?U;N7KL/WAC1.J^+#.'/3='/ G:6KND MPT[\Y"H,N,WL*<$XAC>7""A+5/N-"P1F,CHVI.53PZB$YLJ?=(5-?_6E55(_N/9C>\D,&:Z;QRAB M8>]P;),WZ+9GAA4"ILMDPNLHFCQQ;-R=AOZVNDN/'1$/6R,#CLHXXBU=5OKW M?^_=#Q^>\@MOYQ_)CH2X5?PO$I9SE7Z;QHOJ[,F1$.MV-V/S+8/%]53HQ),C MA@8^ '#]EWRT5S9&2B3PRW%P)>TU2$*OL,;@%RXUT('>RZ[!V8.?AI@YX6=> MEDI!QE33G+P4EDV#OP//C-W?U[.$QH 496$!T[D_?065-;%GB)':!\Z64;!S M$2F)9F?">X*<*=@PRH+?+B3O4$%W^_ED$42[L66,PO<.?.$:;B2_%R(_>O9A M;-">+1YTD;_[7BZM;U0GO/AO&9(NASJN ( M^ M=.'U.X(K-#.XT9"$ME1V]SHXS7)R^BN\[W 6P@Q+%5C\Y\F!65BO'5EH2AFJ ML-,?F12.GRQ$:1S\B'6A+65,8R:TZG]C[:.LG^*UG(U="N M96)'Z+2 63OMLAO.00S2<&PTA39@1&K$5VTQNN"X%9Z%+B_(ZZ*H'N>B*.?< M0W7+3,1@0V ::\>HL=+S$I M9CY*1'P=XE[526_$RU0"FYH8II,3,EG!M;(PC6=3F?,$$D-GZ1A8+S"&!0T@ M9Y;!J,[AL1=>8@$_S0U?UN;6+2X\,%F.;2?;TMT+?[/EI&6Z)*+1%ZKA96^% MI;^Y+_76>F4SB9>6DXIATK'QK*O_8:G2+/N#*):[*_92EIT)Q,-2J%E]A;,D MWXW_AMF%A9.+LOGNRNK= GF=J>,96]N?LJ=N:&O!24^A;*ZRLH!-_62))-H; M^24OE?B Y2(>U7D_=.V'Z72@VO31I'/5"C-L.^U68--&!O+P?:=0'NGW+0JU MAKACYYO9 V0S>Z""%VU'_Q%+];/.;LLGE2T1OMW4MH3$DE6'E@![B&U' M( O<$--$U-W2N>>Y)<*%G :1Z?+@=K[R9#/@=B=+97<-7;1$+#>/?T(.D('U MPZ+3I4;NU"G=E8B5;EQY0.;;GO& T7&PD3HX,C]?$9[=%RFH'3Y'LDST.[U$ MO]1W#,&R91^F0QY/^>V#9#@VZQ\NKNY P37#]I+['?.:RU9NQ4W6+YR;7/AW&:V MG-O<9-QJZ-M;V;Y=*J+<:"?LPKQ&$W#B?[@4X1T]1'+(0J/5$NJM_1?VA90< MG6/ 3!+:C;;0E-/"+%M%_C"=JF/J#W!AAR/L/ .GI'G(A'HM8VT>2R;4Q6S? MWBB>2*BG,$IO76_A>?AIKQDA=.KBR>9WUU-3%5(^ MM X+JT:[!5Y96EAE:R/5C*+3/7U4GL$0] M[<.QPHCL"=_U,(73=K&!SS>6I] =CY=S['Y))]TY=M;Y#[OQ"ZN"/%M-RB0C(?)7_U=SK#'JJY:.]&QN;UEG%_?)YM)(B;,^_1A7OH$*J:M'_X M:"'Y+X'3<4BH'*#Z/\O17:[FX^BA^^O4S_N E!N61 M$)!78YABE*J%$W,LIQ!S7]2?_ZK]"T-#FU+.C\B^_HC9VX#'_5YB&Q2(M+^G M2-G!P(^V6'7FEE%:AA@\\CO_'A"'[6*/X TL7OJ>^4/*'9$9UF M'>\VR@X/41&:0C<"SJ#MA%1%,OF&BE> M5\B^"'E8\N%]$EI"LRX)M5K9M>(X7L.^+A9RLR9(8B[8.5 7BT,UK4A4N%5/ M4_4EQRW+2E1[%;6D<[=Z@"^"W/<1B[./VH>+7:G8M4NIH>H7/$J[6UEY];9] MG707IJH15L@C!/9H"!Y_"1KE?_KWC]W_X:,CW>E[_Z/J"^5/=_X>TSICU@#! M-@AV^,!\+V?.ATEQ.)[^C#,I%1VGST.DS[O\F'U]6O#LA^F MK/_L .O;=F^_)@N=SG:HEJC66M.0,2R([,":-/-6)?O[;.1RM %(1IYWVIW, ML=&N;;(1=LZ#83U8P8^M;?NQFT>U^ OX%)VU5WCS>CY5]A\^125#-,J3VIAO MN!T^C4QY"7:8(>5)C98@U@.ZH&1!>;D<+17ER>T 3"6@/#Q*Q1OY2$)'/L(R M ?UBB+^1PD'[QKA.63;=-5BBBO4PQ7 E3=!1@R%\WR*GTD*C?DGN>MU!;G.@ M=L1=LNR>$1F?;L>,& 1PD,9E,\7BOK0JR-4K&5N8\R M^Q8GEMXI(,+-"0A_@=QJAJE.%#Z9#[T) *']QD!I@OO"QV0_4F C\OLEN3%, M75D&NCN5ZYFBFNS8CR# U8E;EW(]4^F4]+QM\N(5IU><R2L7T_BF,,JTR\H+ZL3Y:V*66=5J@=F^/;P)3Q:#5\$EMOL!K.5Q.;; M\&K^HX+3Q=DT6-1_\^6\,N*?Z\P*R,W:?W"I@QWF47EC:D#VBAL#6:C@-O-^H;9/ <12$VS@3&>^61?A]I1 M%.*T:5-1<2XH?K*-3DO%=&H_%S+MXCKI"LX9?5&!YUPY^@P6#ZO.@GV(G4[[ MDG0G$S9A6]&T-\Y$^"CRN+,1U>(_:;R[H4G5^6AI6FR9"DX'Q>GVRD\4*A@, ML"QGE#@SP; 9)?;[6\WIY -'317% /(WAB),:Z8N+DE/ =O+Z7*T4$PF'^"- MMD?B"!-V!&>6^Y7^;/TA9IOCHG'P.SV>T0^H=P@9C*-;0]? M!W;=PX;><3WE5WCQ@?C&,85#+>%&0$O=?$SZY'N4Y0!K/<:P]1V6=W=O@T?G M:_::60&DN%9FP.-6;*2M D R\24&G\KNCJM]VR\LDZ:JKD-S(U,\+)VO61/J M >D^^33L3+?5MB0TZMMDNHY/@0<..3\'6!B78*?8N%=[1D84FP6KV-36@;6Q+="?0"C$A,!C3]9// M##HBH?3UX:OQ3S060P9*BH(8@59.(#$[D(2&>"?D*%77X7",85>KGEB:=0S\ MAUE>#:$3 >W%E LL'56=+Y8V]PS!0[3VY@H57E!DGA.Z"F?_0[5G?0ZOO@,N M-*NPQW](Q;50;QQS2E2.HXQV"HK-0*WG/)UE\E$VTN?.@9$:6JNXP]4K8,Y1 MHN2B'+VB1ERO*+?\B^"^X+Z+#+<3 O>",7G&V&BCA!XP)?>&38G,PB>JSJD. M 6329\5D'@@;9**8YAO^\H)#&W9-:5E[,_GF/_^^<"_@O/<8+S@<>1Y3# *(UYG? FO\$ (ZS [R(T<,&.7C4<(@A M!*DBXJUF8&!VQYUNP2/B21-_-P)=26^3$X>^"PO0I/FL"0 :=/5=B+N$C0Y\ M.+72*X0]9E0WGY9KT3JL-02Y<9J=LE*D:B8,&Y]2!!,>(<=:G-RR:G^IK=9A-X!PW\DO?^RJH$9W.A:+FX M04'50L^NC4PKG;C$U=X;/UW?"<:V#1V3;G!Q1WA8[*1_J' M(\R[7)9[D=Q\.UP[?'.T._WRJ(@ M7[ZL'P7W66>D7US=K)D:>X1!AL'CT*ATZB1U.47YU ;^_?K6*4(,*R^4+_?' M4D(!\^$@\F 2B/9U"[(PF<3QL!G"RS%Q*5XF&>+W(1^'+C_?+9Z1W+G8L4)B M:[@T8O,U8EV7;]N.%4L[]B0,F>B#L>/;L=+ESG&WI1E[8MB/;\:V2C.V6&:L M7)JQ9V3&IL!F0X.NQ W6^KJMZ,\JG(OW2TC08\W%5H2E3J73 M6N.2].^'W?O?^]_N>J0[&/2&F3==RZ?!6AQ\NCW6XM% %B* 74Z JBP:KCGA?P\#&<$36,P% MJ9NQ>Q2PUA. =7^'DO7]K-J2;+ZEJT^PA^JKJFGK]091)6Z"I4\MTA 2"=CO M]:^@0CA83B=@@8&CK(L;BGM:WT@<'ICI!N3]GC\8[O?/1RE"-,IA_&8=G,9' MP)F^S5@%2ZUO-)*G1&V*5C;!K_<3.SH#8EPI&S(J4Y*$5H3DQ=,O8$@#97#U M5)O>J2^LG\6Z+HL[DKQ9ZPCMUOY&%^\;XIM@!N$3@ZI%26@W]T]_/5(1R=!4 M)I2=ER>3V?@[V*!_'G><>O-X4D@46F)#D*6T 6Y9B MHXXCVJ3W!\.48J/9#AP><\S;V$?3F"S'+%$<*>"XYD3[>%)!ZD@@2M/65YX> MW+*4"E(-Z/M4)6N&M!=/*H ZJC7WEQ\5R9+8&5]Z,MX4S7[C$-^*H9Q7O6BC M1#5&FP)0I M,&4*3%:I LT4S9G*%)A#0#E+:[W1:0J==H8#P\X2XNF,;:DAM+)L3/L>4F": M8ID" M#--)A4Y;:$;P[8ID290I,$@Q*1HSERDP)X:P;%-@P'^0XH]:+9%WG!1%H1.A M^JQ,@3G^1?T1S<8@:,I4# N=3AV\V/V1@!)E1S..14%NUX1F8W]M:A%3 M8.*UE=K?TC1>AD86C:J<3DQ7?I:J.$-OG"GB$YS@L-WNYU6QR"]YS9?Q;V<[ M:V0W.;5J0J>Y;7FQ*Y7PS:8P/Q)O5A3$YK;EP8:DQQLS++C#-D!P:F^7_KY7 M>]*'LJ"@78W-,J'..)/0Q5HY"GUK%'J['(4>BVKC-(NZ4W7Z,+TVZ42U;Y6Q MJJFV2JV@)+;=\U/VK'$J/?B:E^2I]_>'N[_W[W\G=_W['GFX)==/O9O^\#1: M\47%I=N&+SKNMLJ^ILQ95U7X^T#]2;Z#T8DHOL'<3],B'\.5?S-! M8Q;&O-^5G^I\.7]R-\?)P4\:C\X1^KH+*(23!Z:0FWL, 8& 3]=DN&,5G8A MQUHNJ&G1"5"7'="X<0&05(WE/N.MF:#_Q/% LIL\IJ8Q9W#@E"ZLD[CA:F?L]NA%I$:2O'E,Y9=-W<(9WW6!(; MDQRW]_OF#EO%ILDW8#^8ZH)%/%@_UEW4-,)FZ-[48:+8%86\**;*4N@5':"K M\=;30*)W_6\/3V2A@3 0+^7&!P$V.5\L66M6'>A0;C8^R\T:&2F6:EUN]5WO M:AHQEK8%_@YZYBNZY$L"?2+E@;TS 2Y8*.IDM2W5JDR6E"P7\)Z5"F*DBVEO M0+,&Z@2JAW(.YTG+SY1]-Q!Z5P.LQ"5S.=?PD2,092,H1!4SI!M'I ML\(TO0KB:+S2S2^*JH%W@D1= ;J;@E"TW+F0GK5B,2UO+37;;0Q\_?#W_DU5 M[(#7 20R5\>G@-98V,FB&&G'<;K1AFFNF8R5F3)!/(+;:[*.S)9/?^U4<9Z5 MYB@CT%(FLB>;\ E6 WQ_!P=;EX>)4>S#=W('T-"?<3+%#1W9D=T^3^8'??E4 M_+W6);E[ %=OV'OZ3FYZWT[%RPM%F.?;[4%KCC;#%;Z7L0D<.AM('E2-A4). MC@3?'&TR\)@WW,__4<$T^9-P8&Q[S)%=92[K=_C(FQ_N=([Y[J1UY[@2[!S# M^7A06.%#A304K?ZW>I3D[=G1QX:I J303O,LMI7[?(N;B>L_I^@ZAC30URT0 MD @94):TR_82DN ;XAE7?+,*T&="O?/,#@U::DSIQ'*-"P\Z+-ZN$'X/$G[, M%&V4NB95'J9W0&&!![/^FH-_VPEV;JV_ECCR>FH8S.95= NW!N?@Q.N:SA5' M_ )O+*?PW25@]UD 6C'I#!Q^Z@[JMDUUM&2GFWJF"9+&=SCK,Z:/OPE@VRLC M9:YPYW8%*K^O2@)]523 BD. ]_ 'C_8VG%CV9?C%T)E#"R1IOQ&\2'G&B*^# M(^>J:0$^^#-CM8T3PU\F2SP/4/"$OE#-6' GR/"&B^/ <6-D*V!^,*]F0!&&(=GX&+8D9["QN>9IXB.)0"(ZOQF&IL MKA0RB4D,Q.:KBB/O@:S0*S5&L!OVN;7BHO6U"XKP789IL[,6@T.4(K^N10U2 M$4PC$L'DZ,ZLRZ&M* >(%W]T [U,^5)J?'#%#D8;0'R(X$RR"U4@&A64#E # M\T.0#'Z1&X)4[Q"JC&<"#V%X+["1P)Q@!A 9F @ZF^FWBCRX.IM+S"E3K[XW M5*P94MZ(LIW@IH"D64S&T/U*7Q9QFW@8KI#I7W@DM#"T-76M3S8VMYHSR&,M ME]A 8#GGV@_AH[E*GH=>F,SE- ^?3C BA#K&"=.@30$H@FT!NG0,F]I!IR*O MQE*;X*E^$85.JR74ZJWC<4ZPDY"UZ&Q&XH1&SJ)ST]IT?'"+HW-A4D=B6A5# MWS!W$,W6)@NJL_QN8(=02ZBUEMLA1;\=>/3>]K&GWI+!)C?%-)?S MXF$/O)T6\H$))N^08$Y.@?_A>[:J\3_@:74C")W\T2E:]FQ8YB7YPW@%>\GA M:T>=HAY6D*+8A<>K@H]SR]E=L,+(#*U/JZ *,C%;MR*Q=39)5[&O"S;4.Q^T M"$;OM?$"& 8N_X$(Y$+!DPE;5P9;0@.TB;9$H3%U%X37.BM63% ]JNGI#[_W MB9H&+6J0':!@\+8/5O@)9#.>P4$I6X0/OT4\D(_/%%0(FG6$VEHUV'UQ$:M>FD,C662,#(, 2](:!G"U^^Y)>S?#@ M'7 F*D\&%$>(@!9EW/+QVR='I3I_[ M;#6<;2F>9TYU-AJ0B;OU0VW?0=TBQ)?FPK X@/D%EJ,7*B%4*;CGY 3H'M$[ M&S,:Z92YC; U/ ;@ [QCPE.A'*)A+C4%"0GESM> >CD7A'_Q&;B5?:_"#\&MU"V! ,K- M()SQ75."D9WR;^Z?^]C&XR_C%2!FS=0%F1@4]P&48!H+QZ$.5ZI20J7J)1?X M[UF^.[L<^'C[P=U<1#-C._CRP:5*GQU187#P^8[GI@S;D91AZ\ V+KZ4T?$8 MBS> ,*8*7A8B5?._L$YO-O(O61DJ/(N9200P=D'V&DYT!X40G;!;*686^I-$ MN&;$+^%'@'JBJ7/0!0R205K&%U*H\"LS5#/A4=-6@D+UW>2?:]K,N1%X)Q*! MMP],X$S\>E3N7:;[;3*T9<:N?MNB0N>.'2A=0-V# 0I&[/8,[W(%1"Y+_3 Q ML@HJ=)T+T ;C-[^@\^#;] VT#,;,\74YD7+?MP&O;(0U0WKD\9&0_'FIL8.J MV:$KH+YTWD?)C;58*Y/*N0G1<9MH]2Y-BY'_R+FH]F"EJ12CA X8846P[T 2 MH 7%/_JHK P%9]5-Q'X2*LJ8*56,[*R28##0PU>&AQ!OALEWR.64)U+0 ,$B M$/Z$$QIU(YM\5][-#L!/,=\"3G1N+"S6(O%P)]?+VO[J_N'&=__P#>\?;MW[ MAS.\R!7%:#?EM5RO. =B!=+7QY=D][4T-^PW[SK9RC/E MA?),K:7%9=5TB4%AJ\+NG4']KV[%_2FF8#:!_$3)8U)U/F)R90R.Z+IEQ1RW MW7>3)/*E9&7OI23S%5\IVSL/4"U-\/&*X;TJ*D&9*J\R8^^T'IUW89FJ:[GX#!=4 M7XE45U@>QEJQ$/QAE8T$/@B'"@)KIRFEF!,OMJORNRF?4J@X2F'M-?V;;^L* MD1ED*F88,S\>8ZHKZ]I9'+[DWA:[=[,@;O .%/U_> B<90H$R.-OK)1B8:/M M;V*[@HKG,6/ E=T-F\12-!J@"U<:[A*.C=X9ZM)G..C*?O%""OPV!BG(W>6* ME<%N''W;@:7V<&W2\K(G[Z6/X/8#UZYRR?O,UOQ#L;X!"I\ #N!I M3A[,6S#IWAX5-82-Q1TLO#KX*J??=!:NL+PHM 99;D$!3:%4ZB):7JIXI&(A M%/KKR80LQ&T-^"7^T/@.G*M@M1?2P9S=^ VH;6LL^(#GL;;+AQ#-VUDTSO4< M8P/YLM;Z@.&."B;6S 4"]#3F#5B($P5EA4',R"9RLU:= )^P^VG%$59H[X/\ M@6^CDP;/P1,6H6PF^F&7TS'F5$%[G&&-^JS9F^P/= MB@*9B68G%OQ)V)3@+.>G'9+S(PJR5%_/Z+DW7KA7*3H)@LQ;X#5.X!M?O([CS5\2/?%2.Y;[ AP]#=/QG?Z#ZQU.IT!(#WEF@2R(QG M*R"%;M2T;$-$W2C\ MI]5Y@1\/BV[OUY$_KEG'KVMEZLF5E M39)C[J2?^EBM*HO#\S0#@(R*NNE-\.L@ISV/W[KDC,FM4W;QL\Z>:Z8G&F&5 ME5D*"[[.#(WR^P*"7,8RGWFB%JHIE47G_,;_6M+S6HJIM9Q.U;'JJ"=>D.(4 M_+G6Q"6)9I\PHQ7WZ,6^UPP/\'5<,254/')8W7CMN+3%)[VP'''"O;*RJR6*5VB++_2^*$1DSK!6 VXB(3-9+J[\+T5[ M:F40C*G),O^\.VD_'P:D$9+U-,)*8!KA1_73KE3"Z!F$6\F H8F E=2)@&[6 MW_Y$O^J>1+]/:*#L3=#[J#(H>4?WI=(%W4$[Y/&V(JM/^S+T*AL9>AL)>IO; MN@Q/O@M+"=V7?%?).OF.)$Z^JV28?.<40)IDK@"+C[D$R'LM M^#(%^!^\/ ][9AK+YYDO&=7+D<"P(^-HRJTHYXT5_QL#NH)L^FCK3:G0867R M8[[05+:V*PHM&B1 #F".'T-+1JLB$?,N(W%EO(MR1@!>X:1SS8MQDGQN)?#4 MGJF( T1#LGW$3E.H=;8+02IJL&+U3L$,;>_.FE6_S(Q7W6TX@M-1?+< # (C M16.DR7P($Z4.XVLN4/P)V9HZ=4/&%6;4GYLU%ZTL0LRU+N+J@4DOW$*5E?8\ MK%R9<\RMB99]*^:8?AMJ4#;#^IAL^GM!G+F5M>@9OIAJXN5R\-IO;.BG*XO% M&VH5T'UN!HRC0M<^\VX6W9I*45XU=0LPH^%U:]]?*V>OL'+VK>Z"OXAN-JW? M\O4,BH^.&%D]MA&^W:B7%\@O';DF-*0VTXQ@1&#R U/P7@!"J+CQ]%61YR_- MCE!O2=CX%^P?"P-ES/+ SDNL@==Z: ]>+EVV_5%U 0U[+M?\+]TJ0O%$'1H( M;B0-=^[\;9_T5T=@^\:8B>JE0PE.!8K-FOWYFINY*L$' 3#) M/0+ B!$OO*UX 2@-^-77/]N)7+KP7.&2F5Y^R)(YGGM$S_.R+5KNM9AC\C5O M]<%ZP>BT@A8JD$IMCQ_=VA)[%"04Y>8+99&L->'GES@;O6+XM;S$OW,HE7*/=\J\+;#+60!ZK4Y5+"<5S#-@#3C61\[Z5.*GPKX.=[^2E M\Y"&%[#GWNI&+1PO1H,E,&9J<.9C(PSP($M7,7!QL;$2R%80)C:&7H%9[?4L M/Y1=OZ -*7?PWM+M<3A1+1[C<^6D>-F0/VR+C2Q;6Q6'&:5H2=1BCEG4B?K4 ML6M/+S^&Q\LVN,KB,0=V:;O!,TZ$V)>POUG-LW#ZAUB.C+>P#L--IF7O,>F4 MFKQGJ[,(QB%XK<1",6$;RF+FZ,BM]_.$&0$V^VRR*@_4( L@WY_@(MF8 ;:#_9AGOZ[7UK2:=4EN M5BTFX@SC6',VT+C,?$Z*KPT -SV<.X^PIFG-=FL[>+*GL5N*$2YKNW-=&6>; M(0S=$.2 *MR-O)J#;-JE2V?/#_J=:\>$C F3MV'L28M/^8RAR8H6]C7Y2S== M,1DM2 '39F/10D:;3D(+=7E;KJYH85/SK&XD-^V8(CJ A2@\D58&(D>Q]30--; F[#1=ZO<(E]32Z?D /M9!/E &S?7X0:U MYZ9]*:"P2H7/:)5$DKAWWD-8)_"!D[#Z,%TWC=?&0'%,CJFF.:,0F<[!WZV% M,G9_7Y\0R3IB+"S@9/>GK^15G=@S1$KM V_M'05!%Y'FV*ZFV.X8ELDZB;]2 M#.?@=[3)SDGC01,TX0P8A/GMHGD1LF"0O-TOV:^=-(Y'O.,S](CC?[=>OVM* M:'$/CH3-.^9E>O2HHX\/13)2]I!C\I"_%,7?KR/S\Q43C04EGAQ X,K_ "B( M[P<*)2%L$T+6=!!]E/H(-O=L&N!0H?HSS"_$?!Y]E&IU09+;X%$V/FT/6W=T M8D/ZL#U3>&/(555D!KM["GS"'8LQ=-OP;Q[95;D?0B=#>T]%F@'M/-W9>#K* MM.=VBHH7;*MJ.;UY')T9TJ&GV19J[>V_B%7^YE[1U>H(C0C:8!\\ MC@++I"7\N<$2,QFV+[]. I:'IB,9W6TO4UC)O?_!0]*@ M[SZX:M%Q5?U9G:D3 .X7PO^M8BO/JM2ZN*HZEVPGMO/VR>Z\DW#GA[:D=H1Y M(S/J9M+>>FY>I*!R:,1E7TP[>H0GWDI1Y'PGHQ0V+TMIOP,D"LW&?M<\#*D1 M('5F6!*/@*5&0$9,0UCW-,PBK@G-"/?VD?7WIS-' M48K;_Q)%)\E%*RLX%$N=IM!J=4HL'8F1(F))K(E"1]YOIL5%4[:NRN;;ZW'4 M)O=?=K@LN\Y73T)*\"4R,98CC49*NHJU1DYV:U#+I:X^<>:$,??7=Z>_WS*K MRT*KOO\N;#="$T0I3A)7&63-I<65W!0:Y\%>;J-,2&T)+C1]+? M'YIR9ZDP-+4:-:'=CF_O1$"3JTL_LX*]0Q5#KG44WU$^_)%:$.7ZGV0JMK?0:=03Y>,7-H*,XKF9*/4(W4;@=6(ZT; MS1T4_=CI<%-R%:SN(".EO"+4)^HR_\/4"T?V]7MX(T?[=]:K)_WEP)&J$X+1 M7#^Q0'LB'/Z3*N;PU0A)X6O(@A@A6E',>/(Z1AOO!J/802L$IS5):-335H<< M@@>;[P5CM\;2#$&8* OM^JE>ZJRCM/5N4*J^A/&@) ER>W^,(3\>W!&X#,#: M<$9-JDS!L#_Y2',!J*.+@-Q/( U!E+!.ZN@9,TF$0: O'T19&($^RY!+9I,N MK[$-*H"CRWJ=[Z:7-EC83:'=R25LN1EHB1H&R:BK6&@#L1"/?#W XI1C/"JF M_38T%=WB\+%N5&NL&=;27+G?JW;,X6Y]C"73Q&7V=:]#Q]F_=G6JS%7M[S_H7@_[#_>#7S^/KK)L MSQT:6TL<24N":+?Y6#(B.K*4L IEMC#/2AL=SU35)/M[]&DEHK7AJSCW/5,I5/2^TG' M2VR=27B=@,D;;:]>Z-L%CL? P0XXS0'6<6=8K ^M94LKNC)1!-]A9O1M-9#$ MFV?O;'6]Z_WZ"$]E@M/L0%HJ;),6'W1K.=,LV3 B9WL59WB%Y8W6&RTM5:>6 M574+E-8F?'GS4 ..*K!/M^<&LCFKZGRT-"TZN20#D-7N5OPX\B'.Z4N.79%C MM"5/D6GMC 2^!1C[B%T-:_U=[TA)NY.GZ J;8*,-<4<;=1>7<7I+^[O&7I); MZI#$.L%5/((['"99CN UGX$[-+H>65V[5'5KF,[ Y[ I7^WV 9&:T9Z;._:< M'K]=9Y;,2-4TX- MGO6).?C,8_(U[L==N#*%!,H4=Q[]B,X4;>K..0A\RXJ> M*H>@IR?W1-^< S@\U_-M/R3S;-=P@-QH*=U^Y6;P?B?)VM"OD1(W:=94UDR9 MN%.)K0H.KU!?V.V.I^@"*6#'N#U':1(+E8NP4P'B[CP%%TB-E:1#,=(X-UR@ M>P(@2N5(N]Y*2EUR"D699*NB((F[=&74Z2MKQ'1R37Z3&-!R"N,[BPOO7?-R M=#:>S'[S1B 9K_K67&K7CJ[$M*-7)JQ%<6*OMFF[>M8OQQ/_[P_G]EW%H1HX M#85UKE\?V<,&8;C#U7 NL;Y2)FQ4=PQ6[R0M^6"A'7?PP+;&#YOLT AFH#U# M$Y+L=&5J6A1YLZM/?*UX>GPP7PBW[V!UM -,9TEG=/*J:]F:@,[O2"!K_J0H MV?>>8H&LMIXA7&#W^Y96KRY@T/17#/AO# DP!=.T&/@*@,\ M^[S.S8CND:M&6/!A.J0:?5$M;/B"HPY-''8<9EKNT#&N9;GPEF96F[F$#(*Y"82GYO86BX[ M57(DN13L5$_/3>13!FZ=WQVHN,M%D,TF79MWB-\"F$X0]VBBZ^R*B5G4%H:U MO)&.OGEV:+##5S$DYLRJWXP=N,/MU[?IG3J87C+P/^7#!'^=06K.@#5$UBL0PLS ,9U398Q5^!CB!*3>&J;-(7NG M (V8$V!0@=QJA@E4X0S.\PQ;/()I8,0#K5K53A -'@!G8M,K_LXZ4F]% :[R M!K2N3W/$]-"3(*O$%%'/T2,A$]4$X08"P@&J+_#\1)]A:^!'>$BJ_!V)985' MM/UU'!>]-%FE[,@T_F3>!!^]N!W.MHREB3)G;ECLVT@@JZ_KE$ZL->]DQQ2_ M2MPI?FD\EJ0!L+Y[+H#77%W.K4?828A1U4X\L3-IR"OF#N5.L"VR.0]-]9/$ MPEFZ IM>@"(98R#*&.%U"5HE#J4@PC;)Z#(*QQUXOE0AAJ?)Y?"T[>%I8CD\ M+8/A:9%S'WJ*J8-DMAZI.0"K,GZFP\X%3B6OH0-&=O?IOG__^Z#RV'LBUP_? MOS_UFD-@8C8S=? "& .Z(") FV-L'RP8MIK%,B-LA=?% M^,Y@T@6V@L6!YJQTYF3LXRBTEDW=U.:;OBF6.L;P$E('G9QV^510MB_7P:$D1ZR(]\0-56&=B>_-7,I]X=#<@Y# %[7R//#C_;;)MJ A:.5L\H MA74B2_GMU*,?B[_U5'6=K>:''4KPWE/>!:_F3)' &?LLR/>&5;8S9<@=3J" M%*$8Y?1G3@)=? M0+';OL(Q:^92""#WJ%U^TGMVT(EL46IW#U7*7TJCXTJCG#WGXY4\R\&SIZE321HK%*H$1@EV*&AYR M&:-V>?#VPJG!5#\&F*2TTK<4'2ZZIW+-)-8NR:!W_>.I/^SW!J3[8_C'PU/___5N MR.W#$^D/!C^Z]]<]\N/^IO=$>G_[T1_^$Z^B'GOW@RZ6V)+'NVYQZVQ9S#\% M2>1W(\]@=6_ ZO!&5E])=4OQY[*15X5E46()Q\2]?*'*>.:FTL1),H2?'/QL MUW6PNR43;X-,6M&-M3L?MCUB+'@:GF&"LC7IV'C6@8IXZ<_6MGW#\]BW@%"A[,K)3V._7S$D;H"CP .C: M\@C5L*2P-7.^MNWU;'F!WN!E^ .7!Q8]S2*(GNUA]=%%CQA9]#@EM3%$3X*ISQF(GEV!V7BBQSEM M1J(GP0#QM*)':M>%>L#0S7VB1RQBZG$LP]=@Q5V\.N=)M?Y,T9(JREHG8Q># MU7#]8S!\^,X2-L%QOA\^,3>Y*/9Q$@,Y#K(]A>0&D!T%'CO=Y3YX*_^*F%6%AG&19W.N@?H?',-4C>K*J3P-,1..^9B6&=GJS:F M'F(!!?TYQIXO< JQ]L&ME/%.>1D8$?3]3N[] .%]J\+%,:9YBBB7T$9 M6E1?.YA[?^@>,% 8+X"J]DV0[>3^?B"'@.N&30VYJH,UZ0+K.O7M!DPQ("G' M:&:TR9)@X> ?E.=5=7!5VCJ6W+[<;N3[@82/P!)KM)>#V.C3 M1EFDYT^M%,[NDO)*M)+R/"M$,G9TXUD:.5M1_+_=O5V0')-A#[F%1$8.H?_$ M6DB0*BL%B!0:1P6&FDMLQYG92PP!B0TFL.RP&-QVC:4@CGTV#3"H8*4)]5JG MD57KM/TF%=87[5FD,E(TK&#UI *V"_6@F="@V*#-_[^]:W]NV\C]O_.OX&32 MF61.5D3JG=YYQE&YEDZ._8LG7HZP?'3TG7>W3&5K6PJ1\QQ@#DK;.];/1E:(ME0_=QR?0<2;$9\MTT]EQW&YTJ^GB[!RZ:>RZ\"\ ME[62Y@5HTA)+_1CTQ(+D!?- !;2>H0+24 'J,U3 "AT1Z!\:;0"TOQO@E8!( M[?"QP^XRZWOBL:FLUF&]6QJ'MPR#0MS ^"X!A>'R/[(T\\$U*._&6WP;F@FF M!9&T@FQFB?+WE M\]K\J#O&5QD(?/X8?AD:<(Y!0Y!G(//?@\-/Z8)NS^.Q$+!F"E0<_%X3$&G( M'P0[LWW8\SRT57?DW]'K#N@5*; >Q MN,"YN#RKS<9C\#:@7=*-@V!+,*S#H;J 3D>[DW'+X!"<'66TZ6"3(>86\Z-='&"X##.(#:OC8MW17 M$K.)X'IBR&_X0W9ON'0$&, [X2_Y\L'%K8?(]0T?)-AZ6!5G8>?L8[4(+@NW!H( _N= M/40)CY\1<-*ZYBB"N,@QDP)+:XI$8(($K ]0A2$VVCB/@\W=LHDQ,CDDH>9[ M!"!Y&P)\PDL3_0_0]H9S(B["PY8X.B.C/ ^2$H:"'X!Y@%?20UC1"U1,J&Q$ M>'SXSK>BA:3+"(O(^U#'<3XY590(1=V9$KBK3*K(RVV%'8SQ Y<"3 ">PB8V MU/Z%@=.2.2(\6%]VSY_F#\B<=B/(+:WN"8!/MYIA!D[*L"0A>*IT2;PNO5PT M71>J+@!"7=Y$P.6XCPCW*$P(;N@"!8\,B8R A_))3:983#D*I6/!'LJ4G)3# M_13FU1^8YHCCX-3NK+ZS"&+7@'##P[-;!&AE=UN*P>8/'!6#[VS4KQP7B5G7 M$*"'.@8O\U$!?:PYF@: R50%H"/FK0&&4<"!:H@9J.'RM )\1U ;M$XUK .C MU 3]@:H]U<@/"7A"T3 J4+? )D6F!]Y@WR%^$^JHF[164MQ:01R@V_ :_CA& M.!P$F)-.3BGH= \AML/Y/'0,@CKMPE8]6G>4M\#?A="Z4=\K_KM4\ZNZ=(( MO-QN09@1S W_;=PB[B6L?692F@;!I_B%@3%R^2%8C@ENH'NW?7<&:#V(;/FG M,KAY7C;&>V&-OFO7%"(%X,)1'CR:7#!* ND350#[<&4(G:,J!Q)'&&/$G@5! MZX9]#[0<\$A79[8.G_]#49:.%A_= 1AOLONN!LRC+Z/QY:^,T)23I("*((KJ!U3JB($+FNW9IY2"" M'@)C0>EK)!@K6AU>"XO[U46*L845L0_ESQ1/59(_,+\TA-QL\I^.#YRH3]NR M7RA5M0@<1W-LFZ9]1[L6VLE'W3%A=SN=XGT#L?C&X8H/]JV(U[[:]<>W6V-D M/IZ5"MIQ-D3/U4 ]_9LTO)K2"^>X'JH>3R53G<2BY?,HLM=!J-L6P]0%_,JD M?9WY/EE*Q<'*RB..5[EW8FYF) M4HV9#"A?68VY/.O7ZI;C4@].L]= (![?@,4$Z?<@A6EQO* M?6.&*FJMV^S6FFJ_E)"G2K.F0*2FJJUBD+_PQ7/F\*J)E6TK4/_ZIX)0#ON' M%4DO/>7K +G-@]*:@S*^FBT9B 95U[:-I_6VJ>>TGPO8OKFFDE^8DK'B&ZMVV[4VH@9\+0903?(UF1!RN24;O8=M=Y[PM-O]].F M>M7I[PY?=O5H\! M5XJ:UK5% =B6Z&AVTP9OP=+>EK8H>9BQE@Y:M[S4@ M4,NQ_=HZ%;T5PL4B[^9/@NL2KP2,^>L:8O!L79E@N>79UK_>.B'=FM)+.8D] M$**T\FC4UI=7HP@[^48]AQ7>W0G'B\-S+-.CPEQ>TTJ]I#WM/GTD6KH@X56S MV:RUE/4#A=?E9T%;;=4ZS51BY"FQH-EYQ$XA?<);.@80C.*3W2FTRG=D,4M? M:]4\T/S&PAFO7EUX\"-9M_VAR7+5C:STCG#+$O8#7CJ!]7,?,2S[Q5GH;OMK$9YO@[:3%W7[N/\.H ML>+%X>$"4%E^CT(*[]#HC./#$/)$$E7R9;/?HDP[@@$TZPV$=7,%/@?'X,AS M38=WNUA*B2(/F<7&AHUN4 7T;5SG-<(>12^ MX.DH2"8%Z;$7(0ZVGQ$'TXB#S6?$P;(L ;*1R=HQ\,=Q+RO->-E.JQU:1RQT M^JFVU'T_UC9*<0)CQ.D^"UXBH(;0^$58]6CO1FG[KQ.N]A!AJ8?V+:O+1WC1 M]R9Q"RU\28V#8$MB;ARQE'#$AA6'U)HS$]**>>XZ%L=A^#;R"8W0M>D2^93I MAB8 7ZX),3$$_JE+B]4R!UG1N##[7KVU@G+6>."(NBWE_9&20+BI.(83C#J_ M9"F_CJO=2,5!0+O1\,6*Y2Z?5E*SL)YC==7",HC5=:O"D#QSSGQINY+%)BG3 MJ2S:('=0UTC56F1-U]*>"DM@_GEB7 C2CA)>XGE>L-+5!MKB$&&2AN'1 M;F+0NOPA9[,=11;X5H+\C/';:A2V@10[N<;?E@BV;K1I@,_&#]\@(& *! 4D M,2PQ#MM;%<"?LP!E6'1CR9*^TJBI"KD:*;L3P.SS:JW3(X7!?-73 :+, @/B M"$#&/PB_&K!Z#$^XN9W7+J!_\C*N5. _6>>,J1FN?*/4"1G \ MC5Q']ZDQ2SG;I8?=^6:[$^R-;N>G.4833Z7(OK_R.?CSZP *CL)I.ZQ]QGX\ MMP:"K<_.>_?H%:]PPKUFJEIR,?K#_NE6:FJC6^LU4@LE-T[#IHH,T_(7XJ>F M%>XZ_P9E.OUE#6+5M<6FU=V)DK*MXR6WHE2D M<%521G(F#6T%0R\+O47GBT3>"F)*>FN2-&EAY7&NO2'RK99M M<5NAH]BH?8XD9BE>,[\6"9C4%Z^A%&9TR'UG.]1G*;6E..M:,$THJ.D--:VE6B4[]NO9T^B9EY MO@\1'94V!N4-1+"413"VMO TT:,D*W/+V9NJ-IM[?(TISZBB(G8Z.38XVZ\I,X:G1RTY1I411U?B*<&!F21%8N8IYTHSWP/FZ< BI9R6]K*KOF3D0K M2 -_A\IUQ\ ^S3*^7^MWV_S( FS?2Z53Z\%GF7J1IYEQ+6I(ST^W%ZW09DUI M=Z*3^1X>ETHKR0Z;[8@VAV&G.:"-][[$$8V("7S^%M#ONMAK@/RM0\V3;*": M=S6R/:1<,R5LJ(D]ZR;8@0ZH!K6>NJ+3$Z_TE&=Z:>Y:D?92!I(K=R/G/\-= MY)4[_>@PM=NN]]<]2T_5&D43F+7)\$YV?\/[;LW4[];@88=-;%^TG4IT"X.G ML ,>&5Q/_F18-]KWRAJ67+F@#>F VHATH-6GVIWU=&"U\#/6_!TVJ@9*&X-D M2ZJGV6@%9JU$D*@97\;+5C6RQJ]6IC2W-.L3);E@K M:V.]L4N!CT49'(R"I*BU3:P!K>C*FNHQ/-M$"MXT8HYEB"Y2H>6280'IAAHAH7O&DC,_A]%E(,?(6X/@-.5@-O>^UC M*T2/40]0*^C@BO.*M3"5AS;>I@G,P^PKI46OU"G&N[7-6Z0MZ,'()UJ7C_(& M)_1R/1&QBPJ.=!PJO6S5>JH:K@K\LR>VS_$@1_1<3/)4CGB:8"DMCXBI$/2H M:B,:HEEK-EOI(6K2DC'-SI4?^&*V:!"1?Q.*M0VRJ6+L7Q7 MNX?2>;Z'DKZ'TGJ^AU)4Y<9:!*RVDM#V0"S@,'(X6)6,G;6%\5BX\BGN )&C M3Z^!*:5N;1YMZ,FJ49=HB)D-WCA;/O*O87@90@0TP"WXN8G-[*\GDL8K^,DW MTC8>6Y(RS8'=FS-CZ=W(U$?Y2:#4IZP<;O-A$MA^$2OTISP]D\C)..1F>*XF MN-59ETX9GFI,F D[0.Z+5N!+T@.A>\5'W:BCK7V+[7^Q)6_4XS[T]E+X==17 M.[HA Y/"& )"B%3PD(@>8N];'CT$2:B4JR2G2)MA:J&./>9Y12,*A'=WC:*4 MD&Z>A GY(940.2,27$6]HV59V0CGA+8-%@:6 M6+..3, EHXU^^(9KA+W.79?1.I4N+8B)'Y"GU+(<>&FXKH_I8[K\!'_8S@-$ MD!X+6JI'-_!?\L0\1;.1>ACAE0NQS*/'8K\5M?5B D'@&BY#XZDK?;(F2:IL)VO^ST:ZVNFI&+G-[X'NF0H(B*(S"K7N]U?T+S#T]9 M_K2&UFS(T,S%!PU_)JZ.R* \3A3@BTD@Y:_GZ27N18"0C.T(\4_M=&J=3B?6 MU'V&)?*KB*\O\2"D"5N?3,;P[46[UFRU<+T-F9QO*A$;TY.JZAH)^L3;0_3I M+&X'@\;M)K_VCWUH;>J$+D.@:Y#IA%#"]C0S(_/3;48;O>XCLNJ59?PEGLP* M)RY,$+(#+/8PS*>2#[%@%5CDQ<#H4.-X,.JRCH7R#O_-C,,:^8X#^Y"'!850 M='J@VZC;,K.N<2. 'B/XX83IU]$-/1WDX89?2H[A?J?(F$X!R,JAE5QTF2C+ M'(1+\F6_HU(JU490B1@5'KAXU^1IA=CA-MD!S)JBC8IG_$0$0-H)@=3P@5Z] MC:6[$3O=A!?F+FU:<,<'2HA=$GA;IF>-;$;T*)G^$A)==:B%F9$WO( M\QV+K*Y#3=_C9&&DS:B4CT)G?CBE9_V61D$%'C)F14=38O<24&:'_=<3PWQE M4G1XAN&::483#6H>X%7H$- PPOH"!8XP4.X,TZ2-D&%QC( ARRHG028&1RI< MK[V9?944[:M@^6#>#\0!8]NX ;LQM1$+DI!T)KZ]I-3.=?HW/&$0\TK"R)!$ M0*]]-PRT$N=1B)6 1YE\L\M 8TWF3Y%EHPDB$ '[AG2HPO$9IE.;+ND%7\8B M])C5#,TC"(:.-\6V#TRO[X26>NB[N$EWP7@R5^+FD_;:?'' XG1#O\ECF,1! M::"=%ND&718$[3(9:H?K@4<0%ET\%AZTV8[+(QR(Z3TLH, C70I@' -33E(" MG2?.3<*GH*E 7#?5,*D1+GRZX>^BN]9$\2R=_*'HMK$IV$=LDUCD8Y_.C,*L MBI!3M%:E8*W.S7W0NA^BXF D9.#2Q"T__-P=/T37]X0I$0=+:*U@>(RC.#:7 M!=3*WATS;P,_64A,)/J')AOZ?UYH?S<:?SY&6.LBK-R[*SF-%(7"L: M:U/#?'B[[.WTK&O\PS@Q_!X\;*SE9EW^W8?=+QAZ0AY R<,'9O#W>\,=F;;K M8VY/&\*F!6.8[\R3+R#\X??69K,LI5TGIV#&('PWP3B"*=OEPD]JF-*HDH:U MZO+ QG!* *.=H]/24:$JICXPX>-;S>1;"[25T=J9QX&J7(V_BHHEPOPCO KV M4WQW'"3>(## .P7&#?%($E'/["\'$X.-Y>-[-O+)!IW1;MLAWO'O/H3Y0?%= M36:<]8QG@GCH##^F(&7..'HH'VD4E\]-*!\Z^M#9F#("$%%<^%C:J#2U Z7] MBKVFIY6V+OZ*4C:70+K#-Z_'P>;SB-_*4?K-5OQ$17Z%/T":U,;/P<,2/$P? M*3^_G@&R)"Z"9&R=4JT.C[,3^=!W%/39ECB9"752%+7DYZX4?(=5!SSW2J]< MS$QY#C-QTF(">>="P6DH2TQ?BZA%QBC/YB$GQ)J^0_FSD+AXQ42XG>&[$T%G M,%14Y$/'2CBH*X\A%-5CXDS($$B27AFOPXU[319A./YGB&&@BSLK^$*L,H,% M($)X##K%K%T9$SS&V B2V@G-P1>$(P.5F 2$"84<=U 9)0%6.A7PE*\,($T; MC?RI;_*27Q'[^Q:X-2\JF%JT7*,$XYH*PQ4<,V$0^&/2!0M+$.V!9@^!M@[3 M=L71Q+7FA&-%6E2%P!MA4;GX0+H$.X1[G= 74$ <\>Z"E 4X416O<&J+FQ2\ M2E1,7U@'/OOHH,<)9B^]6F!SQPF;.WX]9Y&^ENT1Y1D2A> IE4?(0G&4/ ;% M RI$F3U9$@F/NH/]8[@YQ%6.-5EN9((>8'?TG?':T=3SMF'LXO? MCJY.SDYWBF^8DU=JE;:$RE&=\@?R!VV$.;V*;01Q-Q0D2&OB , 5\/0BPU9+ M%"!8NL'C\Q#SB@=SKF>#2>2YT^0>!IZT,)H-?!+5S<>..\:"Z>!B#VX\/$)8"4P\^A9=$\:Q&'(6ESCLC5RY-F$81H=@5Q56E)K9%,F7- M,2?I\%N787GRR/9-\-$ZQ/PCG"\54 =_U3CP?Z9/QK0ZT)\IF.A:;"!.#G4G MQ"7J8Q[B[I\NO^$I%<4+HG6!V/SB^;*/^?1:HG)&#)<>34J,MK>SX,@>J7-2 M5)LV/=Q@D/_*^S^U+G^Q8%=AN![M*"_I0B6HQS$_#YW987WA]](H)\-T=\;V M/Z/'K8 HMAR_8@D2%K_H?TY[X_*@2RH_E,]]!S8D+DO-I+KX M9%_I';#FCO#4&6++Y+^8)[]C,<%\";,* M0@CROUW_YO"5\AK"5!_W5K& M?AX?+,V-O0+;?6G%XZ7@,'2E5744_BX+0MK 9.*]A155. M5K.6'DDOI1D[AQ+JSK/,.F+(H^<4\U]!L&2%RS0;68L>T!WS#S?6G MS8B9=MJ0>=.#94YRS5]7IO'TLY!7&;I0B)TK)5;7S&:G<]F)1.R+PP4F%-XP M9T92>B/3,*P7J01$\%U=;1M6EFQF4QGS8]!P[(O@%F4"7%1S4J7?+; MDJM:'8&J^02:JN'?CT#WM935NE(5D:N;7\/#>96]O/RW)W^I7]8'==0&&D)I MMAL%6]-J==:TNODUO5,![VF-*PVE?G)Z648M^//=Q6?YQ$*$FA&>GX]\NGY_ M(/#LQ>=Z\#G= L=I6/P*)9;YB0LM=.V!0('A/9JG@8Z8>!^9U^'!-D.FL3SM MFM]CQZ) 74]>F3FQZ/HQ/1B,62_,2DL[PBBLQ]"ML>O]\8?"L.L]WM8Q M-L"M/:K?YZ-WA>'G9VW(S*(JWOG%<6$8=[^8]3K%GSCE:F[GRL:PK^N7)+Z='5U\NCB]W<0\O&'BG5\0R MI7 >VRES%,X(.RE REB**X$/7=#=%\0%)K!NW<I_F>Q.;< ZV=QFIJF=#XM6=1JZ*V-9F MSS_.!L='I_*[D[.#P:_'O]7DD]/!&COI%PL#E16KAI+OV]Q4W^,]N[=4X*]T M@AK%^0=A,RYON,W["6_<-YQ'YPS1!GZI0\SJ6)H_1Q(I6C-9N$"7YMW@VMR, M\DUD?97:'*6#B68X4\T*:@S>V9JCUV@K@=V4* %9:/(S,^G/:W@/:UC^R,9C MASW(EPBZY-@CS2VPYI2*V#_HXF"IUF3J\".3XHUN5]> OMAXH+L-&K(VBALN MG5*Z"[?8>%9U$-^#9>V?YTXZ6>T7^W5<=6+[;'I;QB8[8!11E]XCIHA\E#C7 MWYWO:X\FI3?MNN'>F!JL8A@48*_X*D/E*?B MK?5PU L\_!RI+VC?RY\^0#B- ]A&6-H4QO#=@VM-NWE+F&PI>!]T")T0)U!+Q%0 M9J"YD\WS(T,DG2U2LX9XNL4BIS=+#HU_P<)":5C%%\Q#Z$K>]H#C8E">=_/B MR[!W_4(1F,%!)661B<(3:E:4(@D\#WVS!5N0P3PE99_W0UN&D5!2QOH,LWL( MA^2P"9ZLW;+(;'W@[4@&HAO)%38CX0.!^*^BUB1'86<2L'IGXROM?L->)\O" M*"FK7Y"IK*,Q*?=1CKFH67-).:+'NL)E1&1%2"G_LVTB6AE$I+S.MHG($D?* MUVS2]:TCFI1OV25!&6)24ZYDEP1EB$Q-^8^26(,,::M%=3C+YM+.F$M)/4Z6 MSJ<V3BV C9OK[((2WD/SE%@"W,13&P+:S CN%!#_V$/1\;; M2__FQJ3C6,V,.CM<,&Q-A!"T\CVX,^H;B^T&:C)UVZ(.F=C$U[G%3*SHS!=O.*]9V'A)XX58]IC.CQ/MJ:B2 M.VS=A$^)MET&->>-39NR6E<@"ZHD&F,1%N^$)[CB,M&(#<@0Q]$VE;GJ6%$. M8R/0/'.P535>*>4UY&%SQH.#I:NCU\L0?SX%;Z9[90\F#'R"[=S8 M'-7U")ET%'55YVW 2^NI;8W6)'?IVLKD;K\8%)_Z4]B&C5+& M@-.F,^/M$?;I0#WZ8&K7+P['FNFRX)7BUX ]'#M,&M@[4]=NMC+>M M]#[.A0^$8/\7TYQC2\=SLQ>'![#7.V@JJ??G?W=02LE?SG>L'^ S]\7A[^GW MKO#B8VPY]3" 5SN:>6+I[/X3>WAQV(#_-=N-;K/["*(_VTCKQ+88QUY\<=CN M=0\Z:J^1Q6F)/@S3PGP!&IA\!U?)V!C!H*X-3I>Y:/,M%Q:,Y]V\??/F M[NZN?C]TS+KM7+]1@4%O@AL8/,'-K3+81^R,CD##,(0;^!$-NUG>_ZW0?[T MPQG_,G R 4'1>Y D'--X*_A,*QCXS'DFR^);1G(\I(_"#^G,#MN:.#+-F26F M M:\?FW?OAF$GTG MB]?'YJ+'?M2DE9/\)DY-.#)J4()5AUF<4UZ$ Q:9=5RS/,&#]H'2#%\NOGD$ M#]0R\B"N!QO@0;-T/% "+[(Q'K3*P8.$&5'6,2/*QLU(>R^LBUC"KC$6-X;$%'$3S+%?I._ MBQ.6&B)&W9L9\@JG\ITG(+*&=;2!50*ZX"^W30A11XL^("W__.=O,)+;P77&FA[=L[;U=Z[:I+ MKU!N=KNR[%1KIC7T'#(44>N73(X6*,PJI M E7/L10FCUT4@5<]$;/_[;RR\1R,6O4=0.807-JK9]:94N1UBT@.99L;(5ZVED,O2/M5M/(.>X-X%OU>"V2Y8N M$WU9W&KILFDE%^$6_&OI$E91NRF=C0W+\-AGXY;I)Q:PXMH8FHQZT+CO'G[3 MOMG.P-3B?AOG1>^-=LH__=)O?[Y719Z_QWP\?U,M/ M;V[OWPW^:MSJE\Y?'\_/OGSS+/?=W6CPOO/GL7OZL6,,?SB77=W\<:).3NZ4 MJT_*Q[_NV^]:G_W3_C_3ZQ\WPX_>^/3\Y.M?FN[=L]NOGT:-_I\GBOKCIGO" M//WB:M >:_]5[(OVD;7,^7W?[3?__.?_Y,'EQ?8YVFO)JNT";2U M]?W*T70VU9SO+N]GI[-3;5JES5UILVEKBW3@NYX]9.<+0BRM)FO$L_ M'L> 1O>@V=@D W:?#GD$ Y3>0:.W80TH;?* G_<:V)@9L]/XIMABO6+.]+.M M6;L[8YK54W6C>EK:U$#1Q;19 M86XCOCZ5[D&CO^KZY#]2.YM."$<[W.C M$8 M+0/-LJU+V_2)@J,I2&BDG5BC/<7PC8-&9V7-HQ^IZB8UKZ*IO (8FNTZB(KF M]HHEM\V?E2_*74JT0>;(5$:@E$4MK,TGLV])Y"4JE7VJ12,26T M!4]3VNS/7 G%X@$1[U_93RN0$]MCYUK#]K09*% MJ8SM:/3#-UQJIE8=Y*!>:=,VI13@%E9@:;,?.4QJ*+_!A(V^#VSGQG;HBPK+ ML[19D2K(<_,&ME^Z;,ER>2:Q7%?""2J+U$J74"F?U#9O._NER[E@WDO<9CES M+IES"R)*WE@2'S[M,JU^Z5(U11=L07JF]TN7X4'!7AF>R<[&L,TW;@W=U\PH MB?W.UAS];/S><-C(LQUW,-$,9[HT([>]Y=M<;_FJ[4U*N71IGZ)+>3;X439Y MZ:)?NJ1.T<4U:WI77Y3*YA=EZ3(_19?R;(]Q9:.Q;6GS/ ,;]AF6QS?Z%X;[ M_=W#.V:-)HBL,!,2:29S+]@MLWQVRKR]^SJSG[6L&)HF%I-#7NV887Q MDLUJ:MBS#2N,AK5*IV&K2_QH-+)]RP.ACYAQBZ42RT]I?6L5U$]FSALN72?=6VGNM:OIJX] M^\YBQ6A*17/CS[ZS8'I6U0SYL^\L@*[YEL$5S9UH#G,3Y[M3IKF^PPX%4?1 M\)K@N^C%^*;46WU7?Q%.8N:UAFNW5*7[]LOE^]1;Y3C)\]Y\#HH54)T8@>HP MV S#\9>G/BB>YMDS1BPW30GQS[PP-=A[9ME3PQ+?SAEP(6\SAYQY;5S_C]02P,$% @ $%:P5& D@0?Q!@ *1X !L M !F,3!Q,#,R,F5X,S$M,5]O8V5A;F)I;RYH=&W=6=]OVD@0?D?B?U@AM6HD MAX3FVM,E%"D$VB*E39KR<'U<[#'LQ?;271O"_?7WS:X=2"$MN=*H;1Y,O)Z= MW_/-K-U^.WQWWJG7VF_[ISW\"OYK#P?#\WZG?>!_\?2@?-SN7O0^B8_#3^?] M5XU89_FQ:!U._]PV-#J#0%P2-!=OFJ*G328+F&)R M%2]$/I'Y\<^K^UW__U-85KK1:37%0$SDC(2AF:(Y13!$6?&AD 9V)@MQ15-M M\GI-9^*U-BDD[W\0.A87(/YM0&HA!%C9_N+J/XY3G3=&5%JZ S>E" M7&=ZGE TIL#[QCB/B$B3K=V(%4V(1FI;"SF*I_ 1#NET&G(?*?0 M34>P&Z6!(A*C#J1N0(C ME85)$8$I0K7BL@!A5EQ<4SB:DX23)TF665#ZW]Z5S8D6*68NX?,P=!8V=Q(2)*\Z!6'FL%*>&VES9JZOTF$_VB*X1UG M/#7V5J.$V'."D >C1-D)%PV3I8 MA@&^CY0-$VT+[&-P,#KQH9D:'5*$92N>(1(1(;;>W?V;<"*S,8E3E-U5D8"B M=23W6R^>T5Z]QGM;+R)_N^=8*>Z@F4\*%B"X.%=RQ8>.E=E:4NPYEX)B"&)# M[R:0UX4[QNZ:G;L>_=5\.,)4RL0 T#0B)=O$O07L8L M*'&('RI !I2Q.E&1S)VF(ZLB)8UB"Y3O+0[^,N946(9[5R#6]08'#=H2-,J! M1;QIBEE!A44B 6GU&@QS6BS[!K;X+K3:/O'?B)@0J ,&%#UF>!\]GT9?YM/& M\JW7-M3O6EIM7_E;9Q3W,7?A=:WPCND*Y.(P]*;TJ)I8:;(+>L:8AAJ$[$"]9H;2L:4H<\E M:)MX1%-.7J;!Q.73"$FNIH"SWSJ1PCW1G\FD<+7+/J8XQJ2@9G".K1H^@\%: MD]L"C?SMYB' Y0TV DBL'S5&NLCO56%%7+UVC[S 3R.>!T]2\;>G33&JAC17 M"^1] 85.F/GO'/D($.)]NAX;/GGXKEZON4<;QYP' >W&1V&A>$(K"#Z!JZI MMCG6^4@/7C8$H\_^]%BO/;MG3XQD0D7?)1>EYIA?R1V;^$25%;>*[7FU)M+> M=D#& I=\%#F8=!XI(6R!P]$U)7R&JM?6-@3?[:1?/.'ND?)BZR%9E#.R'X/* MMPA1E:'!LE 9.%:39%FS'.6M_1VL#S:WNDD,-[DVY4C&1&X%/%,'!2BS"='/D*$BA 5WRF6127F)*\9^WWC=NCO9@[WIJ,ZG#XHV.7 MZ ]>ZP4M9(2-EF[+V;__V)09Y:2"/8@N!HK -R +U]@BA5O4O^3Z4@FE&P_R MOWBM;S6?GJ*'Q 9U$\#YY(H=X7-OA\HX!^QER6\K9CJ9$<-P)L?E:RY3 @2E MTT0O"$_G$^U!0=[)(X2=Q Z:5//'O6P=GG;/^^*L?W[^\?+T;/#^S:O&8M7]@X7.591/F/3PR0E@QV :WP]UDLBII6-1_==PWR/:PZM*P(PA%WVR M"EJNIXWRFT5[V*NH2N8O#Y\T.NW7%^^'J_KMQS)5R>+X6QHZ6HN*\ 8U.CV> M,X^]>_SUG5R(ULM /#]\_KQ]P(+XBTGO7H6.=JI/=W'\5:&E5TB^9,O?^KU MWW[Y$_%_4$L#!!0 ( !!6L%1[_G:>\P8 .L> ; 9C$P<3 S,C)E M>#,Q+3)?;V-E86YB:6\N:'1MW5EM3]M($/X>*?]A%:E5D1P@<+1W(8>4D'#- MB0*%Z'3]N+'7R1ZVU]VUDZ:__I[9=5X@I@U'RJGPP<'KV7F?9V;MUOO!A_.3 M:J7UOM?NXI?17VO0'YSW3EI[[A=/]XK'K"U62-5EC/\W8 M0,;"L LQ9=/W7?,8JY',FDR(MT_9IGXDM5Y)$=8 MTG(TSFHGKMO0[4OMJ.P-K)ZV1HTN.M,;QK@2^23&AK MPFGO>M _ZY^V!_W+BZW:<%?D/[G)9#C[P88MI/0]]J<(0RUF[&:7=;A6/C>P M6]-CEHUYUGP9AC9V6>OL\F*PRKT>\EA&L^;W^%M:([\*IPZ\5JV,^40P+292 M3$4 1TG#/N9<(UVB&;L6J=(94PD[4SK&IOI'ID)VZ0N>L(Y4]=.QB#W63WS8 M35J]D&PZH!0R\ >60$%.HK)JQ8=T+A/&DQG+DTSG M@IF,9R)&W9'#.*3"HY)'+.0^EC13L#B>)^B'WPBZ8*%,X%0*T-*) M7K7"$]#CN5XAD$F(:N&9!".9^%$>@"E"M>(R#V&65&$I'$U)0LD31R&!! ,$#W@31^I$R.?00.6D7&TJ1H3"+ LF%O$(E (+;. MW;TO_I@G(\':*+OK/ )%XY#7&T=OQ(Y3HW$4N-L=RTI23T]<4I 1L6YDBLN M=*3,QI)"Q[D0%$(0&7HW@9PNU#:VUU'M]?"WW;=I]CP)\GV!?(=UA<$:?&:Q MLR2BSA7+D'H$[#[/S3?VW,\" .Q0(#J%* ?9*M=@@*J<2&.+'50BL7QHE%G" MQ K45"M:1-S&NP#M98N$O(4ZY M(;BW!6)L;[#0H(R 1AFPB#:E&!BDGT<B922EV@P<;DT0I++%'#VHA/)WV&]"8]R6[OD M8QQ[,"G("9QCS&(2+&ER&Z"1NRT? FS>8". A-(&Q$.59P^JL"+.#<@E\CPW MC3@>-$F%WY\VV7 ^I-E:$,X74.B8F+_DR > $.?3]=C0R<-U]6K%/BH=H:F5M@_=D)_WD M"?> E*/_/"3;5PG!/$.]9:$2<*PFR;)F*9&SP,)!8D+>X-4 @H9@CG\TI U+P#Q.9?0WR9[GOCV MV+7SL[U- 2H.#1)3IY$A'"%\*1,5UBF51L:G@MX3]KG%;]+0RWR*_" M]J4"2DL/\C^@UH_>/>C^8E%B7"/^]<:O]+;N_YA9V^@KH48M>0B(L " D-HW M1D7L/?(\IS<8$Q5-!$%SPD?%JR]=@(:(TTC-!)Y.Q\H!!;^36T@%P;;0N':? MN1 '[Z_.@8^:8SM M=5]%$4^-:++Y?S7[%:4UN)X+F! VHZ'.M M)7=I(&TZ][CK!SYCC;<>.]@_.%B\'AYT'U3H<*OZ=&;-;PHMO#I46:;B)NM$ MW+]EC=TC!,>>C1=!.'RW5;WVS%[)IXI557&YGD=V7>_2&,^SLLS0)V]P+MJF M#S:W?[/,+C6G?'%[1OR%V8==X10C":6?RX YOU)PVIYQIV,I0G:V -A+-^J5 M6[EG4?#D*:!;AS\L\"X6YH6Y?[\]S3]F;JL=/EDT?;2FC]7NZS5]Y/X74$L# M!!0 ( !!6L%1JB]3>M0, T0 ; 9C$P<3 S,C)E>#,R+3%?;V-E M86YB:6\N:'1M[5C?;]I($'ZOU/]AA-0HD?AE:-H[<)&,<8(E A2,U#XN]AKO MU=XEZZ4)]]??K(U#:&G2**9/QP-F=V=GOIGY9M:+.?1N1KVW;\RA8PWP"?IC M>JXW 2W:[(*B]ZI&8K;"*NYSAR<+_;0 M&E\[8-D>6.,!&'_EX!;U>=VN%T OFZ5B/'$>'K+M5F%*T7^XKL- 2$XV5; C M1D-P[JF_4>P[A4D8,A]%1/CVS<2GA.?0^DS4[(@F57"Y7X=S%5$XBX/;C>C: M(ED3OCV3V>BB"A&5=+G%6$MM%E1$5!66)*4!" [)%KYQ<1?38$4[?YC?GM4? M.6 [H]%\:MGN^/I3I5G)QE-K,"C&+T9RQP(5:='FNRXLA0RHK/DBCLDZIX^\P;.BYM4$:^R1 M-[60)"S>=I[S)Y--V;\T=[_2,^IF0ROK'=HM?ITH>1YR[(%KMADB;81U*L$73'5TSPHC&7"1 ME9#&HO>AW$8RI74Y]WY$^(J"Y2NMPOB[_;X+A $<:0WXQG7=I41 M$J;K9"UIJME:U>U8ULG[;^[^]/]_>/S3?E8XZ#PNB!NR!>-#WOB> M9.\.4+M4//UMYTFCNZ@NA5(BZ4 _)OXW,.J7F)Q4Q"QX2$+[8ZFX&FGCQU>B MXU3>/0] 'TWP4^?SJS?D\2DS +_I_&^>#L=\.3Y9G@=VA'T.!8N6U!=$!OBB MBWV+!=CX\I/U#[E5VEGVB]?R7Q[@KVJU/]^0"CPUC$2&Z6&B*-$L]J^_MI1D M6E_K]74^O]_KOP'^ U!+ P04 " 05K!4-YY&XJ # :#P &P &8Q M,'$P,S(R97@S,BTR7V]C96%N8FEO+FAT;>V76W/:.!2 WYGA/YSQ3#/)##=# MT^V"ZQECG.(= A3$3OLH;!EK:TM$%DW97[^2+TG3LDDS=;7 M@&A*,IB36UCQ%+-6,=""-1$T,M1"M73YW'4C2+'8438$+=H;@22?91LG=*>& M!-W%TK"ML>V]G_IC'\&@W^E;W;%R>_F#!MN2[W.C=P-;+B5/R[$OW0@(DT08 M]AG;9OO1+S&M4N!Z*^1?^:Z#_,4N/,4;.!%K#:S+S".7. V^;+\^W% M+TN2\G0SGW@K0%,/UIZ[6?G(]];-AO?>G3KSMQXX+@)G/@'S=>'SIK/NN)W* M_\M>/:Z70-57M9.$_G7()(V.ANVWX \218(<8=V!,18\P$J#&U,2P15EF 44 M)["((AH0T6SP"!8!P:SP;DQYVXU)V@*?!1TXES&!LR2\.?"1R],]9LH2/C-\F)-R1X<\.^JO4(F<\\\#U9K/U MTG']^=LW1L_(WY?.9%*]/]N36QK*6(OV7HQ@RT5(1#O@28+W&5':U0-LKF9Z%))54J[W7ZEY3=1X0F3XI:5XLY^C*:=H13FAR' M3\63RV;T;U*$;]AFQ^IJ9?9#N]733RH>4HS=P95IN#)X=\!"?<7)$59DSX74 M1%UQD98?9Z_]KMF(N #-YTTA"X2%"KUK+((8!F8+^KU^_P'!A:H*8(@.B=(? M*,L)53'<4AGG^@2Y.5!!4M5',E"?QYH$DG)6]85S? '*LGEY'JJ'J-G0:Y3, M05"I]7B?@QBS'0$GD'JY^?O@Y0@P"S6>>6+59?4\2$[B\.1@77;J ZQ_&K!* M]TD\ZK.N0:-,89-B75!5>B8Q90H:RO+*EZQ%F&KR]H)DFH&6GL9)HF!6F.GF MJ2;V"@HUHU=%=TU5*0QIKEJ56TL=D@(AOB4*2HSAQ\?_RU M=_GZ@OA3;0-AJ7H5#56S^\\"J&E+8=C_LK&];W!UMM9OSQG?=4#YNM_J,ZX^ MVQ:'77TF_@=02P,$% @ $%:P5' ,::)K$0 X+ !$ !O8F-I+3(P M,C(P,S,Q+GAS9.U=;7/;N!'^?K\"=6?:ZUP=69(=QVZQ8-=+!8@_/J?#S,'S;'' M;$I.=IHO]G80)B:U;#(YV;D;[)X..MWNSC_?(/33ZS_M[J*WF&#/\+&%1DO4 MH3-W8-IHZ!F$C:DW0S_[L[^A733U??>XT5@L%B],*,-,V\.,!IZ)&7^ =G=! M8"RRXV$N\!A] *G7QA(UFZBY?]P^.-Y_A>Z&'=3::[7"*C^]?F#'S)SBF8&P M@V>8^)?0[#D>&X'CG^Q\#0S''MO8VD&@%X&RGK_K+UW,3G8B3&.#C5Y0;])8 MO6IP^3O(-[P)]F^,&6:N8>)5!6IB@XQLREOEX$7QO7:[&;?AV.3+JC17^6'D M.:*)UMY>N\%?CPR&X^(/N?*+MBC=/#HZ:HBW<5$Z,NWJ. (F4S5^$VD:X6!% M( !RLW%_?340G;PJ"QI9_JI\4LO@R+FKY7G%GP(L&1\%![.WN-7=;S:1X M6]&%-F&^04R\PT?-3PCQ46 00GW#AV$;/8P>NZY-QO1-] @>\@X]CDFXQ6,D MNOB80SG98?;,=3@UXMG4P^.3'=[KNW'G_N88HQ> ,BYB>*9'':SFK^%ZU,6> M;T.7)^@7 G*UTZKRUPUH$SM7CY!W&F^VI8[KX>^N#K3)P%(%61FMMD:3A.$AZ('XC[O;KMQ-";$=2AAU;(L[ M^C/#X<8\F&(,7L.V0K5_\WZ3%DJ,D[C]Q[Y_ QX+IIP!C"\Q(-79 M4CJSY8HL)<5ANQJ'JR(,T3'JN3RR! ' YATQ LN&,C6158CD@;B'I]#%]AR' M;$G)+"J;[YD4G?N;T)EJ!X4-U<16('8P!5 GGG-C,=R@(/ M.,B[OA^N/I=] M",Y]/CVXNR)(35ZKY6>2/?(!-[Y.!3QF"IFG%)F92ST2)9,AYELYHS0A MJ1=EDT2SG?-/4!WQ^H@+J/M?;AD.7R?T#9A0Q7:>88I43,8X)(5*P,O?"G E/CL$J7<#CT6MF M'?D$.66F^#*WS%PUAAY;0] MY%(M*=)RN0&1P%G5KJE)I/+O<05J\96#\S5^C/"HN4LI++0^3R=&J":H9R6:$B2\F_5ONQ7!XB MG1Y2<5(3(L] %%"C+*@FJ7HJ0FE#-6&9<.T<^X;M2..U^+6:G%SZ(!6M13)J MGZ9*$L$_K<#!%&"G@^5T#DA>3+WN:>62!844\DABB2652@]KM=8]PR U5W=5 M3V!! 9AY@ \+KJ*S#7]1CD)MB6G(/Y -B@^W/O/A^M?#_[[GWO3#1X^ MDH,CZ]OA?/)Q2>[.@\7;0^_H\'WK\]UPR9S#N?EMSWGG-_P!?O?ML/WEH6E> M^7N?+B];@_>-^<-9Y^/>W!IX']_U>W>??<+.%F;G_.7]!;MY]](>??4&AY;S MM=N:=A?-X?OFNX\/!V?[5\'-T;?9Y*L[>N>/;_K=#Q\-RW_ \P_OS;VC^VZS M]=4][&+?NAUV#L;&IR:]/3AMX5_&$]]X17H7E[]^:[+WGR]>?OU@'O0N_FWT M[MO35V_O&V?O]C]=!0O:__3YU\,OS&_-+CK3Q5<<4'-P8_NS?]\/+:_;;I_^ M\LO".F.6>_2O^=A:V'[4^@'%YN^3_TIYI_3&@1LZC%))*%^$TGJR+(MS35)!D,, M <48$ >!(A3(IPAPH C(7QERY(?)ZG&2\08VX5NS88_![&\!+7QS@W^;G66: MAA_6D(DH#853E97N8\NME$2][?SQG1)O$S81#1P1!<40$<=8.-Y60,-JHE9: M4)W^J9@Q+4XI%)=1AU2YS%Q!PE0=7=44Y=(+<0\:C[EK:8ZAJ&S)=)!+U"DX MRZ4;5B4-Z;'5FE#IF=4BPU,65%M?+JLG.\"J-L*:L.RF1>%*L^!]V<28R^EE M-RYJ6JH[1@?ZSH>NL^)M(XE3S)6:PV(. MZ,9>M6X=,)-A\;+!>U:Q]]KQXDE.758S*%KC3FL+R:8!+,1MBC8\8W:AD-?'Z%$[]63&6GZ\DHS5[MY[)7 MBJUDB3''D%"$"86@^*L0%DK@JHV\VD'H(LLN+%!.<2XGE3X:74=&&QZ2+J1( M55 YE^[G,CO%)Z;K17XEQLZI&?"4^BFQ+HAO^\LNX=7\ RWK=2-TMR!^&CU*W$(K'\-2>N=3S$ M45.(4U3A_]J-Z^WR1[O-UFZ[^>*!6?%%;6NBX$J'-\6MAR*NMPD*V>V410A8 M?.EDLM+$,%Q1IX$=GZW$B/OS-NN+PBLJ97C*:HI_LQ60"J.C^%K-BHS$%3@5 M!X^M5F8A>QUJ-1J@5H*"E8PT!U559]A\,:'S!K/-*B"RQ?F/5,-1H]%%L:+5 MDYTXMNN-$\>B3D<,)B 3>CN\FU%<2'H,SR"FZ_IXQGW!#C*B4B<[OA?P6Q5% M*1=[-K6&HIX5Q%\8$=MQ>) :EV4!5+;]@+]]Z]' C1NQ07QBDE7#2XQHF5:I M8T?<^\>G0G34L1QL>OS(E+X4N\[7X:;S+93H1UO..BI=#K::TA?1[FHWVES] M8/O3VW"K:TB'4]R)-GC#/30=>V)##2I8P66XGQ=5)-9YM"MX"XO];"N]>#]0 ME(;"Z<+.0.,[VSIV/72#%*!PT$@U OW-ZX-$S;"3^\UD:W$GR- M-Q5<17++01_-2O"MI5EOE6C56;\"E.5QRH,XZET^9Q]8>/24+EA#"?FT>C$>PQ3-8R!S"C,6YG-WC_"QU-18 M=15JN:[\?=^PK3M^CT@Z(-%YJ*M@JR:GP'7#!X;SF/+DPC0F5@%:.D,55H'8 M$WRP&5UB^\-IG(&_GNZ\"KB!'[P+BK5034LVOF'4G;F!^#M? M$.; LB^>NIY1^R?Z@E+D4D>7[K8KVQA%2Z4?ANHDYNJ&'^VU:NS?)8#E$8?D M2\/2+^#TB:\VU$ ZN->6IU&@]@3L2C^_VG)CT5G_(>T2*^ J&LXYGF.'BMCH MC,9[XZ#Z#Q @/$DO6?R[F=0;2GZO'99036IU-]3',.-R4"O)8@R?FA!X,W%> M-1+2Y_D#;B7:=M,&RB@FH2K2XLWQWT??9+4IM[25J,X4FU\ZU'-IZ$LEW:YQ M!SU!J6H^O+)8L%OS]]A=";UD(RMYF*8/\[AINX;S_&/GJ1&]"K7"PQ36^RX3 MTG,H?%/-(,ZQZV'3%B,DBI.[Q'0"BY^EY)G(WO@MI18;4,?2..)?2PWI]*N4 M,L".$V;#3BU^*143'QK-<7ST]$?MG5*]9-ZA#PL1GK2?X-[XVGC@V8)30HS M =D>7WA=>G1V!O^_35@/S[2[8<7OG&=?#V[EY? M/Y;6&]^QU1_ET]5-E."6 MKXZCWEIM,CYN+\;;Q.(,75&#G$X\C+>4Z7ZNB?/INE6<4:)% MJ':) RE&^3'G? V-%O]*=*J9D%?BS)YC9GJVFU] R+5Y1J]5A$INJ7T/1U98KRRN*I+^,T] MV.)3S<4##]/X/16>8<49 YTW&"J 5QWI-C&V6&_,$V<#(SM1:A53%X!5;Y!Q M#\#Z@6=.(?KBGQ=)$H8ZGV->0PM%6'2+W4@ K%9-?A!H=^4_12FH2J0RR7I.<%)K<;_.8['$#@1]STMC "\ J M,XOC,;"^.A\3[CQJ/%R+\4J_-4I\ZAD="=#93Q7!5843RIO M%NR5<(K/\JL MK*S12JXR4M7Q9H@Q)Y@-Z2D,=\?F\L)/P<$K\V^NL#<'*]#9#5750#J%W&)[ M-@H\AN/T1=2O(K\'5A9X6NM?";YLL _IXYGB@BY\UD\#G^K#2K$KACT$IU8@ MK*4W'L*K\"-#?DL=.!0(UG0FO!R[^A, !K@ 1Y__L8I@QK84-3Z7ML5X9>.Y MZ&8[[:8G.IX_AF9'II6QOFD@[MZZ+H& MTBT>.-5#]\V!;_>4NVZ]L0%V^5=1Z;RRAOZZ D)EHM^?8B]_#9LNRJG1J?9> M>=;EDGJSP#$T4:88E&IGD2[YP1)QMDT3'8H@53F&I ?Z#!KE26+%/?'Z7+%7 M"27W]N)2]O#6:+$V^Q]02P,$% @ $%:P5.>"$HL/"P W7H !4 !O M8F-I+3(P,C(P,S,Q7V-A;"YX;6SM76U7XKH6_GY^12_WR[UK%H. CJ-+YRQ$ M=.&H< !'G;/.FE7:%.*T#28I+_[ZDQ2*!9JVE-2",Y_$6O;>?9YDOR6I)W^. M+5,9 DP@LD]SQ8][.078&M*AW3O-W;7SE7:U7L_]^451_CCY3SZO7 (;8)4" M7>E.E"JR!FT-*AVLVL1 V%+^1ZW_*WFE3^G@N% 8C48?-78/T2 &!#E8 X1? M4/)Y)M 36<6 "SQ6[IG4&W6B%(M*,N-C\BW"N4]O;*!>_&W/3.XS&_L'#_J.S>73PZ.BJX?YW? M2F#0C4QLL?!P<]W6^L!2\] F5+4UKH# 8^)>O$::2ETD(^U2A'?PW_+>;7E^ M*5\LY8Y M@GOEJ8C_\BL_\(\JL@DRH$/7=>==2N&1O-:$$N MGMQH334UQW3_C"FP=:![YG/92:>&QQ]3:2)M08W)70?"GA93[0+S M-.>0?$]5!S\JA !*J@[&[LCW \DM(W;@4#690%*A517C"0LHWU33 9*-CZ?3(WJ1Z@I> M?#H5:YYU[.,"SZM>>G9'@3B6Y4K+0^94O.\;&%D1[%&T-G((ZP"S*)U31@#V M^I1_G+JP]0>4IB&'Z6@!#3!];#;< IK2^ I3M3# ME^!YFA@,5*C7Q@.6VP#F]1JT#W": 2Z.QL*7+1_\L6";T72P/!$V23I2R39> M!T]V8 Y! MEEY-K6%\U\::Z?!.U"5"^@B:IO1X'$/EECJJ>' )PG:RV7(-U2Y+O"@$*<7I M 4;3.YK5O1W6-%_#KK4K:T&D*JF.XX;\SY 6D^RENZLXM"Y MN:?V#)ZDPUZ$LMV@*PHQ<2C=I)W05">\0NY@54^I? W3E'%-%8^84*@D!E2F M!SM>R[NCCM/RVF(]NS%10G 2AL]-"$D]C(KU[!0A03?+K6]]&M++9+)-( ,> M<2&FBS&65?.> P,PR:_SRZ=3?MD;I6V;R8A$2ABR)694M\C6WC*I\NG+O"L1 MP4\,Q$2-Z%1+F$QJEZUG*RYVXAB?B+(V1=K//C*94,)[5W0BF9X !9LLV2++ M0K8K,Y75V67QF?I?,3<+:[$KD$B.B!5=A]Q2U6RJD'G[V=#TZ96=$$8KS+;_ M&(^8.+A)#9$L$74LC@68+K8$;,FY1H3'YH;!PK7\-'XM[1D7OS$Y7!=2B05Q M"U 5VD"OJ=AF49SX;&&I%]2@[)0GAL)=F'=Q<$NKT:B@NP0.GV_J*RSMZON2]E:_Y=VE"7>@7&+F 9L8&=(=DE]R8BRF+3;+.-[,&^*C]QJ+Q1\4_ 13%,*OH08 K)JV#)=D2O@BE.7Z>'(O^]OOAW\\_>#-G#&C_;!D?YR..P]3NR[8B/ M#K^6GNXZ$V(>#K67/?.*%F@;7+T?'FKD]NH3[#[C]J%N/M=+_?JHV/E:O'H<'YSM7SNW1R]6 M[WG0O:+&;;-^_ZCJ= R&]U^UO:.'>K'T/#BL ZJW.M4#0_U>1*V#2@E\,'I4 M_6PW:A??7HKDZU/MT_.]=M"H_:4V'LK]SY_7S@@UOS]]._Q):,FJ M5?NC9^ @K7T+J?770T?']7*Y\N'#2#\C^J!PU1E6+\%^L=.=7+:LPYL/:/C< M.SW]1ZFV6_QH:)*1?@MH:FYJ47;FP3;P41<'9HKS0'*I-+=A-HO.6'8@OU@6 M:=D5+@/P"7$V6?1+@HZX)IO) 9)2ZLJ':4I<)_Q"CB@&4_ZAO(2,A#3'/65\ MP3P9[-G3/2_:Q'U_P0P(_&MW'F:7=%8I9G&)K$U%/_V++'"XIH\INMH/,GG@,T_ M#4[!L!"F\&7ZV=;Y3D? /Z>Q$2Z>UFQ+Y\TXBXVLU$/:R[OT4DU"H[1E&EHV M92\"2/%FNH1G+X>0O^6(!;ESY'2IX9C>5GS)I(6JVG$_&0ZCA&/B;B+BU])F MX?V&_>JV[!M=%OH!!?/3Z;&RM#7$9;S6GXR;W2*D(Y!FYAVF2F][1EU@J M=SAMB0?IC,//DDZ_\JV2O+G*S)Z.F'069\1ZLEZFV8RS$/QF1!U)VCHB]MVO MKX]ZLWCH4_G>)MP*I%[!OK=,I P6EU\\E;;/7-7WSN)? * >@<7 Q0D)$]%+ M?]\BY/EU[7*')0)%CS-9&^]6U>N7U"@+??I4ZF[&,>%\TQ\/=X[\LB7_! M4_ Q1[)HQ0QV5'S%V]G]".%_H36U!L"K M_?WDV8+ Z@MHJ[:6P:@-4IQXU+:8'YC"VC#\1VHE/XI0S5:ZU1!J%\\*B+ 3 M#;_-/$O#.(?<3ELGZ1TFC5"VI85B3,:BD)1\T,!3=X$P&RL.UOK\=+J1/GDA M"G=YPL7!FMWB\4J#+79Y@06=A8O^.YL @R1OII\S5[C5QLS M^^T>:+$"J6880)/M=-_8^*Q=0S9<+6TRB)VE1QQ$^0U@5((8\2J WP!&^5?A M^OO:R[E3>QJ&W\:&S0TIQEJ_#?O^+TMI-+*27FWC*FH[@X'I'FM6S7-(-!,1 M!X/ !XQ%Z3KRY-N\H8G9M-.3\C ?+&%XR'E=:X@::6-D=7"\&RJ6OQ3ZCM:W MV6P;_4^4DJ;.O!*NV^R!'0Z#]Y]N*A9?VI&^BRY$E:3WL]VHU,%NY/27_4T, M65P=J&;=OF7H=T; '((;9--^FJ]M6]^63-<'XXP$T:O=$L N^3326M8\ A5W M1BA+[CT3,DZ<4B5]#K/$<^'K&\#8E;W8G]"(;)LZZ5,]15I*P9+8B ODX*S9 M=FW(?*] ZGQ/H1:5-V_#-AQF/K==&WX!MEVH96Y97L.$BL%RWNP)7S3CO69K M2V +=CF'U#\G\W^OS$?&OU!+ P04 " 05K!4_<:;'T N &F0( %0 M &]B8VDM,C R,C S,S%?9&5F+GAM;.U]6W/^ M!AJ-1J/[Y_]Z7GD'&T0"%_OO#D^^>W%X@'P;.Z[_^.[P_>SH='9^?7WX7__W MX. _?O[/HZ.#7Y"/B!4BY^!A>W".5^N9[1[,B>4'"TQ6!_\[7/V?@Z.#91BN M?SH^?GIZ^LZFOQ/8+D$!CHB- O:#@Z,C2C C>4X0(_C3P0=*]=;:'IR<')Q\ M_].KUS]]_^/!^_GYPO#K.?O$P^Q_^:_VK@-OTB)7MR_,?MS MHI5UY/I!:/DV8Q"X/P7Q#V^P;84QDIUR';3^!OO;4?9K1^Q'1R<,&=3)/#Z./G'0X;7P<'/!'OH'BT.XB'^%&[7Z-UAX*[6'I,\_MF2 MH,6[0_Q@NT<,ZA>O$E[_B_WD(_EXCOT >Z[#E'1F>6S,LR5"X>$!(_W^_CH7 M ]O(\A]CYFOW#<^OUQ/ E@A?PXM0CRPR4*7=OR@KXR5\E!#>&:KL$5 MFH7TSRO*3T7L*@DJJG8QF0$@:(G\P-V@A*&*J$UD$F2U2#Q;4J4ML>=0,W?Y M)7+#[9P2>8G)*U%A.10TREF"Q J65QY^4H(S^_98EPF81:N51;9X<6K;./)# MNCM,*3?;1<(KBD="U]2\]C=TIF,B(5;Q$XVJG!*\1B3<3JGI"-F,6BDO'%]A!?4 M)W%<87TU?ZQ1NAOL/\X165V@!V&A2M_HFCKWR&,6ANZ"U 0RK\^RF;\CK,+6 M[W5NI)<6\:DR@BDB=&=983\VWZ(BMGRM"\$9LB/BAM3>G$;ADAJ>K\BAKO-U M$$3,RXA\NLF6&#N4S!*(F]H>++0Z-'0?NG WKH-\1]SS*GT4BZ-' MF"@(J5]!=4HA\$,2CUE8J,:/-2[P^J9XMHW_M!45D4-!J^G.M\NY10VQRCZ; M?JAK035OEG+2<6GHFX/)5BHG6ND;?8Y2>2>5U67CU]K M%^0$Y-+0)RJ+4#B11UT1M[+LA+>0=@HZ#V8YEW6Z -=L 5IT@RJM07FI.^CI M.QCE'!=1&!&T72QZH*UBR 3L^MN/PS6V_M;+V*%6DB Z)8CVX"(=T$G&P3D)>V3D*; M]U_C@1\\]S'V)WL*6R4$L9T\(?=Q2<]OUH;.QT?D1ZL'1/ B8+M8@*.01<39 MU8'B4.3(:S.!!=_T H66*QXF;OA2'^S-3JFDA'PB.FU&XJA*BE?^2!]V51=5 M6J_-G^L3L#%D)"DEEX;&4TO!JY95;\.G.N=<6SA)&D@^&9TQ_F)X0U+,QF^U M6<'&&(>LA#P:&F;D!;8C9K].?>?2#]UP>^VS:V>I6 Z71KK/6\06%;+E&C>[ MA67WMZ]CV1UWQ2ZXL'_DH(45>>'A0ES22KT'%(;AIQ,+O:Q:A9!RHXR]+!=XN*Q; Q, M,B:>]8"\=X=1N/^$+Q2TUJ(V^'!Q$'DW>$+^KOQI/_)]G" G'>'(8EV9R=%+9RST ;= M82"54>613YN]JZ1YYM7!KZ$"I /F)M'-G?V''7@VEL?"9J?AN47(EGK+OUM> MU& 1>^E$C&=A2(:TU#(SB\H2A*]3>4K+)[G$"NZ1C2AG>OZZ0V$JL^Y5Q&.U MV_T'K2H^7*F&3MJ7EXJ*+B)T1:4]72QKKA")ME-8QR9OV?W,9/%^R")@VO6#Y^7P4-FMW8Z8.K:H6-JW$8F5MMLI.Z17)2=Y@@J0!R['V^AR[)[4)47*@0JEV[+3DPUA"Z/, M#F8CTEX7;"(;8I]@ZM3:LM#@G%@.4+2.Q\EDS$A.3UR\0#QZRI%^G;[4G5O/ M""HTT"L/ZS7Q6T0SKK()5$7:JFN7@,'^7*/Y XGCS+VY9^T'O-)W8,,'*H&I4"17%,M?A&LQ9WLL+M5B.,#Y9P$?'HU)*# M\&KEAO%#.J9Z'+^81KZM7QL\3B8/1:KZX2+7Z>&I96CN*83+#]H:TI/ 3"VJ M1R TJ]?I2Q\P,[8@&755\B8MFDS4M8Z+2#Q.[7SJ.#$.= %;+O4CTYVL(('N M@VHW0Z.YP3)Z$@%/(#2G&%>(5E'\YBA.S&BH?W:# W8(F"SHN4!_M$&*N]G- M2DJELKB"1/7NV7LG'SE9L8>"5/3(Y]JN[NU+@.%H5J4(>$#7]75!P=T,P\P":GN8 7$G?Z>[_)'Z;AW8]@9KF#/N8[+[[EV[^/V\\ZK6GGUGV=?R9;G M>?B)@72%R06.'L)%Y-6?!0!=6TCQ'F7ZBR2\4#?O!:>4+H,)B8?CQ,>+*2)I M>4.HXU#VE7,;I M&+9BUNVR:U'19%=U!71-L6<"\<$)D8UKHV!&ST[:C4LK(W-1 M[^I$*YN.=F2ZM:&BBU\(#H(IP0OMT;,B97-H2TS\$A0PC[SS%(?T!2%479%V M/D;/%A+*X" %XI7>6N0S8OSHNCMU-HB$;K#CKED]'RN\: 44>!@\-I,90\J8@.6017?K-YA'Y>Y9K4&@!P%,::C.;R( M@@B5.7_MAXB>^$.8+:A*W:RC(#5?*X_'RR"!Y%'M%BTK&93D>454S'158S\X M0PM,4.'AR^4SE9D*X_H6V5[3V1:PY&/Z)<7$BT>8" X2S8"1=!0G+U!5P5R@ MYZ*DD_B,.E'ZS]!M7(9@CT%75GUV-$ -$Q&Y0R&8+U2F/00M"JW/"B3=KS#4 MD"]T\8D#YV=6X-J:-=#,PYR5;)QM1>Q;0(&9^X6KB[P@>L;X MD>_0_@15T[ MRP'K1PPRH7"BB5N?IA;!ZF>8PI590BO.L*]Q@,\'$N*N''_ZNVP1BNKLWCIT M!03C%@M7U-5P'_TD6PNU )47R(@-I =@QZ!/1R:FG7 M+AA12SV[M,]K:U?ZL&4VUW113F@O0U W__0(2*?7I1?_UKO# #VFYEJC5YM+ ML6O.C/WX_=^S"S:%&GE!J:FQ50M7;:4YV:BR9K!@SAT57A=I:W1#U<;O(E9.@PVXP02/VWD]?'%OK0"M$_7FT7!*8:!M8>,Y]N2TZ'_6'Y; M[HADPG?BVH>6TW@&"TQ#C>9'KB"JX/,R>)4JK)4.M,R]!H;1ES!? >K2-B M+RU*\=1WZ%;D$N1<1(2NP"DB+G8@JAC)E&#F)3MGV__*>/_$XI5K> M)+6<8 :F(,!0ZL"TZKQR#)0&&"0T_W5 MX79%>](R'VWM%[YQFG*1YXQZG;?TKW&!B4!42 M2JPO(L0>=)\N%JY'_7CM%PS=_(R_B-:HR 8T@7SBNMS9/JZ_^Q:?E]FZ/EI7 M80E"$6NJ1W-3@M:6ZV3'JZR:BI]D7YX& =)^SE$4XAO2M1CH4)E-[3M VC%[ M;]MIQN];,L,-: KD0VG38Z6U]AXUVL+YF]-M&\("65):M0S7?U2(Y3?E_];P M%.FD W@G;.PN>!B94MJO@,%(K"[0 M@_Y>K2ULAI>$(S#)RX\[VP"$J<4QS;DUO2@"VDQ;F!E=E1$[J+%C M2XF_]RGI_%+KAJUO(9^=][W1LY,\[-UX:+WSB=D5Q;QP T8O(JA> J@%?<[G M^W=.1.=3CC5O\-KO73@#^ KA$:K@BH@(A7?=,[]FB_2$]5UYQBV!J^AY8E_K)?;W^FP("0&@!5$AKA192&A,%CFPW)Y[M,$>JS=!B2&\."?( M<4.%I1,;C$9B-\UMX5KL90<)^?G>3K6A 9R,4'/(!^ZU#F\2^.;VFS?J_CW? M5/3 !)FD@EQ9=OJ02')'[:!A*&@IJ9M.),0R$/?F[1537%5K@3V$X+MG"Q/E M8W]QW%#[8C,/<[D9?$45][L6=(;D%=ZCN$O2U*('K4+AX,0[5,N<;R8(-*$[ MV2E/[3;*\(Z@#&>S\2Y199=?!DC@.BQG,.M4-8U+<;/L:5::7='>%XC%9( 6 M2"L;Y:ZG%8)0JZ"=C]%#4)?:2OTUVZ$:U W&#-D12=X11.$2$_*IWO^BUCZ2C4=/LAB6UUCV#OO1M\#N@*>T_) M$=:Q$_!],Y^7JL=20H*Q@'?AA5B:.\(*Z;3[:!BL'R^4920&!$Q"_'OVY/8R"-T50(G2 M"G&3;1NDTKVJH PKIEO(ZXHO!53S&D>>V36CJ#B11S65DT\ZC257)6"G&5&V M1J,!D@E?XE@.S:ML3O_*U\4_66"MQ/>>^_4-9GP->&$D24!*&T0AB2CY_D8J M%:#Y2Q7GL$A)_-:__A78";[YNI\+725+JS2X_I?[\F]A;K-,-^-G5K8\W:Q *8<24,9-V(K218> MP7KRIK):>YW4_@YYK<4C2)D-Y9P)L;>3G:@$YD)+O9->E0 7+)]B(KVMWYEO ME%EN.Q4RRM<^I1?!7N5V,S1XMA-/@!,!#JQ24,[[U@K3](9R+=(]63E!]H9O MXQ5T*HKKL,*ZS4E<_:S:6'.Y=KJLDCZS M>.G3\O"I&SIZ4B)\5H\L"481Y6 MEE@Z"DR)EF]&5-_#U,/AK?>IG=&.)@KJU:O2X/R]]42-'"*NY>EOC]/$P]!1 M44@1C2_7RPB!-5/(^5U15 (J+'.O^X9O>/%B53NN<^5#Z*MMYKUL*RT'?#-Z67POV.#.VW MM0#-(H79PAT*:I>0\NIM/A1T :GC+;+6:7NVG=//3Y_=O\M2V7$$/,=G>CQR2H,3 M7+_U>2Z6K5( 4^2M+X0:/[XPHTA@+:*%%7GAOM7(P!0ID2JCRX"$'^]94751 M,TH_*.B)_FVGHS(M("V 6L<*&F!@WY;\V;YPI]0@(_=< ]8XATIP9N,5>YFA MBJ>8L9%$U( E$<53R![(XIFF,&F;H65Z1F+E+M8+:HG> M($$MCUBW)6'RTLF]V0^X]4S@_QH_4H0+G 33IK MN>82)C:F)2,)DTARJ-)ZFBP6KLU72^^EU,QC=*NH!2K!G%"U5&I6Z0'Z]#"K$8SW\_)]'1P?__>'V]]?_\]]_V.OH^4__]5OGZYO-XY];__U%]/3+ M&_+VS6\O/[V?;P/OS<;^^L+[-3P.9^C7KV]>?7X^L6_"%W]=7;V<_7:\>3X[ M__/%QIF1/W^=3MY_"OW@[,D^O_CAC\O@[M/YW,?SOY M]<_GUV??WT1W;[^N'K^L'WX-%W?3ZP]_6D[XC#8??K-?O/WC^N3EE_6;:Q0Z M]_/SUPOKKQ-\__KT)?K7XC&T?O0GEU>_?ST)?OMT^<.7#_;KR>6_KG?[K M7T_.6>"L'Q]7+Z]>7/SVP^*WV[_>?S\[]N;VXNG=N_\Y.)_='QV-S9Q7YU)G M.U#5\ALL[S.N\G;M4U$?"0I@YB^7E=D$2T45\<%+%?9&:W29'6$ #G6#M.K< M&[H$")#DF5:!W@=H$7DW[D+W!:H(QV&>'K@Z$@(2IKM]=J1D[SB*?A9$/A2? MU^A65@=TG><)@-.XIG/X>'0AC(O >4%E^5Q%A*+#'AOXSI7[S/X$LG3:^8S0 MW'% ZSYP:#N"0ZB)PVB 81*^W\#!K-O%5EM,A2/HO?NX#"<+N@'&SPS/T +3 M^6+;T2J**R^?KECEJZ])74#-:TU5C+&I6!WO3I==(?:2G>.$]K#\EP=Z'FK? MK';#3$'\<1\'50ACQ^,TR' C=S%P<4M5]59W'*Q55 A]=3 ;H2/1!5]VZM5] M>5FPBQ=H39#MQG:1_ME#,6A^R5ZVBJE9P=K$&M_JU:>1;,[H:R/>.3+]SRNX MK,:T98IAE^FL/39BY"7&(J[JM$H2A%A]Q'56U5WM)497T:BL:+SBX]-N>JK7 M:I4*5B5&*9.+"*5%)(6DEJ-H9&M3U5;N*4JBIOW9JH00U_[\"?^)+"+FO4L3 M-5@0#%Z#1?#$JDQ J%"CXDRJ2W6^2NI,>U[%%5/\VMRFI'F-E" 137#;OS>& MGEG3)Q2XOLVV3.>)SB,Z>=;(#D,<+A']9&WYV\#;51SL7Q+D,F5ZG3)ED_<^ M83K'\R4Z3YGR^J1W.FZ*3#2LAB!EK;)Y9)\.X/5W/RVU;1TY-D IU)SPK9GH M>#48/GJM2B.MV7UKXI_M>8TK3ZMVJYR^B84J!&GG)M:KI#+$G6-,]UM:<@6T M!!*SS81WDBF4^ N6[SBI%TKW %1U+G"V-<2_37^Y]/'.V>@3#BHF\%8J'E?U M4-ZIXFOXXL>*\2/] BA;S#+]#X@9;>2<;NA/']$]8O,Y^T=6\/%$\YJ49C^, M ?8#"H]OY!6#5A!MJ+,>Y\CDLR-5ZK:S^R050F0Q\6=I,613Q&Q]=_D2;/_ MQWYP5 /VZ(XS6>'GB"3S?^P';VX,SKET\S+[UJXEA&H\JE;S'X66ZP7MW&IW ML5TM-57)JUY+2;,4[PBE2!KJ\-7<-:J_1HN]1)6@[%W03:TD98HNNG$WJ-;, MXFQ[:WW"Y-RCD@)4=I/E#A8QZ2QCI&&1E.M>2L(.TW^V0XR=$'?6"J82G(H$ M\ 7%.&7A%!>,A/*;48_,J@W?3?>Z=X.A?9R/#N)RR+&+SLNGVTO8D^OL\Z#VAT\ M(:8&@ZYZSO^R((-4D;AJGX][>^\I*X"YW#V]BE?!'JP;3)G_'0KWO3=6#_N/(2(K)^O+J-@:N=R_LR7(K:5Q:Q.7'KM@F21$:Y(F M#GL+:0OJISBC&Q'IWV.DOW( PLX-# !=#^$2^9Q)V:XIP?!P?SV A8!;V>RA MWCLGT-L^"]N5(1FPU:D4[4%9KEJ,AE[[:49[F?[8O6#9,S?8\B6.LI5/#)YB MNQ9Z?E2MCA+BS=;DP7,?8]QNSS'])@=4?%H"GOZ1AI1:[:OUM 3)CV*]$ MT J9,BVR2!=T8V%&/J_4VG@,!BE<,^:C=B([#J*FO ?,\L04FP[:+FH#LWLE MO/:4_Y3=:53ODGIX[Q6R0[>FRG )M 0!45MF]G7KK4IW^&95"2V!DKU[.8>I MF5%I\F:3]N1MJ#Q^6KMFJ$I#S;D-J] "A^&OS)X(=A<$[O],+2O6LX4YY'%9 M#7Y1B@$&50RXD6O;"H/1U%A6FS!DNBL )V7(TLV5"3HE+G5LUY8GL[%Q"0Q^ ME0A@(%!$5P_JD@>S+AJ#GO1B*'37PE5/0ED@5M0E772L.$N0LM5?P;B#V="/ M5Z*89=K2E*O,8[LSB_O15IG?X*V:!'29TO1G.Q=7]ZGOG%MK-[2\>'LKQ%N@ MXO,RO,>R "41S52KNP&1D!1&%#J>E2D*8J9#;JS#;"(KSN7-ZSKTJ/R5 ;-# M0;&"%X>0:M&[@LYN+=:AC96)O4=9)?S)(G=BKOT[BNW\"7D;=(O]< FY'N1E M,5X_I5O+;8M% 7B8!Z)20K'2P_,G;'(29"(,H/(EH/9SH($>E4M M*83YDIK0BD^P!BN1)2W0%8YTOSE6DV$0)=6 M9^ K?NB75T<=V-\W<G"^H2FU=_60QSDJT9Q1E14 ./]E8]ZYQ8A6]:O>57O;*+Y M,4B%E=D#KS;U\N$43(K?_Q'X*2W*:"5%&?V(0847P=(B*,!1&(26SYZEZNF1 M5BD!>1=SFRQF,;?)CIOB@5F:? ]/Z@Y1=5- T8W^UJ!EVH/8_50U5UPB%"1*AQ); MX!,YA^YQV[KV-W1OQ83NT&D!!ME0;3;>C-*652&F8XH(:MYS-%2U:.>D7@\] M7"*24\[__7DD2N^[3V@\U!=(FGQH**ZQ\7"D" _$2N\@A M;41$O3\O%J^/E9Z&:^IM M-$MDJ!K<)#'\P@J1[A9#C2R,NDJ"C=]JL,!$),MM1K)VWKI]V&8F)C=PV28[ M.V1 :FVDS5CH47*RN+6>61OB4]^W(H^:,<+X7U'ISUCO3=$\7SF* UT1*M@( M&O.>*P6F]V@S#X,7,9*KI-H^M*.GD.3CK!*K2A-:E5;D-1)#7@5=HQ>\Q=Q? MV*BQ>*>J-Y-5Z*1.7(TR=#1)CK>Z@2G6F)TLJJPT#ZJ#F=&5H*3LHE'J0E+L MZ+VOI7*/-MC;L)7M^@@OS@ERW%!QO20/9"B=24KGRK+9BS!7LJ5M!PE%+R?= MO?,!)_2+O.C1;^,ZK!3S6130GP<44K02IVX[>W@$8AX4,U5%Y[^I<2 MNI'JT\@EH-J)L8&H>*_%UH_WVTU1!-G&%YCE 1OIB)A6&IA:)-S.B>4'= 4Q ML/27H>9Q,MSIL&L2%DT)%S"8#:&%)4AY:CXOLS6J!>:J@*;$*U9KUY7VJM7= MVC):NEJGPL1Z 2H>'],"8RQG$K 0?QL7D]7XI>U?*U1 B5+Q1%@@PAK9S1#9 MN*P.7-8.O"1&,*?D@N9_ K&56D6#"E0*6=:.^5_I+*A1'Z(I*D:GC7:SK7OB MRAN:.X'X@,W<"$GZ\M_Q')&K[Z0<%==._[51=I@6TN/59]\K0M;_GR^F+ M=P45 7K2/$U"M:>R!(G_AS+*4ZT]0I;HR\$E\NWKKPDYKL7IF6=.K$&U[ M$46U.!S97E(9L8@]DP:5#E0KJ"5Z@P2U/&*09*]SR\?^#'M1O").5XBXMG7M MVQ)VI8.$4;LB%.K-#447&+JG=?/;X2O+1GMXAEU@8ZJLBNA%3S=.>G/B\]P- M@JS)XL;R'+\OB7X1#M]?,>9H7J;/F1,VP<,TF9E2K*" M!E/D6UZXW>6Q"D',^]Y8-2XIK+D( +0^R=W3<[RA#*ES^MZG3)*4B3SE17:J MRU,=Q4)0 $N@[XF\TDK9;UE^RZWU"1,WW,;OHI?8HWR#R9-/_W_IKB7742\& MP]\I-( HTAA%DV+5-6;JS7]_/4 T*KFF:_6!.MDLH>_RF;UT8_5BB.5D;7'$ MTJ$$R(S"F(G H;NU2+K%81LA)Y@L6$QJ9@DF?35\9C(746Y3KX]8H!V(?%(= M2S(DP30B]I*5-UZT1@*%$)<@-P[G2@8?D!8@]VB=\I[2(SL58)?&>AW/C?]G M!6<(^??(8;Z$,R%7D>=MIY8KIK$^]$=AM'H!*-!>1#$PDM2PF44/GY =SO$M M/7NRW]XR,5:Q)SA#89CD<[*Q!G"YW+U$&;[KI@=QH6XG_2-DU&%TL>/:Z4/8 M6(XSR_,P]K,?X3-47]V:(V@28@S<8>P/LT#G%!7#7KI=DSTMMWX\"I/0]].!!'+],2+2LCG MK2P6]#R15TU*"@L(&:CF+P?N2/'&G.'+"4WT=XV+KS O%POJQ+L;U!:EUNP/ M=_$>SRE($M/L-E1;8D#A5@052_Y(7!*5OQNZB6H?<(8MU".EE%U6Y!VHZA2? MU]"U(XA8IBI=60%-;+.UF'*=^'F?84"-<9B.R$$3A3%3([\)ZOXJDC1F\: ++Z8GF; M4X*=R XG),EDUO7\J9&LX9?^,C,S2VMMA@?@04_*:)=3CB3>K8HIHX'V/MX/ MMCR=XDV\"OI-H.Q3!5I>6'4HP=B3JUYZT/X6*[_:2=B()]#+W(Z5:)MQBH26 M?.FNJPP(5 &+#?*CN"YHP5BZVGLSM/,Q=^Q6V=P%<-->MB))_E]:Y!$%5SA;RF(.H2@M4P<_9:]+&"2M;ZI2F=W50T0"E!6/2P<1 MUWEUW# B@LH1(F0HSMC#'19!1W,IW#Q.OLN**L^1AS8N M.Y+1);M"A+TD$7,%NJD8C.\J6S0!;$02T%5> @0183'FN&=:M J$$VR;OQS1 MW.>-7RPE?5\!]7,K6%ZXK!"S[Y2CZ J/Q^NDY"+G? I*^5!-),4CY.U?PQVC MFR/C0N 6GJZWCEI##%PV[#=W0R]Y!L!$BBQ/4PB\F:[Q>H^=4RX+^K7@ A!X MK7'ZX(;+V+ Q2[9TUW-\Z8=NN-46$9?E:*;V;>?L;%55%X!:VUDK2* EHJZB M1&-A=@@]BI;%E57F&;:(,UE"\Z7EDE5S;30ES74P,'$N[V&',NUU MP083LV>N,O9G(;8_YV8]ZXS-;#W RQ(AEH;\86%/1 X_L.K3!?:U)NAP:JNS M,GAV[*.R!LRZR[VHZ"D+NK'UG8I:$$.SICJ8F;LDDU95%VR"%63V=MZ,@A"O M$#G'/DN83?N(]F@IQ2,H>?H4HJ26^,ZC+7$<[:0":&1:SJ4R\._.I]UPZ,C5 MDJ_4^ F33+9 TRFU@2B<>1$\H8K.QEU!QSHP ,?4.VL5=U(M,--V(&VG;3!% MJWW"94PV:$ 8^?&'CJ .![N7+#"VKQW@\]GVS/DV\N513X# M=$_I9&;,05IE-+)SI"!DYW)?,U5(03K;=+%6GN_$C'] M&>U" J%"@!8C)4LQ\1N36SM"-%GX#H4PV>V-//8?C95U M-TK)[LTX:3U2Y)6B;9N5Y:;L;.1NF*\&HI96-@;;QJBHIATNF)+_S8ZU7&VE M3B+&$D&UQJ=DVEA+*^(N8D.8+#+>0L#7/C)U*:0$&1+KJ,I0LU,S[ M?FPSFP=%YUW!'B\*+K"==#OTG>1*^-I?8+**Y9:]*'"0^S&C5R#33L+2#F(+Q88[@OYB[O_*0%01;+KRD=CW]0"3)IF' M]^C1#>@"\D/F!/?222-! ^Z*K%J:@=!\5&*,6*%LUW^<;5G\@BE[YS M887]8&XE:B:Q1!;V=DST]EO9V2?%Q!]1LSW 9!\U.RZ4[*.I1BGC>DK%<^*6 M79[53Q%E2F,PZI6Q=SY+4YSYL8?OL=X3S[\A7BTLXH6@D04IQ>E?!Z'Q^ MINP:IC;N'JTQ82_>9J$51OU.%US"8YCQ?&0Z7YZI*>+*]>C!F.XNCYCHF/YE M>F,R[A4DNA^?J;J127EX'8Y.,\516)P6,$2ZG*@COW.IKNA/] 0SJC3'8&E: M\1#H2-(/^T3=NM$O4AU!4( #B?9&(#O[-EM9GI=5.=%@ZKQ(CL/4MV,B MT%>CQV$JN:G5=))*B8W"HZ]#(-(80Q7J:]_&A.HSEHF=D=$YRP4AVW/LZ+AJ MXM,?@9,I!)- :PU5!AUWJ0$>D)8::0DX=AU!_ M-_T/D^]$@S*:J(YF=31"(M0X0Y<*7H*HX.685?!2K"%&/Q6A"9D2O'%]6\=FW4)X=%JH(9.I0ON-;\IPBH/0 M\OYRUYJ\ID:R(_)>FV')M, M9"JMB!FR(T)YGKQ\B(N]](*_1FP4H-VXS$!GH />\<;\D*V[\=F&%UGEG=6OQ\UDC MX?&8_#9D,F5P#LW225;,LA%D]3;R)4+##S>7QYT!VW[6E<7U!K/KFR7V=01] M:L1&8<'K$&1I@ITWN"WI\3\?,P8/5H#83/__4$L#!!0 ( !!6L%2N:?R] M370 $F !0 5 ;V)C:2TR,#(R,#,S,5]L86(N>&UL[7UK<^RVD>CW^RMP MG:W4.;4Z/@_'\=IYW!J]G$DDC3*:8\=QI5(<$J.A#X<";Q(L@ M!Z!WMVJS/I* 1K\(-+H;W7_\?R^[ #WA./&C\$^?O?_\W6<(AV[D^>'CGS[[ M^/!F]G QGW_V__Z,T/_YX_]]\P9]BT,<.RGVT/J(+J+=_L'UT2IVPF03Q3OT M*MV]1F_0-DWWW[Q]^_S\_+E+QB2N'^,D.L0N3N 7Z,T; K >1%C /@-^IY MO76.Z/U[]/YWWWSQY3>_^R_T<76!/KS[\"&;\G_^&/CAI[638$3P#I,_?59; MZ64=!Y]'\>/;#^_>??&V&/A9-O*;%_A%8_SS%W3T^Z^__OHM_6LY-/%9 PG8 M]V__<7OSX&[QSGGCATGJA"XLD/C?)/27-Y'KI)234KP0=P3\]*88]@9^]>;] MAS=?O/_\)?$^R_B&T!_C*,!+O$$4\V_2XQ[_Z;/$W^T#0(C^;AOC#1N1(([? MPORW(7X$UL,B7\,B[W\/B_PF__6-L\;!9PA&?ES.N31]W8"537I;XAG SS<$ MGP:F^"7%H8>] E> (& :78"*J( +D".W 3, YD=Q 9(N_*?/#LF;1\?9__LA M)=CM<)@N-M=^2 3G.\%]E/@@KMDZ26/'3;N<2P@Z%)6-DZPI/CF\MZ"4;W&0 M)L5OWL!O*/MZ+4DXE9,#^#8(*KZ97DS*9*;-@G\'ZX!^!V0R; $X?//QX;,_ MEU-1M$'E9%3,1C\6\__UQPR%/U=B@A]G<5-63NP62))_2@C+1[QU(_*Y[=,W M#1HW<;33DW(::;#FK;8"SI($I\G%(8[),B-K6A-VAN.H:I5&J1/<"'2K@0%' MB58 !.5C4#;#KKHP95+7BRY9;_\\2/XG$?S8FXBBM(5BGHYX^7(=^$7?^,[: M#\@>@4_T63,6L/%M=]%0^L!KT^RJ 5].=97@4*G]O=?@G4XMC'_YM;6%2C!% MX4ND/G W>$@C]],V"CQRF;KZ^>"GQ]'-R6+(5>0)K6H9,62^[W'L1QZQ0^.T/_??,=A_[@1P/:VX M_"MC\;OFMS@BDZ]"KS^+WZNP^->GR._'L7]FH7?R_4^ZW.C?9)_3D(F2ZA&) MG-";\$ZI*FC.P>A&.US>V4_DON&MIL4_9-IL8<@A1\^7KWL<9B,?@/KPC=_]G1P$!XV43$:X7QXJ0H6%($K MG[HZL D<=&3<$ 6[)IA<1"$!?""P\T6B,#G'FRC&V;B5\X*3JQ>RZ42QYX=. M?)R3G2BY(Y21F81*LL3C/$PQD>QICIW38&IZ+S;TW!(C_[*07 5B]" M!M2O>WZ>CN_Z._,=3BOD1OYRFK!M^$8:&' TE(S)]=+N8WE58?77<4 M(]TJR*D$O1O347[,,"Y7=H/>?12!$_]69IBF)<8 2SZ+Q8:<0B.KJ&@E\_:Z M !N._C55KKW#65 T!='5E4I&L:8"U72UZU8Z_6XG6-/6'L='265GJ\_^K;./ MDL+M.+WM32YOSJ8FX9"N)H+'-ED<4L@$A)3)L;6N ]]:V*F-"4>Q\H@(>N6' MF3\[>6TW ,634$-/F,2-?%=6"SVQ,!$$]YA\_E6Q.3. !QT#V?<,ATT4DA^3 MV8L_]LU2O-;;/UO8]5F8<#[*?#>OQI*-G8R>2JJF2'[,[9Q+>O/*KVM47#C) M]CJ(GI/3VQ+=I0P'ET2X*-V*R"1$9S$#37:M!:X@.48"FP/:\29BZP+$^SAZ M\CWLG1\_)MB;AZ5;>^:F_M,I\L-Z+&S^&J2.G,!_YH+:O3J0F>1:]!IB6Q08 MO$FI AU." M$KJ">/1>.J9_Y4P[QZLA:>C'HRD%-5STTQ=?+J*1"]@GKR6*3K MTB1+P/_ ,'UR K!)ET3]8]]-L0=_F(5>\Q>UD??T8C@/W1@[";[$V7_)S\'! MH\%O=TMDAI?$3+G:;/#HYJAAY,=/ZI1[7HU2*/C6O'PV?&KTNX.TO[A;W&'.]SD8<9:?5*0,F/R:H0;_JP2UO(1>NV*T=OU_/QSV M^X Z5)S@TD_<($H.,6:NV=P 83;=U=Y]D=4Z^$UO>"93?OHB)\S.G)HQH"M) MT$$MQN@>P#/7C0Z0W?9X'P6^"X\-3N.T%2QDL((#'PN.>E434#%C(E%=N>0: M[[7%A.LG48&C(B1_/E9:>K+G)/R5C"8."!#A)M7F,U U93(E/Q0DV$R-%5/? MTP60[7;N%GN' $/R5 :=NQ'Q3CDA!!,!1CD:O'A0/@=L*;^:-8&'1^JRJL"\EQR"87/L3OE^3KVZI>=(]:C*:U1SM:+Y73XI6N M7DG2-%167%\SX;6=E=AQ-''FRA\?'/C/Y%;X(K\WE\3U:05BSJ) M.U/:Y[JB5=KI6MSHJW%)G/Y["2Y=59TB$VKZ1'ZJ=*D)R\"]KK&@(-_&3U+? M=0)TBQTP6/.MJ)7#950;F&P'>7=)TMU#;L!S?ZK[? NXR12^YM*\+8 .FLA= MG2V)1K6'+DW:#L3RB+H^I$39;_W0WQUV2Z+S]\YQ1Q/^],P6.3P[9HL4+P6S M94-AH%T&!-$";/LU2/'$]'^)-5%S44L> +T,%50V:(0 ;QLHI#1,P$-+G" C=((I5N, MW Q\]C E00%W7[1IB ]3&8:B#V!Z?P=%^R.CR3$X!QUZX"@#YRO$S-MXE&F( M=#09W)RLN4^/CX 1!^O)R5 Y![)YQ7<"MU_:#@,"?AVE^1\R*VIX\D-%O;;-W[EZX\>HE MY3#H9U!!R2L:RT(@-LHJZ2A#H_!2;ZX--+':JVC'2CA@K 1,V+@H14U*'7,R M'9N4P2X3%C-X(F#&D&"MA\FYY*>8.L?:JYP?;YV?HO@B(%P\@8>Q[^J&@[J] MD.,&>@LHN?NQN_U-X>F@IAXTP\#]^:43&K[Q0_(]7! 3WD^O';>HB-EGOY. M,'/ *F#"\V2126BQ0=DT5,V;QB5.34#E'J? LU'!)=XG9[<=N,L8G2K8N/ MT1X8/,6L$[&TZCN-@-QAN280)5KA> <+:!I03! &-Q0Q)@JF4P"1LI3,0QXH MRM1NJ2(1,5]!"%!X=1^&I0O[2Y8Q:P3)L. J43T-T'JI/M&_\])5K7AM ;5B?2+NXS)Y!(>$KS24/EP1,9GA<0F<\.22:VN/4*JAR>B?(_] MQRW1SMD3CIU'?'?8K7&\V'0*FFF:3[W!VTE3Z8NF@KGUG(-$3@83A10H_"FA M8%%4P;6NF2-I!<,ZTV*M;EY=Y8Q8X9?TG S^5#W7.Y7?26E-LVXH%91XE\G* M(063$9V-JND3>/RB)>V&W:?,'QTW%KS\O/2A*$OH]7.'LV>:NF322RD\(!"H4(+=SQ^CI[=D2J8]Y!^5TG0 MC=TDA]?CHKTP[ZS)AR 88R,=@,=I$#&3AMY[1!W*WP_D"HCCX+C$^R@6[0SJ M8FW#--?'1("%3-SE<)2-MW2I5Y!-6Q%8A [\PN^+"C*73CK.I]Z$>(*J9"HJ MT4!"IA#98$1&(QAN>RM@BJ2M"ET">QJ+=6#7Q")U@A^P$U^3WXAB6>IJT(9I M9VMH82'3A&PX@O&(3K!UR5"03ELC6*0./?[!7^B#NW#$,Z,#]!01!B73H(6( MU$PHQ[DO%9,N@<6U:T/\"HI/Q\2+RQM ',7P+ZB%$ M2*PMC:EG6:-P%,4H!X @L6K1@^!-E5*SI(A&K9R7N8>.:/\C>_2%48[67B0 M39L;0FS$*D4FH>:LSA%D18LD0FOJCXAR?2-DYGE$4DG^GQL_Q.]'T!D65 N[ M$ ,-L:+D(\^*?Z ;FAL>6C^S!&)J:@F/Y"%[2Q?FAY/HR(=IZ,@''1U9/4?3 MTY$/JCKR82P=N2#_7,2KZ#D<3T-J,,TZ/SA8**H'3 "[!:98/F>XPF'J18M2 M3=]' R0U=Q8Q[7(1NF-8O!S %A6DA8JBEI3F;3%O&JK"$1A37UB$CZ$T]U&2 M.L$__?U(ER0F6"O.$A8FBOJ2S4%D4OLB9%-=F*)B*DN79@VOR@-V#S&!^?[# M>N6GP3#EZ SK!+M]7F)V? WR#M[_^'5^C4J9METHO'$4 B>29F&N%>Q [EE M#\?=.@H&R;H)R>QAT5B;)^1L#,H&V?NXF1POQ-HE1'.W+_2CZ'DSV#G*!&CT M3L'"@)=FF@]%Q5C+SE&1--I?=(>\(5>'"R@@%:993 44B]@3 X.G0L V;$0V M*N(S/Y^#RDDHFV4_;B*66//<%U ^R$BC4L^Q%;H)JLZTKCXHP6U<4 M&3-TSI[9#H<>S2<-G&%*U(1D=A]IK,UKX5>,03#(WAG"Y'@AZ2XAFCL&1,=F M,78&!R4:@$Q:#?6%>0\#:5\C_&"@PO4 M]%[/0X0G]=SA5,_>[SSF,*\$$A&5"B$B5F<';SX(R!Z*C/VNHP[5J*.:BX;B MTX[\K4_G<8?5MQT,&;%?=[3I'>2^)E!C)X!ZK2]_PV/<&]H0K<2H6TA(C,)L M,**C$1ENU\' $4G+ZF,0J!&+A:/=@N&L(O]"X@9D [BPQ: M;F*<5/SM-4S=#(182 S&;,XW5KNUBP34U0L6??IE_Z$:R2STX#_0-?+)"3"T M_"IK$7[G! ?1E4)'6]36-.Z4JD3K7ONN+2?3[+$+B;@ MUP&^PZD\YJVU#8F6,GF#54%(D$>%D9-/1'$Y$P60L>\$0?0,/8\22*AS]OLX M>O%WY*X8'-%_?/7^P]F[=^]H?9O_^/T7](>SHB&5_T3&6.VEHZ()C?U.QCWM M@DFS@HO747P9'=;IYA!T5SN1DO9:VZ 5K85@;RTN%1AMHAAY.?QJZ"L_1)=1 M$#AQ\MJZJ::C)@T-[LU*[<*#!WQ-<)]M-G[@PP/-D^@N;Q4;>RL'%VYMWX+; M"?(.1/G(5.04<[V\%::/;7F$%.78*"(H8(#VSC@/GPB,*#Z2K79DY6F -F_= MU9?GMFC*AA U.$,A3NUXCD6B:+99:A&D::#=QWCO^%[>%I78@HMTB^/&96-D M35!9T<+!IX 61W'RF57;7;# (IB-W/RBF76?LWE%Z"'GNIJIKPG'$T)>+B%[,'?/?X.)%S*QADF0HBK:MF4,[2'2533<#&MM6M943*Y-)O: M)>& ]DG6;!:[A"+0B\W')&M"-[)BB=U-T?1W=A%)8TK3;504I MKL'5ZLXZ";-+7:Q--;-D\X7D?C".F=FI3NL)72=Z9D]&[(OG#C.^NB M=V7HT=R\;11XY#."PRT]GB@&H[RL!T'8^.Y_?S%?SJP-'>AQ9N8%=5?>].Y"_HM[:-_:T/@A*] MHX]-H[#;@74"MI&6$C34LS>CQKX\*=A*O9%D&4VT&V&]YV4FPD+*]YF4K6XL MQH7Y;JS;?+'+'4^SWT@6L[#!B#%2WU&BUBT_*"!9#GNHB9=_M6=R1-=,*B)T M]\X1 D8TEGG:A 762N8C) )L>!EU1=1VGTU!9*^#65;3J>328R49\(C6SWJ) M#]B#RKD[O')>\(E,(_XZ-C('>,APW3\P$*4PLE AVSY&J>!:RB,@>,#^ U"[ MIOQI=(>QCCW=Z2+#WWI@?!5R8^B//?7ARXZA/AR:M5-!\ 83*)56UN"/'U.3 MK6;ZOB_!A_=&*)\%>Q'3*+*1"J(FQV8_<3GQ^BX CLEU1T@Q:8;7UK,1LY5B MI1A@*[7L+,OL=)O6NNUS4%G8"D9YBS?:ET"U"Z<5YY,5551#C?L2JNE<8BDA MS2Z /R,_20XT:].-DC3Y-7BA]#T6'26=EN.II\<)@"* ^NOQ.0T3W;L!1QS4 MT_#3'7T"01:)0MC,<.B2\W/D;46TDH6G+WQL>,ZEQ>WM?'5[=;?*8G(7B[O5 M_.[;J[N+^=6#U9\_QL+^XH#O4:5J'=4<5PZ\1N[ M)TR_V*U"M%9_-\JK^YSD'5X;O&F%:2/ VVJRNDT)C$-OT'^\^_S=>W+=C]$3 M3#I#V:LG^O(IR8HZ.8=T&\7^+]C[ _KZ[,MW7Y]]]?77Y1^)30.__.+LZ^J7 M8-^0ZQ_-VZU**$WH\11/%]I[68>?HZC?O1,O8MHMP:.0[W%,/][3:21W10N^ M*06T%%3WK-+9^BLG1.Y,F1:^MGUL*@J;HW)"UN@ZLSH%SF;EIWTZW>NL9,<@ MXV"CI&J=C=#N@:H@1HY6,:G7-,HZ8.=TUS^U(N6KV/ 0<'#IHT+9R6C;'241 MG5!Y:C1KNYXTZVR.HC^V:FZJ(-1'DR)VJ[. M[\W#W+%16W#LJ)]\0?/E>Z0X\:* Y41$'^ 1L\K-YMK6,'6Y-B*":HP84@[( M=0^[0P!6&GW(!Y6(R244X\0M?I!-1#B?:?.BJ2[*NJXITCY@8USB)QP>1O?SEV!M6&[%XAR] M(%\F2IR@7O3"BD(T&=\4>XV <9[0K8@>.!%']?@^,EW-?_;@+F?>M M\E#AFNQ)"BG"CS %)62@Y50JN=2:%KJ0WA&R7O(*"*1L9:7)+ M,>&;J624\\3&S%MADJOKN[QUXD\8H!*%G'E/.$[]I%IC9/61+&9!A\08<2]T MY4 :C-D3H493R(=2$V9=J13HU]6L!QP$\&09AT1O PI_YX<^Z"R$JDZC88J+ MVK!SU%#C=C.EDZFZ.8UYEK>P?E)N1*35^3'\159UTSO5B5A;P5XME0H)Z1GH MTZ&V=RR!@)AG7XO 5Y>\< M7D]%N7J)N*%OZLS0WIL*+T$1@CYW$M\=6=_8:YB^YC&QX'6\R,?2C ,WC]# M)%DZ@AT5$PJQKE%\'E@IM<-%AY6TRY7)KY[Y@VKHU (>E_Z3[^'0*U>XQ"Y1 MU%.&[?E+6LR0XR+%>])4C$=>/O!7\MWWD3TG1BOF57]?4+1V_7]?1S'V'\/L MB9Y[7,5.F 0T[7SF_71(: YQ4R=A&E6T=U]\\9XJFSH@4YJFC!%'S?*I^XM-E"G?@S1-E&HGB[QG@ARZR38(Y>T)4Y]HJ.7AYAL MJ%F?KRS98.R+?)^EC5^X^F"GDC <5Z#H%3_.@-&]+X/RVFKX0T<1.MGG??@U MX%BF:V7I5'7@--WS#C_3OYQ$6Z5KFD\44,*+5\2WJLA"Z'V?:^J:ZB@D"I"; M4+:!0H^$9H8ZT5I@T03>1ZCJ04=9E9@VY-U-=X%,_0VK:'M1*YY1)=1.IJ;, M778Z"LM1"P6-93%0WY4JR)YA62*.2RV1T&/:)2=*W3H1DJ9O5*&IBM(Y)8AOK-KD^AI15W9-AFF7C2J_BV05+3&0Z=.6 M:=4GMHKL*OI)4+20K3X^%=QTB'(IZ,$0%XM!*=@\$@2_AY]<^*I>'1)J?+V& MQ FZ-EH?91^8G4/GE.K:3*D_D;0&W*,O,3D 73\[SG9@9?_BY <=U 3#\.]3 ME.I26]7X!Z6(&+=V5S4[2^*H@;!=PJN7G)NEO-1Y,D@36Q7#\CCL.0[Q9O2L M>MEJUHO%-?&1%8LK-F H_&C57E&4HK!4'(-T?9.:[J4)45%&X\N1=4JXE*6F M7ER$^$V]LBG4D[)VLJ);EKO%R278:N0EIKJW=X0&8NI@'\B5X9;\2#,J%^N$ M4)+BL@NB4NBM!SAS'N6>F"GI4$) H!V%D14UR:&0/2L'8R\BUU^F95RN)Y<& M=?[^6_(3N(G#O)<4ULM=9Y3E*Q8Z5B, M&- /F@&^5?/VU6C!XG I,SL1DG$B$PG3B1 $O%.)%?0)AZG$A!(Q3B M1#*&Z<:).,M=^Z$3NA;56(3 =-18@*6B&F\*"%-78P6-4%!C&*)=.BAR0\DFF_8\2- A?>.A\Z K"RUH9N12L:*"AJ1Q=5EKA:=](.P5KF#K6K"(2/H8?C9I,E)7-' M--^PN2- 1:H0!YC3[F%KU=Q1$$QI[L@HUSA0*-SZH759GLZPFI)N"*8;?8/( MQT.@%_:"F'*NEX*74*87&&<#79*S*/;=%'L#Y=\"- %-:&+$K719#&I?A::A M'VSY2#2%0?D SWEFL)RF1%0;^HA&QM>9YH3X$6I^JAB?XJI/Q:BJLLH9I-': MMRJ8\F'9G&,4$C.3]B=(][.B'WV2_9II-+K+R&V=ER0V88;FVADQNC0Q1$<%#'Y%+'ZR?HN%9 MGY7M[$T],!Q0^\#Z2]Q^TN]?[:#5_6Q(#3LP(QL5RD;62?XZ5HPG+CK"ZG35 ME3R,PC?4*>RG>&\#7!?;;9^(%/)'7JW*CN M>M8L?3%>7"]"(0CP.>,L;.\4L[+:%T[H6[\"J E9I'QLCHR8EU?DXYM(R*NO M9>&"($2(ZX4H1U@]*Y4$)][%VL2.^O;BGEBRCN\5C]:*8K%AUGAH1E\2G%R_ ME)"8A.*I8,KU=]"I55XH?3V4M;"BE3G2_.'&Q/2UCX:(%5F9>0,T_-XYYB_2 M9^[/!W)]N8_!ADZ/]T08*5D+^HCONQ4EA[^65%]XO,"@NBJKH\=3W_QBF$!V MRCZ??(;V,)VJ,BX 6'U6_9BDW7)MGZ^SV-Q$X>,*Q[M+O!Z_T1IG M&0L;*0\7GJ[E@R'Q+B##WZ1D/'VY:[F?EEAPS?Y: HI'V-\6&Y87\41[&FY#5),O:K@2L,)X0*<>)5:R]KWS^FXCG MG?Z%L !^'<65TW:Q.?U>(%C0PL$BQXKKB2A&TVQ;9B#)HI;)Q"'B80=>2*A5.^OT:7IO'*Z:-]$J40KS657NI" M7:FU48=):!ZBBTFW4>>KD9S\TS9//XV**:]K^@6R,F8*C=*S6&(# KII-$JW MH8!]1=ZS0WI',?7NZLWNV"=10LXBYD] -B*RWN=7[=[G=C8TL:A$+<^'GXH/ M_F/H;WP7O$19S!$R)J+ =WVAZ,;Y$K+FJE.+X2:KQ7<1]O;V?+']#B M<N+A8?[U;SNV_1_>)F?C&_>K#\!*Z7H!OY->HL&1 ES&MT52G.IU(^X5)V MJL;P$>+%".^^N[I;+99-K;(3=9$+KAE;D1"KWSW)W6+O$)#;8[E&5C<^74'8 M_F1[F>JR%E[7J>+&V\[RZ>!G\%E1:2O[6$\Q-W:R/OS03_#*02^=YUMBYL6^ M$XP?B&:M8;[4$ ,+GLWE/*-=,68J>Q9+0LS-JD/@D$2L'.8U=-\F^OAM%'DG MTX_F(C:*0[(0X;5&R<>@1QAD-Y%*)"2FBG0)U"[FF$/\-AZ_?WH+N'%/5'-] M>0;4&7J,;5_WV0)A*D%%U9! *2]T?WK;N-?2YB-T/;#CQ>>7B_NKY>J',W1_ M,[M;H=\ZN_T?T-7?/\[O;XE%;=NUJ2/Z5L7M?APZA9H:5\XIJF0?VUHM)VEJ M*JFGB*.IWPWATL@*1D$:5R%8E:,D\">[MZTZE^OR+9$^Q0;R,<&;0W#C;\9^ M"*.RHH5KN@):O+)O2>KO:* D&XI@K.46$:HR5=HN6AS0O9.?'_S XC5L4<>A+YM4F6+^Y*8JSKE9QXW0H[MTYXV#AN M2E^8$NC?TVRO0X(Y6=J<2BL*8(QIC")"')UI3*2*\UQ,91HSIHNOJ NL++VB MR M]7]#U(0Y] AY>$ES[+_"ODVQ)_'4LG'9<9'C/B3<;WZWI$-6M30'$MGDL M%6%].Q*3KGNXT7)AD&EZZI--L)!IUS,?%9XI74S@G6=X$Q%MK5)6ZFT'Q]ZD=-$PK7NZB/*]W@ NJUR8 ME,UG8H ,^>2'Q*I%/U0[&OO?$,[U5W!ZB'^'M[X;M)\:<\RQYV'"3N*L9 MT#.-' 8N3A+;AI"" )NIW6*Z-8-G7$?"*31)LMB4/$DBA;H7N9_; ;@I^92X MRJ7 !JV:R_3@@F>11%6Q-!K'.6.D0 Q77Y;APS.HKV8/S>PSXR>2JCC*DTJ) M5.V:RV5RT?4!;G:W?NCO#KLEK=R:OW.ZCEI5GA-1;AJO.N\8"QDW<,; 6B&6 MMJ' T2Z#CFAQBN(]LU5E'5,]JN+ 8S%5:SML@6V@D"]^>#:/" M[8\=1U<)S5_8.$SU!58J6W_R>QIQ/5:9AZOGZ ?LQ&KWNMY C6^/?3'DJ]?O M+ 5I!DFOIY*U^'#"W6M$]9JJ4O%J+$;0VZEUGE(GU30.U'[RZZE@8ZD5M_FL MDB:U^LA:U!UY\]A,75J-6,HN[D>+CBNI1#BZP>@2JQV>N8B2TSY#X:UBXT$3 M!Q<%Z[VL,.>'M+*O<8OK3V-695:[>AJ%)JV=E!)ZDNW]IA<:>SU_1&SGW?RM(M)CQ^] MLQ.L:\?F)A.D\Q*T;=.$&VP8IXVI9"HI7,1W $V"AI6='D MTO(!IB ^GE)QN@\-,I9.91Y9R.\NEA8:SIRCS*HI(S1>!OG*H>A)%.8U)@N( M"?T7E)NH(TVKVN'VXJ7NYFS@A$[+P<0M;WFV4VM^]F M-(^N ":6G$%4?S?X,UN\"TS#COL=PHF)O]D1^^XB7>.?X8?%'6/O]R#M9 M[^5MW #[(LDMU)./S#66%M,M$J2X/5\M;)FZ.M%H-Z/#,VTMKI_?QG6XY^(V M$_RT=;>8B)QL)MF-!%74]_T[S%1D]%KY_=>?G*[ M,0-);BGJNH4AW8;M&*^Z^J"\$_/X=8J=^/3ZVW/Q">W$ZGK;V8D]IB+S3&'K MMW$])=9@W9"B-BGAN+\.,K=28J**FWQ%"PF8"FAQ2[JM9G??SL]OKM#LX>%J M]6"YYHFR0%M]J)7(U\T2KQ?P:JY$KGA0>>?9#P)CY=Y4,3"]:VK@J%0!KH#5 MZ?9D9X\;DFSDJ]>W. ;Y6+)4^\87(6M5, 4P4U;K&HEEJ> M(7#^V*T>UD>^HOU3P(DA]J:?XAO_"7L=A3?UT*\O C:>*??&4EU!ZQ7.9^P@ MHQV;4U,Q6G:G#M_TWF/X(30+B;'GI]>.FR?K]'R.(8%A-% @08;G)KWZ;G'S M'92:OIG?74'UZ8OEU>5\9<^=KRB8ZF&& MW:&UZ]B=G)TJ^8:QA_%<_"@O=^ M9T'T976UO$675^?6"]\)9=2(/W))U+?'*@L0H,[IP\2LF^+)+Q'4X M*=P1>"T/;5\09')EWP>$C!A2NBYRPN3>.<*=@ODZ9H3MJ+N"^<2'+A*\% C0 MF( ,)[9[WE#X'NP#^VE7 E$U=R4VJ8.4)-OHZJ!/=&@UEK!@:K/PD&L*S$+T MYWU'5RR>8"QYL0ZP#K%ZKPW6@?](K>ADB:EEO8KFH7<@FY;O!)?X"0<1??E\ M'D')(7 )DXMDKR=Y@U8P:CT/0I67;%S!1'$&%/)I_!(L.>E*N&@=E3DU!/)D M=K/Q5*5*9A[,:\U4=ZUU[Z+P]#I?6\1LS;ZAZ)Y$]47;\Z]%^;MJ,U#_6SS7 M+&ET%Z4X/SG*M;-T;NC]GM!>A_DR^<:CI/4:8$T_2NN/(D>W 1 \8P1(=>5^ M")W]_HANG=@/MT1N\^??D MVKA*38RZ/E.8J 9TXAOQ< UAF!5:'!YXAU1>D]@Q[FEUO+:"I3ND!JKC:[E@ MY_Y5Z'E748:H>HO3HZ1<%J_\C\Q->]0$R\Y2-I(M1 BI5N!NIDKR]V++B9,\ MT?+2))GL&%?)>!OG:?3,PB:JB(^NIO'WPZGH&GO'Z\,63:] /3)Z3VX"KK]W M@CZ6J!" <5M3A(WP)>V^&%P&)%$9D9S$5J4LK2H]0L8+O>P9%M2>GE(9#+/9 M,V)D!FC-)+:=/D(3JP[+#3DL<>+6@2XID+2SV#12-,SD8BLN;\/>ZHND:I9% MIIY1:43;/ AU]8"==MZ/DA%7K+7%1V6ZQ*3^6>7A'UEP]X^ )WT9ANAV] MKIIL*A>J)Q(6DNIT\.1K[)?3R)K2D_TPK2T9 M,T*6GO*JUT0E;*LNQ<%*85 =3/FZ^WNK3V0'B7Z0YI9<,6/^TB7])^L[+L7A MUZ&V!%.^VG[U*U/;FNB'J6W!%1-J.]L0L=K7W"8:$[ZK-1#E><#SWHG3XRIVPL2A?= ,E,WHL[*-K;8'?MS'D#>SU=4E MNI\M5S^@U7)V]S"[6,T7=P^62[IH"+VNJGTYH[W)7CDQ5.A*[G'\L'5.IXK\ M=2P\0>$BP]&RJ]GR;G[W[0.ZOUJBB\7M[>(./?QEMKRR[<:22J^N4V*JAQ=I M:<,_=Q+?I<4X@P,D?)@)#O3#PH+R::*J$"EX;I>^"@^[-8[A3PG 3U!T2)/4 M":&\A%6S=*#2L",)_=FIJ_.M"EMWE,V+#5TU650\IAB,K.G]UK:@W[T05"WB M5FFR&^UV43@UA=;2B+H:]^>:]H8-(*&S/!$DM$I-C^0;*3X8,#F.IWT-WW=Y M*V'KBX_+^6I^]8!F'U=_62SG_R2VZO5BB>8/#Q]G=Q=7Z./=);$I MKO[^<4[L5V):W%\1"Q8,6'1_,[-NQ>KJ2F.#UN&E7O+^A9-L+_TGW\.AU[,P M#&>JX M^LFGTU^KE98T[?U108JG2!\?5HM;>K4A6](=N47#!F0W5-1'K*U.\VIL&%+0 M[XFL$,7'[YS@D*>T)SA^:C?]&Z&('W>AL;3KZTR[0OP([@:1?O&1X59"RR= M9PHZT&Z5/IG0FI7YA,3JZTZM*-HEWL?8]2ET\N\ TS<08:-8&K>U_+B6+C>AT4=\%Q3CQFCS@=8K\)#G09S4L4SGN@S1SX1P0N\6 M@T=P[-R&"K"-2G#EZKQ##YK6_9@-^9?EU,6."!J9!4U*=/>7\X,?@).7G)%Q M](2I7^PD%HQ3%!-K1T*_-8FF*%5V1B[&N.Q(&:+X/O77"P\9Q M()=O=@+2D M69K=O1BDF=&?/>,6ZM7PSFO,-4SO54PL5!^WTP:LASCTB3#P9/8JH? :;=*X MM ]XN 270@@-G?S $ZUDX1D2'QON]3^?(3WQ;-A&:9+>?)P$"ED7Q2=K*+(7$ 2@S!J65[6Y$)HSR8>&3K;R;?X:WO!FSI M#]X_6L"-/P1KKL]1D&)05PLL; IL<=3W 09-P^+ 4+N?ILG.P1W]2 1Q&F40 M+F4C746$$"_F6YN"_!"1G=@%%[/M#:2/.%MQ7S$+>CM?DCC]]ZT?^KO#3EV+ MR*2:!I&?*NWIPC-X6^HLSKL196.LJP&7^2!S-C$:>P<%Y+R,*^(&/-,BKB_. MO?2^3$?$+.:7(NX0,^!XN'?2DUTNFK!M' -##ARS\.&HQ =WLL_&(9"&$>]%FD)8RK*HR30 MNC+)V3#$]#PD:;3#\8V?G&B'8:U@7)482/",RWPD"LC02=Q&!")J6)$<$C64 M@]YRB1WJ$9OT.HHAE::/8X(]TVB!/28*O,,E&XLV^> I.,V%S"\=$7PJ]7+0 ME]'1"=+C$KPR?03.FF?6$\7 @/?J-AN9N9ZL'PHRMI>BYA&H&6(K^GKU$')K MBEGY-A>7M5R;A%39+"X%RJ!H_ O7$X[742^VON/Q]8;-U\ES]9WV :C7.*G' M%S5H =/AZB'(GJ!MEU7+;#3U&-BD:V#@2:4[30]U[@'.\-,T=U7&T8DC[EC&TNIESHAOD5P!C MN(6G%"&]CAD3.-"5)5:IEAHS]!,#\J,>"M,5W=UG+_[8CS5YJYP@'! P]$J" MAC"E!*S$:CCZ$298#P!+I-9ML\*F63MFP*G =0+-$:TT^ODITAT!(CQ'4'XH MTBFH-H>A1-,IPL;3(QG]/>\'$,/,O8N+^ ''3V2;4U4?29"9"=:(KO!6E_B% M(8R4C^ZHAN&8LT@D1>B92V'_4PC K?P4"E21RRB4OS@XP4AJP(9KZ,3A(L#S M+,)8J.!4C>[N$H9U02B80AGX1&HFS'=J5)P?SW'H;B$^>8+S1;J*J?9W%'ZRE18JX3%"HU#Y];Y*8J+4&8RTE[# #J^^Y2WSW07ET6> MK=H?8B%4^4U,H@8D(BS2+8[+VB7E/V8IN6,]^"F^C_'.3T:O4Z.\K(4WIJJX M28K8^.1RO7-"YQ%J$J:( $5N+KG?.OLH^4-2/1U+[+[&Z*L$C4<^?;BE_XJ^ M*BAPFV>G"QI-%\VMZB22=*4@=RE1$]#]W@ MX.%D'L)K^<7FVRCRDHKT FG7N]4%-14G\;#)4?:$E$\"$?@0 *"$0 M;$;G=:1:NOUZLTDS2T.XS@,.@NQA[,S;^:&?4&/L"><#D^&Z*%W!:$K7(%1Y M14ZS:?2*[S0F%ON;I0-Q//&K*:T2__1K@(!#G(#RL^O"I9/B]R.?GLPE;-0% M8>#!J\P/HXAMYI$Q=AOM",33>?S*HDW7FEKL,8 *'RGDHIKNV!8^>Q'S%A8; M$8YRS,(0G$R[_$W3FLQ 4(_'9B*R6%P-6YQ/JHX)=H]C<#:0&PSTW*4O:PA_ MG$- -K 85K@F>$)%YF6GO"0O1;D71-.Y5KVPXWFO2QA@=.WRAU-.IE9^#@>! M@!G*9>&PTY)QE0G=FV.Z!4,:FIT?CR?=L8HUC!<,86'!B^T78[-@?O=R:,>; M()(5?[NJDZIIN#9C@FF>B9IE+@%A//U3B(ZB6C3*/>1Y1\3R=J.8 M(+R/:),(%/C.V@_\]&AS-U(38)4'(N>.YGY3KU,+<9R4\-=?!TQ-&EY*6;R8 M!7-:C!'/=JI-*K:B9H)Q 293PL3R/J4FXT:!8SE;^MKD>G0N\5,4/!%U MOHBQYZS?]W$$71"\>7A^2,CODP32[6>/,<;=VM[02)V[L[T\0 >BSLI7NPNKX<9W#Y0C0[J(6."(_0EBJ M^@R:^F^Y1%A_A6AX37IR3=O+!A6*JRQ"LA0FQT2GV/P(<2K.,L8?=?,PX5FC MQ/ST0W+[W1>=&VY4T9'-@U3L$FBEME7O)KD'FV2 M)\'M@\G\NV#YT5,^#CY#7C788G1'P/3.*V4$5:B*J@SEI$XPD[FHOI::3<)AHL!]8"6[S4]">=2T8D!5 MI3G9&-WC*$>(F)E<3$2YF9J7ZBBH+ M-O.NU 56ZHPB+[3M]LC%V$L6&RC_\> $JN9Z9YI)MR$'!_YK.SH0]@GP!=)R M+PD9;[4* 9_S]2)L+ JU+N(W&(RHY)[(8.LDV<,M=@T8)07H <[P]4T=,VY3 MB;!FH^QS.)E3F5L^R&;/R;Z"K76?[,4JW0O@$A=,O(]]ERR3^ZI]G,RI9O_% M26\37AR XWCN^FBX.@6^XEJ ^IEQ+J%30/8 $-=V40)&_R78[ M,@"M"6 4YY!1%*,-P":GHN]9M+D'JT;-N!K&7/U2&M2>3QX.ZY^PFZZB6R?T M8/015MK1*^H#3M. WEO![Y:<+M W"!4+;O0A^/(ZX8'"Q^7\A.>5M>%P'T-3 MZB[ZP>RC^]\?_^^;-^C'[V^_^_)?/_[#W1]>?@B__-K[Y:NGQQ^.X6]>Y.^^^?U]8>'O[U] M>CF_^.'=D_<0__#7^\7'G](P.7]V+RY__X^KY.ZOO_?7/\GG\TY_^A2X> MEF_>Z 7^F[$U&!M5(OLZ[;F3S9IA/#1$!TI9'G0J03Z9($J[ M2$CM@"Z%C.23PF-/=<] "E-SO:DD+C6PXNC4MP76V"4$! ]X!YPD&->K M9)Y0>X1K&<]5%*(C:IPK/7JL/!A6D&/SY;",^I'*[&:E5Y4.'?9,H]%4)@JJ MY7.SLKE3J9;;9#RO0&Z-PI'2G.N9U%>;#7:A:@$O^V/DN[EL;0N>NEX(*KT< M+G/T8P+$4MXL& %QIUX,7&E<->A#?%F^D3*IE@41LW,C74N!E(^:%&MR^9 M]EG6/;FT>4HHXM8,*VXR/!JBSD!3N!(A&PF MA]C!@4\/23?:[9W0MVU+2678K"XOHEW+1KK8.O$C3E;1K&3-1<&9ZZ@H7JYV ME5.%9=:64L2*5PTXFRU2(.A8BI((FY"43ZVJ"10V/*[-MIFIK2ZV6FZ1(D/T?0_9 M'EBJZQTAXQ#'G?O=<$<#?R'C87XN*ESED7?(:XR)#T ;O@2I*!N. M S$3=+OP1FEU0>CN@D>EC4D*Q'!JKPP?WOM6'*MGAG8.J:P21. M_^$1])*B5<96.,!/?D+^3?:O'8[A\:^:Z2R'8N-9DA@EWBFUA13^8BY]JU3. MAE.JF&[[T9*:U.IOF!38H77/GX?)(0:/%.V_<=@ERB]&V#.-7K&8*'!]BOE8 MHB#98+NO-H2,KSUKB;78,4V2'YEE5=*-J=";KF_LL M!6+X,B7#1ZGC7.PGGR:1M]I+3I674(4'NOE#=P?HTKS8%(LH:4EGDM%#J;TZ M1P>R8;3L0M&GS9X_C\?F4LA,HO22D#NM"7L6@Q'--_WY\U'I\>5/H\J5@EBJ M3UY"M^[73@.B_FZ)]U _.7R\CP+?/:[P2WI.9GU2-$O%, P;J$)D1.%O'\H. MY].L'@B*0JF9K'*:M8W7C_#"_BI)_1VDNXULIK: &W>;-=?G*,?'K(P"+H;9 M3L-A2Z1N63+(TM\@.+45RM<3MQ@.*L6=0A&8Z0IBJHCQZ_<4%39J\Q%]@5=" M0#]F,"QUR-:29KVB/FI2J9'1$WN+S:4?8Y>,2"ZVCA_OG%!=$PB4 MFA:0GRH-4%C W.U8C@RW3 "9!/9M.$MBH9EF*9)0(\,R\?!PB ZW+6\SP3H2B M2=M0 :^>(PT!5[,L";A$0"9@,G!: NXPO"/@)FU#^NVX+CR?3*I>9CP\FQH+>AB$JIF6;;65.77Z- C(GWP)D$T1><NEL-<8V2@/!#L$$P&.9F1C M43D8_9@-_Y>-;"LE*=4W!#ZE8_1'B?+:7BO8:93V!,%T _*7H"!M+G&3-Y?( MYJ ?Z2R[!H5<'NQF$UW"]3(@F$#AW_,4MTO^]=&)"L3XE\=^JE%BTEL]9NLD MC1TW_9?-QVTJXA&K2),!.F&%K!8/5;5$?:_HSAK]FL'5A,[:HKI9"7J5C7S= MW1+,5__GL+I6Y)]%FJYQ6(?6[[-GSS1U"C!7%POYTD_<($H.,69]VC8%S?^@ M^61JIZWQ^GQGO HG85>67%K12:?Q%Y46=',*=$#(YXN00#ZQG_"'EJ1 MW_MPSYPE"6;8E7:NFSW$6S\Z ;HEWRW9:';,"X=9Q>!(H @1M>G2#22[6^P= KS8\#6I:SD, MCP^I+FMV?U%%BU\4EDXZ0W0:?89:3K1JH^B*NQ'HZ,,;C$R \OP6%IX@3% "^H/,W0Y:DI]^WE#!H W=(D9B.8IM)EE M3$Q?H_G>FH'<4)-DL/R=CPH"MB +;_.VE$]3V;0AD).P_G40- M1T7-H(=F3+P%_5OIA.:Y.H'$K%/H4_UC&)VYFK?A9L\V>DOID=C!FVS,(QR4DB ^'[:1'#$A"OS &(RG ;'RT;#]T+Y42D6@7TRO=CHQ MT[A+>I\I2H#,I1C+D>EKOB>B8\=\6JFZV&K)I8I=&(*Q>[D0C=Y*P;R' M34(Q^$>8G /]+6W8ER#BM]AD.3WYH]'1#BD^;&.7,2X*LO>^=IWB2I(ICA8Q MC?I/?CL5<,LB*"?Q:TN7,Z(TJM@HU3Z&>:A6.F8:Z0&J[%3,)%5\=6OP8V?.M)!OHLO,1^MTO]A@^WO"1OD;F"6BV@])% MM(D("(1V(SK =!05\Q'DO6+[PN!0QI2(D O&Q:+>!9LEHKZ-PC^W>NB#@8UH2Y+FR+*' )T<_K*P]Z5G^0PJA M;=K -(>&B/IBFV=5/\*[@M7@V_C.4 7Q"AO2L&1)U))(BAYOZ9%\FDY:G''D M@W20VVG40PZYK L[_()\S3\?')A+?GXBGS7=B,_0\]9WM_1;!B@)_>1_^_,A M2O^P+BZ%V8_H%5F?G#K1CM@'Q()_#>!A-"9P88DS\I.?H%R^T N&<"[KO;S% M+?2J#D($9$P?YM&NWC 2#NFD93!9T,+1F@M9. 4&IRQ-&SN@7)M8(.GLH8) M:S@)MGF_VDI%:HI0Z('K!.XAUS;H8PJ=32LQPXG?T=#/[06W3](USKRH(9>G M--CI5J=@>=&S#SF/CA\F*<).')+)1.9/Q P#L07^!A M0_\7LE,6W]LACN'U /G(_,C+;S39G^&(A\F/L!9*R&+9-QSC38#=?$J1C9S[]U]E'R!W1(\.80$&4AV\+GJ""SWLTXSI,1O!I7;)H6 M?:3#4+*^HK5A-@JQ?, !F?!(;*"91S9O/Z&[V!/.!W*WCA$T,LF6IJ:FTUB\ M@)>84]$P"M\HJ^FDE%0FP7Y:JZ8/%JSCJ\V&Z,!B<_5"SJKP$8.IO@CAHOV> MIZ/9E$P_LTGT)H.@C3J99]>=(*"G(S$I[:9-C.QDQ?0*=>\<82SWBI(-S>^6 M^VRP12./@7J'WUSR;&S?Y3N."[*AD7^F"?4J924Z9X\QIL7"%$SYZO&,6T#* M_6QN5K?4*8!QG-1V1-6#_/.BIBC&/N/X04]+]TLBS&[.Z)%*]GBHX4+N;OEQZ91PJ.<'3'WT*HB2Y#7LB)ML_?S =H\H MK3"H3SWCC"Q22HGFD#_2PQ.PP'3KHMZ%!!'K *Z(+MIB#]R)! L'A3@EU@ Y MC2E\, R<$?A'>*LV^SZD/@PT^K55 M'F00LLLP^?YR0%F=I;+ELE=KN;PFP"S:Z^H4,T38CUG&A4F.HT5>:__:MO9.]CWUBJNS)I2+S;4FL M\C4&:[6QV[XJ-MC7Q4F8Q5OA.;&?) =Z1N8Q68C1%A8L'7&&"KL>]NVD]+!M M'2IZJ.L(GS",3\C&FU![."1;.49'[,2PC]?,HRK%PCVZ 3Y#?K8>CNT=RR)F M=S5&*AGS+G\F3G=1:$!ANOK24I>0,#_7&'H_*ZWH[,2F.1YK\.32/)QG<@#Z MOW[EJ7BOIC]M65G8<6Z=\$ L*7)-S=RQWY,+[38Z)+BL/69[?5V\B)RQ]53RAYX")M1;'T3/]))T].4#3 M8QDFR9Q\F^Q4/=)/.SJD$()/R()Q&5-QPF-Y[Z;^E/P6D&L4O9>3S2CP8)_( MUB-;2[XS%+L(@9RD1*, D\S)F%\-Z.+VMH?! F"HVR@B'?NIG505[\BE+G<@ MY,^G5Q&M/CISR7>2^# OWP3OX1SB.Y:K- )Z49+-Q] *9CTPLWB';6'=%P"3+ G\7Z\!_S%+^"E6XV&+WTT44$VW/ MO/3L34'\C9V-?HFL,A_(=1)0)"-+'%G?K>D[IX7=0%]Z'8T0N5M7N;&<3E,;2L+3.KFV12HLUUS%8IG/8U3> ?K[_O^Q^U4VJ( M4*#&V@KQJU%C52?@!#1YBKNF'JM'TCBV4]"PUFTVOELYLK(NKVHYNA&=6OGU MZ(.]33T[SZ:1SR2L*S@^^3:V@,;#SAO?6>?Q*IY [K/73^C)"0XX>WU'SF=< M!&.+SQN\::6&4C$UDB>3+-0N>AQK7'H\3G0E*.:9<7]($Y^E_[A-%YN/2=Z' M1^[Z:$D!Q0 !?!_@0\\MT1">R9*-(]E'F4,TR,D^3DAH;=(EDF-SRK+XDCQ+ M72ZVA$P)<.WUZUGY5HU\?>MCZYD!.6T=/Z1V6/[8()M)GQA4?ZS>S]9/V_4! MCF=PDA'![_S,-W;&0B%+X/1W>\>/Z18-2P.CWT2;-Z5"=5#-# 0&LMVYV6,+ MUXUQ,3I;GZV1EE6R$*=$%9M2-YW$T<+E^@")I;>$_[O#+L\=OSPH:&0,!W-, M)+K+YB(P-(B!5FWZQ3F0%)<)L5F* MW%K\0NQ'8JX0F/1OFXCLES3L2-/]R-:4- 9\CK+,59J>2];PLZN+$X90^C5[ M'):@YRT.R[\7OX1$[AA#M #L(L@.)R((*&'[?1PY[O8L,XCR5;NA[DGM:6)5 MT%3SSKUD@LH^#U?/T0]$%Q2LJJGI>P(O%[S_U?@Q-;[2!TVE;RN4^5V^*NH MY3EI&L L#)U#0(R_&%"_)DPY!VM9L,O?-PHB[/(\#H?"@?>R%% F[S6]8;3] M,:;%VXOJCFPU>&9\0[N'[#>J9O, MF"&WT5.6Z[A8)P1 2L[&)S(_BH^"[R67#ZW;1F"@7?14I(%&.1CZ,)/"L>@: M5B>6)?#*]ORVQOUO#^\0B,3 /1U"/AN>#V:/BW8<-+RM5!VF=09 E<.>@ MJ8^H4;4O,Y^+YY!EPA:N+4J?X7J>7]0)BPB N%VEHUOMSWS#&#G_.DJASG0+ M,84E+IYDW<>$MXM-]0IF3@^(OSC).<;A$GN0/>HMXNM#$!Q%SRXKD&23AA 0 MV9\W)50(*=/ 'QE ] 9#[9,,--R>-@#<\BO- 2QAR'X@>VT$_%\\A^?];?R^_N>3WZE9A MO@2 )94C)C]#=OE:V=^SQ>CY\&PWA7L(8]1DWHO+QF^L#X?]/J"O"9R@>ND- M%8(4:O\5133(Y[VE/JH$/6-B13CPNGN7I9CLH\0G7S/L%6CMA)]H.>I%==9$PP)ZQW/)P,)UYYP MG-+R>T0>)R(%0F0$VV281"<)\3ZOR8'"?P2J\H74Q^=T1YA6#@B/\8TNI% M4($::A=G=4K#Q^QZDB71K+'K'++Z!;6_^7FQ!EKOS>+]I,?WT>-SYWQ;YMT0 M;!2UOOO:-^PDG,^8DUO[*_PZK?K!5*2FJ(U<-32KA_"V"IY4*A3!HWW; S)V M,HU8&,AWN,\ET,9U=!41')K( M]]7TK;\PO?(+&84=T?1CC;$^LPLXMXOGN+5G &(YB6=9/#O$B'7S*A2H-R8* M^8,+L5!4YUL4CRJ*'4'UXXTQD0UUC+UG1B?T85H4[:0V1R^J>#A:6 'J F*:3 M>70WU'N#+70'!G/97Y0VR/^-CU??KQGY#VYDPM* 04"M[KT3ZQ)C="]7Z<3& MDK9LWG^S9G3OQ_9%\2_:0XLZL*0U".BOL(3!R2IF&/TV5?/MV.>Q?*YE@_>$ M&8A&Q53$&*J;#TL@S5'6;)XF&MQX29T6DY9)L1>OGB/Q';DST/Z!4Z+"/6%: M5)DZ4OHE<[.45QW"_X!L=W.V -P-X89 >V\UW_9Q[3+^%(M?"!^I[K39R^7%Y@8J/%5^ M,VES%]D\FXUXQ)AU1*;& F.'$.UPSDC2\'$"YV7^EHE[(*E-M[9?*N+7/:?Z ML,7DOEK/[6 )I/B[3;^Z4F**28^X5K]3OBG0 ]#_M":QAN^3Q)J\].%X"[UF M-RR>\=P=;==N[N+#-)EY1)HZ)?JD+;&--K7Y5FTS RE=!BVM_)$^.:P@BU&2 MD\ EC?C08H MJSN M&3&CM9)Y]NZ$)WEJ9>Z>6'<\<_I4,_<;\32[EO#XK;HGD,X[)(^7G\ [D0S> MD=[L&A73/(1N--B# ,U5T7QZ%3M>86!P/;[RF=8N+'+4.L)1Y8/)"\L-!L=G M5 MND=RVH5)D/6I]'XZ9!6&N!%)A;E63305!+NQ1V6.A#VZY#M0;<)D-A_M MEF0&MQQQ?;=^SP\G>%G1J&EG5NN;O07KR86R\A#2F=8N)G+4NI^#(A],7DP: M[U@4TE=XXZW)@8=0A_MB2DWR_&JSP2ZQP,CEE!;66SHI7H3P:;[GL5TPQ9Y5 M)$"JPWTIS<;>.O3MDL)\[M 'B,T6)68;RA@\TB$D4[V_@\[,_&?'[9$VXT]= M;#ILYY%F+M;$*8HG>K4VA:-@0+T_LP? @[O%WB& (@!U)\F2&FNYJX3<7UH. ME17X+J5I[F/ MEI18P3\N\;P: PW&/!5R P06\_J$.S9$.HX:J5.V/#%Z+TA MER?[#85K[ZHT$/'N16H4#IO<\5M7OVQ_X0J:-=AND0461K+[;9U("P5+5ML8 M*WJ8:T/M/3/JXL)U,G=(,ZG*/=PW4_+7J#AH)N&1F8?)(08T[F.\\P^[1%15 MBSG8ZE;!Q(@1H^<2:3*Q$03]O9]NY[O](84'KEES _"70B%G?BQ>/,_R4U(! M9HRXNPH+#!:BD+>%Y-2?$$^TVM;W-.TQ37H$]"PNB7-_ $R;X:\!:(]DR5I) M]&=WT^5\C*V1EK\^O4;!)K\O27]H-I>Y4VS6V!FM)[:-BGKE-WBQQ>ZGBRC> M1UFUO[9?@=PE7=7;N@;0B534T\!@1:CB4\J="",\9FI"LGBF]4=6 MRQO'XIRE%$!>>N(\7#U'/V G5DS)D<.Q>?;UQ;7[]6HQS=RY*:RE"[&SQ>;; M*/*2ARC@WJ'[P+#FONB#)".BV)=+9AT>T-%MM\1[V!?"Q_LH\-VC-- EF6;9 M"2+$C>$.46"!R8RM_H>VFJKM^<..Q^D?BII'H65A MY;N[HG#RT?:NBVQ\9*QO$&FLREV]^/O23S[);^B"*1:?,O"1ZL:;9#2;8_YN M'X7P/AF*'A(=H&E1]%^0T#,+O<)?#7F%?'GT@6+5@.B'*D-P_?DU;?-"U97< M$Z#%K4\7Y3$L"\-I,8?DS:/C[+,NB>#=<9(MN8!$.US;RKGM(5$^ V53T*M\ MTFL;ES$I*77Q*-)MQ%HH<+ERXI"]&2 *+[P):#5UP"TSJKW$@Z?TZB)[GX2:*=]GWN88^/V[*3>JL3<]ZL@, M5(. ?BQ@_,O6P=635I; >K')X,;5J(=>% (J2J9(LE\0G76&RGFHF&C'X:M$ M$TLX"DPP*)*RX\*W<91P95"..D-TG,TCHXDQB\,LF@RRE%Q?X45'60"HYG]@ M\98,1T A*B><(8NIIA(J6/P6$FS&'BY06>($$R*A]6,MZB\QCXI)M,%Y;1JR M>;%7HH@E#046&/P86J^5F1T%;#_'9N#*8FR'%-/&3QJYG^9)):TB2NPQ M/_*^?N/\^/'!!($2V_M2GT%&I,LGK^ M"(AA"4A*N\DOKWA@>XFS_\[#F>O&!] 8\!ZLG!>%4!>DV^M M\*%0""@'855,/4AEF\P].67&K/.P_^\KHD+I\6'G!$'1-XDGK&PHHF-1,=B* M6#B(UUDOI,W(?E5A<.T'.*LA*V$M#$392!N7$Q;&;)ZV*3*Q[52KSSR/ $TN MR#\7\2IZ#B5LS<>3BQ_\%,4(YM@YKP5$L#G-H=7@'2.KOR8SGK)13'O(PG[= MQ)FU);.H,AED8!:=.C:32IG!AM(*S3UVY=PSQ$K-M1%UD-'&C#ZH,<2LOX/B MLHT";[[;$YN8^GP3H2NOG('J4R;@U^.3PKR,2P@W?#<'LS<*Z0647C=%=GX4 M(CJPO'AG5U9+N3P\"GC&?9=*PZRN^\][;$NM,()D4[(=25#3 7AO " "B&TO A1[N+2DO+5P7XPLGQ8]Y MJW;)C3%&Q6#+E_$&XOR+8XLVH\[#[S'4E<;>[(F8FX^XZ.Q"$R^2Q2%-4B>$ M2OQE$@:+]P40E$/)K^PHVF3I)PFJ0>KDHMCX?GJ1S?IT-/AF5*YE4'KI/),] M',MMD73H),M% 8KC'X),Y>FS!;^9-I21)(C44PI M7.UGB,[J)DI8NCP)2&*Z=F0<,!DDJ5WJRN;&1:;?)78#\A]/[3I;3C^K)SH6 M,&SZ%E1HE%QX);RQD0L [@\<)U I+#U*&-U.)RS<#;&M$U-X2*&\ M=4RO0X04U2 *G091E&+B1"(I+7*$X10FZ0;=_Q=12#Z78C+B**V'N_C -F7?VU!^:ST'O \9/OXO*M.5L>Q)0E5SXZ MAZ:5%+-0XQ&^)7'PR&$+0TR\\?L$)UU"(=V1DU&2 T#L;,A)I91(\B35F6,Z M2.,DD!4+_P'CX,D):)I2>N'$\9%6X[JO M":TPMHTWB[5LVJ:15P)!Q:3YU$W6:8J9O!8,NF4B..[>>5L\/H\0>(&-\%3MA5K(NJXW,W;?R\:B:@+(9UA)W>22T MK2HQJ49MJ?JKC"5DI2XVQ!+/B@?6W#:*+U4HA#?1Y@W\7ONY.:7H+(15!TL2[P?X;*O6Y5UAJ2;D$/A/')B;[&Y]&/LIE&< M7&P=/]XYDOJX=!9X4,MYJ)AH.<0LIZDN)%4.&/[S1)!V*\K'VO=MU MS-G>["YM!C8N.,9NG1?H'"(^M_-!W3/:\ G=0+9](#,H,5H'N)E!0-\9E@_@ M(/'VV0\"P<.Y9CY%_E 1BLP7;^@*&+;]GFJ4LOUJZCPR[/WW'T-_X[M.F.:I M4T7W*W+"2%N U6:C:CHJYJ,?V6D!-@(&2G0R(PD].&0ZK[\,!,J>5U11T*FX M0SO(LWC/H=!DUB4QQ/8X3H_W 2A Z$&",ZV++*R55,PZ0W0>S>DK9W;>8EM@ MOY@LEBQ4&&'6"/5#O-A!%YLE=\C;FU MMWPY! 0@[%O$0@K9)K("4PR^LWS +JVB1,R7+9$"S>GEIPUD8U$QF*8T6_J& M>,BWFC(;/H1L?O;0J'IG/QT[@$>DQ#(0 M\\;P53U_A)O_!_;;#ZJ/C_-_('HHK9XCBY\)EQ;V!L4EVM;S[QHF7+^4D/V+ MT.8NQ:5%E?WFPR)Y'U:)-R4;9-^;4D>VXTWI4F+T]7S_7%=6DNL9.\O5[@8O M3'!5YX#I6W:K!RMT[@RBY!!CJ7^D,1?!9%3-YGE'+)4XD!+)%I8JC2JV%.1\,.H#N8_QWO&]/)MV%GJTTVGF9)941LNGEMG%X*+* MVKT6COA.B30K?BHI@6QGE2)?S-:O\SR:7PA=&WUO'N;% 6LG'O<9:CF3IG7! M\^U\\EGCC8OM;4Q.(4M:JGPQ:(?159=X3V!NG01[1(66./5C1H,P\=.6&@SZ MB>50F)W4+.^'/6AF!DKZLLRL'5?6%"6;MY]LL4=K BG442W&9]60NH54[992 M;5##CCWRZ3:535ZXU-Y_6*_\E%^I@OX1'/+O/[Q:OT;%-%LU0=IH\SR%3;*, MEKAA[YR2.C?-P^1-=9A,YGV7D*X>1XBE6_P-V>FY,2?R-]M1)((",SQ4HFVR M+H?K'G:' -RW]4L.^7> :<_QT*MG]7/#D(*J3@5\5%\ ZLOF2]"#N;X(- MO M!'#/FA%'H"@&U*/@UUD1"[Z! M)*3RY>42/^$X<9HI2);B]EPR.5%["5NLY:QTZB+3O%?!>QB5FM%9\G#CY"?*N39NA7K0N*&>P$?+OM^=K4L$0C(=VL'R]_R+&*9BXY0V/< MV\PI(,#COQR&LA%CY2!3IIAYK/7DETE+A.[6S5+R85;HXQS<(B7JTN3:&IQF MW7U:D!G^^H9"1*7LV1$E&ZZDGCQ@^I.T^&C6G.GVNI:?@;18<[T-^)2:D;"I MX5P51*2;+B'8J@.:!P"*@ TS$-"S7JHL8&);>GI,8+L,]=EI\>5)C\!\Y]F) M/"X_@0P"*SG!^.UP MIQ O%E'$DHB< V8EPGG^6]Y5!M>NE+2>F]##:0;-+ GVY9C)JX!Z5U9-:;(Z MVTY3F@R:>TB3RS&3TJ2V#CQ5)M<28O[X3S@S?L%;=1W%V'\,LYW#/=):4HZ; MN\SI3P'UF,^\GPY)FF_YBPVQF[F.%FI:-I8K;@VO8,779RA?%!6KHMJR11GY M8F%4K4P/3HBRDM4M*\MI6,KT]IQ0>-,I+@2F'O@6X3'7/8Y=]7.\4URH $6? MP%$?NVO9&=N/;MEIK\HYXX]^6,W#A(]->=W3&*DJ=E*+>02Q0R 2^HT&%7,? M$]D@JL2FQ48A8:]TR4%4HYI+'YMR\O4L.F'Y](F)'']SW M9&\6/$C,'_U4@VT_2&0AWTXSXA-H>&\J;>J!1T]U!]$\?&R'EP8<07H\-/<. M^P+\[#%V1 ^N+^C#.3*H_:;:\,=3Q[7]T73I,'N1KQ=DH[WQ:#X:%?IB'?B/ MU*"LN\S?,QC=K$Q'3?JLG%8%8C+!@UX$L[X,#8Y9#C*4WW*.JRQVS@DL5-MA MF8;)C*A/(J; HUDMCB#FF-UN>D6B=/\.K+69DY-7#3T4=_-ET&)9[, M Z=)A*'KRHS'AET[$0F( M"&$)04ZXX1L'H[C7140.OC]^["EHQ.^LS8#?4+J6.N<.KL<1TE;,+6C(A MF(<>?OD;EI7TS4K]#4X2C.N! M+I4ZF'32&6K%!"=4]U)$%5LF4C:8_$+RS"*_3)*5N8IJ,TH/WV0Z'?#)81_" M8N)-!S$@$:!\%%_^8Y8N-IL'/\7W,=[Y"=\'E.5EU.H#E/]$#F15;!! 0068 MB1BWJE1S4R>4.6;T\L%(Z)#EU0@S:JK$F#,T2]/87Q]2>* %KVKN'=NOT034 MLD/I$N:8#:6G9' MO6'6?>R'KK^'*^H/V(E7VQASOYZVNRJ'2,Y^F(KH7*M>;BUJ93'8OGPS:$]_ MA[>^&V#):5*,8GQN%H34Q)G%?!95!IE*K#G?Q>63%#%OL\'58YQI\)A) M.D MY=-JO%!IJS-Z[;HDK*W9[1/?N#-:?QLE(8SM45?@A<5DZU:SX7.\B6)<.PA' MZM&\IG!1/7[-;MML.PF[#S^88:Q!O+584;B.#)1$8S'U6/Y44GJBQ7YI-]+9;IU_SSMMEH='@3Y_KVQU^25?/.'C" MMU&8;OGI >+;;[U5RM3OOFV2!U^!V3PT[>RHK&2HD ,/<)IE<]1C366%A?0X MG21D5?HDP2<%WAC.)\\#*;WJEA2QIFG6*^%3Q/;RRCA@[\V&DO?KFNS[FMLF M3+7]7>F0.XK7L.*;X>JCAR0EAW1\0PPRB?.P&(KHV(EX[!GX,P-_/#(-WK=N MG?@3IO4WP 9^PN0BF%2U%GE<+V?E-X-R7O=:8$4 8JI8LE#A@]D;G%*;AJSU MUBBM+3)0-FW$/B0S+W6]66;2L5%O:B,S]5JM?2:34<0D@GD%XU-KV.I^<+?8 M.P1XL6DF@BL4]LQG4F=3\X5G#0PQZVC4>"K&G9Q>YJ>CR"5#CV]RQ;DF]J83 M@"5R%7J7Y#[/MP*R[R2;D%EN9 J".19?Y?#(J$M 3JZ=0M.L=^]+O'/\L/@C M? [18@(-LM[&D$A MVW[4?,%4E):6M:&@H:?Z]#+RE$-X/:6^%$JT,H_]'EPR*[^B&D'1GT9Z[2DK M,Y3M>J;CN>82PY*)A'*SWISR?M6N^DUV6NCT^.P' ;U(]KJ6=NNCPXE4P!-> M3>W>396Y(+ZL]F2F8=?#?>E7+[M$M8KOL4R,LB0AD>\B]OS0H6&DLHO6E/H( MBREDR4Z%)^;]K(U8(R#Q@>=-939ZD3Q!LN9+;9#%]9@RB#=[1-&7=_=QM.'7 M#:)#4#;&LH%=PY;%T@XQAC<=:($8'O@Q@>+O5K6S0(+%P"8!9C5QB6G6$/E^ MTWIYZ3XM2W(0B,*H5_I6Z%UB21;*-+/%U9-EIB5*M>F:D%S#5% [+I^ @$FH M+DS[5>.XM @^(Q[A1L]8679/OXPGVT:/C!KFA5Z) \;;WR4/A_5/V$U7T2WA MKP,Y/DOLX1WU-CS@- UHE0Q:@T?!\9*W?Z!%<*H 6;X&&$;E*JA:Y@Q5"V45 MC+@5+:P84@/XQ#2Y!O/=Z*=[?O #CU8S#!MU4X05W,I)]*NM3^N66; @4B%- M+)DI,,%@)D$S0GOMN%A2EG:L8DNV/Z\.\A+KSV+/ND9.EF+FF67V-E!F<99! MD^G"+GENO.!-::T(5>/1J,W4?\ZST"XY)N\DT%(._@=WHB#23U]T2H6#HV7&UV6!^S!+@GF7=_&K@SU"U M,LJ&9,FTC5\V9V0H(48Y>BA'EB.&"LQH$Q64X68Y?]VH')@I(Q8TP$RG!ULR_8$ MRRDZW\"#7"64%E8LY*)N$\EG6NX Q:6GK MOI1LLV;* ]D9D]PE3([VZL['BD 7+O!S'+K;G1-_FLBS*B81S,L/GUI#T;A* M!5;.RYQ\A*F_\5V:07=W$/D.1TGJ!/_T]Z+&:;D0\BG$CJ.3$)G5[J1F1P@L6M@2X%-MPJZO&P$K EEJ MX< @:V7SZYCR3)F*"L,O8MLIU/,D.?1+'R=7#CK'ZOV30P?S"B BV7@KB,S# ML,1[*)44/CZD3LJWV(N.$/FKI'(6RJ;9,MM%I+"W#Q'9-MI8J7F":TVMIN?C MY=#"=!N*R#:[_UQFF02SS<8/?')OKMX!BG,-\/63E#L4EAGF+DI!N MT*)L7J@S-T%Q"F"EXO])[A:D(-"EA:0ST'5I#/D;(A5@&9! M$#W36MF;*"Z:4T)]S! M1EEDZ;L^*^QOT,)B.X-8TSE1>5\(G-P[/M=)7;7$P%!AQK=-K(WP].3 [>X)BY9:6^GW)\[HB>@N.G10//[<,DU6BJ?=;I).^ ;[8I/+_ M"=M(0,Y]DARH843GU=V?$^D>(2&.Z0U5XXC9#:?>H*1H29<_-%^$1?(M-]VD MU>JE[,&70T!16+;L.=K=HM3H9(FM#X=L&;?5C6FQ:9@.O8W<"A*C=N-TBV*H M,4!L]/9AHKD@ZBIVP GY<-RMHX GP7P0RD993+)H8-L^FABD&/6 YW>:[YS@ M0%-JECC!\1/_/7-5BKZ<@HHYMD\@/C5LZTM,N^$[165C0WCP(@I3/SP0S<@K M0$9ADC7'JAF-5R]I[$1Y39=YBG?TZ"0SR6(!+1J5[S,_*C6*L\YR^\13L9$O@%_0IE-); R,)PRM3-23F>O^(F]J$FS/&RK MF9YR+=UN-T+;.[F0+I9L%!AA4"R#GIOP_$ECO2.R7>QU"&]8HA^!V8:WV5)9 M\WJ.7&.K^E*+D38+CG;0%GZ(3=I,!J2*\@KUT@KB%_;%C$9MB6GT-N83P^*^ MC'33S1)HHNWBD"8IV90(7KR]K4@IK@VU6^ZNC3CSELRFSG#L-3Y@3_W->SX! M3?#M.Y<63DQ51+AQ)WJ62BAI*U&ZT/.\R6Y+"4ON\P;V/..)EAC(]VE&2N7,6$5@)1/TX;VO=WXD^'KS ML-2\&23N9K7G9'VGJK4@WEVNAKJQE$I5D7K(WH%"R,_?(VJS[A:?#J= M2D_!4N:A=S+167-92!H#=K;O=C] ZWNVH >@@%+#=C@K7"?A/"^*.8V&C *" M5,.5'7D8=/2W"HET$P0%'OMVZ1>R/R)&.J5E :D0R?&H*S+'=+?M6L\G65VQ M9H^KSNW*2HY=!WL6][E$6CL?BOK^R@=$,6%*K=\*G.2'1)-HT\QSG*8$X*Y(,B\&;6.\R=B2$+Y0GFR<9$T9D\\D#/KP MX2T.TJ3XS1OXS>-_Z736N?+8EFTY,.34W; M1$_R-WZ(:7[ J:1?+6 Z*M#!0*X(,!31L?9?DW EQ-2*)I&]=X0D3BM8#^0< M<6(_FKWX2FI!)M=4@OQ4J0,?KB%MX"+ 4X9\"/H1!MD)RDF% 1H@)BRSI'/L MB6Y\RKE-?D-^6!,;$$CZ_U!+ P04 " 05K!4)*R^SADN JP0( %0 M &]B8VDM,C R,C S,S%?<')E+GAM;.U]:W/')# 91X-'G]X\?[NY>?2@_O0":(9"Q<'_R]>_/^#EP?S M.%Y^=WCX]/3TE>L#XZ. M#HZ^_N[U-]]]_>W!^_NS@^-7Q\?9)__VO4^#CP].1 ZXW$'TPXL2I^>'T/^* MA8^'QZ]>O3XL_O!%]I??/8M?5/[^Z77ZUT=OW[X]3/_KYD\C*OM#3O;H\/=W MUW?NG"REO[QFKA.GFNR4ZZ#Q+\2_O2S^[*7XUO MC[YZCKP7F=X.#KX/F4]NR>P@E?R[>+TD/[R(Z&+I"X'2W\U#,OOA!7MPZ4NA MP5>O,Q+_(7[S5_C7&0LBYE-/Z/[4\<50[N:$Q"\.!.GWMU>;03"7.,$#96*( M KY#\0>'C=\?IC+:%?*OJ1.2()Z3F+J.'_65N4[.UA"NN&DMR%W,?UYP?B9B MUTEP4<'%%'8=DCD)(KHB&4,3465D#N$F\-V<@S9GOL=7KXM/"8W7]YS(,0M? MJPK;0@%0SHI*G&A^Z;,G(W46WPK98#28+!9.N&:S$]=E21#S17_*N;F4*%M4 M&PFHJ7D5K/A,9Z&&6.5/ *&,&[Z&4M,UX?N%LH;R MOP94SE7 ]\-'^N"3DR@BL096M>\ 9;HE*^:O^*2\I@%A,^YJ>%09+_G'@-)= ML^#QGH2+<_*@+%3E&ZBIK0\'WHG*ZH1P)/W?.J?)2* R-,$L7 !KZ[*9ZNTY_6JB*V4 !=NC?;Y;W#%V*3?3;_$,J@Y)NEGG2M M-.#F8+:5ZHE6^0;.4:KNI+I82K\&FKG:_A -/OB_H"=A* TY4$7CP M$I^[(K1F=LI;2#,%R(/9ALLR-\"E,$"';U 5&]27NH,>W,%HPW&6Q$E(%C2@ MBV0A8@1+9RT8FNJ]@YZ%$9!GX0N0B ; N[!.-^;?1DKAQS.(Y$0$Z)UA' M_G9%TA^6"1,K,XY/;.$,97SX#/%HE&Z@(F99%TK,)4=LK>E?\S^N?&P*,+ MD)Y;V?R+M=[9KO4FJXB,C!5@?;X)Q'P3\(I-0%_:71)@WO\.#_;@T\?4G^PI M;)V0C>WDB=#'.3^_.2L^'Q])D"P>2,AFD=C%(I;$(M M;@0,AZ)''FP)+/FF MYR1VJ'J86/(EG-KE3JFFA.U$(->,S%'5%*_Z$9SNZBZJ-J[RS^$$E(:,-*5L MI0%X:BEYU;KP2CZ%G'--X21M1;:3@8SQE\,;FF)*OP5;!:4Q#ET)VV@ S,AS MYB9B_3H)O(L@IO'Z*A"WR5JQG%8:^3Z_Y/L-_Y/T=]RX/E9$)<\Q!X!XA;"" MJND5Z,86.%.?N14^OK@C9F'!QG<>B/_#BR1Z^>@XR[\V%WN3V67J#%+'G[*( M"I%/'B*N>S>NJE-(&'$1TTODF1,]I#?).;U#H>=#XL=1\9M4\ZG6M5AF&M0> M3K;.6A*\1CPWF1K.)V%57B=T"S'XCQ60=Z_B\[\X7*;7PR_=.?4W\V,6LH49 M;C%K5A +/1+^\.*52,3@PY@1<9JZSI3:*&8J(W<6(Y+^Y79A,\3K3)SAN"G9 MA*W.8S/!$,"3S])=F';T@HR6V#GX>B?^(7S E>.+2,))?.:$X9H[$+\Z?D* MT5/C66P*F'@VS.(RK(H*!(/9R"2S&X#HEKB$2\B=UQL2YV.#MLPV5H?E36W( MH+8K+,?RJ+_)FH!YGI!+/JJ3V8SZE.\8=G!LXC(:"!O5E*-WC(->$1=8WQ!H MR"JD1[)Z5M610_,:99&+ M=DU!>2LF&$Z*VZDTFGLK8OB3V?LHBYT"@]C."_5DWPUAAZ+ ?!8SEZ4:\N:S MZN+9]1-QW_(C8]X3]7UP5T:!Y;"/^VI: _-X^FR(5G9"5'CZA=)ZK9F5C<\$ MDVOJ// C2YJD&7AW,7,_5MX76 JI*;-%]DA-H557*]P!T$51C9+T_&Q-70J]PRHP')&EJZ@/.7%E=T#6 M?2;TPZ>I!RS358\(4C4N:"7%9<^I+>@KL9V,EEZ!I)WH[_>']:>O^>_W]2*V M7F#W7P]DB[W9]]F34-,E"\]9\A#/$G_W 9.E:R\MWB--'=-4,':&2^D!;$K"O.*EK2-J(\>18J^D3.S4DY*0J42EZI[VD-[A-,Y=M%5WJ*>8 M'6F8'FZ]9X,YN^+ M*W0LN;--7'KL8;=D18($_$)K0Q9[XG< 4XV_%*K =R4C;JCBN5)ZQ"3ABKHD MNF,^_"[4R CSNJ,^*:LK4K-NX' S0>W'D$71-&0S\#AGF3(F+AK&5%$&U+NN MGJG_^;-L6T6MFOD@'\(T8&O1%:I3_LX)/Q(A%[?Y$V]%PIA&6RF!@>Q@AHQF MYW0NX]FE-^0R6'?$]\7#W+0UG9_** IL1VFAPA6Q Z\B4VS/10MG546"A4Q M%F+;"S!R;$0+08ER>JRXO7/?-N)L;YEMH57B@'I;:[)-EK4#%>DP@DMD!]RP M@%4%*PK16')XU)AB+Z0ZN"JJ$?M1SE7 Z9 HMK-!UJEC.SQ:<[M6#*2J)@-W MYVV&6T >1;RHK\.S72]$E;PL^3+A0\H7%!9$IV3&0E)ZTW?QS,?'!:>!$ZZO M^!R.Q*,%_B67RT^UD0W22JS)CJ0C.<-:!0LW%60CO2GL8F"O9?4TI8.D\AAB5>I2E=S"G3D1=8*SD M/##7:>G,+*/4H!;<&'#IOFS3&*(0\)RX/O^'Q9OD9I:#1E)-::#EGU$N&V5= MU8T?,6WN'?+VT^J4N!N;T]]G>S($M'O;VG=H]Y+[3?0QR-+RW*Q[ MCY]ITON01/%B)QNRH0&.$J&!O&_5A4Q-2B1CL?2$IXW38-+;3,VR58U0 M(=[];FKISEQ)>K_GI(Y9^!I@/]OC^UP5GL9[UX9\WGO1CNR5SHOF,O)90=)3 MK2TYMPP&M-/JO<^J UI:GGOK/^,NE@H6I"^SGZDU**2\AM&"JV(J4MW+%66^ M4_I0N<+OB.B-:N]LE],?R';8-E\;CG:%@K"3ZQH>5%O!KYW7,&Q.%4Q*IML4%,I$V$0P^GVX$I'C=+BT>.8]3#1VKQL=5!@Z5#*I_71## "4/LJ,U+=G3V/ZA?'6=4N62>C.G8AX)X''G33*A3A/0KX&3%,[ME'<3H?S M..Q22Y<&Z9M-P-O#/=L24(#/68_ N/54B5G .Y4T>Q2_,R-OR%/Z7ZR@WX[;JKJP)->]5NZ M5KWK_<0Z!@ZW7#$Y6&]-S\\7@0<;Z(!' M:[AE9O2"'26XCHQ#4S6\<#(\^;GRTF=/+TQ]Q$UJ0D')5K&"5E;]XD6"WC1D MXM3MG:[?1Z+*SN;!Y E?:E=9\4P[ S,08#@U\AI1KX6@M%6,6JG_[Q-#-)_] M^TCD-C'NPGGZ=(, MC 4+8_K9R7UWT;2/B)]M]+A3XXHZ:6Q::K5-GB($J.O63C,_JP]=N[AA'IGW M-R\Z-([\G"$=7L3U+BDG#3P=6EEA^RC[F@_M^H:Z.-69"66)[KB7_8[_:UH9 M:_+ 3W D)E?!BJN%A;44DH8'2AKD<$/LMA'7T2M8MEF?*CDN'VNEB(B-P*N4 M#_)1,;:# M9CEWNTQ8GPD2ELA5Z*$@U6]IR$D4$_/QG*,07-2G4U Z8@@F[]4^=]5[W_8+?E[4#2/0)6#H3#/$P M*86MR#ZQ;^#\!N)\2&A(N.I^Z\7KJ M.T',G5:15KC<+5W6_Z9(G?$@0X(*5E.Y$]+0,V1XR.XZ@;8^?!F;A%2C/>Z) M+&X2>>]$O$VB38 O8Y-H53'8X=&LUL@R7[XFLVL6/-Z3<'%.'J"1;V0SQ)0T M!8.HUB!I4B%^*?3I1C+9BV%+^WX#,V13A@&[2Z&X=P&%=)4CG 1" MZB.E?*^V[P=Y.&N9S@*Z5GU@5VD48HC_B0/ARO%)FCO IQ]U\V=6Z4O_\B]* M?YD]&MX-1+I^XJ4=]K8#SI0 ;.5[%GYDCO^^H07KW[+W>3RD:8EZ(X&S&H!- MVB'47>LU /"GR[VG(N)Z-_+)6'YLC?8V/EDN_73/O.L MR!7U&(8_NY3!@2M^UZ<'JJA&#?_DKTX=V\?2,QA9$]2-GG [I%5R0"AT,[0Z M]3'#5M,3SL/;]%S)^;\/./?-=?ZU6%:4#LUMWR-'./2Q:54&R@5V>1#G-')] M%B4AV:T VH!.R^<8[K["9!,PM T::G'K#T)UD^X!1XW0Z("I*P)J(8.QDQUW MJJ?A[-+#2N;L;4T2U8RT7UFR6#CAFLWR;&115Y#YU!4!45,_9I>4K?(FS8Q, M3U_T,: SZHJ4FQWB]UR_IS[\]9P$C_3!)_D;5L.) M^R-CWA/U?6[3=9+6?24]WGT>US41M^=%=7-$C@D; 5\+Z'=K=:1.UBU9,5]4 MC^+$")N=<:%IK&MBXMM)_NVEX^9O#N6VU+3JMI/0-PGIP"2=P1OD:?E<,P@@ MI70M;_^M(\QUK<'WWNU+#75A2&U85)MZ[WT0W=.D<0#7.WT5*X/H8SJ:'DL' MC<'H=6?6IVY+EP9&NK)6GEN8E]]]B*U[)PU,C(,XY9';\COD/#!3YMJA*OL3 M#?H9I7=^2]*NU5.''YE+K5VR,+_ILR\Y24NSOY.=L1TT4;;OE>MPQ@YUJL)= M?=:FH=F1[A]%V_!IVEE)/.8175R,=Y(2N920)6MJ9&.:SUTG:,MDFOD@'U^[ M@*OT+&]6UCAOQ.Z(FX39N2*)YRRDGXDW8Z'H2N<$+DG$3?NV43OA"X'@+&*W M?78@R3*RO;2WY80I\33O92:F0Z5EUTF0=?D[%6T\-W4B;%U&Z[+'WI6TIL!. MKRTM18]T?Q+Y*9MWQB^TXS.5S[5"1?(O-<_=%2)ZQ^V&3W&N!5K56*10R@8Z MQINKLR2*V4+X0WSM#^(P)6QZ'W!+HX\1M\WWG%88.S2P6%RDG9?Q4[>R&@0+ M^P<+)9:8IW E5"M/>Y24.-(U>C='ZG2=_K0VM9H19N&E[S'HXI8L1>^DG-Y: M;\WOHH':;T@I@ZY3"[BO5-Z+HA4744P7%NK UXCC=@W3RG>LJP6VI1-&8F-Z MMV*>!3SR_,8[KA@+"&NYX8S_'S';(#JJ2V[7VEO9V42UUJI+/(O,=WG MKH3*BGJKB1XH63=-F--6@T@?_8&H$;7#;RK2&8OLNJI-7 :+;*=Z ,]L>B%N MMEBR@&2U7POAHO0GD7W"-WKA98O#J"A/HA;ZUB.)L:QWXJ6K%KBB*[AY\SW] MH+]#^GSY/%EEPSD70NSMH*XJ :;SU#NWWDCEP+4R45)"^Y[C1YD9ND5;4+X* M.+W$;MY!-T/4\[IZTJB*ZK!KR&YE?.?$>=Y.M>[\GA9/1?;H228&Z*MJ=J0W M!?*LQ[Z+Y5B3'[>PUTF?.A%U4U_53V+B[*DL:)'FE:9#Y?-:.UF M3C'[RLIXX'ACBNA("T84E4/1C&W M'9$N:4 C/A[A_5N#K,H$)W?/'+6:BL#V^EZX_1BRR!I>&7$47]TN+/39;60TKD51HBC ONG]0+11>;E$>FPK8;G ,DB7.@0? M;)G?OR_%_;O#R51R/5YH%M[Z-]!*'+%KJVN:J%**45FA MYFZLW]-%:AX0__B<+1P:["V1;,L1&6\-(U#+)BOILG30-#31:[Y1OB.+!Q(" M(U,B/$X RIJ!C0)K@W2:\,'1X/%JP7V<5?IV,K("6@LCS.M10P3;U :MMCW(>(S3%!F6!G3@-%]8T74F\,K>^LK9QPJV$:KH]MJFN1Z=<8[O,NL:2 M+'%-8Q&5?3?,QP=R0*3C[M$[%,2P?B5SZOIR''K;4HWXF,!JTD^.UQN<5Z-G M+,V#28L_705\2(]>I_?K![_6 ?OSY.G']^$;]_\?/SA_?TZ\M^LW,^O_)_BP_B. M_/3YS>N/ST?N=?SJS\O+X[N?#U?/IV=_O%IY=^$?/TTG[S_$073ZY)Z=__/W MB^CFIW_2AT_AW1O/_W1U/+]Z.KK_^>BG/YZ_.?WZ.KEY^WGQ^&GY\%,\NYE> M_?:'X\7/9/7;S^ZKM[]?'1U_6KZY(K%W>W_VSXR=;X/) MQ>6OGX^BGS]<_//3;^XWDXM?G,GOK^??_OC[X>E/7_]YG3RQZ9\??GWS,8J/ M%Q=G\Z=/)&'NW0V-%[_\?N^%5Z]?G_SC'T_>:>0MW[F+Z]7J8_*S-00WZM:"JI$F>%KP>5Q<.:X1@R[ 4#T-7"F.:?BE*@[A*@[\Y+T^]H^-.O('V9 MA $5+_0YV4OZ+'ZRLD0V\QGE!MBB-KB[$EO3\W@\TU-Z>V%C?K8P&N0U7KNS MW:(UJ"L?B_/S]7CF9_E2YY8^SN/)C!--7W2?DAGCZX/K)HLD;=]PLA"E*#]G M57R!5U=3,<8WM\TU#GC79FOF?SW\F5_!ICVTKA*MF@.[Z8->"6P@V\%LE-YWEP)S@-_B6&UI SHGG+U+4XWRGWV2 MJC:H;$R-@P&>"&!BC7$]@,.DB&KJQ+!!G\8UR@;_5*Z5U;BV=#7M%>""/"U& M>%HW2XLM+K*;5J' 9=%_I]?3NIT:CD5;'\.G==WT#';76BW)"H^<_GE"\H+9 M2@+K443:20U0$O:@J2V,2@EJ(EX%]T_L#^*$:B<2;:)8RYQ57,M*0WHSHR8H M(*9H2)K.8W4XH1OVZ!7&_HW&\ZO%4I0+2KNND"@N2HHJP==)!,?A[ -;MUX, MK*[1B^QC>-?4>FI7ZQ,F[4M=6,_/:Z M+&>QW4K-%W0*U#F-W]J5](F: +:I8F\C!2"E^\48;TE5L&E3&+&M;$)F+HL3 M>%[N2_.]B=3]&U9L6>E?\S^N?+SQ=S27FM*1O/R6L]9"H8Y6=?M,\X7*'QM& MT. %, Y(5^G_1L0F0;R3%?_M([DEH@)*\1]%]6;HY#AM]@.(Z%B;/I6W_-JX M8-9#+0]K[W-(DSEN>PDXT .XKK2I%3W!VE:[8)RS:= 7UZ>A:KR14W2TZ?QN2:KLA. M!Z_3]3OG PO/?,[80LE37>XXH:1^%EJM6:VI;8AZJ!:FQ5;,&V=AISJJB028 MF?N&AJ0Q.^1*KQ?=,,N?XPZ#K>IQ5=K8&7( ,-64A7S(NP\=CY\]PX_"XTS_ M1T\B2I@!L""JCJ@W+*UX\?K]!Y7!Q+9=V.U%JD.P%[% MCM!A[W.D+6T4YNYWE7WZAN?BV?4348&DZ(D,[G$K,<7RX/I'&:J^MIJ&4:LS M739;\][>4.L*@)3R"#L[3!2/? ZHRWE#XGTO&%*6&#Z*W:5"KEGSX\&*A \, M_YV4SX)'/A,77M%)^H5N3'$;]2QWI3:,KTM)F)M'M6.ZC3YB,@ZF"W^55D.X M'%CB(47-V^9/V32EJ-;"XOWU;R'P+6& '1EKL9!FE8-%J?NC9"T2W<@&];37 M/$6;T6J+&^L ($SSFCF!QFFY]LF 55U#@ M?DIH1,5P--#5((=;NJ(=2AVM8/33VDZUC7AG<^)^/&/ADH69'LU!-*<^9$Q[ MZ PJ0JP%<;7[EVFG)@4R ]X3590 5T1Q($I0=(&;([]F+WFXZQ'E:YZT,$?_ M-ST2#@.:>ZVQ&*EV,%/TBY-J63!PO"0L!N6!=4 FTQ"85VW?J=8JC].+ ^9] MK@*B/=6'E4!A)O8-"^P#7V(R]!6XOQ;ALBZ@#U:YB%-QG5._0^MQP*J1'?Z2 M;:(KI*P-%5&+G0<:USK=@2_;1JH"+(EN^T1MMDQKDQ]6?+YCC=97'E@E<,MH M\QW%M0MXB?VT)%\ZC:16/@=M.I K"" MU68Y"1F[W*I%G:$HEPR^%GD'L^$?.%6U5D"J$SL"*@W:)N)VE=X/ME5^(UA# M-9170*P3'@+M(5#).0N\,V=)8\=/M^52[,O6E8P.[_'8M:9.BSE@$$S:2:*U M.@M0X!^3P:NJL4#<(,ZTBSANWC3;C*M42Z]?^O1653V3J"6$>MYW"F#?.:(I MK:@-?4N*IAJB^7SNDUT%-URQ]T_$7Y%W+(CG-LU&7Q;<6D'=$#>9DX'6X:H2 M6Y\RHA[Y_1/#G"F%"-AU:RU.D8V6D1\MZ0O-)X2M_ I-(9 +XMJ>'9FB,0O/ M:*0R?/D3)-4T8&Z [0ER,N,L M\>=(50S,2&POXS*<.S40<-W6ZFGWS G#-0T>3Q:[/9R 7YC56&&?^L$F0KM" M>WBB3(06:FL%0B#@*2_&ZF3%6(-$Y,6S633G*HY8$D>Q$X@WX_WZ3M9*OMZD M7":SNY3+9,O%,&*@3;['\GQ#^'S@BB37\"V>J[3Q]UM3V,H&5-,7:FD2U?&< M.A%U@;'5XXW>@Q0">DUU(Q_K+YQ0E,*/IB1,);0Q">0\<(-Z$$@WZ&ZDY46N M@A4GQT+N,>1%6/3CXH5F"EIK4>;<9U$2$ODF!U#8IIF3>4N8>$["#>7-#R?Q M9#:[HS&9BB;54;WE9.^Q*+-%OE540+?20T%9FX"OP_9F-I6.[)MGEQ4+,JOS MV]3IW9(A=?/KE9'!U>Y2&W7/*J1QWZ0J0U8]:I55@]24LBQ$WKZ-NZ]^XHDN M;B(%9#(3Y;.B.[8=>^LI18L@ZGLJ+=#T](13CJ15QCOB^\*K";P3;T$#*H88 MTQ4I>O;U![>3 V:D# [L;D4"OZ'Z.#N^!R)KA^A6Z;LJUN (,+>M73 MLXY6_& ]F;USGD4S^Y,@I/\VL2%/KLJ'[,'=8=VK9C='J\S6/9Y2+?N^W<@ ?5P0S98HS@+J]P7;J$#53LS:YN MR8KY*[%>T("PV1D7FL;&QB6(3'(BEXXKGH-2S9[H'23TC2'W*C8#S4B7V?!# M\(IZHES^:1+QWT>1J/=T\A@2LE!UQ_IS03(0-W>H:V[(A"L[ M;3M[3B(WI$L+,5D=SECW_>H3P4B?L->Z^PO^E#*(^M]AI%1L>Q<-3'J]U\Z' MKMZ^M_%CW="4A-"U5@O>5@+8"6KM$Z+^9+R*0KV%KM&,S(NO3)TP7M^'3A!Q M]F+X\&T#VCCAA).Z)GAYK6O5$U:GVP:AK'02:.>%>F.E,(<5H&QH+J"#RYD3 ML.".^4GZ0O1D04+J.E>!JU%KN8,$\BE*4=-=>L"Y!RP&D1=X%"F_%KND-'%! M<^\T%KM F'7_U^F*63C;,3[6WO2+BBHD#G9"81-+KGY"+Y?[*R,(**AAGE M[;"+6KMA0#AVVH#_G1JZ*&@=KJM+WTH3H%U[RQ=W\/T![UT7+*'=\$E-BC>MDH4N?F];UE) MN%=8)R%Q)K-K)_" X2H1QKJ(U(2HK JD-X/%P:SQXK#C_%F_]ANLSJ4#Q0X+6HVYZXSMN(R!7'T/N!R9)?" MFYM_70/1ISIH\S%0$E;YF4H^4'&Y_\[YP$(:K]-'O7/F<]&BR5/ _W].EYK6 MUXO!P+>F?LJ#:EO3&VYS'(<28>")'ZN)9O*$2Q55"QRNZ M':GE-BB0&?3"J*(&K$XOTY"YA'C19"8"N7>.8N*+Y+,!7?DUN!6[(P5LQZ*5 M[2/RL\)HFH3N7-1;GC5&UM5R?]3)#=OST]$+3L^56[+,A9N&U.42;G,(K])Y M]=].=$I(<$L\X>YXD_ R\?WUU*%J4/:A/^@UL)?BP%JYF 0CLMHP=\G#!^+& M]^P=/XJ+OUX+21>I'WM'XMA/G5NAB@FTO40;N5<*H&ZRSC.Z2+@^I<<>7 M,H^Z^=/,5-Y3Q_<9"XI?L5.RNSH QR4UQ!BR:]M?QR9=:GHO))4;/' M@U[MFX=LTD0&KEZU))6_"%:D\P;8"KOY#=UIUM!J>/,3;3N:B;9&2 M74D^&SH6LI'VZ,X"7\#9XLNB!BY#AZQ32P5^_>,RAI50HHB0;5L-^F70_8!&\9:J!X@DM/?ZR^_#KR8 MS?@YAJY(TP4"L*O?Q7LDIT!-A1;P T2#3"X&2;G^CL;57_6[02^!TH$6=^,H M<9F*1$5]>TOUH=IY#1HX17454&(5I"Z+5YA[+MTDV#3=M@AK"].Q>)FJ.BRP MADDNW&,1#^FSO'*1',#GI;9J&':R,[B3:-6+^FMV)4+:5^^M-'?F66K$B0I,4^2VPI>$>)9CY(&Z.N%U M9-&H-,#&$>K5 M+^9.^$BB>W8RFW%_6LASQA9+)^ 27;+"SM3\&55:* =,$\R4E0.VP.CYHG3Q MD/#/B[IM^1#30JX>C9-0$3]Y?KC M8Y]S'[R4@&FG('@[K]%L@8JJ@WH&88KL.R?\2$0%;3M@[I ?V^*YJQ^4%Q3Y M^2VMQGQ/?+*B$?^9KP\+$HJG5FK^2C<5K#.J"40*.H%Z3:'WV"5*0A%_GXK& M=LDB4D[ZEG\Y%HMI&#?LTXJ]73*<.='\G(KZSH%7NEG0JX]8(J%5%5S^I>X! M53("]3N YJ_UG7<9+;V ?SL%%)^@%=VL+&2C_OM%\>]I[&=O8@3UQ/&!POAR MNE@[0N?T+>+##>I B=^?,B?T)K-S&A*7_T5T-G=HN)!7ZS/"J(,!7B2_=5(6 M4'6I![A/^M!F:\'L8(9T(:2- M9Y?.QMIV]2R)8L8/KF>/-OFV_;FGT45RBDK[B]CA3]>G)'#G"R?\:*$[3"<['#/1VFW550?0-L8HD=7Q M290GR=V0V$Y"JY0'9AL7U9E<27*5:PHX^JA9ZMAU1<5E+I9+Z$I,/BL -K)! M[0IC F*SP@#+(P]\35(\B98V&[CCKE[YFDXBP]L!I&&H;F6@K"(WB9CZDUDA MGA(F.Q^AQ.AU$=@=*I2]:QE%?<72K O<]OU83*%-!9"'B;W%8,^9F[52"KR+ M($[;.\]8N$CIZ\=@VZAI98,H$=*>1O\ MAZV3T4K48.=IH-<08^TO*';(56?&" ML![&A8?(>QZ,RR5K&L>O!& :.!?U, MH;?DD0H]!K&(SO6:/U*"*%ZTJID4JI:K J[3BS8VH@0V#1[OUHL'YO<"I4H) MQXIUX:B-'B7<69;YGO\=R,J:$L+P*741J(XZV#1K!:<#S'8!-4S%4=U9!IE^8[;5*.7@[+E^4X_R*J4QK'OU$8/]A#)T)K2HZ0O6F0\_TS:"CPI&U"-XK"H$;".+'U1RJ8/-$YEJJ.([;0H!:TERG8-OELXOE^4%P'8CZKTQK4?U70! MUI'$&)R+!0D?N>_R8\B>XKFT%(<12'*Z8X@+M>H%K(&)J2W-B>_#H50A-XY- M2:8'I.8C9=%_29R0T_+7V6D 9#>JTQP'0(T: >Q68ASE%E4-:'IU#0?3#M&Q M;$G-6@%L3-+C$)LE?0"=8'-B(SD?[2H!K+V(&1Y7@RSX@9 M=">>Q[47Y?\0XS@"@$U&=406)U4*6',22+".K8!U/&ZPCF';C_0#ZXS_. GO MV5/;"T9-J$HTQ^'!-VH$MG6(.4KIMCH)IR%;T<"%<#\:"(\0KQW=%*"AI4SD M@DU9%#O^GW0)Y#%*R8[*O9H<6&E].?7\H1'AP(B+^[?\ 4$L! A0#% @ M$%:P5.>D1#//E0 UZ8& !4 ( ! &8Q,'$P,S(R7V]C M96%N8FEO+FAT;5!+ 0(4 Q0 ( !!6L%1@)($'\08 "D> ; M " 0*6 !F,3!Q,#,R,F5X,S$M,5]O8V5A;F)I;RYH=&U02P$"% ,4 M " 05K!4>_YVGO,& #K'@ &P @ $LG0 9C$P<3 S M,C)E>#,Q+3)?;V-E86YB:6\N:'1M4$L! A0#% @ $%:P5&J+U-ZU P M#1 !L ( !6*0 &8Q,'$P,S(R97@S,BTQ7V]C96%N8FEO M+FAT;5!+ 0(4 Q0 ( !!6L%0WGD;BH , !H/ ; " M 4:H !F,3!Q,#,R,F5X,S(M,E]O8V5A;F)I;RYH=&U02P$"% ,4 " 0 M5K!4< QIHFL1 #@L $0 @ $?K ;V)C:2TR,#(R,#,S M,2YX@ %0 M@ &YO0 ;V)C:2TR,#(R,#,S,5]C86PN>&UL4$L! A0#% @ $%:P5/W& MFQ] +@ !ID" !4 ( !^\@ &]B8VDM,C R,C S,S%?9&5F M+GAM;%!+ 0(4 Q0 ( !!6L%2N:?R]370 $F !0 5 " M 6[W !O8F-I+3(P,C(P,S,Q7VQA8BYX;6Q02P$"% ,4 " 05K!4)*R^ MSADN JP0( %0 @ 'N:P$ ;V)C:2TR,#(R,#,S,5]P&UL4$L%!@ * H L@( #J: 0 $! end